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Science at the Service of Public health, food chain 
Safety  and environment
the belgian Scientific institute of Public health (known as Wiv-
iSP) provides support for public health policy through scientific 
research, expert opinions and divisional tasks.
on the basis of scientific research, Wiv-iSP formulates recom-
mendations and solutions in respect of priorities for a proactive 
health policy at the belgian, european and international levels. 
Wiv-iSP assesses the status of health and health indicators on 
the basis of scientific methods which it approves, develops and 
analyses within a certified quality framework. Wiv-iSP develops 
advanced solutions for the diagnosis, prevention and treatment 
of current and emerging diseases, as well as the identification 
and prevention of health risks, including those resulting from 
the environment.
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2008 and 2009 meant a new milestone in 
the history of the belgian Scientific Insti-
tute of Public Health (WIV-ISP). a new vi-
sion and mission, which are a truer reflec-
tion of what is now expected of a public 
health institute were developed. I would 
like to thank the members of our Scientific 
board as well as our scientific committees, 
stakeholders and partners for their advice 
in adapting our objectives more effectively 
to a rapidly changing environment. In this 
way the institute is seeking to characterize 
itself as an inter-federal institute that pro-
vides support not only to the FPS Public 
Health but also to all federal and federal-
ized stakeholders and partners who play a 
role in developing a public health policy.
To be able to perform this role effectively, 
the long drawn-out merger between the 
former Institute for Hygiene and Epidemi-
ology and the Pasteur Institute of brabant 
has been established. The Pasteur Institute 
and parts of the Microbiology department 
were merged into a newly established op-
erational entity (OD), “Transmissible and 
Infectious Diseases”, which, by consolidat-
ing all the scientific microbiological exper-
tise, should provide a significant competi-
tive advantage.
In addition, three other operational enti-
ties were set up for which the same strat-
egy was followed to group together all 
the scientific expertise needed within the 
same operational management: epidemio-
logical research is now operating under 
the umbrella of the OD “Public Health and 
Monitoring” and chemical research under 
the OD “Food, Medicines and Consumer 
Safety”. Services such as clinical biology, 
biological standardization and biosafety 
& biotechnology have been brought to-
gether in the OD “Expertise, Services and 
Customer Relations”.
In 2009, each OD was given a new man-
ager and, in line with the conclusions of 
the Jenner Project, a business process re-
engineering project, they each drew up a 
suitable management plan and an organi-
sation chart for their OD. These plans will 
now gradually be put into practice in 2010. 
The following actions were selected as 
overall target objectives for all the ODs in 
the coming years:
Focus on expertise to become a centre of • 
excellence in public health domains. 
achieve equilibrium between routine de-• 
mands and research-oriented incentives 
to fit with the institute’s future innova-
tive research strategy.
Make the best possible use of resources.• 
Keep pace with novel trends.• 
Stimulate cooperation with universities • 
through posts for doctoral research and 
provide incentives to increase product-
ivity of scientists (e.g. promotion matrix).
Increase communication and visibility • 
of activities (image building).
based on the procedures proposed in the 
Jenner Project, the support services for 
the former departments were centralized 
at corporate level and new transversal 
processes rolled out, which also included 
changes to the quality management sys-
tem (ISO 17025, ISO 17020 and ISO 9001). Fur-
thermore, a scientific coordination service 
was also set up to support researchers 
attracting and performing their scientific 
projects, as well as making them more ac-
cessible to their target publics.
This report therefore already provides a 
glimpse of just a few of the WIV-ISP’s key 
scientific achievements of the past two 
years. In the future, these will be increas-
ingly grouped together around a number 
of priority areas and actions.
We hope you will enjoy your reading!
dr Johan e. Peeters
General Director
by the chairman of the board
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introduction by Prof. Dr Herman Van Oyen
Population health and the distribution of health within societies is a dynamic phenomenon. 
Never has the rate of improving population health been as great as during the last century. 
There has been a shift, called the epidemiologic transition, in both causes of mortality and 
causes of morbidity from infectious toward non-infectious diseases and mainly chronic 
diseases. The current phase of the evolution is often called the era of “man-made diseases”. 
This refers to the fact that a substantial part of current population ill-health is a result of 
the way society is organised, the way individuals within society make choices about their 
lifestyles and the healthcare system which contributes to the survival of the sick.  
as there are many determinants which affect status and change in population health, 
including the social environment, physical environment, genetic endowment, healthcare 
system, individual response (biological, lifestyle) etc., understanding the underlying 
mechanisms of population health is essential for determining appropriate, evidence-based 
public policy and action. To achieve a better understanding, it is necessary to initiate new 
research axes such as research into the role of knowledge of the human genome on public 
health, the application of more complex epidemiologic methods allowing research into 
different scenarios, and health outcome research. Moreover, it is becoming increasingly 
important to evaluate systematically through health impact assessments the effects 
of public policies and decisions on population health, such as the initiation of cancer 
screening programmes, vaccination policies, anti-smoking initiatives etc. The complexity 
of chronic diseases calls not only for a strengthening of the interaction between exposure 
measures as determined by laboratory examinations (in food, by way of bio-monitoring) 
and toxicological risk evaluations in order to reach a comprehensive evaluation of the 
population health risk, but it is also important to strengthen the support to the quality 
of available health services through research into health services. This is not just the task 
of the Cancer Centre set up in 2008, but is also addressed in various front-line projects, by 
general practitioners and by focusing on a number of specific target groups such as those 
suffering from diabetes, cystic fibrosis, aIDS and HIV.
Considerable attention is also paid to supporting institutional care, hospitals and nursing 
and care homes, mainly by following up care-associated infections and microorganisms’ 
resistance to antibiotics.
Cooperation with health care workers is therefore very important and has materialised 
in a number of networks, including a general practitioners’ network (celebrating its 30th 
anniversary in 2009) and a laboratories’ network. 
The Public Health and Surveillance Directorate is currently working on a network of 
officially recognised reference laboratories. 
The Public Health and Surveillance Directorate assesses public health risks with a unique 
combination of expertise in epidemiology and biostatistics, chronic diseases, infectious 
Public health and 
Surveillance directorate
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diseases, the relationship between food, the environment and health and toxicology. 
During such risk assessments, the Directorate works closely with international partners 
thanks to the establishment of European institutions on issues such as illegal substances 
and drugs, chemical substances and infectious diseases. 
To counter any acute and/or accidental threats, the Public Health and Surveillance 
Directorate has a 24-hour on-call system providing scientific support to the belgian 
authorities involved.
The Public Health and Surveillance Directorate aims to be a Centre of Excellence for 
epidemiological research and an important player in the network of belgian, European and 
international knowledge centres. Many of the Public Health and Surveillance Directorate’s 
research programmes have therefore been ISO 9001 certified, which allows us to solve 
health problems and offer support and solutions to belgian, European and international 
governments at times of health crises.
To adequately inform the policymakers and population on new evolutions relating to 
health, food chain safety, food and the environment, the Public Health and Surveillance 
Directorate runs a number of programmes and activities that allow us:
To gain an insight into population health and well-being and understand the relationship • 
with the determinants; 
To monitor trends in health status and to organise surveillance systems for a series of • 
diseases and health determinants;  
To evaluate the impact on the population health of specific health determinants such as • 
lifestyle, population interventions and public policies; 
To promote quality of care through health service research;• 
To evaluate toxicological risks;• 
To provide information to help public health actors make decisions;• 
To coordinate public health information in belgium.• 
The Public Health and Surveillance Public Service has two divisions: Epidemiology and 
Toxicology.
The epidemiology division's programmes and activities are:
Quality of care in various healthcare settings;• 
Health inequality;• 
Health and the environment;• 
Surveys: Health Survey 2008;• 
Healthy food;• 
Drugs and illegal substances;• 
Care-associated infections;• 
Infectious diseases in the population;• 
T• he development of health indicators;
T• he Cancer Centre;
C• limate change and health;
P• ublic health genomics;
E• pidemiological support in case of acute public health risks.
The toxicology division's programmes and activities are:
T• oxicology risk analysis and providing toxicological advice via national and international 
expert groups;
R• isk evaluations for new and existing chemicals focusing specifically on pesticides;
T• oxicological evaluations of aromas, additives, contaminants and novel foods;
R• esearch and development projects (for example to optimise and adjust the strategy of 
in vitro studies to predict nanoparticles’ toxicity to humans).
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cardiovascular risk and its treatment 
in belgian secondary care recognised 
diabetes centres
n. debacker
P. Van Crombrugge
F. Nobels
C. Mathieu 
introduction
Glycemic control is no longer the single 
key focus of diabetes treatment. The pre-
vention of cardiovascular risk in diabetes 
and its timely and correct treatment has 
gained in significance over the last dec-
ade. Several studies have shown the im-
portance of multifactorial intervention 
to prevent cardiovascular complications, 
both in primary and secondary prevention 
(1-4). The Steno-2-study in particular has 
shown the importance of a multifactorial 
approach in type 2 diabetes patients pre-
senting microalbuminuria, which is a well-
established marker of increased cardio-
vascular disease risk (1, 2). In these at-risk 
patients with type 2 diabetes, an intensive 
intervention with multiple drug combina-
tions and behaviour modification, had 
sustained beneficial effect with respect to 
vascular complications and on mortality 
rates from any cause and from cardiovas-
cular cause (1, 2).
IQED, the Initiative for Quality improve-
ment and Epidemiology for Diabetes, has 
been organised since 2001 in all belgian 
multidisciplinary secondary care diabetes 
centres that have been recognised by the 
National Institute for Sickness and Inva-
lidity Insurance. It aims at assessing and 
improving the quality of diabetes care by a 
continuous system of audit and feedback 
using benchmarking (5). The latter allows 
the diabetes centres to compare its re-
sults, not only with the recommendations, 
but also with their peers, i.e. other diabetes 
centres. Initially the feedback used in IQED 
focused mainly on the quality indicators 
that are generally used, such as the degree 
to which necessary examinations are car-
ried out (process indicators) and the de-
gree to which treatment goals are attained 
(outcome indicators). Due to the increas-
ing importance of correct cardiovascular 
risk treatment in diabetes, in 2008, we also 
began to use benchmarking to inform cen-
tres on the cardiovascular risk of their pa-
tients on the one hand and their treatment 
on the other hand.
The present paper describes the prevalence 
of cardiovascular risk in type 1 and type 2 
diabetes patients treated in these second-
ary care diabetes centres, the treatment of 
the patients with increased cardiovascular 
risk and the degree to which these patients 
reach their treatment goals with respect to 
lDl-cholesterol and blood pressure.
 
methodS
data collection
During the last quarter of 2007 all diabe-
tes centres (n = 120) collected data from 
at least 10% of their patients (at least 50 
patients included for each centre). Pa-
tients were selected through systematic 
sampling from an alphabetical patient list 
starting from the letter “N”. If the obtained 
sample contained less than 25 type 1 dia-
betes patients, the centre needed to add 
type 1 diabetes patients until the number 
of 25 was reached. Collected data covered 
a wide range of diabetes care aspects (de-
mographics, diabetes type and duration, 
frequency of blood glucose selfmonitor-
ing, hypoglycemic treatment, additional 
treatment, glycemic control (Hba1c), car-
diovascular risk (blood pressure, blood 
lipids, smoking status), anthropometry, 
follow-up examinations and presence of 
micro- and macrovascular complications). 
It concerned retrospective data originat-
ing from the most recent consultation dur-
ing the period of 15 months preceding the 
data collection. 
Patients with a history of at least one of the 
following events or interventions, percuta-
neous transluminal coronary angioplasty 
(PTCa) or coronary artery bypass grafting 
(CabG), myocardial infarction, stroke, tran-
sient ischemic attack, and percutaneous 
transluminal angioplasty (PTa) of the infe-
rior members, were considered as patients 
with a cardiovascular history (Table 1). 
Patients over 40 years of age with micro-
albuminuria or manifest nephropathy 
[(macroalbuminuria or increased creatinin 
(≥ 1.5 mg/dl)], were considered as patients 
with a Steno-2-like-profile (i.e. strongly in-
creased cardiovascular risk as in the Steno-
2-study (Table 1) (1, 2). Finally patients over 
40 years of age with at least one of the fol-
lowing cardiovascular risk factors: obesity, 
antihypertensive treatment, lipid-lowering 
treatment, blood pressure ≥ 140/90 mm 
Hg, lDl-cholesterol ≥ 100 mg/dl, smoking 
frequency > 5 cigarettes a day were consid-
ered as patients with ≥ 1 cardiovascular 
risk factor (Table 1).
Statistical analysis
Data were analysed using Stata 9.2. logisti-
cal regression, adjusting for age, diabetes 
duration and gender, was used to compare 
the proportions between different groups. 
all presented results were weighted for 
centre size. a p-value below 0.05 was con-
sidered statistically significant.
reSultS
The sample consisted of 3,494 type 1 diabe-
tes patients (32%) and 7,382 type 2 diabetes 
patients (68%). Median age and diabetes 
duration were respectively 46 and 17 years 
in type 1 and 68 and 13 years in type 2 dia-
betes. almost all type 1 diabetes patients 
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(94%) were treated with at least 3 daily in-
sulin injections, while this was 41% in type 
2 diabetes. Median Hba1c was 7.8% in type 
1 and 7.4% in type 2 diabetes.
In this population of patients treated in 
secondary care diabetes centres 11% of 
type 1 and 33% of type 2 diabetes patients 
presented with a cardiovascular history. 
Next, 10% of type 1 and 20% of type 2 dia-
betes patients had a Steno-2-like profile. Fi-
nally 34% of type 1 and 43% of type 2 diabe-
tes patients were over 40 years of age and 
presented at least one cardiovascular risk 
factor. The proportion of patients “with-
out cardiovascular risk” as defined by the 
present study reached 45% in type 1 and 
4% in type 2 diabetes. 
Table 2 shows the treatment for the differ-
ent cardiovascular risk groups.
Of the patients with a 1. cardiovascular 
history, about 90% were treated with 
antihypertensive drugs and about as 
much with antiplatelets. about three 
quarters received a lipid-lowering treat-
ment. almost all patients with a cardio-
vascular history (98%) were treated with 
at least one of these 3 types of drugs. 
Of the patients with a Steno-2-like pro-2. 
file, 87% were treated with antihyperten-
sive drugs. Treatment with antiplatelets 
and lipid-lowering drugs was seen in 
60% of the patients. almost all patients 
with a Steno-2-like profile (95%) were 
treated with at least one of these 3 types 
of drugs. 
Of the patients 3. older than 40 years with 
at least one cardiovascular risk factor, 
71% were treated with antihypertensive 
drugs, 58% with lipid-lowering drugs and 
51% with antiplatelets. Eighty eight per-
cent were treated with at least one of 
these 3 types of drugs. 
cardiovascular risk category definition
Cardiovascular history Myocardial infarction and/or coronary surgery (PTCa/CabG) and/or stroke and/or transient 
ischemic attack and/or PTa of the inferior members
Steno-2-like-profile Over 40 years of age with microalbuminuria or manifest nephropathy [macroalbuminuria or 
increased creatinin (≥ 1.5 mg/dl)]
≥ 1 cardiovascular risk factor Over 40 years of age with at least one of the following cardiovascular risk factors: obesity, 
antihypertensive treatment, lipid-lowering treatment, blood pressure ≥ 140/90 mm Hg, lDl-
cholesterol ≥ 100 mg/dl, smoking frequency > 5 cigarettes a day
table 1:  definition of the cardiovascular risk.
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as cardiovascular risk lowered, the propor-
tion of treated patients decreased signifi-
cantly, except for the lipid-lowering treat-
ment, where no difference was observed 
between the group with a Steno-2-like pro-
file and the group over 40 years of age with 
at least one cardiovascular risk factor. 
Treatment was significantly higher among 
type 2 than among type 1 diabetes patients. 
However, treatment with antiplatelets and 
lipid-lowering drugs was more or less equal 
among type 1 and type 2 diabetes patients 
in the group with a cardiovascular history. 
In the group “without cardiovascular risk”, 
treatment with lipid-lowering and anti-
hypertensive drugs was also more or less 
equal among type 1 and type 2 diabetes 
patients.
ldl-cholesterol results
In total, we observed 60% of the patients 
with an lDl-cholesterol below 100 mg/dl 
(55% of type 1 and 61% of type 2 diabetes 
patients). among type 1 diabetes patients, 
the proportion of patients reaching this 
goal was significantly higher among the 
patients with a cardiovascular history 
(61%) than in the 2 groups with a lower 
cardiovascular risk (44% among patients 
with a Steno-2-like profile and 47% among 
the patients over 40 years with ≥ 1 cardio-
vascular risk factor). This difference was 
also observed in type 2 diabetes, but it was 
only significant between the group with a 
cardiovascular history and the group old-
er than 40 years with ≥ 1 cardiovascular 
risk factor (66% versus 57% respectively). 
among each different cardiovascular risk 
group, the proportion of patients reach-
ing the lDl goal was significantly higher 
among type 2 than among type 1 diabetes 
patients. Generally we observed a higher 
proportion of patients reaching the tar-
get among those receiving lipid-lowering 
drugs than among those without this treat-
ment. One exception is observed among 
type 1 diabetes patients with a Steno-2-like 
profile, where the proportion of patients 
reaching the lDl target was similar in both 
the treated and non-treated groups.
blood pressure results
In total, 23% of the patients presented 
with blood pressure below 130/80 mm Hg 
(33% of type 1 and 20% of type 2 diabetes 
patients). The number of patients reaching 
this goal was significantly higher in the 
group “without cardiovascular risk” than 
in the 3 risk groups. In type 2 diabetes, the 
proportion of patients reaching the blood 
pressure target was significantly higher 
among patients with a cardiovascular 
history than in the two other risk groups. 
In type 1 diabetes, no difference was ob-
served between the 3 different risk groups. 
The proportion of patients reaching blood 
pressure targets was significantly higher 
among type 1 than among type 2 diabe-
tes patients, except for the group with a 
cardiovascular history and the group “with-
out cardiovascular risk”, where the propor-
tions were comparable. both in type 1 and 
type 2 diabetes patients, the group treated 
with blood pressure-lowering drugs was 
less likely to reach the blood pressure 
target than the group without treatment 
(respectively 23% versus 40% in type 1 and 
19% versus 24% in type 2 diabetes).
cardiovascular history Steno-2-like profile > 40 yrs and ≥ 1 cv risk factor no cardiovascular risk
n (%) n (%) n (%) n (%)
antiplatelets
Total 2,447 (89) 1,040 (60) 2,107 (51) 150 (9)
Type 1 305 (88) 146 (46) 434 (38) 97 (7)
Type 2 2,142 (89) 894 (62) 1,673 (54) 53 (20)
lipid-lowering drugs
Total 2,074 (76) 1,039 (60) 2,436 (58) 161 (9)
Type 1 261 (73) 158 (48) 564 (48) 132 (8)
Type 2 1,813 (76) 881 (61) 1,872 (60) 29 (12)
antihypertensive drugs
Total 2,514 (92) 1,525 (87) 3,014 (71) 192 (11)
Type 1 303 (85) 247 (75) 619 (51) 164 (12)
Type 2 2,211 (93) 1,278 (89) 2,395 (77) 28 (11)
≥ 1 of these drugs
Total 2,734 (98) 1,687 (95) 3,782 (88) 392 (23)
Type 1 351 (97) 287 (85) 904 (76) 306 (21)
Type 2 2,383 (98) 1,400 (96) 2,878 (91) 86 (33)
table 2: Proportion of treated patients by cardiovascular risk (number and weighted proportion) – total and per diabetes type.
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Since the start of iQed, the quality of care has improved mainly regarding 
process and, to a lesser extent, outcome. although it is impossible to at-
tribute these changes to iQed alone, the monitoring aspect as such is im-
portant in the diabetes care setting.
i m P a c t  o n  P u b l i c  h e a l t h
concluSion
Cardiovascular risk in these diabetes pa-
tients treated in secondary care diabetes 
centres is considerable. as expected, the 
cardiovascular risk profile is higher among 
type 2 diabetes patients than among type 
1 diabetes patients. Given that the stud-
ied population concerns insulin treated 
patients only (≥ 2 daily insulin injections), 
these results are not representative for the 
entire belgian diabetes population, but 
they can be considered representative for 
the adult type 1 diabetes patients and for 
the insulin treated (≥ 2 inj./day) type 2 dia-
betes patients. 
The present results have shown that 
recommendations on treatment of pa-
tients with cardiovascular history and 
of patients with a Steno-2-like profile are 
closely followed. although recent guide-
lines and several studies indicate the im-
portance of multifactorial treatment of 
patients with a strongly increased cardio-
vascular risk (1, 2, 6), it is difficult to reach 
100% treatment, because patients may 
have contra-indications or may suffer un-
pleasant side effects to drugs. Indeed, no 
studies regarding secondary cardiovascu-
lar prevention show maximum treatment. 
Compared to international studies, the 
present belgian results are comparable or 
even better (7-12).
although patients were adequately treat-
ed, the results show that it remains diffi-
cult to reach treatment goals, particularly 
for blood pressure. However, without the 
information on treatment duration and 
dose and individual follow-up, it is difficult 
to assess the treatment effect. 
So although the observed results are posi-
tive compared to other health care set-
tings, there remains room for improvement 
(5). by using feedback that is specifically 
directed towards cardiovascular risk and 
its treatment, we aim to bring this to the 
attention of the diabetes teams, because 
due to high morbidity and mortality of car-
diovascular complications, it is of utmost 
importance to screen for these risk factors 
and to act in a timely and correct manner, 
for both type 1 and type 2 diabetes.
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compliance and use of alcohol based 
hand rubs after three national hand  
hygiene campaigns in belgian hospitals
e. leens
J. antoine
M. Costers
a. Simon
and the national working 
group for hand hygiene
introduction
The use of an alcoholic solution for hand 
hygiene is the most important measure in 
preventing the transfer of microorganisms 
between patients, health care workers 
(HCW) and hospital surroundings (1). Un-
fortunately we see that compliance with 
hand hygiene recommendations among 
health workers is generally lacking (2, 3). 
as one approach to health improvement, 
there is a considerable body of evidence to 
support campaigning on health-related be-
haviours (4). Moreover, it is found in several 
studies that this kind of campaign needs 
to be repeated at regular intervals (5-7). In 
this article we firstly would like to describe 
the evolution of the results of three na-
tional campaigns to improve hand hygiene 
practices in belgian hospitals over the last 
five years. The second aim is to evaluate 
the short term and long term impact on 
adherence to hand hygiene guidelines and 
on the consumption of alcohol based hand 
rubs as a result of these campaigns. 
 
methodoloGy
In 2005, 2006-2007 and 2008-2009, a multi-
disciplinary working group with represent-
atives of the Federal Public Service Health, 
Food Safety and Environment, the belgian 
antibiotic Policy Coordination Committee, 
the Federal Platform for Hospital Hygiene, 
the Institute of Public Health, the asso-
ciation belge pour l’Hygiène Hospitalière, 
the belgian Infection Control Society and 
the Nationale Vereniging van Katholieke 
Vlaamse Verpleegkundigen, organised a 
national campaign to promote hand hy-
giene in hospitals under the name “You 
are in good hands”. These campaigns were 
financially, logistically, and politically sup-
ported by the Ministry of Public Health. 
acute care and chronic care hospitals were 
invited to participate on a voluntary ba-
sis. For the second and third campaigns, 
participation was extended to psychiatric 
hospitals.
The national campaigns addressed both 
HCW and hospitalised patients. The cam-
paign was organised into two parts: (a) the 
actual awareness campaign of HCW and 
patients by the provided material, and (b) 
an impact assessment pre- and post-cam-
paign. For the latter, four variables were ex-
amined: (i) the hand hygiene compliance of 
HCW by direct observation; (ii) the alcohol 
consumption and (iii) the compliance with 
the ground rules for good hand hygiene 
(optional). 
The awareness part consisted of a wide 
range of campaign material inspired by 
several sources (3, 8, 9): posters highlight-
ing five hand hygiene indications, the right 
use of hand alcohol and gloves, stand-
ardised training sessions for HCW, a web-
based quiz, an information leaflet with 
gadget for the patient, and an information 
leaflet for HCW. 
Measuring the degree of hand hygiene 
compliance by observation (= percentage 
of observed hand hygiene with soap and/
or hand alcohol divided by the number of 
observed hand hygiene opportunities) was 
carried out by the staff of the hospital hy-
giene team. The measurements were col-
lected through a standardised observation 
grid with a minimum of 150 observations 
per unit and included at least the intensive 
care unit. For each hand hygiene opportu-
nity, the observer recorded whether hand 
hygiene measures were taken: decontami-
nation with alcohol, washing with water 
with or without soap, or no action. The 
data were then entered into NSIHwin4.08 
(software on a MS access database) and 
sent back for analysis and feedback to the 
Institute of Public Health. Feedback to the 
HCW was considered to be a substantial 
part of the awareness.
all data were processed and analysed 
using Stata 9.2. Institutional results were 
returned to the hospital with 95% con-
fidence intervals, individual percentiles 
(position of the hospital in the national 
distribution), national results, and indica-
tors stratified by professional group and 
hospital unit. National results were given 
as weighted mean, thus adjusting for vary-
ing numbers of observations between 
hospitals. One-way analysis of variance 
or Kruskall-wallis tests were performed 
where appropriate. 
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Participation
The number of hospital sites participating 
is shown in Table 1. Some hospitals did not 
send data concerning post-campaign ob-
servations. 
compliance
• General evolution
a total of 594,150 opportunities for hand 
hygiene were observed during the three 
campaigns (317,232 pre- and 276,918 post-
campaign). Figure 1 shows the evolution of 
compliance rates pre- and post-campaign 
for the 3 campaigns for all HCW (“General”) 
and stratified by professional category. 
The overall compliance increased af-
ter each campaign: from 49.6% to 68.6% 
(p < 0.05), from 53.2% to 69.5% (p < 0.05) and 
from 58.0% to 69.0% (p < 0.05) after the first, 
second and third campaigns, respectively. 
This indicates a positive short term impact 
of each campaign. However, differences be-
tween pre- and post-campaign compliance 
rates tended to decrease (19.0%, 16.3% and 
11.0% respectively for the first, second and 
third campaign). This can be explained by 
the fact that post-campaign compliance 
seemed to reach a maximum limit of 70%. 
by contrast the increase of pre-campaign 
compliance rates over time was significant 
(p < 0.05). This evolution indicates a posi-
tive long term impact of successive cam-
paigns.
• by hospital type
The same positive short and long term evo-
lution of compliance rates was observed 
by hospital type (acute, chronic and psy-
chiatric hospitals). In psychiatric hospi-
tals pre-campaign compliance rates were 
low during the second campaign (45.2%), 
although they rapidly increased (+21.7%) 
reaching post-campaign compliance rates 
similar to other hospital types (66.9% and 
64.6% for the second and third campaigns, 
respectively).
• by profession
The compliance rates by profession were 
evolving in a similar way. as stated in the 
literature, nurses had the best final results 
(73.2% post-campaign) whereas medical 
doctors had lower levels of final com-
pliance rates (54.1%) and the campaign 
seemed to have a smaller effect on their 
hand hygiene practices (+16.5%, +12.2%, 
+8.3%) compared to the other professional 
categories. Nurse’s aids improved their 
compliance rates especially during the 
first campaign (+22.9%) and reached 68.3% 
at the end of the third campaign.
• by indication
If we considered the compliance rates by 
type of contact, we noticed that efforts 
should be made on contacts protecting 
patients. Indeed compliance rates be-
fore a contact with patients and before a 
personal/invasive action were the lowest 
(56.8% and 60.0%, respectively, at the end 
of the third campaign), whereas compli-
ance rates after the third campaign for af-
ter contact with patient and after biologi-
cal liquids exposure were 76.6% and 78.8%, 
respectively.
use of hydro-alcoholic hand rubs
The campaign promoted the use of alcohol-
based hand rub to disinfect hands. Results 
showed that the proportion of hydro-alco-
holic hand rub used increased after each 
campaign: from 65.3% to 76.4%, from 67.6% 
to 76.1% and from 73.1% to 77.7% after the 
first, second and third campaigns, respec-
tively. a significant long-term increase 
of hydro-alcoholic hand rub was noticed 
(p =  0.002).
concluSionS
The three multifaceted campaigns were 
successful, not only in terms of partici-
pation rate, but also in terms of results. 
The number of participating hospitals re-
mained very high during the consecutive 
campaigns despite the high work load that 
goes hand in hand with the organisation of 
this kind of campaign. We saw an improve-
ment in compliance when comparing the 
results within the same phase of all three 
campaigns. However, we observed a drop 
in compliance at the beginning of each 
new campaign compared to the compli-
ance of the post-campaign measurements 
from the last previous campaign. This is a 
known phenomenon (10) and indicates the 
importance of repeating campaigns such 
as this one in order to achieve a long-last-
ing result. Therefore, the working group 
plans to repeat these national campaigns 
every two years from now on with a fourth 
campaign already scheduled for Novem-
ber 2010.
The use of alcohol-based hand rubs seems 
to have achieved a maximum score after 
the third campaign. The message seemed 
to be accepted and the resistance against 
the use of alcohol-based solutions con-
quered. 
hospital type
campaign 2005 campaign 2006-2007 campaign 2008-2009
before after before after before after
acute hospital sites 143 124 143 128 135 121
Chronic hospital sites 5 3 3 3 5 4
Psychiatric hospital sites 0 0 32 27 26 20
total 148 127 178 158 166 145
table 1:  number of hospitals types participating before or after the 3 national hand hygiene campaigns in belgium, 2005-2009.
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Despite the general results of compliance 
and alcohol-based hand rub use being very 
good, a more detailed look shows possible 
tracks for future campaigns. 
although compliance rates increased for 
all types of HCW, it was remarkable that 
compliance was clearly lower among phy-
sicians than among other HCWs. This con-
firms reports of other authors (6, 7, 11-15), 
but the study by Salemi et al. (12) clearly 
showed that improvement of hand hy-
giene compliance among physicians is fea-
sible. Influencing the compliance amongst 
physicians could have an effect on the 
compliance among other HCW and could 
even increase the overall compliance post- 
campaign. The working group is already 
brainstorming on interventions that spe-
cifically target physicians in the next cam-
paign. Furthermore, compliance increased 
for all indications but was clearly higher 
figure 1: evolution of the general hand hygiene compliance and the compliance by professional category, pre- and post-campaign in belgium, 2005-2009.
after than before patient contact. This ob-
servation has also been reported by other 
authors (6, 7, 14-16). apparently, HCW are 
more inclined to protect themselves than 
to protect their patients.
as most of the studies in this research 
field, our study had several limitations (10, 
17). Firstly, we used an uncontrolled before 
and after design because we wanted to 
implement the campaign in a maximum 
number of institutions (no control group 
at the hospital level) and to limit the work-
load of the IC teams, inclusion of control 
units was not required (no control group at 
the hospital unit level). Secondly, although 
direct observation is considered to be the 
most appropriate method for measuring 
hand hygiene compliance rates (3), it still 
has several drawbacks including the ‘Haw-
thorne effect’ concerns with inter-observer 
reliability, and the fact that it only repre-
sents a sample of all hand hygiene oppor-
tunities (18, 19). Thirdly, rates of healthcare 
associated infections were not evaluated 
but the linking of our data with data from 
the national surveillance of nosocomial 
infections remains a possible future op-
tion. Finally, hand hygiene technique was 
not used as an outcome measure since 
standardised evaluation of this qualitative 
measure is extremely difficult, especially 
when so many observers are involved (19).
On the other hand, our study has several 
unique strengths. Until recently, national 
hand hygiene improvement programs in 
health-care settings were not widely or-
ganised (3). In 2005, belgium was one of 
the first countries organising an interven-
tion to improve hand hygiene on such a 
large countrywide scale, with a grand total 
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acKnoWledGmentS
hand hygiene is the key factor in preventing the spread of microorganisms 
in hospitals causing healthcare-associated infections (hais). each year 
107,500 patients hospitalised in belgian acute care hospitals suffer from 
hais, resulting in 2,500 to 3,000 deaths, and generating excess costs of at 
least 116 million euros.
i m P a c t  o n  P u b l i c  h e a l t h
of 594,150 opportunities observed over a 
5-year period. Furthermore, the scope was 
unprecedented with inclusion of acute 
care, chronic care and psychiatric hospi-
tals and observation of all types of HCW on 
a broad range of different hospital units. 
Furthermore, we also provide data after 20 
and 40 months of follow-up, and since our 
efforts are ongoing we are able to evaluate 
the long-term sustainability of our results. 
We conclude that countrywide campaigns 
to promote hand hygiene are feasible and 
can have positive results. However, such 
campaigns need to be repeated regularly 
to obtain lasting effects. 
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the cytome test as an instrument in 
human biomonitoring and genetic 
toxicity testing a. maes
r. anthonissen
l. verschaeve 
introduction
Human biomonitoring has been defined as 
“monitoring activities in human beings, us-
ing biomarkers that focus on environmen-
tal exposures, diseases and/or disorders 
and genetic susceptibility, and their poten-
tial relationships”. It is an effective tool to 
assess human exposure to environmental 
pollutants and potential health effects 
of such pollutants and it is an essential 
element in a strategy aiming to integrate 
health and environment. biomarker data 
are considered more relevant for risk as-
sessment than extrapolations from chemi-
cal concentrations in soil, water, air or 
food. Human biomonitoring may involve 
the measurement of chemicals in human 
tissues for assessing people’s exposure to 
pollution (1) but also the cytogenetic sur-
vey of subjects which consists of determin-
ing the frequency of, for example, chromo-
somal aberrations in white blood cells of 
people from a test population compared to 
control subjects. assessing chromosomal 
damage in cells from an “exposed popula-
tion” has proved to be useful in biological 
dosimetry for dose assessment following 
ionising radiation exposure [e.g.(2, 3)] and 
in the prediction of cancer risk within a 
population (4-6). The same holds true for 
the so-called micronucleus assay which 
detects micronuclei in cells that reflect the 
presence of structural and/or numerical 
chromosome aberrations (7). looking at ge-
netic damage in cells from a study popula-
tion is therefore considered an important 
tool in biomonitoring studies, which can 
be used as a biomarker of exposure as well 
as a biomarker of effect [see also (8)]. Per-
forming chromosome aberration studies is 
labour intensive and time consuming and 
that is why the micronucleus test, which al-
lows a faster evaluation, is often preferred. 
It is used regularly in human biomonitor-
ing studies, e.g. on pesticide workers (9), 
subjects exposed to radiofrequency ra-
diation (10), tannery workers (11) and many 
other occupationally or environmentally 
exposed subjects [e.g.(12, 13)]. a couple of 
years ago, an extension of the ‘classical’ 
micronucleus test was presented, which is 
now known as the cytome assay (14-16). In 
this assay, not only the frequency of cells 
with micronuclei are scored but also other 
morphological features that allow a better 
insight into (genetic) effects of pollutants 
and their mode of action. It is thought that 
this cytome assay can be very useful in 
human biomonitoring studies. So far this 
test has already been applied in research 
on alzheimer’s disease (17), the interactive 
effect of alcohol and folic acid on genome 
stability (18), the identification of lung can-
cer cases amongst smokers (19), effects of 
food supplements on biomarkers of cancer 
risk, oxidative stress and immune function 
(20) and radiation biodosimetry (21). 
because of the anticipated importance of 
the cytome assay in future biomonitoring 
studies and genetic toxicity testing, we 
considered it worthwhile to introduce this 
test in our laboratory and to evaluate its 
applicability in determining mechanisms 
by which environmental mutagens induce 
genetic effects. 
 
20 WIV-ISP SCIENTIFIC REPORT 2008 | 2009
Public health and Surveillance directorate
materialS and methodS
We investigated different chemicals with 
different modes of action in the cytome 
assay. For this, C3a cells were exposed to 
subtoxic doses of the chemical for a pe-
riod of 24 hours according to the protocol 
of Fenech (15). Doses were determined 
following a preliminary toxicity evalua-
tion using the neutral red uptake test. C3a 
cells are derived from the human HepG2 
hepatoma cell line which has already been 
used for several years in in vitro toxicity 
studies. C3a cells have conserved both 
phase I and phase II metabolic capacities 
and are therefore to be preferred over the 
HepG2 cells that have partially lost their 
metabolising power, or other cell lines that 
have often completely lost their metabolic 
potency. Cells were blocked in their (binu-
cleated) telophase stage of cell division, 
fixed and spread onto microscope slides. 
after staining, 2,000 cells were investigated 
using a normal transmitted light micro-
scope for the presence of micronuclei, nu-
clear buds (indicating gene amplification), 
nuclear bridges (dicentric chromosomes), 
apoptosis, necrosis and cell division dis-
turbances (non disjunction or centrosome 
abnormalities) as indicated in Figure 1. as 
micronuclei (due to chromosome breakage 
or chromosome loss) are formed at cell di-
vision, we should investigate dividing cells 
only; this is why binucleated telophase 
cells are studied. Non disjunction (= abnor-
mal cell division) results in daughter nuclei 
with an abnormal chromosome number; 
the distinction can eventually be made 
test compound mechanism of action cells with 
micronuclei
(/1,000)
cells with 
nuclear bridge 
(/1,000)
cells with 
bud(s)
(/1,000)
complex 
alterations
(/1,000)
Negative control - 6.0 0.5 1.5 0.5
D-mannitol (5 mg/ml) - 4.5 1.5 5.0 0.0
Colcemid (0.01 µg/ml)
Colcemid (0.025 µg/ml)
aneugen 23.5
27.5
2.0
1.0
5.5
12.5
0.5
1.0
CdCl2 (73 µg/ml)
CdCl2 (183.5 µg/ml)
Clastogen 18.0
22.2
6.0
11.1
13.5
44.4
1.5
20.0
Chloramphenicol (250 g/ml)
Chloramphenicol (625 g/ml)
antimicrobial agent and 
enzyme inhibitor
22.5
27.0
6.5
15.0
15.5
40.0
2.0
13.0
table 1:  results of the micronucleus/cytome assay for a few selected chemicals. results are given per 1,000 analysed cells.
using particular probes (not done here). 
Structural chromosome rearrangements 
such as dicentric chromosomes form 
bridges between both daughter nuclei 
whereas gene amplification (presence of 
multiple copies of a gene) is visualised by 
‘nuclear buds’ (the nucleus is trying to ex-
pel the supernumerary DNa content). Cen-
trosomes are organelles that serve as cell 
division organising centres responsible for 
the distribution of daughter chromosomes 
over two daughter nuclei. abnormalities in 
centrosomes result in an abnormal chro-
mosome distribution and hence in an ab-
normal number of daughter nuclei. 
apoptosis (programmed cell death) and 
necrosis (cell death) were not particularly 
induced by the subtoxic doses that we ap-
plied and are therefore not discussed here. 
The same holds true for the cell prolifera-
tion rate that was also studied for addi-
tional toxicity evaluation. Due to the ab-
sence of any sign of toxicity, results of this 
investigation will not be presented here.
figure 1: 
different types of genetic events that can be visualised in the micronucleus/cytome assay 
with the aid of a light microscope.
Genotoxic
event
apoptosis
necrosis
centrosome
abnormalityGene
amplification
chromosome
breakage
and lossdicentric
chromosome
G0
G1 , S , G2
non-
disjunction*
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Table 1 and Figure 2 give an example of 
the main results found in 5 of the inves-
tigated chemicals, including a negative 
(unexposed) control. It can be seen that 
the frequency of micronucleated cells in 
unexposed C3a cells is 6/1000 (0.6%) which 
is in accordance with literature data and 
our own historical control values. There 
were, as expected, only a few cells with 
other aberrations. D-mannitol is known 
to be non-mutagenic and therefore the re-
sults should be comparable to those of the 
negative control. This was indeed the case, 
although there were somewhat more cells 
with nuclear buds. It is not clear so far if 
this is artefactual or meaningful. 
Colcemide is a mitotic spindle inhibitor and 
therefore a well known aneugen (= com-
pound inducing numerical chromosome 
aberrations). as micronuclei reflect struc-
tural as well as numerical chromosome 
aberrations, we expect increased micro-
figure 2: 
Some examples of characteristic cell alterations indicating particular types of genetic effects as shown in the micronucleus/cytome assay: 
a) cell with small micronucleus (clastogenic effect); b) cell with large micronucleus (aneugenic effect); 
c) cell with nuclear bridge; d) cell with nuclear bud; e) apoptotic cell; f) cell with complex alteration (multiple buds?). 
a) b) c)
d) e) f)
nucleus frequencies with this compound. 
Such micronuclei contain predominantly 
whole chromosomes and therefore the mi-
cronuclei are larger than those that are in-
duced by clastogens (= chromosome break-
ing agents). although we did not measure 
micronucleus diameters or assessed aneu-
ploidy using other methods (Fluorescence 
In Situ Hybridisation) we indeed undoubt-
edly found many more larger micronuclei 
than with the other treatments (Figure 2b). 
Our results are therefore in accordance 
with our expectations. There were also 
somewhat more buds compared to the 
controls but it is not clear whether this in-
creased gene amplification is related to the 
aneugenic nature of the compound. CdCl2 
is a known clastogen and this is confirmed 
by the larger number of small micronucle-
ated cells compared to the control cultures 
(Figure 2a). The presence of nuclear bridges 
indicates that, whereas most chromosome 
aberrations were chromatid type aberra-
tions, some chromosome type aberrations 
(dicentric chromosomes and/or transloca-
tions) were also induced in this unsynchro-
nised cell line where exposures may have 
been over more than one cell cycle. There 
were quite a lot of nuclear buds indicating 
that this compound is an inducer of gene 
amplification as well. 
Chloramphenicol was shown to induce 
micronuclei as well as nuclear bridges and 
this is also in accordance with the litera-
ture. It was indeed shown that this widely 
used antimicrobial agent appears to cause 
chromosomal effects in somatic cells al-
though it does not induce other genetic 
effects (22). as for CdCl2 this compound is 
also an important inducer of gene ampli-
fication as indicated by the high number 
of nuclear buds. There were also many 
complex buds and alterations with a de-
gree of complexity far above that of other 
compounds (Figure 2f). The significance of 
this is not clear at the present time but it 
is certainly worthwhile further investi-
gating this compound and its mechanisms 
of action.
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the micronucleus test is generally considered to be a very valuable tool 
in human biomonitoring studies. extension of this test into the “cytome 
assay” provides an interesting tool to add information on working mecha-
nisms of environmental genotoxicants and may increase the predictivity of 
diseases such as cancer.
i m P a c t  o n  P u b l i c  h e a l t h
The above results only give a few examples 
that were obtained with a range of chemi-
cals. In all cases, the results were in accord-
ance with their known mode of action.
concluSion
This investigation showed that agents 
with known properties regarding their 
genotoxic potency (or absence of geno-
toxicity) do show the expected response in 
the micronucleus/cytome assay. Some of 
these agents furthermore seem to induce 
gene amplification and sometimes exhibit 
complex aberrations that are less expected 
and merit further attention. The cytome 
assay proved to be suitable as a tool to 
investigate genetic effects of environmen-
tal agents and to provide insight in their 
working mechanisms. It is anticipated that 
this assay will also be useful in human bio- 
monitoring studies. For example, prelimi-
nary results indicate that nuclear bridges 
might be a better predictor for cancer risk 
in a human population than the frequency 
of micronucleated cells or structural chro-
mosome aberrations (Fenech, personal 
communication). 
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eco-, geno- and human toxicology of 
bio-active nanoparticles for biomedical 
applications
P. troisfontaines
r. anthonissen
introduction
Nanoparticles have attracted huge inter-
est in recent decades covering a wide vari-
ety of applications and industries. One re-
search field, in which these particles have 
been widely applied and studied, is the 
field of biomedical applications. One of the 
main advantages of nanoparticles within 
this field includes their very limited size: 
nanoparticles are typically smaller than 
100 nm and can thus be easily taken up by 
cells. This opens up a huge range of inter-
esting applications including the develop-
ment of drug and gene delivery systems. 
Gene delivery has become an increasingly 
important strategy for treating a variety of 
human diseases. To avoid the difficulties 
of using viral carriers, non-viral gene de-
livery nanoparticles are being developed. 
The polyethylene imine (PEI) is considered 
to be one of the most effective polymer 
based solutions. PEI have been used for 
delivering DNa into various cell lines and 
in vivo applications (1-4, 5-7). PEI was, for 
example, successfully used as a carrier for 
the delivery in a tumour of the suicidal thy-
midine kinase gene, and the subsequent 
suppression of the tumour (8). Polymer-
based gene delivery systems provide 
unlimited DNa packaging capacity with 
well-defined physico-chemical properties. 
The interaction of the positively charged 
polymer backbone and negatively charged 
DNa leads to the spontaneous formation 
of nano-size complexes of polymer:DNa 
(polyplexes) in aqueous milieu (9, 10). Nev-
ertheless, an important concern with PEI is 
its significant cytotoxicity (11, 12). The tox-
icity observed immediately after transfec-
tion is due to the membrane destabilising 
activity of free PEI which can constitute 
an important part of the PEI:DNa mixture 
after the complexation (13), while the de-
layed cell death observed after transfec-
tion may be the result of the perturbation 
of nuclear function by PEI molecules that 
reached the nucleus. Therefore some alter-
native polymers have been investigated, 
such as PDMaEMa. These methacrylate 
polymers have excellent biocompatibility; 
they have been therefore used for medical 
purposes, such as contact lenses and artifi-
cial organs (14-16).
In this paper, we present the cytotoxic 
properties of two polymers (PEI and PD-
MaEMa) and their polyplexes (DNa covered 
nanoparticles) on human hepatocytes. The 
results obtained demonstrate the neces-
sity to use a large variety of different tests 
for a comprehensive risk assessment.
material and methodS
cell culture
We used HepG2 hepatocytes (ECaCC cat n° 
85011430) from passage 5 to 15. The cells 
were grown in DMEM (Gibco), 10% FbS. 
The cells were tested in 96-well plates 
(6.4x104 cells/well for NRU delayed tests, 
4x104 cells for acute cytotox tests, 8x104 
cells/well for ROS tests) or 24-well plates 
(4x105 cells /well for the Il-8 secretion) 24 
hours after seeding the plates.
dna, polymers and polyplexes
The PEI and PDMaEMa were kept at -20°C in 
1 ml aliquots of 10 mg/ml, thawed and di-
luted when required. The polymer solutions 
were sterilized by filtration (Millex – GS, 
0.22 µm filters units, Milipore) and a loss of 
4.3% was taken in account.
The polyplexes with different charge ra-
tios (2 (+) for 1 (-) [2:1] and 4 (+) for 1 (-) [4:1]) 
were prepared in sterile deionised water 
with a final concentration of DNa of 40 
µg/ml. The charge ratio of the polyplexes 
is determined by the polymer/DNa ratio. 5 
µl, 10 µl, 15 µl of the polyplex preparation 
were added to the test plate 30 minutes 
after the complexation. The DNa used is a 
calf thymus extract (Fluka). It was precipi-
tated with ethanol and then resuspended 
in sterile water, a stock solution of 0.1 mg/
ml was used.
cell viability
The CbQCa assay assesses the survival/vi-
ability and is based on the capacity of the 
cells to incorporate and bind a fluorescent 
dye (aTTO-TaG CbQCa, MolecularProbes) to 
the protein amines. Each condition was 
tested in 7 wells and repeated 3 times. 
NRU acute and delayed cytotoxicity test: 
the cells were treated for 24 hours with 
the tested nanoparticles. The cytotoxicity 
is assessed from the uptake of neutral red 
and the results quantified by the NI50 (the 
concentration of nanoparticles required 
to reduce the neutral red uptake [NRU] 
by 50%). In the case of delayed tests, the 
culture is maintained for 5 more days in 
normal growth medium after one washing 
step. Each condition was tested in 7 wells 
and repeated 3 times.
reactive oxygen species production
The ROS production was evaluated with 
the fluorescent molecule dichlorofluor-
oscein diacetate (H2-DCFDa, Molecular 
probes), which become fluorescent upon 
cleavage by intracellular esterase in oxida-
tive conditions. The ROS production was 
evaluated after 1 hour or 4 hours of exposi-
tion to the materials in 8 wells of a 96-well 
plate/condition and the experiment was 
repeated three times.
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Pro-inflammatory response
The secretion of Il-8 was evaluated with 
the anti HU Il-8 EaSIa kit from biosource. 
100 µl of supernatant from a 24-hour cul-
ture was used for the test. Each condition 
and the controls were tested in duplicate 
and repeated twice.
reSultS
We worked with HepG2. These cells, isolated 
from a hepatocellular carcinoma (17), are 
easy to manipulate and commonly used in 
in vitro pharmaco-toxicity assays. The liver 
is the main site for biotransformation and 
defence against the xenobiotics. It has al-
ready been shown that nanoparticles (PEG 
coated quantum dots, polystyrene beads, 
metallo-fullerene) can translocate from 
the circulatory system to the liver (18, 19).
cell viability
Preliminary shallow testing was per-
formed in order to gain an idea of the con-
centrations and exposure time to use. The 
concentration ranges and the charge ratio 
tested were determined to avoid precipita-
tion of the nanopolyplexes.
Using CbQCa to monitor the decrease in 
cell viability after 24 hours of contact with 
increasing concentrations of polymers, 
we obtained with the PDMaEMa exposi-
tion a curve that was quite irregular (not 
shown here). This unusual figure showed 
that there are interactions between the 
polymer and the test system. It seems that 
CbQCa reacts quantitatively with the free 
amines of the proteins; it is probable that 
the positively charged PDMaEMa interacts 
with CbQCa and disturbs the test. On the 
other hand, the acute NRU assays showed 
a steady decrease of cell viability with the 
increasing concentration of polymers. The 
calculated NI50 were close to the ones de-
termined during the shallow testing: PEI 
had a NI50 of 28 µg/ml after 24 hours of ex-
position with HepG2 cells, and PDMaEMa 
had a NI50 of 33 µg/ml after 24 hours of ex-
position with HepG2 cells.
Given the perturbations of the test ob-
served with the CbQCa, the cytotoxicity 
of the polyplexes with a charge ratio of 
2:1 and 4:1 was tested only with NRU. We 
observed a decrease of 20% of the HepG2 
cell viability when the cells were in contact 
with the highest amount of 4:1 PEI:DNa 
polyplexes, but also when the cells were 
in contact with 15 µl of a solution with 
the same amount of polymers than the 
amount used to prepare the 4:1 polyplexes. 
although the 4:1 PEI:DNa polyplexes har-
bours fewer charges than the PEI alone, it 
induces the same cell mortality in these 
test conditions.
With the NRU delayed tests, we observed 
that, after 5 days, the effect of 24 hours 
exposition to the polymers is quite strong 
(Figure 1). The delayed NI50 of PEI is at 7 µg/
ml, while the delayed NI50 of PDMaEMa 
is at 21 µg/ml. The dramatic effect of the 
PEI is not only due to the decrease of cell 
viability from the first 24 hours of exposi-
tion to the polymer, as we could monitor 
a loss of cells day after day following the 
medium replacement (observation with an 
inverted microscope). 
Figure 2 shows that 4:1 PEI:DNa polyplexes 
also have a strong delayed effect on HepG2 
cells. We could determine that the addi-
tion of 8 µl of a suspension of 4:1 PEI:DNa 
complexes made from a mix with 40 µg/
ml DNa reduces the capacity of the NRU of 
HepG2 cells by 50%, five days after 24 hours 
exposition. However the effect of the con-
trol with the polymer alone is quite close 
(NI50del = 8.6 µl).
oxidative stress
an imbalance in the redox state of the cell 
is often linked to particles’ cell toxicity. 
Here we looked at the oxidative activity in 
HepG2 cells in contact with the PEI or the 
PDMaEMa polymers and their respective 
polyplexes. The cells were grown for 24 
hours in 96-well plates, then loaded with 
H2DCFDa and exposed to the polymers/
polyplexes for 1 hour or 4 hours in PbS. af-
ter this exposition, the fluorescence was 
measured and compared to the florescence 
of unexposed cells. We did not observe any 
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figure 1: 
effect of the polymers on the hepG2 cell viability, 5 days after a 24 hour exposition. the cells 
were incubated for 24 hours with increasing concentrations of polymers (0, 15, 30, 45, 60, 75, 90 
µg/ml), then the medium was renewed and the cells kept in culture for five more days. on the 
fifth day the ability of the cells to uptake the neutral red was assessed. each concentration 
was tested 7 times per experiment; data are representative of three experiments.
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increase in fluorescence but rather a de-
crease in certain cases that were not con-
centration or time dependant (not shown 
here). With this single endpoint tested (oxi-
disation of a quite unspecific fluorescent 
probe), it is hard to explain this decrease in 
comparison to the negative control.
il-8 secretion
The measurement of the pro-inflammatory 
response of the cell is interesting in order 
to assess the stress that the cell is under-
going when in contact with nanoparticles. 
In vivo, unbalanced pro-inflammatory re-
sponse may lead to more damage than the 
event at the origin of the response. The ca-
pacity of the polymers and the polyplexes 
to elicit a pro-inflammatory response was 
investigated through the level of Il-8 se-
creted by the HepG2 cells in contact with 
the material for 24 hours. We made two 
assays with the different polymers and 
polyplexes. We clearly did not observe any 
relevant increase in the Il-8 secretion, rath-
er, our results suggest a decrease in the 
secretion of Il-8. Only a few tested condi-
tions were significantly different from the 
controls: 20 µg/ml of PDMaEMa, 150 µl/ml 
2:1 and 4:1 PDMaEMa:DNa polyplexes.
concluSionS
We were able to test the effects of the 
polymers and their relative polyplexes on 
different cellular processes. The cell vi-
ability assays showed that both cationic 
polymers are quite toxic for the cells. PEI is 
slightly more cytotoxic than PDMaEMa in 
the acute cytotoxicity testing. The PEI poly-
plex with a 4:1 charge ratio was also the 
only one to cause a reduction in cell viabil-
ity at the highest concentration tested. 
an even bigger difference between PEI and 
PDMaEMa was visible with the delayed cy-
totoxicity tests. With PEI and the PEI:DNa 
polyplexes, some elements promoting cy-
totoxicity remain after the medium shift. It 
is probable that some PEI was still present 
in the cell culture, or even more likely in 
the cells, and continued to impair cell vi-
ability for five days after the medium shift, 
as observed with the delayed NRU tests. 
The CbQCa assay was shown to be unfit 
to assess the effect of these positively 
charged polymers on cell viability.
The testing of the oxidative stress and the 
pro-inflammatory response were less con-
clusive. To reach further conclusions, anal-
ysis of the oxidative activity of the cells in 
contact with polymers and polyplexes is 
required using other means such as the 
use of another probe like aPF or HPF or the 
measuring of the glutathione (GSH) activity 
of the cell. Our results suggest a decrease 
in the secretion of Il-8 in the presence of 
the highest concentrations of PDMaEMa 
but we cannot exclude that polymers/poly-
plexes interact with a part of the secreted 
Il-8. This should be further tested in order 
to draw any firm conclusions.
We did not distinguish a sharp difference 
in cytotoxicity between the polymer and 
the corresponding polyplexes (nanoparti-
cles). This may be due to the fact that, after 
the complexation, a large amount of free 
polymer still remains in the mixture add-
ed to cells (13) or that the 4:1 polyplexes 
present still have enough charges to desta-
bilise cell functions in a way similar to the 
cationic polymer.
The short paper presented here is part of 
a larger study including results from many 
different endpoints (20). Despite the large 
number of studies published using differ-
ent types of nanoparticles, there is still a 
lack of studies in which an in-depth analy-
sis of the overall toxicological profile of na-
noparticles is performed. Most studies are 
limited to the determination of the cyto-
toxicity without addressing the eco-, geno- 
and human toxicology of the developed 
nanoparticles. Nanomaterial researchers 
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figure 2: 
effect of the 2:1 and 4:1 polyplexes on the hepG2 cell viability, 5 days after a 24 hour exposition. 
the cells were incubated for 24 hours with three different amounts of polyplexes (5 µl, 10 µl, 15 
µl from a complex suspension with a base of 40 µg/ml of dna), then the medium was renewed 
and the cells kept in culture for five more days. on the fifth day, the ability of the cells to uptake 
the neutral red was assessed. each amount of polyplexes was tested 7 times per experiment; 
data are representative of three experiments. bars significantly different from control are 
marked with a * (p < 0.05). 5 is for 5 µl, 5 pol is for 5 µl from a solution with the same amount of 
polymer that was used for the complexation and without dna, idem for 10/10pol, 15/15pol.
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the important message is that the risk assessment of nanoparticles is a 
complex task and several test systems have to be used in order to draw 
a thorough conclusion. conclusions based on a single test need to be ap-
proached with caution. this work gives grounds for performing a whole 
battery of tests for a comprehensive characterisation of risks.
i m P a c t  o n  P u b l i c  h e a l t h
also face increasing concern from the gov-
ernmental, environmental and industrial 
groups regarding the potential health haz-
ards of nanoparticles. Despite these con-
cerns and the will of the EU to identify pos-
sible risks related to nanoparticles [COM 
(2004) 338], there are as yet no regulations 
for the safe use of nanoparticles at the 
European level.
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hiv infections and Sti co-infections in 
men who have sex with men in belgium: 
sustained increase in hiv diagnoses
a. Sasse
a. defraye
introduction
Re-emergence of HIV epidemic and contin-
uous high notification rates of newly diag-
nosed HIV cases in men who have sex with 
men (MSM) have been observed in many 
Western European countries (1-6). Diag-
noses of concurrent other sexually trans-
mitted infections (STI) have also increased 
substantially. In this paper, based on sur-
veillance data collected by the Epidemiol-
ogy division at the Scientific Institute of 
Public Health in brussels, we describe the 
trends and epidemiological features of HIV 
and STI among MSM in belgium. 
material and methodS
hiv infection
The total number of screening tests was 
provided by the National Institute for Sick-
ness and Invalidity Insurance (INaMI-RIZIV) 
based on reimbursement figures. HIV test-
ing is widely available and used in belgium. 
People may seek HIV testing from their 
general practitioner, a hospital or a family 
planning centre. 
all serums with positive screening test 
results are submitted for confirmation to 
one of the seven aIDS Reference laborato-
ries. For each confirmed test, a form is sent 
to the patient’s clinician. based on biology 
results and information collected at the 
consultation, the clinician provides data 
on age, sex, nationality, residence, sexual 
orientation, probable mode of HIV trans-
mission and CD4 count at the time of HIV 
diagnosis. Data are validated for duplicate 
recording and included in a HIV database 
maintained at the Scientific Institute of 
Public Health in brussels since 1985. In 1990, 
HIV and aIDS databases were integrated. 
Sexually transmitted infections
Data on co-infections of HIV and other 
STI in MSM were collected from the bel-
gian aIDS Reference Centres. These cen-
tres are specialised in STI/HIV counselling 
and treatment. Seven of the nine medical 
Centres have participated in the ongoing 
surveillance of STI since the beginning of 
2007. The reported STI included chlamydia, 
gonorrhoea, syphilis, lymphogranuloma 
venereum (lGV), hepatitis b virus infection 
(HbV) and sexually acquired hepatitis C vi-
rus infection (HCV). In the surveillance sys-
tem, only recent, active syphilis infections 
have to be reported; no information on the 
stage of disease is collected. For hepatitis 
b and C, only acute infections have to be 
reported. In order to minimise the work-
load for the voluntarily participating phy-
sicians, no information on the laboratory 
testing results is collected. 
Statistical methods
Stata 10 (Statacorp, College Station, Texas, 
US) was used for analysis and processing. 
logistic regression was used to analyse 
factors for late HIV diagnosis. 
reSultS
hiv infection
In 2008, there were 1,079 persons newly 
diagnosed with HIV in belgium. This is the 
highest number ever reported. During the 
period 2003-2008, a plateau was observed; 
the rate of newly diagnosed cases of HIV 
infection fluctuated between 96 and 102 
per million population. before this plateau 
phase, the rate of newly diagnosed cases 
had increased by 47%, from 69 per million 
in 1997 to 101 per million in 2003.
In the past decade, the yearly number of 
new HIV diagnoses in MSM increased by 
228%, from 101 cases diagnosed in 1999 to 
332 cases in 2008 (Figure 1). The proportion 
of MSM among all newly diagnosed HIV 
cases, for whom the probable transmis-
sion mode was known, increased from 23% 
in 1999 to 46% in 2008. During the same pe-
riod, the trend in new HIV diagnoses in het-
erosexuals was reversed: in a first phase the 
yearly number of new diagnoses increased 
by 61%, from 298 cases diagnosed in 1999 
to 480 cases in 2003; in a second phase, this 
number decreased by 27% to 350 cases di-
agnosed in 2008 (Figure 1).
In 2008, almost half of HIV diagnoses were 
in MSM (46%), even if heterosexual trans-
mission remained the predominant re-
ported mode of infection (48%). Only 2% 
of patients were infected by intravenous 
drug use. Transmission mode data were 
available for approximately 70% of new 
diagnoses. 
During the period 1999-2008, increasing 
rates of newly diagnosed HIV cases in MSM 
per 100,000 male population were observed 
among all age groups: the rate in age group 
20-29 years increased by a factor of 4.5, and 
the rates in age groups 30-39 years and 40-
49 years by factors of 2.8 and 3.5 respec-
tively. The median age of MSM at time of 
diagnosis remained constant. For period 
1999-2008, the median age was 37 years. 
The majority of new HIV infections in MSM 
were diagnosed among belgian citizens 
(72%), followed by other European nation-
alities (13%). among new diagnoses in het-
erosexuals, 59% were patients from sub-
Saharan africa, and 27% were of belgian 
nationality.
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Surveillance data suggest that HIV testing 
behaviour has evolved in MSM and that a 
significant improvement was made regard-
ing early HIV diagnosis during the last few 
years. a steady and significant increase of 
CD4 count at HIV diagnosis was observed 
between 2001 and 2008, suggesting that 
HIV infections were diagnosed earlier in 
recent years. The mean CD4 count at HIV 
diagnosis among MSM was 526 in 2008 ver-
sus 395 in 2001 (p < 0.001).
Furthermore, the proportion of late HIV 
diagnoses (defined as CD4 cell count < 200 
per mm3 at diagnosis or aIDS diagnosed 
within three months) among MSM signifi-
cantly decreased over time (Figure 2). In a 
multivariate analysis, controlling for time 
of diagnosis and nationality, older age was 
independently associated with late HIV di-
agnosis (p < 0.001).
hiv testing
an average of 56 HIV tests per 1,000 popu-
lation are performed yearly nationwide, 
excluding tests related to blood donations. 
The number of tests performed remained 
remarkably stable over time, varying be-
tween 51 and 57 HIV screening tests per 
1,000 individuals per year during the pe-
riod 1997-2008.
Sexually transmitted infections
For 2008, seven of the nine aIDS Reference 
Centres reported 267 episodes of STI diag-
nosed in 241 MSM living with HIV. Numbers 
of episodes per STI diagnosis were as fol-
lows: syphilis: 162; chlamydia: 29; gonor-
rhoea: 29; lGV: 31; hepatitis C: 14. MSM 
represented 95.6% of all HIV-positive pa-
tients reported with a new STI episode in 
these centres for 2008. In 215 cases, pa-
tients were aware of their HIV status at 
the time of the STI consultation. In 26 cases 
(10.8%), HIV infection was diagnosed at the 
STI consultation.
among 162 syphilis diagnoses, 67 (41.4%) 
were reported as re-infections. In 26 pa-
tients (10.8%), two STI other than HIV were 
diagnosed at the same time. Syphilis was 
associated with chlamydia in eight cases, 
with lGV in six cases, with HCV in three ca-
ses and with gonorrhoea in one case. Gon-
orrhoea was associated with chlamydia in 
five cases and with lGV in three cases. 
diScuSSion
after years of steady decrease, from 1997, 
a reverse has been observed in the number 
of newly diagnosed HIV infections in bel-
gium (6). 
In 2008, the number of reported new HIV 
diagnoses among MSM was higher than 
ever since the beginning of the epidemic, 
including among young MSM. The increas-
ing trend in belgian MSM was continuous 
from 1999 until 2008, while the numbers 
reported in heterosexuals of sub-Saharan 
origin seem to decrease in recent years.
Changes in HIV testing may influence 
trends in HIV diagnoses (7). In belgium how-
ever, the increase in HIV diagnoses does 
not reflect an increase in HIV testing since 
the number of tests performed nationwide 
has remained remarkably stable over time. 
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figure 2: Proportion of late* hiv diagnoses among mSm, 1992-2008. 
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figure 1: new hiv diagnoses per mode of transmission in belgium, 1997-2008.
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Source
the analysis of hiv/aidS trends in belgium, determining factors of the epi-
demic and risk factors, as well as the communication of this information, 
contributes to the setting up of prevention programs and forecasting in 
terms of caring for and monitoring patients carrying the infection.
i m P a c t  o n  P u b l i c  h e a l t h
On the other hand, increasing trends may 
partially reflect changes in the targeting of 
most at-risk groups during the period 1997-
2008, as suggested by the fact that MSM 
are being diagnosed earlier in recent years. 
Testing promotion campaigns focused on 
MSM have been launched in recent years.
The steadily increasing trend in newly di-
agnosed HIV infections among MSM, and 
the high rate of co-infections with other 
STI are worrying (8, 9). In 2008, in 11% of 
HIV-positive MSM co-infected with STI re-
ported by the participating aIDS Reference 
Centres, HIV seropositivity was discovered 
following the STI consultation. This finding 
underlines the importance of offering an 
HIV test to patients presenting with a STI. 
These observations corroborate recent 
studies indicating increasing prevalence 
of sexual risk behaviour among MSM, 
including those who are aware of their 
HIV-positive status. a survey in the French 
Community of belgium carried out in 2004 
and 2005 among 942 MSM pointed out that, 
although the majority of the respondents 
mentioned a high level of protection dur-
ing anal intercourse, a quarter of respond-
ents had at least one unprotected anal 
intercourse in the last year with a partner 
whose status was unknown or different 
from their own (10). Moreover, HIV-positive 
men and men who were not sure about 
their HIV status were found to be more like-
ly to admit unprotected anal intercourses 
(10). In the Flemish Community of belgium, 
1,793 MSM completed an internet ques-
tionnaire in 2007; this study found a higher 
rate of STI infections among HIV-positive 
MSM compared to HIV-negative MSM. The 
characteristics associated with sexual risk 
behaviour in this study were drug use, low-
er educational level, lower score on mental 
health, less social support, more sensation 
seeking and more sexual partners (8). 
It is essential to adapt and to reinforce 
prevention interventions aimed at high 
risk groups. The survey conducted in the 
French Community showed that knowl-
edge of ways of transmission and treat-
ment of HIV among respondents was good, 
nevertheless many engaged in high-risk 
sexual practices. Hence, while providing 
information on HIV and STI remains neces-
sary, it is not sufficient and has to be com-
bined with other preventive interventions. 
Development of behavioural surveillance 
and more qualitative research on reasons 
why people practice unsafe sex are needed 
in order to develop more effective preven-
tion strategies. 
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human biomonitoring of heavy metals in 
the vicinity of non-ferrous metal industries 
in ath, Wallonia
S. fierens
introduction
The quantification of pollutants or their 
metabolites in biological samples, known 
as human biomonitoring, is a reliable and 
sensitive approach to assess the degree 
of contamination of exposed populations 
and to estimate their possible health 
consequences. Originally limited to occu-
pational medicine, biomonitoring is now 
largely used for assessing environmental 
exposure. Moreover, the usefulness of a 
systematic implementation of this ap-
proach on a large scale is becoming in-
creasingly recognised. This is the case in 
Flanders with the Flemish biomonitoring 
program (Flemish Centre of Expertise on 
Environment and Health), in Germany with 
the German Environmental Survey on Chil-
dren (GerES), and in the U.S. with the Na-
tional Health and Nutrition Examination 
Surveys (NHaNES).
In industrialised countries, environmental 
pollution by heavy metals is mainly the 
consequence of past emissions from non-
ferrous metal industries, emitting large 
amounts of pollutants during the 19th cen-
tury. although emissions have declined 
overall, soils can remain contaminated 
for decades, which is still a concern for 
populations living in these polluted areas. 
Furthermore, in the case of contaminated 
soils, pollutants can be captured by plants 
and enter the food chain, where biocon-
centration of pollutants can occur, lead-
ing to increased exposure of people eating 
contaminated foods.
The presence of two non-ferrous metal 
industries in a residential area led the 
authorities of the municipality of ath to 
undertake an assessment of the potential 
environmental pollution. Relatively high 
levels of heavy metals had been detected in 
surface soil samples collected near houses 
located in the vicinity of these industries 
(1). The present study was conducted in 
order to evaluate the potential transfer of 
this contamination into the human body 
and, consequently, the health impact on 
the population.
methodS
We performed a population based cross-
sectional study. Human biomonitoring was 
used to assess environmental exposure to 
five metals. This study was submitted to 
the belgian Commission for the Protection 
of Privacy and received the agreement of 
the Ethical Commission of the Medicine 
Faculty of the Université catholique de 
louvain (UCl). Each participant has given 
his signed informed consent. For children, 
the informed consent was given by their 
parents or tutors.
Study area
The study was carried out in the munici-
pality of ath, in the Walloon Region of bel-
gium. The region of ath is mainly agricul-
tural. The city is mostly residential but has 
two non-ferrous metal industries, located 
in the heart of the city. We defined two 
areas of investigation. The first is the ‘cen-
tral area’, formed by a circle of 1 km radius 
around each of the two industries that are 
± 500 m away from each other. The cen-
tral area is where we expected to find the 
population most exposed to metals. The 
second area is the ‘peripheral area’, with a 
population expected to be little exposed 
or not exposed to the metals emitted by 
the industries of interest. The peripheral 
area is composed of six villages within the 
municipality of ath, located more than 
three kilometres away from the industries.
Study population
The study population was restricted to 
environmentally exposed persons. Poten-
tial study subjects were screened for oc-
cupational exposure and, if present, were 
therefore excluded. Three target groups 
were investigated: young children aged 2.5 
to 6 years, children aged 7 to 11 years, and 
adults aged 40 to 60 years. The time of resi-
dence in the study area had to be at least 10 
years for adults, 1 year for children aged 7 
to 11 years, and 6 months for children aged 
2.5 to 6 years. Participants were recruited 
at random, stratified by the 3 target groups 
and with an equal sample size between the 
two studied areas.
Questionnaire
Participants were asked to fill in a ques-
tionnaire, adapted differently for adults 
or children. The questionnaire consisted of 
five parts: i) general and socio-demograph-
ical questions, ii) questions on housing and 
surroundings, iii) lifestyle and behaviour, 
iv) health status, and v) food consumption 
habits.
biological samples
all samples were taken in the same place 
in ath, between 26 February 2009 and 20 
March 2009. adults and children aged 7 to 
11 years provided a urine sample in a metal-
free container by the midstream technique. 
They also gave two tubes of venous blood 
taken by a physician. The tubes were trace 
element free. The first, containing EDTa, 
was used for the measurement of lead and 
cadmium. The second, containing lithium 
and heparin, was used for the measure-
ment of serum ferritin. This protein, corre-
lated with iron levels in the body, is used as 
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a determinant of anaemia, which is known 
to increase gastro-intestinal absorption of 
cadmium and lead. a distinct, less invasive 
procedure was adopted for young children 
aged 2.5 to 6 years. approximately 10 drop-
lets of capillary blood were taken by a little 
prick at the end of the digit. This sample 
was intended to measure lead, the only bi-
omarker quantified for this age group.
all the biological analyses were done by 
the laboratory of Industrial and Environ-
mental Toxicology, Department of Clinical 
biology, University Hospital Saint-luc, brus-
sels. blood cadmium and blood lead were 
quantified by Graphite Furnace atomic 
absorption Spectrometry (GFaaS). Urinary 
cadmium, chromium, cobalt, and nickel 
were quantified in urine by Inductively 
Coupled Plasma – Mass Spectrometry (ICP-
MS). Urinary parameters were expressed in 
µg/g creatinine. Urinary samples with cre-
atinine concentrations < 0.3 g/l or > 3 g/l (10 
children and 14 adults) were excluded from 
statistical analyses. 
central area Peripheral area total
children aged 2.5 to 6 years n = 49 n = 49 n = 98
age, years * 4.6 (1.4) 4.5 (1.5) 4.6 (1.5)
Gender, n
    Male
    Female
27 (55%)
22 (45%)
24 (49%)
25 (51%)
51 (52%)
47 (48%)
bMI, kg/m² * 16.0 (2.1) 16.1 (1.2) 16.0 (1.7)
Higher education of parents, n 43 (88%) 42 (85%) 85 (88%)
School in the city of ath, n 36 (78%) 6 (12%) 42 (44%)
locally grown vegetables consumption, n 17 (35%) 33 (67%) 50 (51%)
children aged 7 to 11 years n = 38 n = 36 n = 74
age, years * 9.4 (1.5) 9.6 (1.5) 9.5 (1.5)
Gender, n
    Male
    Female
22 (58%)
16 (42%)
20 (56%)
16 (44%)
42 (57%)
32 (43%)
bMI, kg/m² * 17.8 (3.5) 17.4 (2.4) 17.6 (3.0)
Higher education of parents, n 28 (78%) 28 (80%) 56 (79%)
School in the city of ath, n 27 (77%) 6 (18%) 33 (48%)
locally grown vegetables consumption, n 19 (50%) 25 (69%) 44 (60%)
men n = 27 n = 25 n = 52
age, years * 52.8 (5.7) 50.3 (6.2) 51.6 (6.0)
bMI, kg/m² * 30.9 (3.0) 28.0 (3.4) 31.1 (2.2)
Higher education, n 14 (52%) 13 (54%) 27 (53%)
Work in ath, n 10 (37%) 6 (25%) 16 (31%)
locally grown vegetables consumption, n 14 (52%) 11 (44%) 25 (48%)
Daily consumption of alcohol, n 9 (35%) 11 (44%) 20 (39%)
Current smokers, n 5 (19%) 5 (20%) 10 (20%)
Women n = 28 n = 26 n = 54
age, years * 50.3 (5.7) 51.3 (6.3) 50.8 (6.0)
bMI, kg/m² * 28.1 (5.7) 27.4 (7.1) 27.8 (6.3)
Higher education, n 21 (75%) 16 (62%) 37 (69%)
Work in ath, n 16 (59%) 9 (39%) 25 (50%)
locally grown vegetables consumption, n 11 (39%) 20 (77%) 31 (57%)
Daily consumption of alcohol, n 7 (25%) 9 (35%) 16 (30%)
Current smokers, n 6 (21%) 4 (15%) 10 (19%)
table 1:  baseline characteristics of biomonitoring study participants, ath, 2009. 
* arithmetic means (standard deviation). bMI: body Mass Index
32 WIV-ISP SCIENTIFIC REPORT 2008 | 2009
Public health and Surveillance directorate
Statistical analyses
Data were encoded with the software EPI-
DaTa 3.0. Statistical analyses were done 
with the software SPSS 16.0, SPSS 18.0, 
and STaTa 10.1. a p-value ≤ 0.05 was taken 
as the level of significance. When needed, 
log normal transformation was performed. 
Outliers were excluded from analyses. The 
Student’s t-test and analysis of variance 
(aNOVa) were used for mean comparisons. 
The Pearson’s or Spearman’s correlation 
coefficient was used to test association be-
tween quantitative variables. Proportions 
between groups were compared by the 
Chi-square test or the exact Fisher’s test. 
Stepwise multiple linear regression analy-
ses with biological parameter concentra-
tions as dependent exposure variables 
were applied on the combined groups of 
central and peripheral areas, for adults, 
children aged 7 to 11 years, and children 
aged 2.5 to 6 years separately. For urinary 
parameters, the values under the limit of 
quantification (lOQ) were estimated by 
giving them the value of 1/2 lOQ.
reSultS
The response rate was 24%. This rate is 
comparable to that found in other human 
biomonitoring studies in the general popu-
lation, such as the Flemish biomonitoring 
(response rate of 22.3%). The final number 
of participants who have taken part in our 
study is 278, composed of 98 young chil-
dren aged 2.5 to 6 years, 74 children aged 
7 to 11 years and 106 adults (52 men and 54 
women). The most relevant characteristics 
of the study population are given in table 1.
Table 2 shows the values of the biological 
parameters in the central and peripheral 
areas, by age group and by gender in 
adults. The metal concentrations observed 
in this study are within the same range as 
those found in the general population in 
belgium or other industrialised countries, 
as reported by other studies. Furthermore, 
if we compare the blood lead and urinary 
cadmium levels from this study to those 
found by previous studies several years or 
decades ago, we note that concentrations 
of these metals have decreased with time 
in the general population (2). This reflects 
a global decrease in exposure that has al-
ready occurred over several decades.
The situation for small children is however 
particular. The mean blood lead level of 
children aged 2.5 to 6 years is significant-
ly higher in the central area than in the 
peripheral area. Even if the difference of 
means is very weak and if the range of val-
ues is comparable between the two areas, 
this difference could be the consequence 
of the pollution from the industries. Our 
results, showing an effect of the location 
of residence in children aged 2.5 to 6 years 
but not in older children or adults, con-
firms the importance of studying young 
children, as a risk group of the population.
While for cumulative metals such as cad-
mium and lead, concentrations observed 
in children are, as expected, lower than 
those observed in adults, the observed 
concentrations of cobalt, chromium and 
nickel, which reflect recent exposure, are 
similar or even higher in children than 
in adults. For nickel, 12% of the children 
values are over the adult reference value 
of 3 µg/g creatinine, while only one adult 
reaches this threshold. This could reflect 
differences in exposure, but also in physi-
ology between children and adults. as less 
is known about the safety factors concern-
ing health effects in children, this under-
lines the need for specific reference values 
for children. More broadly, a systematic 
evaluation of baseline values for a panel 
of pollutants in the general population is 
lacking in Wallonia. Our study stresses the 
usefulness of a human biomonitoring pro-
gramme at a regional or greater level.
We performed multiple regression analy-
ses, stratified by age group, in order to 
identify determinants from the biological 
parameter concentrations. Table 3 shows 
the significant determinants identified by 
the models. The only parameter for which 
the geographical area is a significant de-
terminant is, as expected, blood lead in 
children aged 2.5 to 6 years. For this age 
group, no other significant determinant 
was found by this analysis. No significant 
determinant was found for cobalt, chromi-
um or nickel in this age group. In children 
aged 7 to 11 years, blood lead concentra-
tions were significantly influenced by the 
housing age, children living in houses built 
before 1950 having higher concentrations. 
blood lead concentrations in adults were 
not only influenced by gender (men having 
higher values) but also positively related 
with alcohol consumption and age, and 
negatively related with bMI. In adults, while 
33 Public health and Surveillance directorate
central area Peripheral area total
children aged 2.5 to 6 years n = 49 n = 49 n = 98
blood lead, µg/l 18.2 (15.9-20.9) [6-66] 14.8 (12.6-17.4) [3-68]* 16.6 (14.8-18.2) [3-68]
children aged 7 to 11 years n = 38 n = 36 n = 74
blood lead, µg/l 15.5 (13.2-18.2) [4-47] 14.1 (11.8-17.4) [4-50] 14.8 (13.2-16.6) [4-50]
blood cadmium, µg/l 0.13 (0.11-0.15) [0-0.3] 0.14 (0.12-0.16) [0-0.2] 0.13 (0.12-0.15) [0-0.3]
Urinary cadmium, µg/g cr 0.07 (0.05-0.09) [0.01-0.22] 0.06 (0.04-0.07) [0.02-0.20] 0.06 (0.05-0.07) [0.01-0.22]
Urinary cobalt, µg/g cr 0.38 (0.29-0.50) [0.08-1.27] 0.29 (0.23-0.36) [0.09-0.68] 0.33 (0.28-0.39) [0.08-1.27]
Urinary chromium, µg/g cr 0.18 (0.15-0.21) [0.06-0.47] 0.18 (0.15-0.23) [0.07-0.48] 0.18 (0.16-0.21) [0.06-0.48]
Urinary nickel, µg/g cr 1.75 (1.46-2.09) [0.37-3.92] 1.75 (1.37-2.26) [0.30-5.74] 1.75 (1.51-2.03) [0.30-5.74]
men n = 27 n = 25 n = 52
blood lead, µg/l 31.2 (26.4-36.9) [14-85] 32.3 (26.1-40.0) [12-118] 31.7 (27.9-36.1) [12-118]
blood cadmium, µg/l 0.25 (0.19-0.33) [0.1-1.2] 0.38 (0.29-0.50) [0.1-1.7] 0.30 (0.25-0.37) [0.1-1.7]
Urinary cadmium, µg/g cr 0.22 (0.16-0.30) [0.05-0.87] 0.20 (0.14-0.30) [0.04-0.78] 0.21 (0.17-0.27) [0.04-0.87]
Urinary cobalt, µg/g cr 0.15 (0.11-0.20) [0.06-0.58] 0.18 (0.13-0.25) [0.06-1.84] 0.16 (0.13-0.20) [0.06-1.84]
Urinary chromium, µg/g cr 0.13 (0.10-0.16) [0.05-0.33] 0.16 (0.13-0.21) [0.05-0.35] 0.14 (0.12-0.17) [0.05-0.35]
Urinary nickel, µg/g cr 0.65 (0.51-0.84) [0.21-2.58] 0.69 (0.51-0.92) [0.20-2.16] 0.67 (0.56-0.80) [0.20-2.58]
Women n = 28 n = 26 n = 54
blood lead, µg/l 22.5 (18.0-28.2) [4-57] 20.3 (15.6-26.5) [6-93] 21.4 (18.1-25.3) [4-93]
blood cadmium, µg/l 0.37 (0.29-0.47) [0.2-1.9] 0.39 (0.32-0.47) [0.2-1.6] 0.38 (0.33-0.44) [0.2-1.9]
Urinary cadmium, µg/g cr 0.23 (0.17-0.33) [0.04-0.78] 0.25 (0.18-0.34) [0.05-1.0] 0.25 (0.20-0.30) [0.04-1.0]
Urinary cobalt, µg/g cr 0.20 (0.16-0.26) [0.07-0.40] 0.22 (0.17-0.29) [0.09-1.12] 0.21 (0.18-0.25) [0.07-1.12]
Urinary chromium, µg/g cr 0.17 (0.14-0.20) [0.06-0.32] 0.18 (0.15-0.21) [0.07-0.29] 0.17 (0.15-0.20) [0.06-0.32]
Urinary nickel, µg/g cr 1.30 (1.05-1.61) [0.66-3.25] 0.96 (0.72-1.29) [0.17-2.02] 1.10 (0.91-1.33) [0.17-3.25]
table 2:  biological parameters of biomonitoring study participants, ath, 2009.
Data are geometric means (95% Confidence Interval) [minimum-maximum]. 
* Statistically significant difference (p < 0.05) between central and peripheral area using the Student’s t-test.
cr: creatinine. RbP: retinol-binding protein.
dependent variable independent variable Partial r² β estimate p-value
children aged 2.5 to 6 years
blood lead, µg/l Geographical area 0.400 -0.092 0.050
children aged 7 to 11 years
blood lead, µg/l Housing age 0.129 -0.141 0.005
bMI 0.081 -0.020 0.016
Urinary cadmium, µg/g cr bMI 0.159 -0.038 0.002
adults
blood lead, µg/l Gender 0.115 -0.158 0.001
alcohol consumption 0.072 0.010 0.027
age 0.057 0.010 0.020
bMI 0.038 -0.010 0.033
blood cadmium, µg/l Smoking status 0.304 0.388 0.001
Ferritine 0.046 -0.120 0.008
age 0.030 0.011 0.005
Urinary cadmium, µg/g cr age 0.211 0.022 0.001
Smoking status 0.056 0.219 0.016
table 3: multiple linear regression analyses of the biological parameter determinants of biomonitoring study participants, ath, 2009.
cr: creatinine. bMI: body Mass Index. 
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acKnoWledGementS
this study allowed us to assess heavy metal exposure of the population of 
ath, in a contaminated environment. human biomonitoring is a useful tool 
providing authorities and affected populations with information on human 
load and consequential health effects of pollutants from the environment. 
i m P a c t  o n  P u b l i c  h e a l t h
smoking status is the main determinant of 
blood cadmium (explaining 30% of the vari-
ation of concentrations), urinary cadmium, 
more closely related to the body burden, is 
mainly influenced by age (explaining 20% 
of the variation of concentrations).
The effect of the consumption of locally 
grown vegetables was further assessed 
by testing mean differences of adjusted 
metal values between categories of locally 
grown vegetables consumption (no con-
sumption, < 50% of the total consumption, 
and ≥ 50% of the total consumption) sepa-
rately in central and peripheral areas. We 
did not observe any significant difference 
between consumption categories, what- 
ever the metal, category of age, or geo-
graphical area.
lifestyle determinants of blood lead levels 
in children aged 2.5 to 6 years were fur-
ther assessed by area. No effect of sucking 
one’s thumb, biting one’s nails, or of the 
frequency of hand washing was observed. 
On the other hand, time spent outdoors 
is a significant determinant of blood lead 
levels in the central area, while not in the 
peripheral area. In the central area, chil-
dren spending more than 5 hours/week 
outdoors have significantly higher blood 
lead levels than those spending less or 
equal than 5 hours/week outdoors (24.8 
µg/l vs. 16.5 µg/l respectively, p = 0.009). 
Moreover, the same effect of time spent 
outdoors is seen in children aged 7 to 11 
years in the central area (19.4 µg/l when > 5 
hours/week vs. 13.18 µg/l when ≤ 5 hours/
week, p = 0.015) but not in the peripheral 
area. The link between blood lead levels in 
children and the time they spent outdoors, 
existing in the central area but not in the 
peripheral area, reinforces the hypothesis 
of exposure from environmental contami-
nation that could come from the indus-
tries. However, even in the central area, 
and even in children who spent more time 
outdoors, the blood lead levels observed 
are comparable to levels observed in chil-
dren of the same age in the general popula-
tion, not exposed to a known specific envi-
ronmental exposure (3, 4). 
concluSion
The metal concentrations found in the 
population of ath are comparable to those 
found in other similar biomonitoring 
studies in the general population.
With the exception of the small difference 
in blood lead levels in children aged 2.5 to 
6 years, human exposure to heavy metals 
does not differ significantly between the 
central area, where two non-ferrous metal 
industries are located, and the peripheral 
area. The consumption of locally grown 
vegetables in the surroundings of the 
industries does not appear to influence 
heavy metal concentrations of inhabit-
ants. However, spending ≥ 5 hours/week 
outdoors is associated with an increased 
lead exposure of children living in the vi-
cinity of these industries. 
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monitoring illicit drug use among 
female sex workers in europe, 
2000-2008
m. roelands 
introduction
Popular beliefs as well as opinions from 
medical staff have suggested a relation-
ship between illicit drug use (hereafter 
referred to as “drug use”) and sex workers 
(SW). From a public health perspective, it 
is important to investigate its validity, as 
decision makers in the field of prevention 
and treatment need to have a clear view on 
the needs of this vulnerable group, in order 
to provide the necessary services. Drug use 
among SW can endanger their health as it 
interferes with safe sex practices and can 
facilitate physical and mental abuse, and 
violence. Moreover, unsafe injecting drug 
use (IDU) is a risk factor for the spread of 
infectious diseases to the general popu-
lation. The aims of this study were to de-
scribe the current status regarding the 
monitoring of illegal drug use among SW 
in European countries and to present an 
overview of the prevalence estimates.
methodS
Sources of references
literature was reviewed with PubMed to 
find peer-reviewed articles. additionally, all 
yearly National Reports that the National 
Focal Points of all European countries pro-
vide to the European Monitoring Centre on 
Drugs and Drug addiction (EMCDDa), in the 
years 2000 to 2008, were searched in order 
that unpublished reports from health care 
services were included. The National Re-
ports ought to describe findings of all stud-
ies on the epidemiology of drug use in sex 
workers that are reported in the scientific 
and grey literature. 
inclusion criteria
a publication was included if it met all of 
the following criteria: it included informa-
tion on female SW; an estimate of the prev-
alence of drug use in SW was provided; it 
was a scientific article or an (un)published 
report; the original document or the refer-
ring document was published between 
2000 and 2008; and the geographical area 
was restricted to Europe. 
reSultS
Using PubMed over the period 2000- 2008, 
the 165 hits provided three studies that 
met the inclusion criteria. Moreover, infor-
mation about the prevalence of drug use 
among SW was presented in 29 of the 222 
National Reports on Drugs that were pub-
lished between 2000 and 2008, considering 
14 of 32 countries. 
Prevalence of drug use in the total group
Only indirect estimates were found for 
some countries, such as personal estimates 
provided by outreach workers (Slovakia) 
(1), or estimates based on the assumptions 
that all SW on the street were known to a 
health service and all were drug users, and 
on an estimate of all SW in the country 
(Denmark) (2) (Table 1).
In other countries, continuous recording 
of drug use in this population exists but it 
is very limited. It is only recorded whether 
the use of alcohol or illegal drugs was dis-
cussed when SW ask for information or 
help (belgium) (3). Unfortunately, informa-
tion on the prevalence of drug use and on 
the substances discussed was not avail-
able, despite the large samples of SW that 
were contacted every year. 
In countries where some information on 
the prevalence of drug use in SW is avail-
able, the subject is studied through single 
surveys or through surveillance systems 
in the context of interventions focussing 
on the prevention of infectious diseases. 
Surveillance by health care and preven-
tion services can be successful, suggest-
ing increased use compared to the general 
population. However, apart from a general 
measure of the prevalence of drug use in 
SW, some sources provide no further in-
formation on the methods used or more 
detailed results (Italy) (4). another source 
studied a vaccination campaign against 
hepatitis b in SW in three cities (belgium) 
(5). Drug use and IDU were investigated 
through face-to-face interviews on an on-
going basis. However, only pooled data 
covering a 10-year period were presented. 
The working environment and the preva-
lence of IDU and non-IDU were mentioned, 
but no information was provided regard-
ing specific substances. 
More frequently, the topic has been stud-
ied through single surveys, which also sug-
gest a high level of drug use. However, the 
scopes of the studies differ and often little 
information is available on the substances 
used and on the study methods. In one of 
the earlier studies, earning money to buy 
drugs or alcohol is mentioned as a reason 
for sex work, which is the only estimate of 
drug use prevalence (Ireland) (6, 7). a lack 
of information on methods and results 
was also the case in a study performed by 
health services in 3 cities (The Netherlands) 
(8). Prevalence of unspecified drug use was 
reported, but not the prevalence of specif-
ic substances, the number of IDUs and the 
time frame of the prevalence measure. 
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Some single surveys of SW presented more 
detailed information on the substances 
used. However, most often the study in-
vestigated the use of a limited number 
of substances, most often hard drugs. 
Moreover, the prevalence of using at least 
one substance was not stated and some-
times the prevalence of IDU was absent 
(belgium, United Kingdom and France) (3, 
9-12). On the contrary, some studies are, 
by their scope, e.g. HIV infection, limited to 
IDU (Czech Republic) (13). This study distin-
guished between injecting methampheta-
mine, heroin and cocaine. 
Two studies described drug use in SW more 
fully. The lithuanian aIDS Centre reported 
on the prevalence of drug use in the last 12 
months and the use of specific drugs (can-
nabis, tranquillisers and heroin) among 
SW, including also the prevalence of IDU 
(14). and the latvian aids Prevention Cen-
tre performed a survey that investigated 
lifetime prevalence and last month preva-
lence regarding heroin, amphetamines, 
tranquillisers, cannabis, cocaine, ephe-
drine, heroin plus cocaine, and barbitu-
rates (15). last month prevalence of IDU 
was also included.
Prevalence of drug use by age group
Four studies took SWs’ age into consid-
eration and found a higher prevalence in 
younger age groups (latvia, Estonia, bel-
gium and Estonia) (15-20). 
Prevalence of drug use by working 
environment
a high level of hard drug use in street SW 
has been found repeatedly (The Nether-
lands) (8, 21-23). SWs’ working environment 
proved to be an important factor in those 
studies that included it as a variable, allow-
ing comparisons among subgroups within 
the same study to be made. Prevalence of 
IDU has been found to differ in persons de-
pending on whether they work in private 
places, in bars or on the street (belgium) 
(24). The importance of careful sample 
selection and reporting was also demon-
strated in another study. Prevalence of the 
use of any hard drug in the last 6 months 
was found to differ by working environ-
ment (street prostitution districts versus 
clubs) (The Netherlands) (8). In Estonia (19, 
20) prevalence of lifetime use was found 
to be higher in SW who were offering their 
services in public places compared to SW 
who were selling their services via phone/ 
advertisement and SW who were working 
for a company.
Few surveys included different substances, 
but regarding all substances, all of these 
studies found the highest prevalence of 
use among street prostitutes. all were con-
ducted in the United Kingdom. Outdoor 
workers were found to use more crack and 
cocaine in the past six months compared 
to indoor workers (25, 26). Information on 
the sample, estimates of the prevalence of 
specific substances and information on the 
number of IDUs were absent. Prevalence of 
daily use of crack and heroin in the last 30 
days was found to be higher in street SW 
compared to sex parlour workers (27, 28). 
Similar differences were found in a small 
study among street-based and indoor SW 
(29).
Prevalence of drug use by geographical 
area
a Romanian study in 12 cities took geo-
graphical area into account (30). Injecting 
heroin was clustered in one city. although 
information on the composition of the 
sample regarding the working environ-
ment and on the use of other substances 
was not available, the results suggest dif-
ferences in drug use prevalence and pat-
terns of use between cities and regions in 
one country.
trends in drug use 
although information on trends in drug use 
in this population is scarce, available data 
show a considerable increase in drug use. 
a surveillance system of drug use in SW in 
three cities found an increased prevalence 
of drug use between 1998 and 2006 (bel-
gium) (18). a survey of street SW from most 
cities in lithuania compared the preva-
lence of illegal drug use in 1998 with that 
of 2001 (lithuania) (14). However, it was not 
reported whether this increase was found 
for all substances and was equally found 
for IDUs. The level of crack use among SW 
has been reported for two cities in the 
United Kingdom (10, 31). an opposite trend 
was noticed in Norway (32), but little infor-
mation about the study is available.
concluSion
a limitation of this literature review is the 
inclusion of mainly unpublished reports. 
The use of grey literature has some inher-
ent limitations: information on the study 
methods (sample, measures, data collec-
tion) is often not available as it is often 
not included in these reports, a copy of 
the original report is hard to find and the 
report is often unavailable in English. This 
hampers critical reflection on the methods 
used. However, the lack of research pub-
lished in peer-reviewed journals necessi-
tated this approach. The National Reports 
to the EMCDDa proved to be a useful ad-
ditional source of additional references 
and information in this context, including 
information from the grey literature. 
In spite of this intensive search, this review 
showed that information on the situation 
is completely absent in many countries. 
Moreover, in most countries where data 
on the subject was available, information 
was limited. Single studies were few in al-
most all countries. Recording drug use in 
the context of interventions focussing on 
the prevention of infectious diseases was 
only exceptionally a source of information 
on this subject. 
It was also a significant finding that, in 
most cases, the information presented in 
the National Reports was incomplete. Re-
garding the content of the studies, there 
were various shortfalls including: the prev-
alence of using any drug was often miss-
ing; only a limited number of substances 
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country name of 
study
year of data 
collection
Sample measure Prevalence
belgium EUROPaP 2001 City: unknown
N = 83;
Current use Marijuana: 18% (15/83)
Cocaine: 6% (5/83)
Speed: 5% (4/83)
Espace P 1998-2002 3 cities (liège, Namur, 
Charleroi) N = 934; 
Mixed environments
Vaccination campaign of 
outreach service
Unknown IDU
Total sample: 7.4% (49/664)
In private places: 4%
In bars: 7%
In street walkers: 32%
1998-2007 3 cities 
N = 1649; 97% females
Mean age = 31.4 y
25% missing information on 
drug use
Mixed environments (details 
available: a.o. 4% street 
walkers)
Vaccination campaign of 
outreach service
Unknown Non-injecting drugs: 11.5%
IDU: 5.6% 
Non-IDU in period 1998-2006
< 25 y: 9.8%
25-34 y: 8.4%
≥ 35 y: 1.7%
PaSOP 2005 and 
2006
In 2005: 
N contacts = 2,674
N SW = 745
In 2006: 
N = 2,371
N SW = 703
Registration with adminis-
trative aim
“Use of drugs or alcohol was 
discussed in contacts when 
SW asked for information 
or help”
In 2005: 2.1%
In 2006: 1.8%
Czech 
Republic
bruckova et 
al., 2006
Multi-cities survey
N = 585
lifetime prevalence IDU: 10.1% (59/585)
Denmark 1999 and 
2001
Estimates by drop-in centre 
for drug-using SW
Number of drug-using SW on 
street divided by number of 
SW in country
Drug using street SW: 10% 
(620/5,450 to 7,800)
Estonia Trummal 2005 City: unknown
N first time = 106; 
N repetitive clients = 72
SW that are clients of health 
care centre 
Survey
last 6 months prevalence In first time clients: 30%
In repetitive clients: 28%
“Half” of the 18-24 year olds
above 24 years old: 6%
amphetamines and canna-
bis; only few cocaine.
Trummal 2006 N = 227
RDS and interviewers’ 
contacts
lifetime prevalence
last 4 weeks prevalence
Drugs: 66%
≤ 24 y: 75%
25-34 y: 70%
Offering in public places: 
84%
Selling via phone/advertise-
ment 53%
Working for company: 49%
Drugs: 26% (60/227)
France Cagliero & 
lagrange
2002 Paris, Marseille, lille
N = 165
Survey
lifetime prevalence  
(“experimented”)
Recent use
Cocaine or crack: 20% 
(30/165)
Heroin: 5%
Ireland O’Connor 1995 Region: unknown
N = 84
Survey
Current use? (not explicit) Drugs or alcohol: 11% (9/84)
table 1:  Prevalence of illicit drug use in sex workers by study, presented in national reports 2000 to 2008.
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country name of 
study
year of data 
collection
Sample measure Prevalence
Italy 1996 Region: unknown
N = 334
Outreach service
Drug dependence Drugs: 20% (67/334)
latvia 2002 N = 92
Mean age = 25.7 y  
(min 15, max 47)
Survey
lifetime prevalence
last month prevalence
Drug use: 75%
15-19: 100% (14/14)
20-24: 89% (31/35)
25-29: 75% (12/16)
30-34 y: 41% (7/17)
≥ 35 y: 50% (5/10)
Drug use: 63%
IDU: 62%
Heroin: 90%
amphetamines: 26%
Tranquilisers: 16%
Cannabis: 14%
Cocaine: 4%
Ephedrine: 4%
barbiturates: 2%
Heroin + cocaine: 4%
lithuania 1998 Region: unknown
N = 73
Street sex workers
Survey
Unknown Use of drugs or psychotropic 
substances: 23%
2001 Region: unknown
N = 220
Street sex workers
Survey
Unknown Use of drugs or psychotropic 
substances: 65%
2000 Vilnius
N = 96
Survey???
last 12 months prevalence Drugs: 80%
Cannabis: 65%
Tranquillisers: 45%
Heroin: 37%
IDU: 34% 
Slovakia Probably 
2003
Estimates provided by out-
reach workers
Unknown (current use?) IDU: between 5% and 53% 
depending on working 
environment
The Nether-
lands
EUROPaP 2002-2003 amsterdam, Heerlen, Twente
N = 80+ 80 + 40
Current use? (not explicit) Drugs: 34%
2002 Rotterdam
N = 109
last 6 months prevalence Hard drugs: 32%
Cocaine: 26%
Crack: 24%
Heroin: 20%
Street sex workers:  
54% hard drugs
Sex workers in clubs:  
10% hard drugs
Korf et al. 2004 amsterdam
N = 92
Median age = 40 y 
(min 13, max 58)
Street sex workers
“Field study”
last month prevalence
lifetime prevalence
Cannabis: 51%
Cocaine: 9%
Crack: 89%
Heroin: 68%
Cannabis: 87%
Cocaine: 61%
Crack: 91%
Heroin: 81%
Norway 2003-2004
2-3 years 
earlier
Oslo
SW in contact with prostitu-
tion competence centre
“Drug addiction” Drugs: about 30%
Drugs: nearly 80%
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were reported; when using a general meas-
ure of drug use, the substances included 
were not specified; the focus of the study 
was limited to IDU or, in other cases, IDU 
was not studied/reported; only a few stud-
ies presented prevalence estimates by age 
group, although age is an important back-
ground variable.
Moreover, basic aspects of the methods 
used were often not described, such as a 
definition of the study population, the sam-
ple selection method, the sample size and 
the level of non-response. The time frame 
of the prevalence measure was not made 
explicit or loosely defined, such as current 
use or recent use. Therefore, it was not pos-
sible to reflect on the validity and reliabil-
ity of the estimate presented. Often infor-
country name of 
study
year of data 
collection
Sample measure Prevalence
Romania aRaS 2005 12 cities
N = 395
Survey
Snowball sampling
Previous year prevalence 
(in 2004)
IDU heroin (total sample): 
11%
IDU heroin in bucharest: 33%
United 
Kingdom
Chrurch 
et al.
unknown leeds, Glasgow and Edin-
burgh
N = unknown
Outdoor and indoor workers
Survey
last 6 months prevalence Illegal drugs 
  Outdoor workers: 93%
  Indoor workers: 69%
Crack
  Outdoor workers: 32%
  Indoor workers: 4%
Cocaine
  Outdoor workers: 17%
  Indoor workers: 15%
Jeal & Salis-
bury, 2004
N = 71 sex parlour workers
N = street workers
Daily use in last 30 days Parlour workers
Drugs: 23%
Crack: 7%
Heroine: 6%
Street workers
Drugs: 96%
Crack: 87%
Heroine: 85%
Jeal & Salis-
bury, 2004
N = 71 street ers Current dependency 
problems
alcohol or drugs: 96% (68/71)
Heroin: 83% (59/71)
Heroin and crack: 78% (55/71)
IDU: 60% (41/71)
Ward et al. 1989 – 91 london lifetime prevalence Crack cocaine: 11%
1995 – 96 london
N = 143
last 3 months prevalence
lifetime prevalence
Crack cocaine: 10% (14/143)
Crack cocaine: 34% (48/143)
McCullagh 
et al.
1996
2004
liverpool
N = unknown
Street sex workers
unknown Crack cocaine: 17%
Crack cocaine: 75%
the project revealed: 
increased prevalence of drug use in sex workers compared to the general population; • 
that most countries lack surveys and surveillance systems providing estimates of sex workers’ drug use; • 
the need to include more extensive presentation of study methods in national reports to facilitate interpretation of results.• 
i m P a c t  o n  P u b l i c  h e a l t h
mation on the unpublished source could 
not be retrieved. References were difficult 
to trace and to control by researchers.
a multitude of factors are responsible for 
the existing lack of information on the 
prevalence of drug use in SW. an important 
factor is situated at the cultural level: cur-
rently in Europe, SW, mostly called pros-
titution, as well as illegal drugs are sensi-
tive subjects. Researchers and politicians 
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referenceS
deciding on research financing are affected 
by this factor. Moreover, in many countries, 
SW who use drugs, attempt to remain un-
dercover because of the double illegality. 
apart from being liable to prosecution be-
cause of drug use, in many countries they 
face legal prosecution because of their job, 
i.e. sex work. a third factor is the setting of 
the interview, which involves time, as SW 
are contacted at their place of work. Fourth, 
the main focus of organisations in the field 
is on performing preventive interventions, 
such as vaccination and providing harm 
reduction information, not on research. In 
this multi-cultural group, language barriers 
can also hamper an interview. 
as valid as these barriers may be, up-to-date 
information on the situation is needed to 
develop preventive and curative health 
interventions for SW. Surveillance or re-
peated studies of drug use in SW should be 
considered in order to provide this infor-
mation in the future.
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the results of successive health inter-
view surveys show that socio-economic 
inequalities in health-related lifestyles 
have persisted over the last decade
S. demarest
h. van oyen
 J. tafforeau
introduction
Numerous studies show, almost without 
exception, that people with a low social 
status have a poorer state of health, poorer 
living habits and lower life expectancy than 
people with a high social status. These so-
cial inequalities can be found in most Eu-
ropean countries (1). belgium is, in this con-
text, not an exception. Recent research in 
belgium has shown inequalities in morbid-
ity and disability free life expectancies (2), 
mental health (3), access to health care and 
mortality (4-6) and several health-related 
lifestyles. an essential question is whether 
social inequalities in health are a steady 
phenomenon or whether indications can 
be found showing that these inequali-
ties tend to increase or decrease. Recent 
European research indicates that social 
inequalities are quite stable or do tend to 
increase (7, 8). In this contribution, results 
of the successive belgian Health Interview 
Surveys (HIS) will be analysed to assess 
if, and to what extent, social inequalities 
in health-related lifestyles have changed 
during the last decade.
data and methodS
The HIS is a large scale, recurrent and cross-
sectional survey performed in 1997, 2001, 
2004 and 2008. Since the results of the last 
survey have not yet been completely ana-
lysed, only the three first surveys will be 
addressed. Methodological details of the 
HIS can be found on the website (http://
www.wiv-isp.be/epidemio/epinl/index4.
htm). 
alongside extensive data on health related 
topics, data on the socio-economic pro-
file of the participants are also gathered 
in the survey (education, income, profes-
sional status, etc.). In this contribution, we 
have opted to assess the social position 
by means of the equivalent household 
income. In order to make the income of 
households of different size and compo-
sition comparable, the adjusted OECD 
equivalence scale was used in which the 
monthly available income is divided by the 
sum of 1.0 for the first adult in the house-
hold, 0.5 times every additional adult and 
0.3 times every child (9). For each survey 
year, income quintiles were calculated, re-
sulting in 5 groups, each covering 20% of 
households: the first quintile refers to the 
20% of households with the lowest equiva-
lent income, the fifth to the 20% of house-
holds with the highest equivalent income. 
by using year-specific income-quintiles, 
changes in the global level of incomes and 
in the distribution of incomes are taken 
into consideration. When referring to the 
income quintiles it should be understood 
as ‘members of the household that belong 
to a specific quintile’. 
When analysing the relationship between 
social position and health-related life-
styles throughout time, one has to account 
for changes in age- and gender composi-
tion of the population. To account for this, 
it was decided to present the results strati-
fied for gender and standardised for age, 
using the 2004 population as the standard 
population. 
To assess differences in social inequalities 
in health, three parameters will be used:
a first parameter is the difference in • 
prevalence between those in the low-
est income quintile and those in the 
highest quintile. This parameter is quite 
straightforward, yet it does not take into 
account the prevalence of the remaining 
income quintiles.
a second parameter is the population • 
attributable risk, calculated as the dif-
ference between the overall prevalence 
and the prevalence in the highest in-
come quintile, expressed as a percent-
age of the overall prevalence. It can be 
understood as the proportional reduc-
tion of the overall prevalence that could 
occur in the hypothetical case that the 
prevalence in all income quintiles would 
be the same as the one of the highest 
quintile.
The third parameter is the relative risk • 
(RR) between the lowest and the highest 
income group and can be understood as 
the proportion of persons with a worse 
health related life style among those 
in the lowest income quintile divided 
by the same proportion among those 
in the highest income quintile. an RR 
of 1 means no differences in lifestyle 
between the lowest and the highest in-
come group. an RR higher than 1 implies 
that the risk of a worse lifestyle is higher 
among those belonging to the lowest 
quintile. RRs will be presented with their 
95% confidence intervals (CI). an easy-to-
grasp interpretation of a 95% CI is that 
in 95% of all possible surveys using the 
same method in the same population, 
the value of the estimated RR will belong 
to the interval. 
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The HIS provides many indicators of health 
status, lifestyle and medical consumption. 
In this contribution, only social inequali-
ties in four lifestyle indicators in the bel-
gian population are presented: 
The prevalence of • obesity in adults 
(18+ years), based on the (self reported) 
height and weight. The body Mass Index 
is the individual’s body weight divided 
by the square of his/her height. In ac-
cordance with the criteria defined by 
the World Health Organisation, a bMI of 
30 or higher, suggests that the person is 
obese.
Prevalence of smoking is assessed by • 
comparing daily or occasional smokers 
with current non smokers (15+ years)
The prevalence of binge drinking is meas-• 
ured by asking respondents whether, in 
the last six months, they have ever drunk 
six alcoholic beverages or more on one 
day. This group is compared to abstain-
ers and those not indicating binge drink-
ing in this reference period.
Information on leisure time physical • 
inactivity is collected by asking respon-
dents to select what best describes their 
leisure time physical activity, ranging 
from heavy sports activities to merely 
sedentary activities. Comparable data 
on the level of physical activity through-
out the different survey years is only 
available for leisure time physical activ-
ity and is based on how respondents 
describe their leisure time. For the 2004 
survey, it was decided change the mode 
of data collection concerning these 
questions. Comparing the results from 
2004 with those from 1997 and 2001 is 
consequently affected.
reSultS
Concerning the prevalence of obesity, an 
unusual development was found in the 
male population: in 1997, the prevalence 
of obesity seemed not to be related to the 
income position (Table 1). This is reflected 
in all parameters: a prevalence difference 
of only 1%, a limited (and negative) popula-
tion attributable risk and a non significant 
relative risk. In 2004 the situation changed; 
compared to the highest income quintile, 
the prevalence of obesity is 4.3% higher in 
the lowest quintile. From a negative value 
in 1997, the population attributable risk 
is 43.1% in 2004. This implies that, in the 
case where the prevalence of obesity for 
quintiles being the same as the one for 
the highest quintile, the overall prevalence 
would drop by 43.1%. The relative risk, non 
significant in 1997, is 2.4 (95% CI: 1.7 – 3.4) 
in 2004.
This change of prevalence in the male pop-
ulation is not reflected in the female pop-
ulation: social inequalities between the 
lowest and highest quintiles were already 
observed in 1997 and appear to be quite 
stable over time. In 2004 the relative risk 
of being obese in the female population in 
the lowest income quintile is twice as high 
(RR: 2.95% CI: 1.5 – 2.6) compared to this risk 
in the female population belonging to the 
highest quintile.
During the last decade, the percentage of 
males (aged 15+) that describe themselves 
as daily or occasional smokers has de-
creased from 29.3% in 1997 to 26.7% in 2004 
(non significant decrease). For all years of 
the survey, the picture remains similar with 
a higher prevalence of smokers in the low-
est income quintiles. For example, in 2004, 
35.4% of males in the first income quintile 
describe themselves as being a smoker, 
whereas for the same year, this value is 
23.9% for the highest quintile, providing a 
prevalence difference of 11.5% and a rela-
tive risk of 1.4 (95% CI: 1.3 – 1.7).
The prevalence of (daily or occasional) 
smoking in the female population is lower 
than in the male population. In 2004, 18.6% 
of all females indicated being a smoker, a 
percentage that hardly changed between 
1997 and 2001. like in the male population, 
clear social inequalities in smoking behav-
iour can be observed in females, with high-
er prevalences in lower income quintiles. 
For example, in the hypothetical case that 
the prevalence of smoking in all quintiles 
would be the same as the one observed for 
the highest quintile, the overall prevalence 
of smoking would drop to not less than 
36.5% in 2004. The inequalities in smoking 
behaviour by income quintiles have not 
changed over time.
The indicator on excessive alcohol con-
sumption is interesting since it gives an 
example for which social inequalities are 
inversed; in the male population the preva-
lence is higher in the highest income quin-
tiles. This phenomenon is observed in all 3 
surveys. In males, the overall prevalence of 
the excessive use of alcohol is quite stable 
over the years (around 35%). The popula-
tion attributable risk shows that, in the 
case where all males would follow the “ex-
ample” of males belonging to the highest 
income quintile, the overall prevalence of 
excessive alcohol consumption would in-
crease by 10% (figures for the survey year 
2004). In females, the rise in the prevalence 
of people reporting binge drinking has in-
creased over the years; from 9.4% in 1997 
to 13.9% in 2004. This increase can be found 
across all income quintiles but is more pro-
nounced in the highest quintiles. This is re-
flected both in the prevalence differences 
(-3.4% in 1997, -8.2% in 2004) and especially 
in the evolution of the population attribut-
able risk (-9.6% in 1997, -32.4% in 2004).
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Considerable social inequalities can be 
observed in both males and females for 
all survey years in regard to leisure time 
physical activity. Males and females in the 
lower income quintiles more frequently 
report that they hardly do any leisure time 
physical activity. The prevalence difference 
is more pronounced in females than in 
males. also, the relative risk remains quite 
stable; the risk of physical inactivity dur-
ing leisure time is 70% higher in the lowest 
quintile compared to the highest quintile.
males females
1997 2001 2004 1997 2001 2004
obese
Overall prevalence 9.5 10.5 10.2 9 11.3 11.5
Prevalence difference -1 1.1 4.3 6.8 8.6 7.8
PaR -7.4 21.9 43.1 53.3 47.8 37.4
Relative Risk (95% CI) 0.9 (0.7 – 1.3) 1.1 (0.8 – 1.5) 2.4 (1.7 – 3.4) 2.6 (1.8 – 3.7) 2.4 (1.7 – 3.4) 2 (1.5 -2.6)
Smoker       
Overall prevalence 29.3 26.8 26.7 18 18.4 18.6
Prevalence difference 14.7 6.8 11.5 7.1 7.9 11.2
PaR 18.4 7.8 10.5 48.9 34.8 36.5
Relative Risk (95% CI) 1.5 (1.3 – 1.7) 1.2 (1.1 – 1.4) 1.4 (1.3 – 1.7) 1.6 (1.3 – 1.9) 1.5 (1.3 – 1.8) 1.8 (1.6 – 2.2)
excessive use of alcohol       
Overall prevalence 35.1 39.3 37 9.4 13.8 13.9
Prevalence difference -9.3 -16.3 -13.2 -3.4 -3.5 -8.2
PaR -19.1 -19.6 -10.5 9.6 7.2 32.4
Relative Risk (95% CI) 0.8 (0.7 – 0.9) 0.7 (0.6 – 0.8) 0.7 (0.6 – 0.8) 0.6 (0.5 – 0.8) 0.8 (0.6 – 1.0) 0.7 (0.6 – 0.9)
Physical inactivity       
Overall prevalence 34.7 32.5 23.1 43.4 42.7 34.1
Prevalence difference 11.5 15 10.9 15.7 15 19.6
PaR 27.1 22.7 22.1 19.8 19.7 21.4
Relative Risk (95% CI) 1.5 (1.2 – 1.8) 1.7 (1.4 – 2.0) 1.7 (1.3 – 2.1) 1.5 (1.3 – 1.7) 1.5 (1.3 – 1.7) 1.7 (1.5 – 2.0)
table 1: inequalities in health damaging lifestyle (summary) by income quintile, year and gender, health interview Survey, belgium, 
 1997, 2001 and 2004.
concluSion
Despite the limited number of health-re-
lated lifestyle indicators addressed in this 
contribution and the restricted character 
of the applied statistical analysis, the re-
sults show that, in general terms, social 
inequalities in lifestyle do exist and persist 
over the years. It should be mentioned that 
the reference period of 7 years (1997 – 2004) 
is perhaps too short to adequately describe 
trends in social inequalities. 
as mentioned in the introduction, persist-
ing social inequalities in health-related 
lifestyles are not a specific belgian phe-
nomenon, but can be found in all other Eu-
ropean countries and regions. The complex 
mechanisms responsible for this remain 
under debate. Some authors stress the im-
portance of ‘cultural capital’ that interacts 
with the economic and social capital in 
the social structuring of people’s health 
chances and choices while others under-
line the phenomenon of ‘reproduction’ of 
health-damaging behaviour in the sociali-
sation process (with parents as the peer 
socialisation agents) (10). an interesting 
perspective is the one of the (partly social 
determined) future time perspective, a dis-
position to ascribe high value to goals in 
the future and to anticipate, in the present, 
the long-term consequences of a poten-
tial action (11). Perhaps in lower income 
groups, this perspective is less prevalent. 
It could explain why a policy aimed at pre-
venting unhealthy behaviour – by pointing 
out its long-term health consequences – 
risks becoming more successful in advan-
taged groups, with growing inequalities as 
a latent result. 
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even in a modern welfare state such as belgium, social inequalities in 
health-related lifestyles exist and seem to persist over time. Preventive ac-
tion should take account of the economical, social and cultural specificities 
of their target groups.
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tackling health inequalities in 
belgium: some results and 
policy recommendations
r. charafeddine
P. Deboosere
V. lorant
S. demarest
M.-I. Farfan Portet
h. van oyen
introduction
It has been established in the scientific 
literature that, in general, mortality and 
morbidity rates follow a social gradient 
whereby those at the top of the socio-eco-
nomic hierarchy (high educational level, 
high revenues or high professional grade) 
have lower mortality and morbidity rates 
compared to those at the bottom of this 
hierarchy. Such health inequalities have 
been detected in belgium where studies 
have found socio-economic disparities us-
ing a series of health indicators including 
life expectancy, healthy life expectancy, 
self reported health, access to health care, 
and health behaviours such as tobacco 
use, eating habits and physical activity (1, 
2). These health inequalities are a major 
challenge for policy makers as they are 
the causes of inequitable and preventable 
health problems in the population. There-
fore, there is a critical need to develop 
effective policies and interventions to re-
duce theses inequalities in health. 
It is within this context that the TaHIb 
project (Tackling Health Inequalities in 
belgium) has been initiated in 2006. This 
project aims at generating a better under-
standing of the determinants of health 
inequalities in belgium and at proposing 
effective policy recommendations. Re-
searchers from three institutions have 
collaborated on this project: the Scientific 
Institute of Public Health (WIV-ISP) that 
is also the coordinator, the Vrije Univer-
siteit brussel (VUb), and the Université 
Catholique de louvain (UCl). One of the 
objectives* of this project is to describe 
the time trends in social inequalities in 
mortality and morbidity. This is an impor-
tant endeavour for several reasons. Firstly, 
exploring the trends in health inequalities 
provide policy makers with up-to-date in-
formation that can guide the development 
of effective intervention programmes and 
policies. Secondly, such research can help 
predict future trends. Thirdly, findings from 
such work enable researchers and policy 
makers to assess the impact of different 
health promotion programmes on differ-
ent population subgroups and to identify 
which interventions are more effective in 
reducing social inequalities. 
as part of this project, Deboosere and col-
leagues (3) have examined the evolution 
of life expectancy by educational level at 
the turn of the century in belgium. They 
found that life expectancy increased for 
all educational groups, but this increase 
was more marked for those with higher 
educational levels. as a result, inequalities 
in life expectancy by educational level in-
creased between 1991 and 2001. Yet, study-
ing the trends in mortality is not sufficient 
to examine the trends in the health of the 
population. To add a quality dimension to 
the quantity of years lived, Van Oyen and 
colleagues (4, 5) examined the evolution 
in socioeconomic inequalities in healthy 
life expectancy between 1997 and 2004. 
For this, they used the disability free life 
expectancy (DFlE) indicator, which divides 
the years of remaining life in disability free 
years and years spent in disability. In this 
paper, we will present the research de-
scribed above conducted by Van Oyen and 
colleagues°. 
methodS
To assess DFlE, two types of data are need-
ed. Data on mortality enable the estima-
tion of the total life expectancy. Data on 
the prevalence of different health states 
are applied to the life table to estimate the 
person-time lived with and without dis-
ability. 
Mortality data by educational level were 
generated based on two sources of data: 
the national censuses of 1991 and 2001 
that provide information on the distribu-
tion of the population by educational level, 
and the national register that provides 
information on mortality and emigration 
for the periods 1991-1994 and 2001-2004. 
These two datasets were linked based on 
a unique identifier present in both the 
census and the register files. as a conse-
quence, the socio-demographic character-
istics in the census were unambiguously 
matched to mortality and emigration data 
in the population register with a follow-up 
period of three years after each census. 
The prevalence of the disability was ob-
tained from the 1997 and 2004 Health In-
terview Surveys. The methodological ap-
proach did not change between the two 
surveys•. The National Register was used 
*  The three other objectives are: 1. analyze social inequalities in health in relation to the longitudinal changes in social position and study the effect of chang-
ing social position on health, 2. Study the effect of macro-social factors on social inequalities in mortality and morbidity, 3) Evaluate the time trends in the 
association between social inequalities in health and social inequalities in health behaviors.
° Seven other studies were conducted in the context of the TaHIb project. Details of these studies are found in the final report (5). 
•  http://www.wiv-isp.be/epidemio/epien/index4.htm (see protocol) (accessed May 5, 2009)
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as a sampling frame to select a sample us-
ing a multistage sampling method (6). The 
number of subjects aged 25 years and over 
in the 2 surveys was respectively 6,763 and 
9,271. life expectancies without limitations 
were estimated by gender and educational 
level starting by age 25 up to age 100 using 
the Sullivan method (7).
Socio-economic position
The socio-economic position was defined 
by the highest level of educational attain-
ment. The census and Health Interview 
Survey used the same question and re-
sponse categories. based on the Interna-
tional Standard Classification of Education 
(ISCED) (8), the educational attainment was 
recoded as one of five categories: no diplo-
ma, primary education, lower secondary, 
higher secondary and tertiary education. 
health domain
activity restriction was used to define 
disability and was classified based on dif-
ficulties in doing one of 7 aDl-functions 
(transfer in and out bed, transfer in and out 
chair, dressing, washing of hands and face, 
feeding, going to the toilet, continence), or 
having mobility problems (walking a dis-
tance of maximum 200 metres) or having 
problems in seeing (ability to recognise a 
person at a distance of 4 metres even wear-
ing glasses) or in hearing (ability to follow a 
TV program with the volume turned higher 
than acceptable to others even with a 
hearing aid) (9). 
Summary measures of socio-economic in-
equalities
Guidance for measuring inequalities in 
health suggests using both absolute and 
relative measures (10). We firstly used a 
population attributable life loss index 
(Pall). This index represents the increase in 
overall DFlE that would be achieved if all 
groups had the DFlE of the best group. as 
the distribution of educational level in the 
population has changed between 1990 and 
2000, we need to account for this change 
while studying the evolution in inequali-
ties. For this, we used the Composite Index 
of Inequality, which accounts for the popu-
lation size of the educational classes. The 
absolute Composite Index of Inequality 
(CIIabs) is the sum of the weighted (wi) differ-
ence in the DFlE between the educational 
groups and the highest educated category, 
with wi proportional to the population size 
of the educational categories. The relative 
Composite Index of Inequality CIIrel is the 
CIIabs divided by the overall population’s 
values and is interpreted as the percent-
age change in the overall health expectan-
cy that would occur if all socio-economic 
groups had the health expectancy of the 
population with highest educational level. 
For example, for the DFlE, the CIIabs and 
CIIrel are estimated as:
reSultS
The distribution of the educational attain-
ment in the census of 1991 and the census 
of 2001 is presented in Table 1. between 
the two censuses there was a substantial 
increase in the educational attainment. In 
2001, about one quarter of the population 
has a tertiary education degree compared 
to less than 20% ten years earlier. There are 
fewer people without a diploma in 2001 
(males 10%, females 12%) compared to 
1991 (males 26%, females 32%). 
The results show that in 1997, there is a gra-
dient in DFlE where those at the top of the 
educational hierarchy live longer without 
disability than those at the bottom of this 
hierarchy. In 2004, men and women with 
the highest educational level continue to 
live even longer without disability than 
in 1997 (Table 2). For instance, men with a 
tertiary education have an increase of 2.86 
years in their DFlE while those without 
a diploma had an increase of 1.28 years. 
When we look at the absolute inequality at 
the population level, we note an increase 
in educational inequalities in DFlE by 0.44 
for males and 0.86 for females. 
a different picture emerges when we take 
account of the general improvement in the 
educational distribution of the popula-
tion. When we account for these changes, 
we see for men decreasing inequalities in 
absolute (-1.15 years) and relative terms 
(-4.01%). For women, inequalities persist 
even after accounting for the changes in 
the educational distribution (absolute dif-
ference is 0.44 years and the relative dif-
ference is 0.50%). These results were not 
statistically significant. Therefore, we can 
conclude that at best there is no evidence 
to suggest that social inequalities in DFlE 
have been reduced in the last decade.
as a conclusion, findings from the TaHIb 
project suggest that inequalities in mor-
tality and morbidity between educational 
groups have increased during the last dec-
ade in belgium. However, when we account 
for the general improvement in the educa-
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education men men Women Women
 1991 2001 1991 2001
% % % %
No diploma 26.1 10.3 32.0 11.8
Primary education 14.9 15.5 17.2 19.2
lower secondary 18.3 23.7 16.0 23.0
Higher secondary 23.2 25.0 19.7 22.3
Tertiary 17.6 25.4 15.1 23.8
table 1: the distribution by educational level of the total belgian population aged 25+, 
 1991 and 2001.
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tional level of the population, we find that, 
in some cases, inequalities did not change 
overtime or they even decreased. This find-
ing points to the importance of tackling 
upstream factors, such as education for 
reducing health inequalities in the popula-
tion. 
Policy recommendationS 
The findings reported above examine the 
trends in socio-economic inequalities 
in mortality and morbidity. In the TaHIb 
project, other issues have also been exam-
ined resulting in four policy recommen-
dations. These recommendations are not 
only based on the findings of TaHIb, but 
also on the European experience in set-
ting policies to reduce health inequalities 
and on the discussions with the steering 
committee that followed up the project for 
four years. 
raise the awareness on the issue of the 
social gradient in health in contrast to 
the binary approach focusing on poverty, 
which is often the most common political 
approach
The presence of the social gradient in 
health is not new. It has been repeatedly 
shown in the scientific literature that 
health inequalities do not only exist be-
tween the extreme categories of the soci-
ety (rich versus poor or educated versus 
non-educated); rather social inequalities in 
health follow a distribution that is socially 
stratified in the population where each 
social category shows mortality and mor-
bidity rates that are higher than the social 
category that precedes it on the hierarchy. 
It is important to highlight this issue in or-
der to avoid the focus being on the issue 
of poverty but rather discuss poverty in the 
context of health inequalities. 
appoint a governance body to tackle 
health inequalities 
In belgium there is no institutional stake-
holder responsible for tackling health 
inequalities. This is an important issue 
because tackling inequalities is not the 
responsibility of one sector but rather a 
number of sectors such as health, social 
work, and employment. Therefore we need 
an institutional body that coordinates and 
supports policy actions, interventions, and 
research in this area. 
The need for such a body is based on the 
experience of other European countries in 
reducing health inequalities. a main com-
ponent of successful policies is political 
commitment (11) and political commit-
ment cannot exist without responsibility. 
education men men change Women Women change 
 1991 2001 91-01 1991 2001 91-01
% % % % % %
No diploma 26.5 27.8 1.3 33.3 28.9 -4.4
Primary education 32.6 36.7 4.1 34.7 36.3 1.6
lower secondary 37.4 39.7 2.3 40.9 42.0 1.1
Higher secondary 42.6 41.5 -1.1 43.4 41.3 -2.1
Tertiary 43.5 46.3 2.8 44.7 47.1 2.4
total 38.1 40.5 2.4 38.9 40.4 1.5
Pall 5.4 5.9 0.5 5.8 6.7 0.9
CIIabs 7.3 6.2 -1.1 6.3 6.7 0.4
CIIrel(%) 19.3 15.3 -4.0 16.1 16.6 0.5
table 2: disability free life expectancy (dfle) and summary indices of inequality at age 25 by educational level and sex, 1991 and 2001.
develop a national action plan to reduce 
health inequalities
In belgium, there are a number of initia-
tives to reduce inequalities, but these ini-
tiatives are scattered. Therefore, there is a 
need to develop a national action plan to 
coordinate and develop actions to reduce 
inequalities. The basis of this plan may be 
the conceptual framework used by Michal 
Marmot and his colleagues in the WHO 
Commission for Social Determinants on 
Health (12). This conceptual framework 
recommends tackling inequalities at the 
root of the problem by tackling upstream 
factors such as education. 
develop a research strategy to better 
understand, monitor and reduce health 
inequalities and to provide the frame-
work for evidence-based policy and policy 
evaluation
The knowledge about health inequalities 
in belgium is already sufficient to be able 
to start tackling health inequalities. How-
ever, a number of questions need further 
exploration to effectively reduce health in-
equalities. One of the issues that requires 
greater insight is how to intervene to re-
duce health inequalities. In other words, 
we already know a lot about the problem 
but not enough about the solution. This 
recommendation is echoed by major 
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the results and policy recommendations of this project will be used by the 
King baudouin foundation to raise awareness about social inequalities in 
health among the general public and among politicians, and to propose so-
lutions to reduce these inequalities. 
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concluSion
Finally, it is important to emphasise that 
the elimination of these inequalities can-
not be achieved in the near future, but it 
is possible to reduce them to levels that 
are more acceptable. The appropriate solu-
tion is not solely to invest even more in the 
health care system and in new technolo-
gies, rather it is important to tackle the 
roots of these inequalities and implement 
focused actions based on a range of policy 
entry points that are evidenced based. This 
takes political commitment, strategies 
that are effective, sustainable and inte-
grated, and the readiness to engage in the 
long term. 
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introduction by Dr Michaël Kalai
The Communicable and Infectious Diseases Directorate (OD) was officially established 
by a Ministerial Decree on the 26th of august 2008. It represents the final stage of a major 
reform project carried out by the WIV-ISP leading to the merger between the former 
Pasteur Institute Department and the bacteriology, Virology and Mycology divisions of 
the Microbiology Department. This project, carried out in the frame of the business plan 
re-engineering-Project Jenner, started in 2007 and its recommendations were validated in 
2008. The primary phase defined the medium-term research strategy of the new scientific 
direction and aimed to answer two questions: 
What are the scientific themes that should be developed, maintained, reduced, 1. 
transferred or abandoned?
What means - human and financial - specific (per theme) and general (the entire scientific 2. 
direction) are deemed necessary to achieve the strategic orientations proposed? 
answers to these questions led to the second phase concerning the ongoing reorganization 
of the OD, which was one of the main challenges facing the WIV-ISP in 2009. 
The primary mission of the new Communicable and Infectious Diseases Directorate is 
the early and rapid detection of existing or (re)-emerging infectious and communicable 
diseases in belgium, their prevention and treatment. The Directorate is a recognized 
centre of excellence for the research of infectious diseases. It plays an important role in 
the belgian, European and international network of surveillance, reference laboratories 
and centres of expertise for infectious diseases and food safety. Through its work and 
expertise, or in collaboration (coordination of surveillance and crises management) with 
other Directorates (notably the OD Public Health and Surveillance), the Communicable 
and Infectious Diseases Directorate reliably informs policymakers and the public on new 
developments in public health, security of the food chain, food and the environment. 
The OD assures national and international surveillance of multiple pathogens via its 
National Reference laboratories (NRl) including: NRl-Tb and mycobacteria, NRl-Salmonella 
and Shigella, NRl-listeria, NRl-Neisseria, NRl-Meningococcus, NRl-aminoglycosides 
resistance (resistance to antibiotics: Streptococcus pneumoniae and Staphylococcus 
aureus), NRl-Phage Typing  [Salmonella and Staphylococcus aureus (MRSa)], NRl-food 
microbiology, NRl-botulism & tetanus, NRl-Human or animal toxoplasmosis, NRl-Influenza, 
NRl-Measles & Rubella, NRl-viral hepatitis, NRl-Rabies, NRl-Medical Mycology.
The multiple services provided by the OD include: identification, genotyping, serological & 
molecular diagnosis, molecular epidemiology and surveillance of bacterial, viral, fungal or 
parasitic pathogens, in human and animal clinical samples and in food. The OD conducts 
investigations and identifies pathogens in indoor environments: hospitals, workplaces, 
communicable and 
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schools and housing. Through a network of four sampling stations, it monitors air quality 
by identifying and measuring the quantity of allergenic pollen and fungal spores in the 
open air in belgium. 
 
The research projects carried out by the OD focus on: research and development of 
extraction and identification methods of pathogens, biotoxins, rapid identification of 
markers of resistance to treatment, development of animal and cellular models of infection 
for the study of virulence mechanisms and development of new prevention (vaccine) and 
treatment methods. The OD participates in epidemiological surveys on the prevalence and 
immunization coverage of viral or bacterial diseases. It also studies the immunological 
mechanisms responsible for allergy and pulmonary hyperreactivity associated with mould 
spores. 
 
These scientific activities, realised in the two WIV-ISP sites (Ixelles/Elsene and Uccle/
Ukkel), were organised within 5 functional programmes (bacteriology, Virology, Mycology 
& aerobiology, Immunology & Vaccinology and Tuberculosis & Mycobacteriology) which 
are supported by transversals platforms and themes including an animal facility. access 
to high containment biosecurity level l3 laboratories is provided for handling (re)emerging 
pathogens representing an important risk to public health.
bacteriology: The programme regroups the reference and research laboratories assuring 
the surveillance, diagnosis, typing and study of bacterial pathogens and toxins (excluding 
mycobacteria), foodborne pathogens and human and veterinary parasites. The programme 
monitors and identifies markers of antibiotic resistance and studies mechanisms of 
virulence and prevention approaches for toxoplasmosis.
virology: The programme regroups all the reference and research laboratories assuring 
the surveillance, diagnosis and study of human and zoonotic viral pathogens including: 
Influenza virus, Hepatitis a, b, C, D and E viruses, Measles, Rubella and West Nile virus. It 
develops new diagnostics and studies new prevention and treatment techniques. It 
provides diagnosis and treatment of rabies in humans and serological monitoring of 
vaccination in humans and animals.
mycology & aerobiology: The programme hosts the medical mycology reference centre 
and the national collection (bCCM/IHEM) of filamentous fungi and yeasts presenting an 
interest for public health (humans and animals fungal pathogens, fungi isolated from 
the environment of atopic patients and mycotoxin-producing fungi). It investigates the 
microbial quality of indoor and outdoor environments and assures the identification of 
filamentous fungi and yeasts in human, animal, food and environmental samples.
immunology & vaccinology: The programme includes three research laboratories: an 
allergy laboratory studying the immunological mechanisms involved in pulmonary 
hyperresponsiveness associated with mould spores; a laboratory of Mycobacterial 
Immunology centred on the development of immuno-diagnostic and more effective 
vaccines against tuberculosis, paratuberculosis cattle, and buruli ulcer, and a laboratory of 
Mycobacterial biochemistry, which studies the importance of the biosynthesis of essential 
elements (vitamins, amino acids...) for the virulence and survival of Mycobacterium 
tuberculosis. 
tuberculosis & mycobacteriology: The programme hosts the National Reference Centre 
assuring the microbiological diagnosis of tuberculosis and mycobacterioses, their 
molecular identification and typing, and the study of their susceptibility to antibiotics. It 
includes several research laboratories mainly interested in the study of the mechanisms of 
virulence and drug resistance of Mycobacterium tuberculosis. The programme is developing 
and studying both ex vivo and in vivo models of infection to evaluate the effectiveness of 
new antituberculosis therapies.
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current status of botulism intoxication 
in belgium: the need for monitoring
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introduction 
botulism is a severe intoxication caused 
by seven different heat-labile neurotoxins 
(a to G) produced by different strains of 
Clostridium botulinum, a spore-forming 
obligate anaerobe. botulism is not spread 
from one individual to another. The three 
main forms of “natural” human botulism 
are: foodborne botulism caused by the 
ingestion of botulinum neurotoxins pro-
duced during the growth of C. botulinum 
spoiling preserved or stored food, infant 
botulism resulting from the colonisation 
of the intestine by C. botulinum and the in 
situ production of toxins, and wound botu-
lism, the rarest, due to toxins produced by 
bacteria growing in a contaminated wound. 
The botulinum neurotoxins are considered 
to be the most lethal substances known, 
since as little as about 1 ng/kg can be le-
thal to an individual. all types of neuro-
toxins produce the same illness. They bind 
to and enter inside peripheral cholinergic 
nerve terminals, from which they inhibit 
the release of acetylcholine, with ensuing 
flaccid paralysis. If the paralysis extends 
to respiratory muscles, the individual dies 
of respiratory failure. botulism can occur 
in humans as well as in animals with one 
difference of susceptibility to neurotoxins. 
Types a, b, E, and rarely F cause disease in 
humans. Type C is the most common cause 
of botulism in animals. Mainly, this type 
has been associated with botulism of birds. 
Type D is often seen in cattle, and type b 
can occur in horses. Type G rarely causes 
disease, although a few cases have been 
seen in humans. The current report analy-
ses the results obtained by the National 
Reference laboratory for botulism during 
the years 1988-2009.
the objectives for the national reference 
laboratory for botulism 
The National Reference laboratory (NRl) 
for botulism, of the Scientific Institute of 
Public Health (ISP-WIV), is the only labora-
tory in belgium to perform all laboratory 
tests for biological confirmation of botu-
lism in human, animal and food specimens. 
The NRl has the following objectives:
T• o assist physicians and veterinary sur-
geons when botulism is suspected in an 
individual by the examination of suspect 
foods and clinical specimens submitted 
for analysis;
T• o rapidly alert the Federal agency for 
the Safety of the Food Chain (FaSFC) 
when food contains botulism;
T• o take part in the monitoring of an 
outbreak of animal botulism in the na-
tional programs “cattle sounder” of DGZ 
(Dierengezondheidszorg Vlaanderen) 
and aRSIa (association Régionale de 
Santé et d’Identification animales) in-
cluding control of the milk in affected 
farms;
T• o take part in the annual monitoring 
programs of FaSFC for C. botulimum and 
its toxins in food;
T• o maintain reference strains of Clostrid-
ium botulinum;
T• o publish an annual epidemiologic re-
port of the botulism in belgium;
T• o develop new in vitro laboratory tests 
for the identification of all forms of bot-
ulism.
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methodS
laboratory tests for the confirmation of 
botulism
a case of botulism requires definitive labo-
ratory confirmation:
Human foodborne botulism requires • 
confirmation of intoxication in a person 
by the detection of the botulinum toxin 
in serum, stool, gastric aspirate or food 
or by the isolation of C. botulinum from 
stool or gastric aspirate, in addition to 
biological confirmation that the patient 
ate food containing the toxin or the bac-
teria;
Infant botulism requires confirmation of • 
intoxication in a baby less than one year 
of age by the detection of botulinum 
toxin in stool or serum or the isolation of 
C. botulinum from stool;
Wound botulism requires confirmation • 
of intoxication in a person by the detec-
tion of botulinum toxin in serum or the 
isolation of C. botulinum from a wound;
animal botulism requires confirmation • 
of intoxication in the individual by the 
detection of botulinum toxin in serum, 
stool, gastric aspirate or organs after the 
autopsy or the isolation of C. botulinum 
from stool, gastric aspirate or organs 
after the autopsy. In addition, the origin 
of the intoxication may be detected in 
feed, water or environment. absence of 
toxin in milk of positive farms has to be 
confirmed.
The NRl performs all the tests to analyse 
human, animal and food specimens for 
biological confirmation of botulism by the 
very sensitive reference method, i.e. the 
mouse bioassay. after the extraction from 
the samples, the neurotoxins are detected 
by the lethal test in mice and the identifi-
cation of the toxin type by neutralisation 
with specific antitoxins. after enrichment 
in anaerobic conditions, the presence of 
the causative organisms in specimens is 
demonstrated by specific toxicity of the 
culture supernatants and by further char-
acterisation of the selected C. botulinum 
bacteria. These laboratory tests allow the 
identification and the typing of the neuro-
toxins a, b, C, D, E and F, and the identifica-
tion and the characterisation of C. botuli-
num strains. Clostridium tetani can also be 
identified in this way.
national botulism database and surveil-
lance
The NRl has had a National botulism Da-
tabase since 1987, collected from all cases 
of botulism suspected and confirmed in 
belgium. Each year, the cases of human, 
animal botulism and food positive for bot-
ulinum toxin, the botulinum toxin types 
and the C. botulinum strains identified are 
recorded and used for further analysis and 
surveillance of botulism in belgium. This 
database is used to follow the evolution of 
the outbreaks of human and animal botu-
lism and the identification of foodborne 
botulism.
reSultS and diScuSSion
Surveillance and notification of human 
botulism (nrl database: 1988-2009)
The majority of European countries have 
their own NRl for botulism. all of which 
have developed their scientific expertise, 
in parallel to their surveillance programs. 
Since 1971, human botulism is a legally 
declarable disease and its notification in 
belgium is obligatory. The NRl is in charge 
of confirming diagnosis of all cases of 
botulism, by identification of toxin and 
Clostridium botulinum, and of further sci-
entific investigation. The NRl database 
shows that human botulism is rare in bel-
gium (Table 1); only 13 cases of foodborne 
botulism have been confirmed during the 
last 22 years. 10 cases of botulism type b 
were associated with the consumption of 
Database for National Reference laboratory for botulism of the Scientific Institute of 
Public Health
year number of cases toxin type food source
1988 0
1989 2 b ham
1990 1 b ham
1991 0
1992 1 b ham
1993 1 ? unknown
1994 a 1 ? unknown
1995 0
1996 1 a potatoes with onions and bacon
1997 3 b ham
1998 1 b olives
1999 0
2000 0
2001 0
2002 0
2003 0
2004 1 b ham
2005 0
2006 0
2007 0
2008 1 b
2009 0
a: 1 case declared by the French community
table 1: cases of human botulism in belgium (1988-2009).
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ham (8 cases), olives (1 case) and 1 case of 
which the origin was not identified, 1 case 
of botulism type a is associated with the 
consumption of potatoes with onions and 
bacon. For one case, the origin and toxin 
type were not identified and another was 
declared by the French speaking communi-
ty without notification of origin and type. 
The evolution towards a reduction of cases 
of human foodborne botulism over the 
last decade suggests that the awareness 
of the public about the risk of botulism in 
food, improvements in food conservation 
methods and the treatment of industrial 
food products have succeeded in making 
human botulism rare in belgium.
detection of botulism in foodstuffs (nrl 
database: 2000-2009)
To maintain the safety of the industrial 
food chain, the NRl received specimens 
for the detection and the identification of 
botulinum neurotoxins and C. botulinum 
bacterial strains. These analyses were re-
quested by industrial food companies or 
by the FaSFC. During the last decade, no 
massive contamination of foodstuff by 
botulism was detected (NRl database). 
However, from 18 honey samples analysed 
for the FaSFC (in 2005 and 2006), 2 samples 
appeared positive for C. botulinum type D 
and type b. In 2009, another honey sample 
positive for C. botulinum type C was identi-
fied. Consequently the Scientific commit-
tee of the FaSFC recommended that all 
honey containers on sale in retail markets 
carry the label “do not administer to chil-
dren of less than one year old”. Several 
studies showed that honey can sometimes 
contain dormant spores of C. botulinum 
(1). This bacterium can be dangerous to 
infants as this vegetative form can be 
rapidly transformed into toxin-producing 
bacteria in the infant’s immature intesti-
nal tract, leading to illness and even death. 
Until now, no infant botulism has been 
reported in belgium. Thus, the monitor-
ing of botulism in foodstuffs by industrial 
food companies and by control of the food 
by the FaSFC is important to avoid the ap-
pearance of human foodborne botulism in 
belgium.
bird botulism 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Number of samples 60 36 48 44 49 52 29 22 16 16
Toxin type C
18/60 
30%
12/36 
33%
11/48
23%
12/44
27%
18/49
16.3%
11/52
21%
16/29
55%
6/22
27.2%
3/16
50%
7/16
43.7%
Toxin type D
0/60
0%
0/36
0%
0/48
0%
4/44
9%
2/49
4%
0/52
0%
0/29
0%
1/22
4.5%
0/16
0%
0/16
0%
bovine botulism 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Number of samples 9 11 41 65 26 43 81 157 195 283
Toxin type C
0/9
0%
0/11
0%
0/14
0%
0/65
0%
0/26
0%
0/43
0%
4/81
4.9%
3/157
1.9%
2/195
1.02%
2/283
0.7%
Toxin type D
0/9
0%
0/11
0%
6/14
41%
8/65
12%
0/26
0%
5/43
11%
6/81
7.4%
17/157
10.8%
16/195
8.2%
56/283
19.6%
table 2: cases of botulism in belgium (nrl database: 2000-2009).
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acKnoWledGementS
although the incidence of human botulism remains relatively low, the 
incidence of animal botulism is on the rise. this may provoke foodborne 
botulism by human consumption of products derived from contaminated 
animals. thus, surveillance of botulism in humans, animals, food and envi-
ronment remains important for public health in belgium.
i m P a c t  o n  P u b l i c  h e a l t h
evolution of outbreaks of animal botulism 
(nrl database: 2000-2009)
Each year, many cases of animal botulism 
are identified in belgium by the NRl. bird 
botulism is often associated with toxin 
and C. botulinum Type C (Table 2). In spite 
of the low number of samples analysed, 
our results suggest that this type of botu-
lism is on the rise in birds in belgium. The 
first cases (4 cases) of bird botulism type 
D were detected in 2003, but the outbreak 
of this type of botulism remains sporadic 
(Table 2).
bovine botulism is often associated with 
toxin and C. botulinum Type D (Table 2). The 
first cases (6 cases) of bovine botulism type 
D were recorded in 2002. Since then, the 
number of analysed samples and positive 
cases has increased. In 2006 the first cases 
(4 cases) of bovine botulism type C were de-
tected and, from then on, sporadic cases of 
this botulism type have been detected in 
cattle (Table 2). The origin of this outbreak 
has not been found. Many published re-
ports suggest that the source of toxins or 
C. botulinum strains type C, and type D are 
associated with carcasses of birds, particu-
larly of poultry, or small animals that may 
have contaminated the animal feed, water, 
pasture or litter (2, 3). This is also described 
in belgium (4).
animal botulism type b is rare in belgium. 
This botulism is sporadic in horses and 
only 2 cases were identified in bovines; one 
in 1998 (5) and another in 2009 (NRl data-
base). botulism Type b is often associated 
with the ingestion of putrefied vegetables, 
containing the toxin or the C. botulinum 
type b, present in the ensilages (5, 6). C. bot-
ulinum type b contaminated bovines may 
eliminate the bacteria in their faeces (6). 
Consequently, their milk may then be con-
taminated by the faeces through the cow’s 
udder. The presence of neurotoxin type b 
in milk from a cow presenting mastitis has 
been described (7), which clearly shows a 
possibility of toxin passage in milk. This 
neurotoxin type b may cause human botu-
lism.
research and development
Currently the mouse bioassay method is 
the only reference method for detecting 
botulinum toxin during botulism investi-
gations. although highly sensitive (5–20 
pg/ml), this method is time-consuming 
and requires specific authorisation and fa-
cilities such as mouse breeding in order to 
perform the test. The test takes a minimum 
of 4 days to detect a neurotoxin in clinical 
or food specimens. The identification of 
C. botulinum neurotoxin after culture of 
clinical and food samples can take a mini-
mum of 9 days. The routine availability of 
alternative, rapid, sensitive and specific 
methods for detection of both botulinal 
toxins and botulinogenic bacteria is an ur-
gent matter. Therefore, we are developing 
such in vitro methods. 
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introduction 
The causal link between fungal exposure 
and allergic problems has been clearly de-
monstrated by numerous international 
studies as the association between asth-
ma severity and mould (but not pollen or 
animal) allergen sensitisation (1). Strong 
evidence for an association between sen-
sitisation/exposure to moulds and life 
threatening exacerbations of asthma has 
also been obtained, further highlighting 
the detrimental properties of these aller-
gens (2). The reported worldwide preva-
lence of sensitisation to mould allergens 
is quite variable and evidently depends on 
differences in exposure. Nevertheless, an 
overall prevalence of fungal immunologic 
sensitisation determined as the presence 
of specific IgE as opposed to atopic dis-
ease, ranging from 3% to 9% in the general 
population and from 7% to 50% in asthmat-
ic children is often acknowledged (3). In the 
general population of the United States the 
prevalence of sensitisation to alternaria, 
one of the main allergenic moulds, was 
reported to be 12.9% (4). This prevalence is 
only an approximation since the diagnosis 
of mould sensitisation is hampered by the 
variability, complexity and lack of stand-
ardisation of available fungal extracts and 
therefore, for practical reasons, the meas-
urement of mould sensitisation is very of-
ten restricted to some species only.
Moulds are ubiquitous in nature and are 
present not only outdoors but very often 
also in the indoor environment, due to the 
colonisation of damp dwellings. If present 
in large numbers, especially in the case of 
dwelling colonisation, some mould species 
can represent a health hazard potentially 
causing or triggering allergic reactions 
and respiratory problems due to inhala-
tion of allergens. Moulds also produce 
secondary metabolites such as macrocy-
clic trichothecene mycotoxins which are 
known protein synthesis inhibitors. Some 
case studies and laboratory evidence sug-
gest that these toxins may contribute to 
reported complaints such as headache, 
eye and throat irritation, nausea, dizziness, 
nose bleeds, and both physical and mental 
fatigue in subjects occupying a mouldy 
environment (5). because of the increasing 
frequency of allergic diseases and the rec-
ognition of moulds and their metabolites 
as inducers or triggers of allergic and res-
piratory problems, the presence of moulds 
in houses, schools and other dwellings has 
become a major issue of public concern. In 
Northern Europe and Canada it has been 
estimated that 20 to 40% of house dwell-
ings are contaminated with moulds (6). 
Therefore it has become increasingly im-
portant to control the indoor environment, 
i.e. to identify mould contamination and 
quantify the levels in indoor environments 
using validated methods.
Current assessment methods of indoor 
mould contamination are based on sample 
cultivation or microscopic spore counts. 
although these techniques may be inform-
ative on a case by case basis they have 
major drawbacks. The direct microscopic 
spore count method is time consuming, 
subjective, shows a low sensitivity and 
high data variability. Methods based on cul-
ture analysis can overlook fungal species 
that are not easily cultured, may give an 
underestimate of those fungal types that 
grow slowly because they are overtaken 
by faster growing colonies and ignore the 
presence of nonculturable and non-viable 
spores or mycelia fragments (7). Recent de-
velopments in molecular techniques have 
provided significant advances in rapid 
detection and characterisation of micro-
organisms irrespective of their viability 
or cultivability. However, these molecular 
assays require skilled laboratory person-
nel, are not easily implemented for routine 
analysis and more importantly are expen-
sive. Surrogate markers of mould contami-
nation that measure quantitative loads of 
indoor fungal biomass such as β-glucan or 
ergosterol are useful for providing infor-
mation about the global amount of fungi. 
However their measurements are also very 
expensive and they require highly trained 
personnel and sophisticated analysers 
(HPlC and mass spectrometer) which ham-
per the routine use of these markers (8).
Therefore there is a need for the develop-
ment of better techniques able to identify 
environmental exposure to moulds and it is 
clear that the development of new assays 
will allow the development of new preven-
tive measures for public health purposes. 
Indeed, in its report “Damp Indoor Spaces 
and Health”, the Institute of Medicine of 
the US National academy of Sciences iden-
tified the development of valid and stand-
ardised quantitative exposure assessment 
methods (particularly methods based on 
non-culture techniques and measuring 
constituents of micro-organisms such as 
allergens, β-glucans, fungal spores, etc.) as 
a high research priority (9). 
Monoclonal antibodies (Moabs) are power-
ful tools for the detection, quantification, 
and targeting of specific molecules. There-
fore, immunoassays have become com-
mon techniques in diagnostic laboratories. 
Nowadays Moabs are frequently used for 
the detection of numerous compounds 
and for the assessment of exposure to 
numerous agents. Immunodetection 
techniques are very flexible, inexpensive, 
easily implementable and standardisable 
and could be interesting tools for the de-
velopment of new assessment methods of 
indoor fungal contamination. Therefore 
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we developed a panel of rat Moabs specific 
for mould antigens and for the Verrucarin-
a, an important trichothecene mycotoxin. 
We also established immunoassays for the 
detection of these compounds. We will de-
scribe here two immunoassays that we es-
tablished and which would be helpful for 
the rapid assessment of mould contamina-
tion in dwellings.
methodS
lOU/c rats were immunised weekly in 
both footpads with 106 spores of alter-
naria alternata (IHEM 18586) or with 20 µg 
of Verrucarin-a coupled to bovine serum 
albumin (bSa). after the third immunisa-
tion, lymphocytes were obtained from the 
popliteal lymph nodes and fused using the 
polyethylene glycol method, with HGPRT 
mutated IR-983F myeloma cells. The cell 
mixture was then cultured in microplates 
in HaT medium containing the selective 
drug. as immune cells, although not sen-
sitive to the HaT medium, survive for only 
about one week in culture and the IR-983F 
myeloma cells are drug sensitive they will 
all die within a week or so. The only cells 
that can survive during a culture in the HaT 
medium are those hybrid myeloma cells 
that obtained a normal HGPRT gene from 
the immune cells.
The supernatants of growing hybridoma 
were collected and analysed for the pres-
ence of mould specific or verrucarin-a 
specific Moabs. The presence of mould 
specific Moabs in the supernatants was 
analysed by fluorocytometry on spores 
from relevant mould species contaminat-
ing indoor environments (5 different a. 
alternata strains; C. herbarum, cladospo-
rioides, sphaerospermum; P. chrysogenum, 
brevicompactum; a. niger; S.chartratum; 
U.botrytis). Two yeasts were used as nega-
tive controls (C. albicans and S. cerevisiae). 
Spores were obtained from 15-day cultures 
on PDa medium. Moulds antigens were ex-
tracted from the spores by overnight agita-
tion in PbS. The presence of Verrucarin-a 
specific Moabs in the supernatants was 
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figure 1:
flow cytometric analysis of the specificities of lo-mo-1, -3 and -5. mould spores were 
incubated with the indicated antibodies. bound antibodies were detected using an fitc la-
belled anti-rat antibody. the fluorescence was analysed on a facScalibur flow cytometer. the 
blue histogram gives the non-specific binding. the red-line histogram indicates the specific 
binding of the lo-mo-1, -3 and -5 respectively.
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detected using an indirect immunoassay. 
ElISa plates were coated with Verrucarin-a 
coupled ovalbumin (OVa). Then superna-
tants were added and the binding of Moabs 
was detected using a peroxidase labelled 
mouse antibody directed against the 
kappa light chain of rat immunoglobulins. 
Positive clones were subcloned and then 
expanded in small bioreactors. The medi-
um containing the Moabs were repeatedly 
collected and the antibodies were purified 
by immunoaffinity.
Mould antigens were detected using a sand-
wich ElISa. “In-house” developed mould 
specific antibodies were used as capture 
antibodies and biotinylated antibodies 
and streptavidin labelled peroxidase were 
used for the detection. Verrucarin-a was 
detected using a competitive ElISa. Plates 
were coated with OVa labelled Verrucarin-
a. The binding of Verrucarin-a specific Mo-
abs to the coated antigens was inhibited 
by the free Verrucarin-a added in solution. 
The bound Moabs were detected using a 
mouse antibody directed against the ka-
ppa light chain of rat immunoglobulins.
reSultS
Popliteal lymph node cells from lOU/c rats 
immunised in the footpads with spores of 
a. alternata were fused with IR-983F cells. 
Growing hybridomas were selected in HaT 
medium and positive clones were selected 
by flow cytometry. Five different Moab 
were obtained. lO-MO-1, -3 and -5 were able 
to bind alternaria spores in flowcytometry 
and also recognised alternaria mould ex-
tract using an indirect ElISa. These Moab 
are all IgM. lO-MO-2 and -4 were of IgG2c 
and IgG1 isotype respectively and did not 
recognise mould extract by ElISa.
The specificities of lO-MO-1, -3 and -5 were 
further analysed using a FaCSCalibur flow 
cytometer (Figure 1). lO-MO-3 binds to 
alternaria spores IHEM 18586 and also to 
four other alternaria strains (not shown). 
However this antibody does not bind 
Cladosporium, Penicilium, aspergillus, 
Stachybotrys nor Candida or Saccharomy-
ces strains demonstrating that it is species 
specific. Nevertheless, it also recognises 
Ulocladium botrytis, a species phylogeni-
cally very close to alternaria ssp. The two 
other Moabs (lO-MO-1 and -5) recognise 
all mould strains tested so far but not the 
two yeast strains (C. albicans and S. cerevi-
siae) indicating that these two antibodies 
bind an antigenic determinant common to 
moulds but not to yeasts. These two anti-
bodies may therefore be used to determine 
the total mould biomass in dwellings while 
the lO-MO-3 could be used for quantifying 
specifically alternaria antigens.
a sandwich ElISa using the lO-MO-5 was 
established and used to detect the pres-
ence of the recognised antigen in various 
mould extracts prepared in the labora-
tory. as shown in Figure 2a, this assay was 
figure 2:  mould specific eliSa. 
a. detection of mould but not yeast antigens in various extracts prepared in the laboratory using 
  a lo-mo-5 based sandwich eliSa. 
b.  detection of mould antigens in dust vacuum- cleaned from dwellings. the numbers indicate 
 the equivalent c.herbarum spores (x103)/ml in these field samples. 
c. detection of verrucarin-a in solution using a competitive f24-1G2-based eliSa. two samples 
 containing the free verrucarin-a or the free roridin-a were analysed. only the free verrucarin-a 
 was able to inhibit the binding of the f24-1G2 moab to the verrucarin-a labelled ova.
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acKnoWledGementS
the association between fungal exposure and allergic-respiratory problems 
has been clearly established. moulds are ubiquitous and can be present 
indoors due to their colonisation of damp dwellings. the development of 
new methods allowing an easy and rapid testing of mould contamination 
will contribute to the safety of our environment.
i m P a c t  o n  P u b l i c  h e a l t h
able to efficiently detect mould antigen in 
extracts from a. alternata, C. herbarum, S. 
chartratum, P. chrysogenum and a. niger 
while extracts from C. albicans and S. cer-
evisiae were not recognised, confirming 
the flow cytometric results.
Using this lO-MO-5 based ElISa we are now 
determining the quantity of mould anti-
gens in air and dust samples from dwell-
ings (Figure 2b). an extract of C. herbarum 
spores is used as an internal standard for 
the quantification of field samples and a 
“logit” regression is applied to calculate 
the standard curve. The intra-assay coeffi-
cient of variation (CV) for this assay is be-
low 10% and the inter-assay CV is 20.58%. 
The sensitivity of this assay was estimated 
to be between 4000 and 2000 equivalent 
spores per ml. We are currently compar-
ing the results obtained with this rapid as-
say with those obtained with the classical 
microbiological techniques currently used 
for the determination of mould biomass in 
the air.
another interesting antibody has been 
obtained from rats immunised with bo-
vine serum albumin coupled to the tri-
chothecene mycotoxins Verrucarin-a. 
Of the 553 tested clones, 70 clones (13%) 
produced antibodies recognising the Ver-
rucarin-a bound to OVa. Only one of these 
clones (F24-1G2) produced a Moab which 
was inhibited by free Verrucarin-a in solu-
tion. This antibody is able to bind to OVa or 
bSa labelled Verrucarin-a but not to these 
same proteins labelled with Roridin-a (an-
other trichothecene mycotoxin with a very 
similar structure) or to the unlabelled pro-
teins, demonstrating the specificity of this 
Moab towards the Verrucarin-a only. In a 
competitive ElISa, free Roridin-a was un-
able to inhibit the binding of the F24-1G2 
antibody to the OVa-Verrucarin-a while 
this binding was efficiently inhibited by 
free Verrucarin-a (Figure 2C). Once opti-
mised, this assay showed an intra-assay CV 
below 15% and an inter-assay CV of 29.9%. 
The overall sensitivity of this competitive 
ElISa ranged between 1 and 2 ng/ml of free 
Verrucarin-a. 
concluSion
We have developed rat Moabs recognis-
ing ubiquitous mould antigens (lO-MO-1 
and -5), an alternaria specific antigen (lO-
MO-3) or Verrucarin-a, an important tri-
chothecene mycotoxin. Using these Moabs 
we have developed several sensitive and 
reproducible ElISas able to detect these 
components. We are currently comparing 
the efficacy of this kind of detection with 
the classical microbiological techniques 
for evaluation of mould biomass in dwell-
ings. We hope that these Moabs will allow 
the development of new rapid methods for 
the efficient evaluation of indoor mould 
contamination, permitting a better estima-
tion and control of microbiological pollu-
tion in dwellings.
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discovery of a fascinating thiamine- and 
siderophore-auxotrophic fungus
h. beguin
K. Goens
introduction
Exposure to fungi may induce respiratory 
or allergic diseases. During an investiga-
tion of indoor fungi as potential allergens, 
we isolated a hyphomycetous species 
parasitising a Penicillium sp., apparently 
causing no harm or inhibition to the host 
(Figure 1). This mycoparasite was depos-
ited in the bCCM/IHEM Culture Collection 
hosted by the Scientific Institute of Public 
Health, brussels, belgium.
The first attempts to obtain this mycopara-
site in axenic culture failed. This fungus 
thus had an absolute requirement for one 
or more nutrients produced by the Penicil-
lium host, just like biotrophs (obligate par-
asites with balanced relationships) depend 
on nutrients from their hosts. biotrophic 
mycoparasites are divided into two main 
groups: filamentous haustorial biotrophs 
belonging to families formerly classified 
in Mucorales, and contact biotrophs, all 
hyphomycetous species producing spe-
cialised branches to contact the host 
hyphae to absorb nutrients. The most fre-
quent growth factor of contact biotrophs, 
referred to in the literature as “mycotroph-
ein”, is present in hot water extracts of their 
hosts, in particular in alternaria alternata. 
Other fungi release this growth factor into 
the substrate, thus supporting saprobic 
growth of these biotrophs. Until now, the 
chemical nature of this growth factor had 
remained unknown.
among the substrates tested, the isolated 
mycoparasite was able to grow on rabbit 
droppings. In this regard, Hesseltine and 
co-workers (1) have shown that dung or 
dung extracts, required for the growth of 
some strictly dung inhabiting fungi, could 
be replaced by an iron containing com-
pound from the fermentation liquors of 
a number of bacterial and fungal species. 
They named this growth factor ‘coprogen’. 
another study reported that ferrichrome 
could replace coprogen or dung decoction 
in culture media for culturing these spe-
cies (2). later, it was shown that coprogen 
and ferrichrome functioned as iron-trans-
porting agents in microbial metabolism. 
Obviously, the Penicillium culture filtrate, 
the growth factor mycotrophein, and the 
commercially available compound ferri-
chrome had to be tested on our newly iso-
lated fungal strain.
The purpose of this study was to determine 
the requirements for the axenic growth of 
this mycoparasite, and to try to clarify its 
nutritional relationship with its host. 
materialS and methodS
The host Penicillium strain was cultivated 
in a 1,000 ml Erlenmeyer flask containing 
250 ml of Sabouraud Glucose broth, and 
stationary incubated in continuous dark-
ness at 25°C. The liquid phase was recov-
ered 15 days later and sterilised by filtra-
tion (single use filter unit of 0.2 µm from 
Sartorius). To assess the effects of this cul-
ture filtrate on the mycoparasite growth, 
decreasing quantities of the filtrate were 
mixed in 9 cm Petri plates to approximately 
30 ml of melted malt extract agar (MEa), or 
the glucose-casein hydrolysate agar (GCH), 
a vitamin-free medium supplemented or 
not with biotin and thiamine at concen-
trations of 20 and 100 µg l−1 respectively. 
after cooling, the mycoparasite conidia 
were inoculated alone or with those of 
Penicillium sp. (at the same time and the 
same place), and Petri plates were incu-
bated at 25°C in continuous darkness for 
21 days. 
Hot water extract of a. alternata was ob-
tained as described by Hwang et al. (3). This 
extract and ferrichrome were blended into 
Petri plates to the basal medium MEa, sin-
gly or together, in various concentrations. 
Mycoparasite conidia were then inoculat-
ed, and Petri plates incubated at 25°C, for 
21 days.
The ferrichrome stock solution (ferri-
chrome iron-free from Ustilago sphaero-
gena, Sigma), was prepared by dissolving 
1 mg in 50 ml distilled water (2 µg ml−1). 
Successive concentrations from 0.001 mg 
l−1 to 1 mg l−1 were tested. 
all experiments were repeated three times 
or more. 
reSultS 
Peculiar properties of the Penicillium cul-
ture filtrate
 
Mycoparasite conidia deposited on semi-
synthetic culture media (GCH, GCH + thia-
mine & biotin, and MEa) germinated but 
the germination process stopped imme-
diately; only relatively long germ tubes 
were formed. The fungus grew on media 
supplemented with 1 ml of a culture fil-
trate from the 15-day-old Penicillium liquid 
culture. However, sporulation observed on 
the vitamin-free medium GCH to which the 
filtrate was added was abnormally low. Un-
like biotin, the injection of thiamine alone 
to the mixture mentioned above support-
ed the normal growth of the fungus. When 
the Penicillium sp. and the mycoparasite 
conidia were inoculated jointly, the latter 
appeared only after the fourth day on the 
top of the Penicillium colonies, without 
showing a significant difference accord-
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ing to the culture medium. The mycopara-
site then received the nutrient(s), possibly 
mycotrophein, as well as a vitamin essen-
tial to its growth from the host mycelium 
via the culture medium or via absorptive 
structures.
Presence of particular morphological 
structures 
Microscopic observation of cultures 
showed no tropism between germ tubes 
of the mycoparasite conidia and hyphae 
of the host. The mycoparasite did not form 
structures resembling haustoria or absorp-
tive branches which would indicate it was 
a haustorial or contact biotroph. 
Growth factors activity 
Hot water extracts from a. alternata acted 
at infinitesimal concentrations since a 
1,000-fold dilution of the extract (less than 
0.1 ml) in the basal medium MEa already 
induced an axenic growth of the myco-
parasite. However, sporulation of colonies 
formed by the fungus with this extract was 
weak (even when more extract was incor-
porated into the medium). Moreover, the 
conidia from these colonies were unable 
to germinate on a culture medium, mean-
ing that they were lacking something cru-
cial for germination. Successive hot water 
extracts of alternaria produced the same 
result and affected identically the growth 
of the parasite. Since they came from a 
fungus known to produce mycotrophein, 
these extracts theoretically contained this 
growth factor. Similarly to mycotrophein, 
these extracts acted at infinitesimal con-
centrations, were heat stable, and soluble 
in water and acetone. This suggested that 
mycotrophein was not the exact require-
ment of the fungus, or that it needed an 
additional substance (a third after thia-
mine and mycotrophein). However, when 
ferrichrome was added alone in the MEa 
medium, the mycoparasite grew normally. 
a concentration of 0.1 mg l−1 (≈ 10 µM) 
gave the same sporulation as that ob-
served with the Penicillium culture filtrate. 
Moreover, conidia produced with the a. 
alternata extract germinated on MEa sup-
plemented with ferrichrome, or with Peni-
cillium culture filtrate. However, addition 
of ferrichrome to the vitamin-free medium 
GCH failed to support axenic growth of the 
mycoparasite. Unlike biotin, the injection 
of thiamine alone to the same mixture sup-
ported the normal growth of this curious 
fungus.
These experiments showed that our myco-
parasite required thiamine and a growth-
promoting iron chelate (ferrichrome or a 
related compound). 
diScuSSion and concluSionS
Thiamine, a water-soluble vitamin (vitamin 
b1) plays a pivotal role as coenzyme in in-
termediary carbon metabolism. although, 
most fungi are able to synthesise this vi-
tamin, our parasite cannot! Knowledge on 
thiamine production pathways in fungi 
mainly comes from the yeast Saccharo-
myces cerevisiae, which either utilises 
external thiamine or can synthesise the 
cofactor itself (4). Thiamine is complicated 
to synthesise, its biosynthesis is an ener-
gy-costing process (4, 5), and exogenous 
thiamine represses genes encoding the 
enzymes involved in the metabolism of 
thiamine (6). Therefore, our mycoparasite 
probably became thiamine auxotroph fol-
lowing a continuous external supply as in a 
close and long term relationship between 
a mycosymbiont and its host. This hypo-
thesis is all the more plausible since sever-
al studies have shown that concentrations 
of thiamine in the natural environment are 
much lower than those normally required 
by thiamine dependent organisms (7).
Most fungi produce distinct cellular and 
extracellular siderophores in order to solu-
bilise environmental iron, particularly in 
low-iron environments. These low-molec-
ular-mass complexing agents, covering a 
wide range of physico-chemical properties, 
have an extremely high affinity for extra-
cellular ferric iron and bind this metal avid-
ly (8, 9). approximately 100 to 150 different 
fungal siderophore structures have al-
ready been described (9). The ferrichromes, 
figure 1: 
a five-week-old culture of the mycoparasite and its host Penicillium sp. on mea. 
the mycoparasite (coloured ochreous) appeared a few days after inoculation in the middle 
of the Penicillium colony.
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coprogens, fusarinines and rhodotorulic 
acid represent the four structural families 
of the hydroxamate-type identified in the 
asco- and basidiomycota (10). Our parasite 
is unable to acquire iron in an independ-
ent manner since its growth is dependent 
on the presence of the siderophore ferri-
chrome in the culture medium.
If this mycoparasite was able to grow with 
the hot water extract of alternaria, it was 
because an iron-chelating agent present in 
this extract had provided it with iron. alter-
naria is known to make only ferricrocin and 
coprogen-type siderophores (8). assuming 
that siderophores are interchangeable as 
growth factors for the mycoparasite, our re-
sults suggest that ferrichrome is a far more 
efficient iron donor. In addition to captur-
ing and transporting iron, siderophores 
store solubilised iron in the fungal cells. 
Since conidia are dormant cells that re-
quire a large input of iron for germination, 
intracellular siderophores are essential for 
an iron storage function, and have been 
recognised as conidial germination factors 
of some fungi (11, 12). Most conidia still 
contain a certain amount of siderophores 
that are released during germination (13). 
Moreover, intracellular siderophores have 
a crucial role in conidiogenesis, and a defi-
ciency in these cellular compounds leads to 
reduced conidia production in aspergillus 
nidulans and aspergillus fumigatus (14, 15).
Such phenomena were observed during 
this study. When the mycoparasite grew 
with the siderophore ferrichrome, sporu-
lation and conidial germination were 
normal, whereas with the alternaria ex-
tract the sporulation was reduced, and 
conidia were unable to germinate. These 
conidia had become siderophore-depen-
dent. Just like conidia without intracellu 
lar siderophores, lacking an active iron 
transport mechanism. The most plausible 
explanation would be that, whereas the 
ferrichrome was transported inside the 
cells, which implied that conidia contained 
some, the unspecified siderophore present 
in hot water extract of alternaria yielded 
iron to the cells without concomitant up-
take of the ligand.
Symbiosis is, in its broad sense, an asso-
ciation between different organisms liv-
ing together that range from parasitism 
to mutualism. This study showed that the 
major (or the only) route for thiamine ac-
quisition by the mycoparasite came from 
an exogenous source via a symbiotic re-
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iron plays a central role in fungal-host interactions. essential mechanisms 
intended to ensure the iron homeostasis in pathogenic and symbiotic fungi 
are still little known and their understanding requires the study of these 
associations. Siderophore biosynthesis pathways are currently the subject 
of several studies, in order to find new antifungal agents.
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lationship. Since energy is required for 
the siderophore biosynthesis and for the 
essential mechanisms intended to avoid 
toxic accumulation of intracellular iron, 
and because its host excreted enough hy-
droxamate ligands, the mycoparasite prob-
ably also became siderophore auxotroph. 
In mycosymbionts of fungi, an association 
in which one symbiont benefits and the 
other suffers no adverse effects is known 
as a biotrophic fungal symbiosis (16). Such 
is the case for the relationship between 
this mycoparasite and the Penicillium sp. 
However, an interfungal association based 
on utilisation of siderophores has not 
been previously reported. Moreover, this 
thiamine- and siderophore-deficient mu-
tant does not live in intimate association 
with the cytoplasm of its host. Indeed, it is 
neither a contact biotroph nor a haustorial 
biotroph, the two groups in which the my-
cosymbionts of fungi are classified. There-
fore, our fungus represents a new type of 
biotrophic mycosymbiont.
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effect of the neutralisation of il-17a on  
the immune response to mycobacterium 
tuberculosis infection
d. freches, h. Korf
C. Uyttenhove
J. Van Snick 
M. Moser
K. huygen
m. romano
introduction 
With about 9 million new cases and 2 mil-
lion deaths each year, tuberculosis (Tb), a 
disease caused by infection with Myco-
bacterium tuberculosis (Mtb), remains a 
major health problem. It is estimated that 
a third of the world population is latently 
infected with Mtb (1). among infected in-
dividuals, 10% are susceptible to develop 
symptomatic Tb during their lives and thus 
may become contagious (2). a major risk 
factor for the development of Tb is HIV co-
infection (3). The attenuated M. bovis bCG 
(bacille Calmette-Guérin) strain is still the 
only available Tb vaccine. bCG is however 
poorly efficient against pulmonary Tb, the 
most common form of Tb in adults (4). De-
velopment of more effective Tb vaccines 
is essential and requires a better under-
standing of the immune response against 
Mtb. Mtb is an intracellular pathogen able 
to replicate and to enter into a dormant 
state in pulmonary macrophages. Protec-
tive immunity against Mtb depends on in-
teractions between T cells (CD4+ Th1, CD8+, 
CD1-restricted and γδ) and macrophages. 
Interleukin-12 (Il-12) produced by infected 
macrophages and dendritic cells (DCs) is re-
quired for the induction of IFN-γ and TNF-α, 
which are both essential in controlling Mtb 
growth and granuloma formation (5, 6). The 
role played by other cytokines such as Il-
17a in the response against Mtb is still not 
fully understood.
Il-17a is the founding member of a newly 
described family of cytokines (Il-17a to Il-
17F). Il-17a is a proinflammatory cytokine 
primarily produced by CD4+ T cells (Th17) 
that promotes the granulopoiesis and the 
recruitment of neutrophils to the site of 
infection through the induction of CXC 
chemokines lIX (CXCl5), KC (CXCl1), Il-6, Il-
8, G-CSF and TNF-α. In the context of auto-
immune diseases (such as experimental 
auto-immune encephalitis (EaE) and rheu-
matoid arthritis), Il-17a has detrimental 
effects by promoting inflammation. Il-17a 
plays an important role in the protection 
against different pathogens like C. albicans 
or K. pneumoniae and is produced during 
Mtb infection (7). However, little is known 
about the role of Il-17a in Mtb control and 
published data is controversial. Studies by 
Khader et al. have shown that although Il-
17a response is dispensable for protection 
against Mtb during primary infection, Il-
17a response is nevertheless implicated in 
an optimal IFN-γ recall response in the lung 
(8, 9). Moreover, lung-infiltrating T cells of 
Il-17a-deficient mice challenged with bCG 
produce less IFN-γ in comparison to wild 
type mice and a defective granuloma for-
mation is observed (10). Our laboratory has 
shown that boosting of bCG vaccinated 
mice by subsequent Modified Vaccinia 
ankara virus expressing antigen 85a (MVa-
ag85a) resulted in increased IFN-γ respons-
es and induced an Il-17a response. This 
bCG-MVa-ag85a vaccination protocol did 
not result in increased protective efficacy 
of bCG and we hypothesised that ampli-
fied inflammation possibly linked to the 
observed Il-17a responses had occurred 
with this protocol (11). Hence our inter-
est in analysing in more detail, the role of 
Il-17a in the context of Mtb infection and 
Mtb vaccine development. 
Here, we have analysed the effect of the 
neutralisation of Il-17a on the course of 
Mtb infection in mice. Il-17a was neutral-
ised using an anti-Il-17a auto-vaccine de-
veloped by Drs Uyttenhove and Van Snick 
(Institut De Duve, UCl, bruxelles) (12). The 
aim of this preliminary study was to un-
derstand the role of Il-17a in Mtb infec-
tion and to evaluate the potential effect 
of a treatment neutralising Il-17a on the 
susceptibility to Mtb infection. Indeed, 
development of therapeutic agents able 
to block Il-17a bioactivity is in progress to 
treat auto-immune diseases. 
materialS and methodS
mice
7 weeks old Dba/2 (H-2d) female mice were 
used (obtained from Janvier).
il-17a neutralisation
To neutralise Il-17a bioactivity, mice were 
vaccinated with anti-Il-17a auto-vaccine. 
This vaccine is composed of recombinant 
murine Il-17a dimer cross-linked to oval-
bumin with glutaraldehyde and is admin-
istered subcutaneously with Gerbu100 
adjuvant (Gerbu biotechnik). Mice were 
injected seven times at two-week intervals 
with 2 µg Il-17-OVa complexes suspended 
in 50 µl PbS and 50 µl Gerbu100 adjuvant. 
The neutralisation of Il-17a was checked 
by Drs Uyttenhove and Van Snick for each 
mouse using an Il-6 bioassay (12). Uninject-
ed mice were used as control. 
m. tuberculosis infection
Mice were inoculated intratracheally three 
weeks after the last anti-Il17a vaccination 
with 104 CFU of luminescent Mtb H37Rv. 
This strain is transformed with the pSMT1 
plasmid, which encodes a bacterial luci-
ferase under the control of the constitutive 
mycobacterial hsp60 promoter. bacterial 
load in lung and spleen homogenates was 
quantified by enumerating the number of 
bioluminescent organisms (determined as 
relative light units [RlU]). 1% n-decanal in 
ethanol was used as substrate. We have 
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previously shown that RlU counting corre-
lated with CFU enumeration on agar plates 
(13). animals were sacrificed by cervical dis-
location 2, 4 and 13 weeks after challenge. 
isolation of cell populations from lung 
tissue
CD11c+ cell fraction was isolated from 
homogenised lung tissue samples using 
magnetic beads coupled with antibody 
(becton-Dickinson). Single-cell suspensions 
of lung tissue were prepared by digestion 
with RPMI 1640 medium supplemented 
with 2.4 mg/ml collagenase (Sigma-aldrich) 
and 1 mg/ml DNaseI (Roche) for 30 min at 
37°C. The digest was passed through a 70-
µm cell strainer, and erythrocytes were 
lysed with NH4Cl-Tris buffer. 
rt-qPcr
RNa was extracted using a commercially 
available RNeasy kit according to the manu-
facturer’s instructions (bIORaD). cDNa was 
synthesised using a TaqMan Reverse Tran-
scription Reagent kit (Roche). RT-qPCR was 
performed on an abI Prism 7700 Sequence 
Detector (applied biosystems) using a qPCR 
Core Kit for Sybr Green I (Eurogentec). Each 
RT-qPCR amplification was performed 
under the following conditions: 50°C for 2 
minutes and 95°C for 10 minutes, followed 
by 40 cycles at 95°C for 15 seconds and 60°C 
for 1 minute. Hydroxymethylbilane syn-
thase (HMbS) mRNa was used as reference 
housekeeping gene for normalisation. The 
level of target mRNa, relative to the mean 
of the reference housekeeping gene, was 
calculated as previously described (14).
assessment of leukocyte distribution in 
bal fluid
Mice were killed and broncho-alveolar lav-
age (bal) was performed. The total volume 
and cell number recovered from the bal 
were recorded. Number and composition 
of cells infiltrating the lungs were deter-
mined using cytospin for individual mice. 
Cells were classified as mononuclear cells, 
neutrophils and lymphocytes using stand-
ard morphological criteria after staining 
with Kwikdiff coloration (Thermo). at least 
200 cells were counted per cytospin prepa-
ration, and the absolute number of cells 
for each cell type was calculated.
reSultS 
vaccination with the anti-il-17a auto-
vaccine induces the production of il-17a 
antibodies
To block biological activity of Il-17a, Dba/2 
mice were injected seven times with an 
anti-Il-17a auto-vaccine formulated with 
Gerbu100 adjuvant before Mtb infection. 
This immunisation induced the production 
of antibodies able to neutralise the bio-
logical activity of Il-17a (data not shown). 
anti-Il17a antibodies levels in the sera re-
mained stable throughout the infection 
and were comparable to the levels ob-
tained in SJl mice, which were vaccinated 
with the same auto-vaccine and could be 
protected against EaE (12).
il-17a neutralisation has a moderate ef-
fect on the susceptibility to mtb infection
 
Control mice and mice vaccinated with the 
anti-Il17a auto-vaccine were infected by 
the intratracheal route with a low dose of 
104 CFU of luminescent Mtb H37Rv. 2, 4 and 
13 weeks after infection, mice were sacri-
ficed and the number of bioluminescent 
bacilli was evaluated in spleen and lungs. 
The bacterial burden in the spleens of the 
Il-17a neutralised mice and control ani-
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Figure 1: Bacterial counts in the lungs and spleen of DBA/2 mice with IL-17A neutralized □ or not ■ at different time points
after intratracheal instillation of luminescent Mtb (104 CFU). Dots represent the mean log10(mRLU) values obtained for
individually tested animals and the bar represents the mean value for each group. Statistical significance between groups is
represented in the figure by **(0.005 < p < 0.010) and was evaluated by Student’s t-test.
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figure 1:
bacterial counts in the lungs and spleen of dba/2 mice with il-17a neutralised γ or not γ at different time points after intratracheal instillation of lu-
minescent mtb (104 cfu). dots represent the mean log10(mrlu) values obtained for individually tested animals and the bar represents the mean value 
for each group. Statistical significance between groups is represented in the figure by **(0.005 < p < 0.010) a d wasevaluated by Student’s t-test.
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mals were comparable at 2, 4 and 13 weeks 
post-infection. Regarding bacterial burden 
in lungs, no effect was observed at weeks 
2 and 4 post-infection but a moderate in-
crease in the anti-Il-17a vaccinated mice 
(0.5 log10mRlU ) was observed at week 13 
(Figure 1). Moreover, Il-17a neutralisation 
had no effect in terms of weight loss and 
lung histological analysis did not reveal 
any difference between the two experi-
mental groups (data not shown).
il-17a neutralisation induces a loss of 
neutrophils recruitment in the lungs dur-
ing the first 4 weeks after mtb infection
Il-17a is implicated in the recruitment of 
neutrophils to the site of infection via its 
induction of the production of neutrophil 
recruiting chemokines such as CXCl5/lIX 
(7). We have therefore performed an analy-
sis of the composition and the number of 
cells infiltrating the lungs, by performing 
a cytospin analysis of the bal cells. Our re-
sults demonstrate that neutrophils are ab-
sent at least during the first 4 weeks after 
infection in the lungs of Il-17a neutralised 
mice as compared to control mice, never-
theless neutrophils infiltrating the lungs 
were observed 13 weeks after infection in 
these mice (Figure 2). No differences were 
observed for lymphocyte or macrophage 
recruitment between the two groups (data 
not shown). Moreover, 4 weeks after infec-
tion, a lower CXCl5/lIX mRNa expression 
was observed in CD11c+ lung cells of the 
Il-17a neutralised group versus control. 
These results confirmed the specific role of 
Il-17a in neutrophil recruitment (Figure 2). 
concluSion
a clear understanding of the role of Il-17a 
during Mtb infection is still not available. 
In this study, we have investigated the ef-
fect of the neutralisation of Il-17a during 
Mtb infection in mice. For that purpose, we 
have used an anti-Il-17a auto-vaccine in-
ducing long-lasting Il-17a-neutralising an-
tibodies that block the biological activity 
of Il-17a (12). To perform this study Dba/2 
mice were selected. Indeed, among the 
mouse strains generally used to study Mtb 
infection, Dba/2 mice are more susceptible 
to Tb than C57bl/6 or balb/c (15) and this 
has been attributed to an increased neu-
trophil recruitment in the lungs of Dba/2 
mice after infection (16). Our results show 
that the number of neutrophils infiltrating 
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Figure 2:
A. Neutrophil infiltration in the lungs of DBA/2 mice with IL-17A neutralized (□) or not (■) at
different time points after intra-tracheal instillation of luminescent Mtb (104 CFU). Shown
are absolute numbers of neutrophils. Data are mean ± SEM (n = 4-5).
B. mRNA expression of LIX/CXCL5 by CD11c+ pulmonary cells of DBA/2 mice with IL-17A
neutralized or not, 4 weeks after intra-tracheal instillation of luminescent Mtb (104 CFU).
Data are expressed as relative mRNA levels, normalized against reference housekeeping
gene. Dotted lines denote mRNA levels obtained from non infected mice.
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figure 2:
a. neutrophil infiltration in the lungs of dba/2 mice with il-17a neutralized () or not () at different time points after intra-tracheal instillation of 
 luminescent mtb (104 cfu). Shown are absolute numbers of neutrophils. data are mean ± Sem (n = 4-5). 
b. mrna expression of lix/cxcl5 by cd11c+ pulmonary cells of dba/2 mice with il-17a neutralized or not, 4 weeks after intra-tracheal istillation of 
 luminescent mtb (104 cfu). data are expressed as relative mrna levels, normalized against reference housekeeping gene. dotted lines denote 
 mrna levels obtained from non infected mice.
the lungs during the first 4 weeks of infec-
tion was decreased in the group of mice 
that had received the Il-17a auto-vaccine 
compared to infected control mice. This 
can be attributed to the fact that Il-17a 
is implicated in neutrophils recruitment. 
Indeed, CXCl5/lIX expression in the Il-17a 
neutralised mice was lower compared to 
infected control mice. lIX has chemoat-
tractant activity for neutrophils and is 
induced by Il-17a. Therefore these results 
both confirm that vaccination with Il-
17a-OVa + Gerbu100, indeed induced the 
neutralisation of Il-17a. However, at 13 
weeks post infection, neutrophils were 
observed in these anti-Il-17a vaccinated 
mice despite similar Il-17a antibody lev-
els at week 13 post-infection and before 
infection. It is likely that neutrophils are 
recruited by other factors at this late time 
point. absence of neutrophils at the early 
time points after infection did not corre-
late with differences in the bacterial load 
in the lungs. However, the bacterial load 
13 weeks after infection was higher in Il-
17a neutralised mice compared to control 
infected mice. The role of neutrophils in 
mycobacterial infections remains a sub-
ject of controversy. One study showed an 
increased bacterial load when neutrophils 
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Source
tuberculosis is a worldwide health problem. investigating immune factors 
involved in host response to mycobacterium tuberculosis is important for 
the development of new, more efficient tuberculosis prevention strategies. 
it is also essential for determining the impact of new immunotherapy, under 
development to treat other diseases, on the susceptibility to tuberculosis.
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are depleted at early time points after in-
fection (17) but another study failed to 
detect any difference in bacterial counts 
in neutrophils-depleted mice (18). a recent 
study demonstrated that neutrophils have 
the capacity to activate DCs. bCG-infected 
neutrophils facilitate full maturation, cy-
tokine production and antigen presenta-
tion by DCs. Therefore, it was suggested 
that neutrophil deficiencies lead to non 
optimal protective antimycobacterial im-
mune responses (19). The decreased neu-
trophil infiltration observed in our study 
in the first 4 weeks post-infection may thus 
explain the differences in bacterial loads 
observed at week 13. Further experiments 
are needed to confirm this hypothesis.
The aim of this preliminary work was not 
only to acquire knowledge about the role 
of Il-17a during Mtb infection, but also to 
investigate potential effects of the Il-17a 
auto-vaccine on Mtb infection. Indeed, 
this auto-vaccine is protective against EaE 
in SJl mice and has a potential as a future 
treatment against auto-immune disease 
(12). In this context, it was interesting to 
analyse the impact of this Il-17a neutrali-
sation on Mtb infection susceptibility. In 
future experiments, it will be interesting to 
use the auto-vaccine after infection to ana-
lyse if this treatment has an effect on the 
reactivation of a latent infection.
In summary, our data show that the neu-
tralisation of Il-17a induces depletion of 
neutrophils in the lungs during at least 4 
weeks after Mtb infection and leads to a 
moderate increase in lung bacterial loads 
at the latest time point tested. However, 
more experiments are needed to conclude 
on the impact of Il-17a neutralisation on 
Mtb infection. 
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environmental Staphylococcus 
contamination in a production plant 
at the origin of a foodborne outbreak
n. botteldoorn
S. denayer
c. Wildemauwe
K. dierick
introduction 
Staphylococcal food poisoning outbreaks 
are one of the most significant among 
foodborne outbreaks in Europe and are 
characterised by nausea, vomiting, abdom-
inal pain and diarrhoea. The incubation pe-
riod is short (2-8 hours) after the ingestion 
of contaminated food. The symptoms are 
caused by the staphylococcal enterotoxins 
(SETs) produced during the massive growth 
of Staphylococcus aureus in the foodstuff. 
The most susceptible food items are dairy 
products such as raw milk cheese, sliced 
soft cheese and meat products. The main 
factors contributing to outbreaks are poor 
temperature control during preparation, 
cooking and storage of the food. Epide-
miological studies report that an ingested 
dose ranging from 20 to 100 ng of toxin 
types SEa and SEH is sufficient to cause 
initial symptoms in the most sensitive 
people. During the investigation of the cur-
rent outbreak, different Staphylococcus 
isolates were characterised by toxin pro-
duction, presence of the toxin genes (sea 
to seo), drug susceptibility testing, phage 
typing and MlST. 
case study 
In the summer of 2007, a foodborne out-
break occurred at a Scout Camp at latinne, 
in the south of belgium. about 4 hours af-
ter a lunch consisting of hamburgers with 
cheese, the children, aged between 5 and 8, 
developed symptoms of vomiting, abdomi-
nal pain and diarrhoea. In total, 15 children 
out of 34 and one of the adults became ill. 
The belgian Health Inspectorate was alert-
ed and decided to hospitalise the children. 
The children recovered very quickly and 
left the hospital the same day, except for 
one who was hospitalised for one night.
because the symptoms started almost si-
multaneously in all children, it was obvi-
ous that food was probably at the origin of 
the infection. The inspectors of the belgian 
Federal agency for the Safety of the Food 
Chain (FaSFC) were contacted immediately 
and started an investigation. The hamburg-
ers had been bought frozen in a supermar-
ket. They were grilled for 12 minutes and 
then stored in a casserole at ambient tem-
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perature until all hamburgers were cooked. 
although it was a warm summer period 
with temperatures at noon reaching 30°C, 
the camp site was equipped with minimal 
infrastructure; only one refrigerator was 
present for the storage of leftover food. 
all of the leftovers from the lunch in the 
refrigerator at the camp site were sam-
pled. These included hamburgers, cheese 
and ketchup. leftover boiled pasta from 
the previous evening, water and UHT milk, 
which were present in the refrigerator 
were also collected. all samples were taken 
to the National Reference laboratory (NRl) 
of foodborne outbreaks for analysis at the 
WIV-ISP. The next day, hamburgers from the 
same production batch at the supermarket 
where the original hamburgers had been 
bought were sampled. 
a high level of contamination with co-
agulase positive Staphylococci (CPS) (> 108 
cfu/g), was detected in the leftover ham-
burgers together with the presence of 
enterotoxins. The hamburgers sampled at 
the supermarket were also contaminated 
by coagulase positive Staphylococci. How-
ever, the contamination level was very het-
erogeneous, lower than 105 cfu/g, and no 
detectable toxins were present in the sam-
ples. according to the European legislation, 
no recall of the hamburgers was necessary. 
Nevertheless, the supermarket did recall 
all the hamburgers from the same produc-
tion batch, which were imported from the 
Netherlands. after the European Rapid 
alert System for Food and Feed (RaSFF), 
international recalls soon followed. In the 
Netherlands the officers of the “Voedsel en 
Waren autoriteit” (VWa) performed a thor-
ough investigation at the production plant. 
Other food products (fricandel, chicken 
nuggets) prepared at the same production 
site were found to be contaminated with 
Staphylococcus aureus. In the manufactur-
ing environment, Staphylococcus aureus 
was found in 2 of the 5 production lines at 
the rapid spray cooling stage of the food 
products following pasteurisation. This led 
to heterogeneous surface contamination 
of the products. Molecular and phenotypi-
cal characterisations were performed on a 
selection of Staphylococcus strains to de-
termine the relation between the strains 
and to confirm the origin of the outbreak. 
materialS and methodS
microbiological examination of food and 
environment
The suspected food and environmental 
samples were analysed according the EN 
ISO methods 6888-1 (belgium) or 6888-2 
(The Netherlands) for the enumeration of 
coagulase positive staphylococci. Typical 
colonies were further used for molecular 
characterisation.
For the detection of the enterotoxins, the 
method described in the European screen-
ing method version 2 (EURl-Staphylo-
coccus) was used. after extraction and 
concentration of the toxins, detection of 
the enterotoxins was done using the Vidas 
SET2 (bioMérieux, Marcy-l’Etoile, France) 
automated kit. 
Further differentiation of the staphylo-
coccal enterotoxins types a to D was per-
formed on samples detected positive by 
the Vidas SET2, using the SET-RPla (Oxoid, 
basingstoke Hampshire, UK) detection kit 
which is based on an agglutination reac-
tion. Positive samples were also sent to the 
Community Reference laboratory (Mai-
sons-alfort, France) for confirmation of the 
results and for a quantitative detection of 
the toxins by their in house ElISa method 
(aFSSa lERQaP/CaT baC/nr 3).
Other bacterial parameters measured in 
the food were: total colony plate count 
at 30°C, enumeration of bacillus cereus, 
enumeration of E. coli, detection of Sal-
monella and Campylobacter. These were 
performed according to their respective 
ISO methods 4833:2003, 7932:2004; 16649-
2:2001; 6579 and 10272-1.
molecular and phenotypical typing of the 
strains
For further differentiation the strains iso-
lated in the outbreak, several approaches 
were followed. besides molecular typing 
Parameters analysed* frozen hamburgers from the same production 
batch (highest contamination level)
contamination level of leftover  
hamburgers at the camp 
TCC 7.1 104 cfu/g 3.9 108 cfu/g
E. coli < 10 cfu/g 3.8 108 cfu/g
CPS 6.5 104 cfu/g 8.1 107 cfu/g
SET absent in 25g present in 25g (a: +++, D:+)
SET –RPla production by isolated strain enterotoxin a + enterotoxin a +
bC 80 cfu/g < 100 cfu/g
Campylobacter absent in 25g absent in 25g
Salmonella absent in 25g absent in 25g
table 1: bacteriological and toxin results of the hamburgers.
*TCC: total colony count at 30°C (ISO 4833:2003); CPS: Coagulase positive staphylococci ISO 6888 part1); SET: staphylococcus enterotoxin 
(European screening method version 2); bC: bacillus cereus (ISO 7932); E. coli 16649-2: 2001; SET-RPla: differentiation of the enterotoxins of 
Staphylococcus by the reversed latex agglutination test kit; Salmonella detection (ISO 6579); Campylobacter detection (ISO 10272-1)
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isolate 
number
origin country 
isolated
atypical 
growth in bhi
Sequence type 
(mlSt)
Phage type toxin genes 
present 
162 Hamburger camp bE No 1 53 sea+seh
164 Hamburger same batch bE No 1 53 sea+seh
223 Production line Nl Yes 1 53 sea+seh
224 Production line Nl Yes Other ST 53 sea+seh
227 Fricandel Nl Yes 7 NT -
228 Hamburger Nl Yes 1 53 sea+seh
225 and 226 * Production line Nl Yes ND 81 -
table 2: in-depth characterisation of the Staphylococcus isolates from hamburgers and the production plant.
*cns: coagulase negative Staphylococcus aureus
of the strains with Multi locus Sequence 
Typing (MlST), phenotypical methods such 
as phage typing and typical characteristic 
growth in bHI at 37°C, were also used. 
The sequence type (ST) of five Staphylococ-
cus isolates was determined by the MlST 
method on seven housekeeping genes 
using the primers described by Enright 
et al. (1). For each locus, sequences were 
compared and distinct sequences were as-
signed allele numbers (http://saureus.mlst.
net). For each isolate the alleles at each of 
the seven loci defined the allelic profile 
corresponding to its ST.
Phage typing was performed as described 
by blair and Williams (2) using the Interna-
tional Typing set of bacteriophages at the 
routine test dilution (RTD) and the 100-fold 
concentration (RTDX100).
The presence of different enterotoxin 
genes was tested by PCR. Primers used 
were described previously in PCR methods 
for the detection of the seo and sen genes 
(3) sea, seb, sec, sed, seg, seh, sei, sej, sek, sel 
and sem genes (4).
all strains were tested by PCR for the pres-
ence of the meca resistance gene which 
codes for methicillin resistance using the 
primers published by Perazzi et al. (5)
reSultS
Table 1 gives an overview of results from 
the hamburgers analysed in the scope of 
this outbreak. all other food items were 
found to be negative. The leftovers of the 
hamburgers were highly contaminated 
with CPS and toxins were also present in 
the analysed food extract. Hamburgers 
from the same production batch were 
contaminated with CPS at a level that al-
most corresponded with the total aerobic 
colony count at 30°C. Therefore, we can as-
sume that the contamination was almost 
exclusively due to CPS. The Staphylococcus 
contamination of the batch was very het-
erogeneous as determined on 10 different 
samples and ranged from 100 to 65,000 
cfu/g. In these hamburgers, no enterotox-
ins were detected. However, enterotoxin a 
production by the isolates was observed. 
Using PCR, the seh gene was detected be-
sides the sea gene in all Staphylococcus 
isolates from this outbreak. 
The concentration of SEa found in the 
leftovers of the hamburgers was 0.93 ng/g. 
assuming that 100 g of hamburger is con-
sumed per person, the dose causing the 
infection was approximately 100 ng. This 
is almost twice the toxic dose described by 
Ikeda et al. (6), where only 40 ng of SEa and 
SEH was enough to induce symptoms such 
as vomiting and diarrhoea. 
The CPS isolated from the environment of 
the production plant in the Netherlands 
showed an aspecific morphology on solid 
RPF agar and in brain Heart Infusion broth. 
Growth resulted in agglutination of the 
isolates from the production line whereas 
this phenotype was not observed for any 
of the hamburger isolates. To provide evi-
dence of the origin of the outbreak, 7 iso-
lates were further characterised by phage 
typing and genotypic typing. all strains iso-
lated from the food and production plant 
belonged to the same MlST type (ST1) and 
also to the same phage type 53, indicating 
a common source of contamination. Some 
isolates revealed to be coagulase negative 
staphylococci, were classified by phage 
typing as phage type 81. all tested isolates 
were meca negative. 
The results indicate that different staphy-
lococcus strains circulated in the produc-
tion plant and that the isolates from the 
leftovers at the camp site were identical to 
those isolated at the production site.
looking back at results of analyses per-
formed at the production plant on behalf 
of quality control, it was obvious that the 
staphylococcal contamination had existed 
for a long time prior to this outbreak. a 
thorough investigation by the Dutch food 
safety authorities revealed that the spray 
cooling system, which was used to rapidly 
cool the pasteurised hamburgers, was con-
taminated with high levels of Staphyloco-
ccus aureus. Staphylococcus aureus em-
bedded in biofilms is difficult to eradicate 
and can cause long lasting problems in a 
manufacturing plant. Further phenotypic 
and molecular characterisations of the Sta-
phylococcus aureus isolates collected dur-
ing this outbreak, demonstrated that the 
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acKnoWledGementS
this accidental foodborne outbreak investigation demonstrated that using 
different in depth characterisation techniques is useful in identifying the 
common origin of a contamination and allowed the detection of the source 
in a food production plant. this resulted in a recall of contaminated meat 
products and thus prevented further staphylococcal intoxication. 
i m P a c t  o n  P u b l i c  h e a l t h
strains isolated in the production line in 
The Netherlands showed atypical growth 
in brain heart infusion broth (clumping) 
which might be correlated with a stressed 
phenotype or a phenotype which is ex-
pressed in a biofilm. In clinical microbiol-
ogy, the formation of biofilm represents 
an important virulence factor of certain 
strains of Staphylococcus aureus. The abil-
ity of bacteria to aggregate, forming bio-
films, is strictly related to the capacity of 
producing an extracellular polysaccharide 
(7). little information is available regard-
ing biofilm formation by Staphylococcus 
aureus strains isolated from food or food 
production environments. Recently Rode 
et al. (8) indicated that food processing 
conditions such as temperature, salt and 
glucose concentrations relevant for food 
processing could promote biofilm forma-
tion. Nevertheless, biofilm formation was 
not further investigated in this study. 
In the production plant coagulase nega-
tive Staphylococcus aureus strains, which 
may also be the origin of contamination of 
meat products, also circulated. However, 
these strains were negative for the tested 
enterotoxin genes. both phenotypical and 
genotypical typing techniques did further 
discriminate the Staphylococcus aureus 
strains. 
concluSion
We demonstrated that in depth characteri-
sation using different techniques is useful 
to confirm the common origin of a con-
tamination source. From the investigation 
of this outbreak, we can conclude that an 
initial staphylococcal contamination level 
of hamburgers below the legal limit was at 
the origin of a foodborne outbreak, prob-
ably due to growth during thawing of the 
hamburgers and storage at ambient tem-
peratures before and after cooking. The 
contamination was caused by spray cool-
ing of the hamburgers after the pasteuri-
sation step in the production line, and the 
presence of a biofilm containing staphylo-
cocci in the cooling system. because the 
contamination of the product was never 
higher than the 105 cfu/g legal limit, no ac-
tions were taken by the manufacturer af-
ter detection of positive samples in batch 
controls. Nevertheless, the manufacturer 
should have taken measures to reduce the 
Staphylococcus contamination in the envi-
ronment by applying strict hygiene rules. 
However, this was not evident and the real 
source of contamination was not found 
until the current accidental foodborne 
outbreak. 
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immunogenicity and protective efficacy 
of dna vaccines encoding maP0586c and 
maP4308c of mycobacterium avium sub-
sp. paratuberculosis secretome
v. roupie, b. leroy
v. rosseels, v. Piersoel 
I. Noël-Georis, m. romano 
M. Govaerts, J.-J. letesson
R. Wattiez, K. huygen
introduction 
Johne’s disease, or paratuberculosis, 
caused by Mycobacterium avium subsp. 
paratuberculosis (MaP) was first described 
as an atypical case of intestinal bovine 
tuberculosis by H.a. Johne and l. Frothing-
ham in 1895. MaP is the etiological agent of 
severe chronic enteritis of the small intes-
tine in domesticated and wild ruminants. 
Disease is prevalent worldwide though is 
mainly found in temperate and humid are-
as (1, 2). It causes substantial financial loss-
es in the livestock industry, particularly the 
dairy sector, due to weight loss, reduced 
milk production, premature culling and re-
duced fertility of affected animals (3, 4). 
MaP specific vaccines are composed of 
whole bacteria (killed or attenuated) for-
mulated in mineral oil adjuvants. These 
vaccines confer partial protection against 
MaP, thus containing the excretion of bac-
teria in faeces and reducing the number of 
diseased animals. However, these vaccines 
do not protect against infection, they in-
terfere with the tuberculin skin test used 
for the diagnosis of bovine tuberculosis 
and with indirect tests used for the diag-
nosis of paratuberculosis (antibody and 
IFN-У ElISa). Therefore, the development 
of sub-unit based vaccines using MaP spe-
cific antigens, which would not interfere 
with existing diagnostic tests for bovine 
tuberculosis or paratuberculosis, may con-
tribute actively to the control of Johne’s 
disease.
Recently, we carried out a large-scale post-
genomic analysis of MaP proteins, to iden-
tify MaP specific antigens that could poten-
tially improve the serodiagnosis of bovine 
paratuberculosis. Performing systematic 
proteomic identification and immuno-
proteomic analysis of MaP protein extracts 
and MaP culture filtrates with sera from 
MaP and M. bovis infected cattle, we have 
identified 25 candidate antigens. Five of 
these, i.e. MaP0586c, MaP1693c, MaP2677c, 
MaP3199 and MaP4308c were tested in an 
antibody ElISa assay for their diagnostic 
potential on a limited panel of field sera 
and the combination of three of them 
competed in performance with available 
commercial assays, reaching a test sen-
sitivity of 94.7% and a specificity of 97.9% 
(5). These five antigens were also evaluated 
for their vaccine potential as plasmid DNa 
vaccines in an experimental mouse mod-
el. We present here the results obtained 
for two of them, namely MaP4308c and 
MaP0586c. Sequence analysis identified a 
possible lytic transglycosylase SlT domain 
in MaP0586c protein and a class I fructose-
bisphosphate aldolase activity for the 
MaP4308c protein. balb/c mice were im-
munised with either plasmid DNa alone or 
immunised with a DNa prime-recombinant 
protein boost protocol. Vaccinated mice 
were challenged by the intravenous route 
with MaP and bacterial replication in the 
spleen was monitored by luminometry 
and CFU plating on solid Middlebrook 7H11 
agar as previously reported (6). 
materialS and methodS
mice
Female balb/c mice were bred in the ani-
mal Facilities of our Institute, from breed-
ing couples originally obtained from 
bantin & Kingman (United Kingdom). all 
animals were 6 to 8 weeks old at the start 
of the experiments.
Preparation of genomic dna from m. avi-
um subsp. paratuberculosis atcc 19698
Genomic DNa of M. avium subsp. paratu-
berculosis aTCC 19698 was prepared as de-
scribed by Tanghe et al. for M. ulcerans (7). 
construction and preparation of dna vac-
cines encoding maP0586c and maP4308c
MaP0586c and MaP4308c genes were 
cloned as bglII/EcoRI fragments in pV1J.
ns-tPa-his containing a hexa-histidine tag 
coding sequence in 3’ of the bglII restric-
tion site of the pV1J.ns-tPa vector (Merck 
Research laboratories, Pa, USa) (8). briefly, 
MaP0586c and MaP4308c genes were am-
plified by PCR (Expand Polymerase; Roche) 
using M. avium subsp. paratuberculosis 
aTCC19698 genomic DNa as a template and 
using primers:
5’-GGaaGaTCTTGTGCGGTGTGCCCGTGaGGG-3’ 
(forward MaP4308c), 
5’-aTaGaaTTCGCCGGCGaCCGaGGCGTCGTa-3’ 
(reverse MaP4308c), 
5’-GGaaGaTCTTGGTGaGCaaTCGGCGCaCC-3’ 
(forward MaP0586c), 
5’-TaTaGaaTTCCTGCGGGTGCGCCGCCaCG-
TaGTCGG-3’ (reverse MaP0586c). 
PCR fragments were purified on column, 
digested with bglII/EcoRI and ligated into 
bglII/EcoRI digested pV1.Jns-tPa-his. after li-
gation (T4 DNa ligase, Fermentas) and trans-
formation into DH5-α chemical competent 
E. coli cells (Invitrogen), positive clones 
were screened on lb-kanamycin medium 
(50 μg/ml) and plasmid was checked by re-
striction digestion and sequencing. Finally, 
sufficient amounts of these DNa plasmids 
for vaccination experiments were purified 
using the PurelinkTM HiPure Plasmid DNa 
Gigaprep kit (Invitrogen).
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cloning, expression and purification of 
recombinant maP0586c and maP4308c 
proteins
The genes coding for histidine-tagged 
MaP0586c and MaP4308c were cloned in E. 
coli expression plasmid pQE-80l (Qiagen) 
from pV1.Jns-tPa-MaP0586c and V1.Jns-tPa-
MaP4308c respectively using primers:
5’-GGaaGaTCTGTGaGCaaTCGGCGCaCCGCa-3’ 
 (forward MaP0586c), 
5’-TaTaaGCTTCaCTGCGGGTGCGCCGCCaCG-
TaGTCGG-3’ (reverse MaP0586c), 
5’-TaTaGGaTCCTGCGGTGTGCCCGTGaGG-3’ 
(forward MaP4308c), 
5’-TaTaaGCTTCaGCCGGCGaCCGaGGCGTCGTa-3’ 
(reverse MaP4308c). 
Plasmids were checked by restriction di-
gestion and sequencing. Recombinant 
MaP0586c and MaP4308c were expressed 
as his-tagged protein in Top-10F’ E. coli af-
ter IPTG induction and purified by affinity 
chromatography on immobilised nickel-
chelate (Ni-NTa) column, as described pre-
viously (9).
vaccination
Mice were vaccinated four times 
(MaP0586c) at 3 week intervals. For DNa 
immunisations, mice were sedated with 
ketamine/xylazine and injected intramus-
cularly in both quadriceps muscles with 
2 × 50 µg of pDNa. For protein boosting 
(last immunisation only), mice were inject-
ed subcutaneously (s.c.) in the back with 20 
µg of purified protein emulsified in incom-
plete Freund adjuvant (IFa).
cytokine production
DNa vaccinated mice were sacrificed 
3 weeks after the last immunisation, 
Spleens from three to four individual 
mice per group were removed aseptically 
and homogenised by gentle disruption 
in a Dounce homogeniser, and cells were 
adjusted to 4x106 white blood cells/ml in 
RPMI 1640 medium (Gibco, Grand Island, 
NY) supplemented with 10% foetal calf 
serum (FCS), 5x10-5 M 2-mercaptoethanol, 
penicillin, streptomycin and fungizone. 
Cells were stimulated with purified recom-
binant antigens (5 µg/ml) and incubated at 
37°C in round-bottom, 96-well microtiter 
plates in a humidified CO2 incubator. Cy-
tokine responses against whole protein 
were tested on spleens from individual 
mice. Culture supernatants were harvested 
after 24 hours for interleukin-2 (Il-2) assays 
and after 72 hours for IFN-γ assays, when 
peak values of the respective cytokines can 
be measured. Supernatants were stored 
frozen at -20°C until testing. 
il-2 bio-assay
Il-2 activity was measured using a bio-
assay on Il-2 dependent CTll-2 cells, as de-
scribed before (10). Each sample was tested 
in duplicate. Il-2 levels are expressed as 
mean counts per minute (cpm) of incorpo-
rated (3H) thymidine.
 
ifn- γ eliSa
IFN-γ activity was quantified by sandwich 
ElISa using coating antibody R4-6a2 and 
biotinylated detection antibody XMG1.2 
(both bD Pharmingen). antigen-specific 
cytokine levels were considered positive 
when values were at least fivefold higher 
than those of unstimulated cells.
mycobacterium avium subsp. paratuber-
culosis challenge
Immunised balb/c mice were challenged 
6 weeks after the last immunisation. lumi-
nescent MaP aTCC 19698 (11) were grown in 
Middlebrook 7H9 medium supplemented 
with OaDC, mycobactin J (allied laborato-
ries Inc, Synbiotics Europe, 2 µg/ml) and 
hygromycin (100 µg/ml), to an optical den-
sity ranging between 0.6 and 0.8. bacteria 
were centrifuged for 30 minutes at 2000 
figure 1:
maP 4308- and maP0586c– specific ifn-У (a) and il-2 (b) production in spleen cell cultures from 
mice vaccinated only with v1J.ns-tPa-his-maP4308c or v1J.ns-tPa-his-maP0586c dnaor boosted 
with maP4308c or maP0586c protein
a. ifn-γ levels (picograms per millilitre (mean ± S.d.) for three to four mice tested individually) in 
 spleen cell cultures stimulated or not for 72 hours with purified maP4308c or maP0586c 
 protein (5 µg/ml). mice were sacrificed 3 weeks after the last immunisation.
b. il-2 levels (counts per minute (mean ± S.d.) for three to four mice tested individually) in spleen 
 cell cultures stimulated or not for 24 hours with purified maP 4308c or maP0586c protein 
 (5 µg/ml). mice were sacrificed 3 weeks after the last immunisation.
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rpm, suspended in PbS to a concentration 
of 107 CFU/ml (8.5 x 106 RlU/ml). lumines-
cence was measured in a lumat lb 9507 
luminometer (berthold Technologies) as 
flash emission (15 sec. integration time) us-
ing 1% n-decanal (Sigma) in ethanol as sub-
strate. Mice were infected intravenously 
in a lateral tail vein with 0.2 ml of bacteria 
and eight weeks after challenge, mice were 
sacrificed and the number of biolumines-
cent bacteria was determined in spleen 
homogenates. For statistical analysis (one 
way aNOVa, Tukey’s Multiple Comparison 
Test), results obtained in Relative light 
Units (RlU) by spleen were converted to 
log10 values (6).
reSultS
th1 type cytokine secretion in response to 
maP0586c and maP4308c in plasmid dna-
vaccinated balb/c mice
Vaccination of balb/c mice with the 
MaP0586c DNa vaccine (including a vacci-
nation regimen in which DNa vaccination 
was combined with a recombinant protein 
boost for the last immunisation) induced 
elevated levels of antigen-specific Il-2 and 
IFN-γ (Figure 1). IFN-γ ElISPOT levels were 
two to threefold higher in mice that had 
received the combined DNa/protein im-
munisation. Il-2 levels also tended to be 
higher in balb/c mice that had been vacci-
nated with the DNa/protein combination, 
but this difference was not statistically 
significant. 
MaP4308c-specific immune responses af-
ter vaccination of balb/c mice are summa-
rised in Figure 1. as for MaP0586c, elevated 
Il-2 and IFN-У levels could be detected in 
mice and again Il-2 levels were increased 
by the DNa/protein combination. 
Protective efficacy of dna vaccines en-
coding maP0586c and maP4308c
Immunisation with MaP0586c conferred 
partial protection to balb/c mice from 
an experimental challenge infection with 
luminescent MaP (administered 6 weeks 
after the last immunisation), as analysed 
at 8 weeks post-infection and compared to 
mice vaccinated with empty vector (Figure 
2). both the DNa and the DNa/protein com-
bination effectively reduced the number 
of bacteria in the spleen, as determined by 
luminometry and CFU plating. 
DNa vaccine encoding MaP4308c did not 
confer any protection against an experi-
mental challenge infection with lumines-
cent MaP at 8 weeks post-infection (data 
not shown).
diScuSSion
Several countries have initiated control 
programs to stop the spreading of Johne’s 
disease. However, increasing national and 
international trade, the extremely long in-
cubation period, the long survival time of 
the bacteria in the environment and the 
large proportion of subclinically infected 
animals (difficult to identify with present 
diagnostic tools) seriously hamper the con-
trol of this disease (3). 
The development of a marked subunit vac-
cine composed of one or more MaP specific 
and protective antigens, which would not 
interfere with current immunodiagnosis of 
bovine tuberculosis and paratuberculosis, 
would be an invaluable tool for the control 
of Johne’s disease. Several research groups 
have identified MaP antigens for use in se-
rodiagnosis (5, 12-15) and have identified 
antigens for T cell based diagnosis with 
a strong IFN-γ inducing activity (9, 16-21). 
However, only few of these antigens have 
been analysed for their actual vaccine po-
tential, particularly in target species. 
In order to analyse the vaccine potential of 
MaP0586c and MaP4308c, we used the tech-
nique of DNa vaccination. It is well estab-
lished that intramuscular DNa vaccination 
of mice is an easy and effective method for 
generating strong humoral and Th1 biased 
cellular immune responses, enabling high 
throughput screening of possible vaccine 
candidates (22). Here we have shown that 
DNa vaccination and homologous DNa-
prime/recombinant protein-boost vaccina-
tion induced substantial production of an-
tigen-specific IFN-γ and Il-2 in balb/c mice 
and MaP0586c DNa vaccine conferred sig-
nificant protection against MaP challenge 
in balb/c mice. 
In conclusion, our results show that 
plasmid vaccination with MaP4308c and 
MaP0586c DNa induced strong Th-1 type 
immune responses and a partial protec-
tion from infection with MaP in mice. Pre-
liminary testing of these two antigens in 
separate herds of naturally MaP and M. 
figure 2:
Protective efficacy of maP0586c vaccine 
in balb/c mice. bacterial replication in 
spleen from balb/c mice vaccinated with 
control dna, maP0586c-dna, maP0586c-
dna boosted with recombinant maP0586c 
protein in ifa adjuvant, and vaccinated 
with m. bovis bcG and infected with biolu-
minescent m. avium subsp. paratubercu-
losis atcc 19698 8 weeks before. Spleens 
from individual infected mice were ho-
mogenised, and the number of bacteria/
organ was enumerated by luminometry 
(results in rlu converted to log10). data 
represent mean ± S.d. values of 3–5 mice 
(numbers given in parentheses). Statisti-
cal analysis was performed using Graph-
Pad Prism 4: one-way-anova tukey: *** (p 
< 0.001), ** (0.001 < p < 0.01), *(p < 0.05) as 
compared to log10 rlu values in control 
dna vaccinated mice.
4
4,2
4,4
4,6
4,8
5
5,2
5,4
5,6
C
o
n
tr
o
l D
N
A
D
N
A
-M
A
P
05
86
c
D
N
A
-M
A
P
05
86
c 
-
rM
A
P
05
86
c
M
. b
o
vi
s 
B
C
G
Lo
g
10
 R
LU
  /
 s
p
le
en
unstimulated
.
.
.
.
.
.
.
communicable and infectiouS diSeaSeS directorate 75 
bovis infected cattle also showed a very 
limited cross-reactivity in the ex vivo 20h- 
IFN-γ assay and a clear potential as specific 
diagnostic reagents (M. Govaerts et al., data 
not shown). It is obvious that more work is 
needed to confirm these findings in target 
species of Johne’s disease, such as sheep, 
goats and cattle. 
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acKnoWledGementS
crohn’s disease is a human illness with similar histopathological findings 
and symptoms to those observed in Johne’s disease in cattle. discovery of 
new specific antigens may enable a possible link to be found between these 
diseases and eventually confirm the implication of mycobacterium avium 
subsp. paratuberculosis in crohn’s disease.
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molecular genetics of para-aminosalicylic 
acid resistance in clinical isolates and  
spontaneous mutants of mycobacterium 
tuberculosis
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introduction
Tuberculosis is a highly contagious pulmo-
nary infection caused by Mycobacterium 
tuberculosis. With one third of the world’s 
population infected and around 1.7 million 
deaths annually, this disease represents 
an important epidemiological problem (1). 
The recrudescence of HIV co-infection and 
the emergence of drug-resistant strains are 
also worrying. a growing source of public 
health concern has been the emergence of 
resistance to multiple drugs (MDR-Tb), de-
fined as an isolate resistant to at least iso-
niazide and rifampin, the two most potent 
anti-tuberculosis drugs (2). MDR-Tb is asso-
ciated with very high morbidity and mor-
tality, prolonged treatment to cure, and an 
increased risk of spreading infection with 
drug resistant isolates in the community. 
Today, the emergence of M. tuberculosis 
strains resistant to first-line antibiotics has 
renewed interest in second-line anti-tuber-
culosis agents, such as para-aminosalicylic 
acid (PaS).
In 1943, lehmann discovered that an as-
pirin-like drug called para-aminosalicylic 
acid (Figure 1a) presents anti-tuberculosis 
activities (3). PaS was successfully intro-
duced to clinical use as far back as 1948 (4). 
It was the second antibiotic found to be 
effective in the treatment of tuberculosis, 
after streptomycin. Combination therapy 
of tuberculosis with streptomycin and PaS 
brought much hope in the fight against tu-
berculosis (5). With the advent of antimyco-
bacterial agent isoniazid in 1951, triple or 
combination therapy, including PaS, was 
maintained until the mid-60s. although 
PaS-combination therapy proved highly 
successful, side-effects attributed to PaS 
were documented as early as 1951. In addi-
tion to PaS-associated gastrointestinal tox-
icity, elevated and repetitive dosing com-
plicated therapeutic regimens. PaS therapy 
was discontinued after the introduction of 
rifampin (rifampicin) and pyrazinamide to 
the treatment. PaS tuberculosis treatment 
was reintroduced in the United States in 
1992, following several outbreaks of MDR-
Tb isolates (6). Since then, the need for new 
antibiotics for the treatment of MDR-Tb 
has led to the development of novel for-
mulations of PaS; which were proven to be 
less toxic (7). Today, PaS is used primarily as 
a second line drug to treat MDR tuberculo-
sis but despite its introduction to clinical 
use in 1948, the exact mode of action of PaS 
is not yet known (8). 
Using transposon mutagenesis, Rengara-
jan and colleagues have shown that PaS 
resistance is associated with mutations 
of thymidylate synthase a, encoded by the 
thya gene and required for thymine biosyn-
thesis in the folate pathway (Figure 1b) (9). 
Thya catalyses the reductive methylation 
of dUMP (deoxyuridine monophosphate) 
to yield dTMP (deoxythymidine monophos-
phate), required for de novo thymidine 
synthesis. It is hypothesised that the bac-
teriostatic activity of PaS results from per-
turbation of the folate pathway, although 
the underlying mechanism has yet to be 
elucidated. In our laboratory, we aimed to 
extend the understanding of mechanisms 
underlying PaS resistance by analysis of six 
genes of the folate metabolic pathway and 
biosynthesis of thymine nucleotides (thya, 
dfra, folC, folP1, folP2, and thyX) and three 
N-acetyltransferase genes (nhoa, aac1 
and aac2) within the genome of 118 well-
characterised PaS-resistant clinical iso-
lates and spontaneous mutants. To better 
understand PaS resistance, the identified 
mutations were correlated with the Mini-
mal Inhibitory Concentrations (MIC) and 
the protein three-dimensional (3D) Thya 
structure (10).
materialS and methodS
Samples
Fifty-one PaS-resistant isolates were se-
lected from the M. tuberculosis collection 
maintained in the Public Health Research 
Institute (PHRI), Newark, NJ. all of the 
isolates were typed by multiple genetic 
techniques in order to establish their ge-
netic diversity or relatedness. In addition, 
55 spontaneous mutants resistant to PaS 
were selected on agar plates containing 
PaS (11, 12). To avoid strain bias, spontane-
ous mutants of eight well-characterised 
clinical strains were selected. before DNa 
extraction and stocking, colonies were 
subcultured in the presence of various 
concentrations of PaS for determination of 
the MIC. Twelve PaS-resistant and PaS-sus-
ceptible reference strains were also used 
as positive and negative controls, respec-
tively. In total, 118 samples were analysed.
Sequencing drug target regions
Mutations in the thya gene (Rv2764c) were 
identified by sequencing. The loci folP1 
(Rv3608c), folP2 (Rv1207), thyX (Rv2754c) 
and dfra (Rv2763c) were also analysed. The 
folC (Rv2447c) gene was sequenced in 12 
PaS-resistant isolates that did not include 
any other mutations in genes of the folate 
biosynthetic pathway. Three additional 
genes were further sequenced in 5 of these 
PaS-resistant isolates (without mutation 
in the other studied genes), including the 
nhoa (Rv3566c), aac1 (Rv1347c) and aac2 
(Rv0262) recently showed to be implicated 
in some mechanism of resistance to anti-
tuberculosis drugs.
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mic
The Minimal Inhibitory Concentration (MIC) 
of all the clinical strains and spontaneous 
mutants were determined by the agar dilu-
tion method and bactec/alert 3D system 
(bioMerieux, France). Growth curves were 
determined for 6 clinical isolates, 2 sponta-
neous mutants with an early stop codon in 
the thya gene, 6 spontaneous mutants with 
other mutations within the thya gene, and 
6 PaS-resistant isolates including wild-type 
genes in the folate and pyrimidine biosyn-
thesis pathway. Growth curves were done 
on 7H9 broth containing 0, 16, 32, 64 and 
128 µg/ml of PaS.
Structural analysis
a 3D model of the M. tuberculosis thymi-
dylate synthase Thya homodimer was 
built with the Modeler program using the 
X-ray structure of Escherichia coli thymi-
dylate synthase as a homologous protein 
template (13). Thermodynamic stability 
changes resulting from a single-site muta-
tion were predicted using the PoPMuSiC 
webserver (14). Finally, at each mutated 
position, the conservation of wild-type 
residues and the occurrence of mutant 
residues were evaluated on an alignment 
of 279 thymidylate synthase sequences.
figure 1:
a.  para-aminosalicylic acid. 
b.  thya catalyses the reductive methylation of dumP (deoxyuridine monophosphate) to yield dtmP (deoxythymidine monophosphate), required 
 for dna synthesis. thya requires the 5,10-mthf (methylene tetrahydrofolate) as cofactor. thyx, encodes a functional homologue of thymidylate 
 synthase. folP1 and its putative homologue folP2 are dihydropteroate synthases. the dihydropteroate (dhP) is converted to dihydrofolate (dhf) 
 by the dhfS (dihydrofaolate synthase) which is reduced by the dfra (dihydrofolate reductase) to generate the cofactor tetrahydrofolate (thf). 
c.  mutations found in the thya gene.
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reSultS and concluSion
mutations in the dfra, folP1/folP2, and 
thyx genes are not associated with PaS 
resistance
Three mutations in the dfra gene were 
identified in two clinical isolates that, in 
addition, already bore a mutation in the 
thya gene. No PaS-resistant isolate with a 
polymorphism only within the dfra gene 
was found; consequently, it is not known 
whether the dfra mutations alone contrib-
ute to a PaS-resistance. No mutations were 
found within the thyX gene or flanking re-
gions in either the clinical isolates or the 
spontaneous mutants. likewise, the folP1 
gene and flanking sequences were con-
served, while some polymorphisms were 
noted in the upstream region of the folP2 
gene (-19aG). This single-nucleotide sub-
stitution was found in both PaS-suscepti-
ble and PaS-resistant isolates, suggesting 
that this mutation is not associated with 
PaS-resistance, but rather, is a molecular 
characteristic of some related strains. 
Indeed, all isolates characterised by this 
mutation were correlated with a phyloge-
netic lineage, rather than PaS resistance 
(15). additionally, no polymorphism was 
identified in folC and three N-acetyltrans-
ferase genes, including nhoa, aac1, and 
aac2. Thus, no mutations within the genes 
encoding enzymes in the folate and thym-
ine biosynthetic pathway, other than thya, 
were correlated with a PaS-resistant phe-
notype.
thirty-seven percent of PaS-resistant 
strains have a mutation within the thymi-
dylate synthase a (thya) gene 
To our surprise, only 37% of the PaS-resist-
ant clinical isolates or spontaneous mu-
tants encoded mutations in enzymes of 
the folate pathway. Overall, 24 distinct mu-
tations were identified in the thya gene, in-
cluding 4 polymorphisms found uniquely 
in clinical isolates and 20 observed in the 
spontaneous mutants. It is noteworthy 
that most polymorphisms were distinct 
(Figure 1C). Protein structural predictions 
figure 2:
representative growth curves of PaS-susceptible and PaS-resistant isolates, possessing a 
thya mutation or not, in the presence of various concentrations of PaS (in µg/ml).
communicable and infectiouS diSeaSeS directorate 79 
indicate that all the mutations recorded 
reside within essential functional or struc-
tural sites. 
Only the mutation (202aCCGCC; 202Ta) 
most commonly found in clinical isolates 
was also identified in a single spontaneous 
mutant. The divergence in mutation type 
observed in clinical isolates and spontane-
ous mutants could result from experimen-
tal bias due to PaS-resistance selection at 
elevated concentrations of PaS or to the lim-
ited number of PaS-resistant isolates inves-
tigated. alternatively, Thya may not be an 
essential enzyme for survival in vitro while 
assuming a significant function in vivo. 
PaS-resistant m. tuberculosis P strains 
have dual mutations in thya
Sequence analysis of 15 PaS-resistant 
strains belonging to the P strain family was 
realised. These isolates belong to a larger 
cluster of over 120 isolates associated with 
MDR outbreaks in New York City and neigh-
bouring states (16). Their analysis revealed 
a characteristic mutation in codon 202 of 
thya. among these, 12 included a second 
mutation in the stop codon (stop264R), 
suggesting that the P strain acquired the 
202 mutation prior to the one in the ter-
mination codon. association of the dele-
tion of the stop codon with PaS-resistance 
could not be confirmed as no isolate with 
the obliterated 264 stop codon alone was 
identified. additionally, two of the double-
Thya-mutant P strains developed second-
ary mutations on the flanking dfra gene, as 
described above.
Predicting the structural implications of 
the thya mutations identified
To understand the impacts of the identi-
fied mutations on protein function, a 3D 
homodimer structure of M. tuberculosis 
Thya was modelled. analysis of the muta-
tions positioned within the structure mod-
el revealed three groups of mutants: 
1. Mutations that modify the length of the 
protein (stop mutations and insertion/
deletion alterations introducing early 
frameshift). Such modifications are expect-
ed to render the enzyme non-functional 
due to the loss of its ternary structure; 
2. Mutations of amino acids involved in the 
active catalytic site or within the cofactor 
or substrate binding site, and;
3. Mutations that could destabilise the 
ternary structure of the Thya protein, ren-
dering the enzyme dysfunctional or less 
active. The observation that most mutants 
reported here affect highly conserved posi-
tions otherwise rarely found in the protein 
family of thymidylate synthase is notewor-
thy. 
These detrimental alterations to Thya were 
permissible in M. tuberculosis due to the 
presence of the complementary functional 
homologue ThyX, which, per se, does not 
seem to be susceptible to PaS. 
elevated mics in PaS-resistant spontane-
ous mutants and clinical isolates 
The MICs of selected clinical isolates and 
spontaneous mutants were determined. 
Samples including mutations within the 
thya gene proved to be highly resistant to 
PaS. In addition, the growth curves of re-
presentative PaS-resistant samples were 
followed in triplicate over a period of 32 
days (Figure 2). Growth curve profiles of 
PaSR thya-mutated strains were all similar, 
independently of the PaS concentration. 
However, the response of PaS-resistant 
mutants encoding wild-type Thya pro-
teins was found to be dose-dependent. For 
these isolates, growth was proportionally 
inhibited as the dose of PaS was increased, 
clearly indicating the presence of a differ-
ent PaS resistance mechanism.
conclusion
In conclusion, mutations in thya were 
identified in only 37% of the PaS-resistant 
samples. The absence of mutation in the 
thya gene and the 8 other genes consid-
ered in this study, in 63% of the PaS-re-
sistant strains reveals that PaS-resistance 
in M. tuberculosis involves mechanisms 
or targets other than those pertaining to 
the biosynthesis of thymine nucleotides. 
The differences between the growth curve 
profiles of PaS-resistant mutants present-
ing mutations or not, indicates that the 
as yet unidentified alternative resistance 
mechanism(s) is PaS concentration de-
pendent, in marked contrast to thya-mu-
tated PaS-resistant isolates. 
The observation that PaS is active only in 
the presence of a functional Thya enzyme 
supports the idea that, like other antimy-
cobacterials (isoniazid, ethionamide, and 
pyrazinamide), PaS could be a prodrug 
whose activation somehow requires a vi-
able mycobacterial enzyme.
understanding the mechanisms of resistance to anti-tuberculosis antibiot-
ics may improve the molecules or lead to the development of new effective 
compounds. moreover, identification of specific genetic markers associ-
ated with resistance may allow the rapid detection of resistant strains and 
thus permit the avoidance of applying ineffective treatments. 
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Shigella species are important pathogens 
responsible for 5-10% of diarrheal diseases 
and dysentery occurring all over the world 
(1). Human infections can usually be either 
foodborne, waterborne or are caused by 
human-to-human transmission. Shigello-
sis produces inflammatory reactions and 
ulceration on the intestinal epithelium 
followed by bloody diarrhoea and mucus 
in the stool. Infection may lead to dehy-
dration and sometimes, most particularly 
in immunocompromised individuals, even 
death.
Despite the disease being self-limiting, 
antibiotic treatment is recommended 
because it reduces the duration of illness 
and the transmission rate of the disease 
by shortening the excretion period of the 
pathogen. Until 2007, fluoroquinolones, 
-lactams and combination of trimetho-
prim-sulphamethoxazole (cotrimoxazole) 
represented the drugs of choice to treat 
shigellosis (2). However, the use of these 
drugs is becoming compromised by the 
emergence of strains resistant to these 
commonly used antibiotics.
 
The National Reference Centre for Sal-
monella and Shigella (NRCSS) has been 
conducting a continued surveillance pro-
gramme for antimicrobial resistance of 
Shigella infections in belgium since 1990. 
With approximately 400 cases of Shigella 
infections annually reported, shigellosis 
is the third most important bacterial gas-
trointestinal disease in belgium. The ma-
jority of these infections (68%) are caused 
by the species Shigella sonnei. The current 
study presents the evolution of antimicro-
bial resistance in clinical Shigella sonnei 
strains isolated in belgium over a 19-year 
period (between 1990 and 2009) (4). 
methodS
identification, typing and antimicrobial 
susceptibility testing of Shigella isolates
Data were collected by the National Refer-
ence Centre for Salmonella and Shigella, 
which confirm and type the Shigella strains. 
Serotyping was performed by slide aggluti-
nation with commercial antisera from Den-
ka Seiken Co (Derbyshire, United Kingdom). 
The susceptibility of thirteen antibiot-
ics was determined by the disc diffusion 
method (Kirby-bauer) following recom-
mendations of the National Committee for 
Clinical and laboratory Standards Institute 
(ClSI), formerly the National Committee for 
Clinical laboratory Standards (NCClS) (5).
reSultS
between 1990 and 2009, a total of 8,068 
strains, mainly isolated from stools (98.2 %) 
were diagnosed by peripheral laboratories 
before serotyping confirmation as Shig-
ella by the NRCSS. 5,458 were serotyped as 
Shigella sonnei (67.6%), 2,051 as S. flexneri 
(25.4%), 287 as S. boydii (3%) and 178 as S. 
dysenteriae (2.2%) (Figure 1).
among the 5,458 S. sonnei strains isolated 
between 1990 and 2009, 3,413 (62.5%) were 
randomly selected for antimicrobial sus-
ceptibility testing. These Shigella sonnei 
isolates were resistant to streptomycin 
(Str) (82%), sulphonamide (Sul) (76%), tri-
methoprim (Tmp) (80,8%), sulfamethoxa-
zole-trimethoprim (Sxt) (95.7%; only tested 
from 2000 to 2009) and tetracycline (Tet) 
(63,8%). 
In 1990 the resistance to Str, Sul and Tmp was 
74.4%, 70.8% and 61.1%, respectively. Howev-
er in 2007 resistance increased and reached 
the respective levels of 90.4%, 79.8% and 
90% (P < 0.01). Resistance to Sxt increased 
from 72.2% (2000) to 83.8% (2007) with a 
peak of 97.2% in 2005 (P < 0.05) (Figure 2).
a significant rise in resistance to nalidixic 
acid (Nal) has also been observed since 
1998 (P < 0.01), from values ≤ 2.5% in the 
Surveillance of antibiotic susceptibility  
patterns among Shigella sonnei strains  
isolated in belgium show that 
cotrimoxazol is no longer appropriate 
for the treatment of shigellosis
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figure 1: Prevalence of S. sonnei and S. flexneri in belgium from 1990 to 2009. 
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nineties to 13.8% in 2009. Moreover, all 
these strains exhibited reduced suscepti-
bility to ciprofloxacin (Cip) (MICs between 
0.25 and 0.5 µg/ml).
Multidrug-resistance (MDR), defined as 
resistance to at least 4 antibiotics, was 
common among S. sonnei strains with an 
average of 68.3% between 1990 and 2009. 
The MDR frequency increased from 55.9% 
(1990) to 80.8% (2009) and reached a peak of 
89% (P < 0.01) between 2004 and 2005 (Fig-
ure 2). Predominant MDR profiles observed 
in S. sonnei were TetRStrRSulRTmpR(SxtR) 
(45.1%), ampRTetRStrRSulRTmpR(SxtR) (6.36%), 
ampRStrRSulRTmpR(SxtR) (5.6%), and 
TetRNalRStrRSulRTmpR(SxtR) (3.7%). Taken to-
gether these 4 MDR profiles were responsi-
ble for 93.3% of the multidrug-resistances 
in S. sonnei between 1990 and 2009. The 
incidence of these 4 predominant MDR 
profiles, already present in 1990 (47.6%), 
rose to 75.3% in 2007 with a peak of 87.2% 
observed in 2004 (P < 0.01). 
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figure 2:
Percentage of Sul, tmp, Stx and mdr profile of S. sonnei strains in belgium from 119 to 2009. 
concluSion
This study represents the first report of 
long term surveillance concerning anti-
microbial resistances in clinical S. sonnei 
strains conducted in belgium since 1978 
(3).
as observed in other countries, the NRCSS 
of belgium also recorded an increase in an-
tibiotic resistances in S. sonnei during their 
surveillance programme from 1990 to 2009. 
In particular, resistance to streptomycin 
and trimethoprim/cotrimoxazole (trimeth-
oprim + sulfamethoxazole) substantially 
increased during this period to reach re-
sistance levels of 80% of resistant isolates, 
and 90%, respectively. The high prevalence 
of resistance to cotrimoxazole could be ex-
plained by the prolonged use of this anti-
biotic to treat shigellosis, thereby ensuring 
a continuous selection pressure and thus 
the maintenance of the resistance profile. 
Indeed, in the 1970s, the use of cotrimoxa-
zole for the treatment of shigellosis was 
highly recommended due to the capacity 
of this antibiotic to be absorbed from the 
gastrointestinal tract. Furthermore, it was 
proved that using cotrimoxazole signifi-
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resistance to ciprofloxacin (MICs between 
0.25 and 0.5 µg/ml) has been detected so far 
in S. sonnei isolated in belgium.
at the present time, ciprofloxacin is still 
one of the most potent antimicrobials 
available for medical treatment of inva-
sive gastro-intestinal infections in adults 
(6). However, a decreased susceptibility 
to fluoroquinolones has become a major 
problem in medical practice. aarestrup et 
al. (1) reported several treatment failures 
in patients infected with Salmonella iso-
lates due to a decreased susceptibility to 
fluoroquinolones. Therefore, in belgium, 
the emergence of naladixic acid resistance 
and the possible decrease in the suscepti-
bility to fluoroquinolones must be closely 
monitored in Enterobacteriacae.
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analysis and surveillance of antibiotic susceptibility of Shigella have a 
direct influence on the guidelines for antibiotics prescription in cases of 
shigellosis in belgium. the 2009-2010 edition of the Sanford guide to anti-
microbial therapy will be amended on the basis of the recommendations 
included in this publication.
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In conclusion, when antibiotic treatment 
of shigellosis is indicated, cotrimoxazole 
should no longer be considered as an ap-
propriate empirical therapy for shigellosis 
in belgium. Resistance rates to nalidixic 
acid should also be carefully monitored to 
detect any shift in fluoroquinolone resist-
ance because it represents the first line of 
antibiotics used in the treatment of shigel-
losis. 
 
cantly reduced the duration of the illness. 
although the Sanford guide to antimicro-
bial therapy (belgium/luxembourg ver-
sion) still recommended in 2007 the use of 
cotrimoxazole in case of treatment failure 
with fluoroquinolones (2), our study has 
demonstrated that this antimicrobial is 
no longer appropriate for the treatment of 
shigellosis in belgium.
Together with the increase of cotrimoxa-
zole resistance, the frequency of MDR iso-
lates increased from approximately 50% 
in 1990 to 80.8% in 2009. This increase was 
clearly associated with the emergence of 
MDR profile TetRStrRSulRTmpRSxtR (45.1%) 
and to a lesser extent with MDR profiles 
ampRStrRSulRTmpRSxtR, ampRTetRStrRSul-
RTmpRSxtR and TetRNalRStrRSulRTmpRSxtR. 
Interestingly, all these MDR profiles har-
boured resistance to streptomycin and 
cotrimoxazole combined or not with ampi-
cillin, tetracycline and naladixic acid resist-
ance.
In 2007, the Sanford guide to antimicrobial 
therapy (belgium/luxembourg version) 
recommended the use of second genera-
tion fluoroquinolones or norfloxacin to 
treat Shigellosis. It must be noted that, 
since 1998, the NRCSS recorded an in-
creased resistance rate to Nal, while no full 
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unusual aspergillus species in patients 
with cystic fibrosis: interest in accurate 
identification and characterisation
f. Symoens
H. Haase, M. Pihet 
J. Carrère, h. beguin
N. Degand, l. Mély
 J.-P. bouchara
introduction
Patients with cystic fibrosis (CF) are at 
high risk of colonisation of the airways 
by various microorganisms, mainly bac-
teria, but also several filamentous fungal 
species, particularly some aspergillus or 
Scedosporium species, Exophiala der-
matitidis and the more recently described 
fungus Geosmithia argillacea. among the 
aspergillus species associated with CF, a. 
fumigatus is the most common agent of 
chronic colonisation of the airways with a 
high prevalence rate, ranging up to 56% (1). 
Other aspergillus species recovered from 
respiratory specimens of CF, which may be 
responsible for chronic colonisation, are a. 
terreus, a. flavus, a. niger, a. nidulans and a. 
versicolor, with a varying prevalence rate 
within the different European countries. 
In the routine laboratory, other unusual or 
poorly sporulating aspergillus species are 
generally identified as aspergillus sp. How-
ever, identification of clinical aspergillus 
isolates at the species level may be impor-
tant as species may differ in their antifun-
gal susceptibility patterns (2). For instance, 
some unusual aspergillus species are in 
vitro resistant to some of the antifungal 
drugs commonly used for treatment of a. 
fumigatus infections, i.e. itraconazole (ITZ) 
and voriconazole (VRZ). The prevalence 
rate of these “uncommon” species is un-
known, possibly low, but probably under-
estimated as molecular methods are re-
quired to ascertain reliable identification 
at the species level. Moreover, their clinical 
significance may be important. Here, we 
report four cases of colonisation of the air-
ways in CF patients by unusual aspergillus 
species belonging to the section Fumigati, 
but initially identified as aspergillus sp. 
due to discrepancies with key features of 
Fumigati section species. Detailed analy-
ses confirm that these isolates belonged to 
a. lentulus or Neosartorya pseudofischeri, 
two species which can be isolated from the 
environment and show a worldwide distri-
bution (3).
case reports
• Patient 1
Male, born in December 1979, homozygous 
for the F508 Del mutation, he was diag-
nosed for CF at the age of 5 years. The 
patient was colonised by Staphylococcus 
aureus at the age of 8 years, by a. fumiga-
tus and S. apiospermum at 11 years, and by 
Pseudomonas aeruginosa and Candida al-
bicans at 12 years respectively. at this time, 
antibody response for a. fumigatus and S. 
apiospermum started to be positive and 
the patient received discontinuously ITZ 
from eight years. Sixty-one multiple and se-
quential isolates of a. fumigatus were col-
lected for molecular typing during a 9-year 
period (from 1991 to 2000) (4). During mor-
phological reassessment of these isolates, 
one “atypical” poorly sporulating isolate 
was observed among the 5 isolates collect-
ed from one sputum sample (13/01/1999).
• Patient 2
Male, born in 1982, and homozygous for 
the F508 Del mutation, he was diagnosed 
for CF at the age of 5 months. He was colo-
nised by S. aureus since the diagnosis of 
CF, and later by a. fumigatus and achromo-
bacter xylosoxidans subsp. xylosoxidans 
at the age of 17 and 22 years, respectively. 
Serology for a. fumigatus always remained 
negative. Nevertheless, one year after the 
beginning of the colonisation by a. fumiga-
tus, the patient received discontinuously 
and successively ITZ and VRZ. In November 
2008, an “atypical” poorly sporulating iso-
late was recovered and the same observa-
tion was made 5 months later (april 2009).
• Patient 3
This male patient also homozygous for the 
F508 Del mutation was diagnosed prena-
tally in 1998. The patient was colonised by 
methicillin-resistant S. aureus and devel-
oped Pseudomonas aeruginosa infection 
at the age of two and five years, respective-
ly. The patient was then colonised by sev-
eral hyphomycetes: aspergillus fumigatus 
since he was 7 years old, Scedosporium ap-
iospermum and Geosmithia argillacea at 8 
years, and S. prolificans at 9 years respec-
tively. Two years after colonisation by a. fu-
migatus, the patient developed aspergillus 
derived asthma and he was treated by ITZ 
and corticoids. Two years later (18/06/2009), 
a. fumigatus was isolated together with an 
“atypical” poorly sporulating isolate. Iso-
lates with the identical morphology were 
isolated 2, 4 and 6 months later (25/08/2009, 
05/10/2009 and 14/12/2009).
• Patient 4
For this male patient born in 1984 and colo-
nised by S. aureus since early childhood 
(exact date unknown), CF was diagnosed 
at the age of 3 years with homozygosity 
for the F508 Del mutation with presence 
of IVS8-T tract 7T variant. When starting 
medical attendance in November 2003, 
the patient was diagnosed with S. aureus, 
achromobacter xylosoxidans subsp. xylos-
oxidans and an “atypical” poorly sporulat-
ing aspergillus isolate. The patient was 
in continuous medical attendance until 
November 2006 and was then lost for fur-
ther observation but of note, he was still 
alive in November 2009. Isolates with the 
same atypical morphology were collected 
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on 27/07/2004, 04/10/2004 and 19/07/2005, 
whereas two typical isolates of a. fumiga-
tus were recovered from a sputum sample 
collected on 04/09/2006. During the 3 years 
of attendance, there were no signs for 
aPba, especially no specific anti-a. fumiga-
tus antibodies detectable. likewise, there 
were no pancreatic insufficiency or signs 
of diabetes mellitus (body mass index 17 
and FEV1 1.38 l (33%) in November 2006). 
Despite intermittent antibiotic treatment 
with ceftazidime and tobramycine, a. xy-
losoxidans could not be eradicated. Due to 
the relative good condition of the patient, 
no attempt was done to eradicate this 
atypical aspergillus during his medical at-
tendance.
materialS and methodS
fungal isolates
all the isolates presented in this study (Ta-
ble 1) were recovered from sputum sam-
ples. They were preserved and referenced 
in the bCCM/IHEM Collection (Scientific In-
stitute of Public Health, brussels, belgium 
(http://bccm.belspo.be/db/ihem_search_
form.php). The reference strains of a. len-
tulus and N. pseudofischeri (Table 1) were 
obtained from the CbS (Centraal bureau 
voor schimmelculturen) Culture Collection 
(Utrecht, The Netherlands) and the refer-
ence strain of a. fumigatus (af293) from the 
National Collection from Pathogenic Fungi 
(NCPF, bristol, UK).
molecular identification 
Molecular identification was performed 
by sequencing of ß-tubulin gene (5). The 
obtained sequences were assembled us-
ing the SeqMan II software (lasergene 8.0, 
DNaStar, Inc., Madison, WI, USa) and finally 
compared to available sequences in the 
Genbank database using the blaSTn pro-
gram of the National Centre for biotech-
nology Information.
Source
ihem or 
cbS number 
molecular
identification isolation date
conidiation
rate
mic 95 (µg/ml)
amb vrZ itZ
Reference CbS 175.97 a. lentulus ++ 8 8 1
Reference CbS 116883 a. lentulus + 2 4 1
Reference CbS 208.92 N. pseudofischeri ++ 0.5 4 2
Reference NCPF 7367 a. fumigatus  +++++ 2 1 0.5
Patient 1 IHEM 22112 a. lentulus 13/01/1999 ++ 4 8 2
 
IHEM 22113 a. fumigatus 13/01/1999 +++++ 1 2 1
IHEM 22114 a. fumigatus 13/01/1999 +++++ 1 1 0.5
IHEM 22115 a. fumigatus 13/01/1999 +++++ 2 0.5 1
IHEM 22116 a. fumigatus 13/01/1999 +++++ 2 1 0.5
Patient 2 IHEM 22905 N. pseudofischeri Nov 2008 ++ 0.5 4 1
IHEM 23044 N. pseudofischeri apr 2009 ++ 0.5 4 1
IHEM 23045 a. fumigatus apr 2009 +++++ 2 1 > 16
Patient 3 IHEM 23161 N. pseudofischeri 18/06/2009 +++ 0.25 8 1
IHEM 23434 N. pseudofischeri 25/08/2009 +++ 0.5 8 0.5
IHEM 23435 N. pseudofischeri 05/10/2009 +++ 1 8 0.5
IHEM 23463 N. pseudofischeri 14/12/2009 +++ 1 8 1
Patient 4 IHEM 23146 N. pseudofischeri Nov 2003 ++ 0.25 8 1
 
IHEM 23147 N. pseudofischeri 27/07/2004 ++ 0.25 4 1
IHEM 23148 N. pseudofischeri 04/10/2004 ++ 0.5 8 2
IHEM 23149 N. pseudofischeri 19/07/2005 ++ 0.5 8 1
IHEM 23150 a. fumigatus 04/09/2006 +++++ 2 0.5 0.5
IHEM 23151 a. fumigatus 04/09/2006 +++++ 2 0.5 0.25
table 1: isolates of aspergillus lentulus and neosartoya pseudofischeri: sources, isolation dates, conidiation rate and antifungal 
 susceptibility.
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morphological characteristics and growth 
rate
Morphological criteria to discriminate 
a. fumigatus, a. lentulus and N. pseudo-
fischeri are used according to data accu-
mulated by Samson et al. (3). all isolates 
were cultured on Malt Extract agar (MEa) 
with incubation at 37°C. Texture and colour 
of the colonies, conidiation and its impor-
tance, vesicle form and size, and conidia 
form and size were recorded. The isolates 
of N. pseudofischeri were also grown on 
medium with straw in order to stimulate 
the sexual reproduction.
Growth at different temperatures of incu-
bation 25°C, 37°C, 45°C, 48°C and 50°C was 
evaluated for the 22 isolates listed in Table 
1 (a. fumigatus, n = 8; a. lentulus, n = 3; N. 
pseudofischeri, n = 11). 
antifungal susceptibility testing
broth microdilution antifungal susceptibil-
ity testing of reference strains and patients’ 
isolates of a. lentulus, N. pseudofischeri 
and a. fumigatus was performed according 
to ClSI 38-a2 protocol with slight modifica-
tions using amphotericin b (bristol Myers 
Squib, braine l’alleud, belgium), itracona-
zole (Janssen Research Foundation, beerse, 
belgium) and voriconazole (Pfizer, brussels, 
belgium). all experiments were repeated 
twice on different days.
reSultS 
molecular identification
For species identification of the poorly 
sporulating isolates, molecular identifica-
tion was required. Sequences analyses of 
the ß-tubulin gene allowed us to identify 
the isolate IHEM 22112 from patient 1 as 
a. lentulus (99% identity with the corre-
sponding sequence EF669825.1 from strain 
CbS 117885, ex type strain of a. lentulus). 
Sequences obtained for the poorly sporu-
lating isolates from patients 2, 3 and 4 ex-
hibited 99%, 100% and 99% identity with 
the ß-tubulin sequence aY870742 from the 
N. pseudofischeri strain CbS 208.92 (ex type 
strain of N. pseudofischeri), respectively.
morphological characteristics and growth 
rate
a further morphological investigation was 
performed for all the isolates in order to 
substantiate the results from ß-tubulin se-
quence analysis. Isolate IHEM 22112 from 
patient 1, identified as a. lentulus, was 
poorly sporulating. The sporulation rate 
of the 11 isolates from patients 2, 3 and 4, 
identified as N. pseudofischeri, were vari-
able from one patient to another (Table 1), 
but all isolates recovered from a given pa-
tient exhibited the same sporulation rate. 
after several subcultures, particularly on a 
medium containing straw, conidiation was 
enhanced, except for the reference strain 
(type strain) which showed a very low 
sporulation rate. all attempts to obtain the 
full sexual state, including several subcul-
tures on straw-containing medium, were 
unsuccessful for all the isolates studied 
including the reference strain.
Figure 1 shows the mean diameter of the 
colonies for the three species measured 
at 72 hours. Growth was enhanced for all 
isolates and reference strains at 37°C. N. 
pseudofischeri grew a little slower than a. 
fumigatus, and the smallest colonies were 
observed for a. lentulus. Increasing the in-
cubation temperature markedly affected 
the growth for a. lentulus and N. pseud-
ofischeri. Conversely to a. fumigatus which 
gave colonies covering more than half of 
the plates after 72 hours of incubation at 
45°C, small colonies were obtained in the 
case of a. lentulus and N. pseudofischeri. 
a very restricted growth was observed at 
48°C for a. lentulus and N. pseudofischeri 
isolates respectively, and none of them 
grew at 50°C.
antifungal susceptibility testing
antifungal susceptibility of patients’ iso-
lates and reference strains is shown in Ta-
ble 1. The isolate of a. lentulus from patient 
1 was resistant to amb and VRZ, but it was 
strikingly susceptible to ITZ. The MIC values 
were similar to those obtained for the ref-
erence strains of a. lentulus. The 11 isolates 
of N. pseudofischeri from patients 2, 3 and 
4 exhibited quite the same antifungal sus-
ceptibility pattern: they were all resistant 
to VRZ (MIC values ranging from 4 to 8 µg/
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figure 1:
mean diameter of the colonies of a. fumigatus (n = 8), a. lentulus (n = 3) or n. pseudo-fischeri 
(n = 11) clinical isolates or reference strains after 72 hours of incubation.
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Source
this report underlines the role of the national reference centre in medi-
cal mycology for identification at the species level of unusual fungi and for 
determination of their antifungal susceptibility profile.
i m P a c t  o n  P u b l i c  h e a l t h
ml, which were very close to the MICs ob-
tained for the reference strain). Conversely, 
they were all susceptible to amb (MIC val-
ues: 0.25-0.5 µg/ml) and ITZ (MIC values: 0.5-
2 µg/ml). additionally, only one out of the 
7 clinical isolates of a. fumigatus (IHEM 
23045) recovered from these patients was 
resistant to ITZ.
concluSion
This study underlines the difficulties in 
identifying poorly sporulating aspergillus 
species from the section Fumigati only 
on the basis of morphological criteria. 
aspergillus fumigatus, a. lentulus and N. 
pseudofischeri have overlapping morpho-
logical characteristics (3) and therefore use 
of sequence based methods is required 
for correct identification at the species 
level. Moreover, it is not uncommon that 
clinical isolates of a. fumigatus exhibit 
atypical phenotypes, with white or grey 
colonies instead of the typical dark green 
colour and poor sporulation. a very useful 
and important physiological property of a. 
fumigatus for its differentiation from the 
other species of the section Fumigati is its 
ability to grow at 50°C. both species a. len-
tulus and N. pseudofischeri here recovered 
from patients with CF are poorly suscepti-
ble to current antifungal drugs. a. lentulus 
showed resistance to amb and VRZ where-
as N. pseudofischeri isolates were found to 
be resistant to VRZ. The obtained MIC val-
ues were in agreement with the literature 
(2, 5- 7). We also showed that N. pseudo-
fischeri may coexist with ITZ-resistant iso-
lates of a. fumigatus. The fact that a. fumi-
gatus was reported to colonise bronchial 
mucus of CF in the form of biofilms may 
explain higher MICs. additionally, one may 
speculate that repeated therapies with 
antifungals in CF patients colonised by a. 
fumigatus may account for the ITZ resist-
ance of the isolates studied. antifungal 
treatments may also lead to elimination 
of susceptible a. fumigatus isolates and fa-
vour persistence of resistant species such 
as a. lentulus and N. pseudofischeri.
In conclusion, this study underlines the 
importance of identification at the spe-
cies level of unusual or poorly sporulating 
aspergillus isolates since some species 
within the Fumigati section may be poorly 
susceptible to some of the current anti-
fungal drugs.
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virological surveillance of influenza 
a(h1n1)2009 pandemic: the role of the  
belgian national influenza centrec. Gérard, b. brochier
S. Quoilin, f. Wuillaume
 v. van casteren, i. thomas
introduction
On 24 april 2009, the World Health Organi-
sation (WHO) first reported the emergence 
of a new influenza virus in the United 
States of america and Mexico (1). This nov-
el influenza virus was identified as a new 
a(H1N1) subtype resulting from a re-assort-
ment of avian, human and swine influenza 
viruses. This virus, which was later referred 
to as a(H1N1)2009, rapidly demonstrated 
its capacity to transmit among humans (2). 
On 11 June 2009, the WHO decided to raise 
the pandemic alert to the maximum phase 
6 level (3). 
Influenza in humans is caused by one of 
three types of influenza viruses a, b and 
rarely C, which all belong to the orthomyxo-
viridae family, and have two glycoproteins 
on the surface of their virions, the Hemag-
glutinin (Ha) and the Neuraminidase (Na). 
These proteins elicit antibody responses 
to the influenza virus. So far sixteen dif-
ferent Has (H1 to H16) and 9 different Nas 
(N1 to N9) have been recognised. Several 
combinations of Ha and Na proteins are 
possible, each combination representing a 
different subtype (for example a/H1N1, a/
H3N2, a/H1N2…). an important character-
istic of influenza viruses is their ability to 
evolve continuously to escape the immune 
response. The mechanisms behind this 
evolution are either antigenic drift (point 
mutations in the Ha and Na genes) or anti-
genic shift (re-assortment between differ-
ent Influenza viruses).
For a virus to cause a pandemic, two major 
criteria must be met: the virus must be new 
(antigenic shift), as such a large proportion 
of the population is susceptible to infec-
tion, and the virus must be transmissible 
from person to person (4, 5). In this context, 
the initial reporting of this novel transmis-
sible influenza variant to the WHO and the 
continuous surveillance of this virus is of 
the highest importance. It enables virus 
evolution to be monitored and the risk to 
public health worldwide to be reduced (6).
In belgium, Influenza virus surveillance is 
ensured by the National Centre for Influ-
enza (NIC). according to the WHO (7, 8), the 
responsibilities of a NIC during a pandemic 
period are: 1. to provide laboratory diagno-
sis for monitoring the geographical spread 
of the pandemic in the country; 2. as the 
pandemic intensifies and becomes wide-
spread, adjust virological surveillance in 
order to monitor the progress of the pan-
demic in the country; 3. maintain adequate 
virological surveillance to assist the WHO 
in monitoring for example antigenic and 
genetic changes in the pandemic virus, 
pathogenicity, and susceptibility to antivi-
ral treatment. 
methodS
Sampling during the containment phase
From 26 april to 13 July 2009, a contain-
ment strategy was implemented according 
to the WHO and CDC recommendations, in 
order to limit the extension of the epidem-
ic (9). The Interministerial Influenza Coor-
dination Committee established a series 
of measures and protocols to manage all 
suspect cases and contacts regarding noti-
fication, sampling, prophylaxis, treatment 
and isolation (10). an active surveillance 
system was then established, to detect all 
suspect cases of a(H1N1)2009 and to trace 
their contacts. In collaboration with the 
community health inspectors, physicians 
were asked to take a sample from each 
patient showing flu symptoms and return-
ing from infected countries or regions. Due 
to the rapid geographic extension of the 
pandemic, the list of such countries was 
updated regularly.
During this period, more than 3,000 sam-
pling kits were sent to physicians, labo-
ratories and hospitals all around belgium 
and additional kits were provided on re-
quest. Each kit contained 4 swabs, trans-
port medium, FFP2 masks, an information 
form and a detailed sampling procedure to 
take respiratory secretions from nose and 
throat. Samples needed to be sent to the 
NIC on the same day, in order to give a diag-
nostic result within 5-6 hours. The WIV-ISP 
laboratory was operational 24/24 hours, 
7/7 days, in collaboration with all involved 
public health authorities.
Sampling during the mitigation phase
From 13 July 2009 onwards, because of the 
sustained community spread, belgium’s 
strategy shifted to a mitigation phase 
(week 29 to recent), where systematic labo-
ratory confirmation testing was no longer 
required. Only high risk and hospitalised 
patients were to be tested for a(H1N1)2009 
if suspected.
During this phase, the NIC strengthened 
the nationwide surveillance system to 
study the a(H1N1)2009 virus circulation in 
the belgian population and to help reduce 
influenza morbidity and mortality. The in-
fluenza virological sentinel surveillance 
network, previously composed of 98 gen-
eral practitioners (GPs) distributed across 
the whole country (11), was expanded to 
139 GPs (78 GPs located in Flanders, 49 in 
Wallonia and 12 in the brussels-Capital Re-
gion). The latter GPs were all part of Senti-
nel General Practitioners composed of ap-
proximately 160 GPs, who are also involved 
in clinical influenza surveillance (11). The 
decision to enlarge the virological sentinel 
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surveillance network was taken when the 
first three positive a(H1N1)2009 cases in 
belgium were diagnosed via this network 
during week 27.
laboratory testing
at the start of the pandemic, there was still 
a lack of information about the pathogen- 
icity and transmission of the virus. Therefore, 
and to avoid any possible re-assortment 
between strains from swine and human 
origins, manipulation and RNa extraction 
of suspect specimens were performed in 
the biosafety level 3 laboratory (bSl3) of the 
WIV-ISP instead of bSl2 facilities where sim-
ilar samples are routinely tested within the 
framework of monitoring seasonal flu. Viral 
RNa from clinical samples was extracted in 
duplicate with the QIaamp® Viral RNa Kit 
from QIaGEN (Hilden, Germany). 
The extracted RNa was submitted to a se-
ries of real time PCR tests in a bSl2 envi-
ronment. The real time PCR reactions were 
performed on a Stratagene Mx3000P™ 
thermal cycler using the SuperScript® III 
Platinum® One-Step qRT-PCR System from 
Invitrogen (Carlsbad, California, USa). 
at first, there was no specific test avail-
able for the new pandemic influenza virus. 
Therefore the suspect samples were tested 
for influenza a and b, and subtyped for 
seasonal influenza a/H1 and a/H3. Primers 
and probes for each type (a/b) and subtype 
(H1/H3) were designed in a conserved gene 
region, selected either from the literature 
or after multiple-sequence alignment with 
a large amount of recent human and ani-
mal strains available at Genbank. Regions 
of the matrix gene (12) and of the Hemag-
glutinin gene (13) were amplified for typ-
ing a and b respectively. For the subtyping, 
a region in the Ha gene was amplified. a 
sample which was positive for influenza a 
and negative for both seasonal subtypes 
(H1N1 and H3N2) was considered as a prob-
able case.
From 3 May 2009, specific primers and 
probes for a(H1N1)2009 virus were sent by 
the Centers for Disease Control and Pre-
vention (CDC) of atlanta (14) and used as 
standard tests in our laboratory. The work-
flow of the tests is shown in Figure 1.
a series of randomly selected samples 
from the start, the peak and the end of the 
pandemic, as well as samples from more 
severely affected patients, were also se-
quenced, in order to detect any mutations 
in the hemagglutinin or neuraminidase 
gene, including mutations associated with 
resistance to neuraminidase inhibitors. a 
selection of approximately 200 samples 
was sent to london (WHO Collaborating 
Centre) for antigenic characterisation and 
monitoring of antiviral resistance. 
reSultS
On 12 May 2009, the NIC confirmed the first 
case of influenza a(H1N1)2009 in a patient 
returning from the United States. In total, 
614 patient samples were tested during the 
containment phase (week 18 to 28) in bel-
gium, of which 123 cases were confirmed 
positive for a(H1N1)2009, the majority of 
them being imported cases. One sample 
out of the 614 analysed samples was posi-
tive for influenza b, 15 samples were con-
firmed to be a/H3N2 positive and 13 others 
were found to be positive for influenza a 
but could not be subtypted. This may be 
due to the lower sensitivity of the PCR test 
for subtyping H1 in comparison with the 
PCR for typing a or due to evolution of the 
virus leading to mismatches with the prim-
ers or probes. 
During the mitigation phase, 729 addi-
tional suspect cases were tested, with 285 
confirmed cases for a(H1N1)2009, 3 cases 
positive for influenza a/H3N2 and 47 cases 
positive for influenza a which could not be 
subtyped. 
In the first phase of the pandemic, a high 
number of suspected samples received 
from belgian physicians, laboratories and 
hospitals (non-sentinel network), was ana-
lysed but revealed a relatively low number 
of a(H1N1)2009 confirmed cases (Figure 
2a). This is especially true for week 28. 
Several factors could be implicated: the 
low incidence of influenza a(H1N1)2009 
at that time, the high media attention to 
the flu crisis, the subsequent psychologi-
cal impact on the population and also the 
first people returning from holidays from 
countries where the a(H1N1)2009 strain 
was already detected. a second peak in the 
number of analysed samples was observed 
in week 46, coinciding more or less with the 
figure 1: Workflow of laboratory tests in case of influenza a(h1n1)2009 suspicion in a patient. 
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epidemic peak, characterised by a high per-
centage of confirmed a(H1N1)2009 cases. 
a low number of influenza a/H3N2 could 
still be detected until week 34, probably 
corresponding to the end of the seasonal 
influenza epidemic 2008-2009 which was 
characterised by a high prevalence of the 
a/H3N2 subtype. In week 21, an increase 
in the percentage of a(H1N1)2009 positive 
samples was observed, resulting from a 
higher number of confirmation tests (sam-
ples already tested positive for influenza a 
but still unsubtyped by other laboratories) 
at this stage of the epidemic.
Figure 2b shows the weekly evolution of 
the number of analysed samples and of 
influenza a(H1N1)2009 positive samples in 
the sentinel network. In belgium, the pro-
portion of positive samples increased from 
28% in week 40 to 73% in week 44 (corre-
sponding to the epidemic peak) (11). The 
proportion then decreased slowly from 
week 46 (51%) to week 52 (25%). From week 
43 to 44, the graph shows a drastic de-
crease in the number of analysed samples. 
This is due to a change in the sampling 
strategy. Until that time, GPs were asked 
to take a sample from each patient who 
presented Influenza like Illness (IlI) symp-
toms. but from then on, they were asked 
to take a maximum of 2 samples a week, 
in order to decrease the number of analy-
ses. Still, until week 50, the epidemiological 
criteria were respected: the rate of doctor 
visits was above the epidemic threshold 
(established at 141 doctor visits per 100,000 
people) and among patients with IlIs, more 
than 20% people were positive for influen-
za a(H1N1)2009. 
The genetic and antigenic analysis of a 
series of a(H1N1)2009 strains isolated in 
belgium revealed no significant difference 
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figure 2:
a.  Weekly evolution of the number of analysed samples and influenza a positive samples from week 2009-18 until week 2009-52 in the non-sentinel  
 network. 
b.  Weekly evolution of the number of analysed samples and influenza a positive samples from week 2009-19 until week 2009-52, by the virological  
 sentinel surveillance network.
a
b
communicable and infectiouS diSeaSeS directorate 91 
centers for disease control and Prevention (dcd). Swine influenza a (h1n1) infection in two children – Southern california, march-april 2009. mmWr 1. 
morb mortal Wkly rep 2009; 58(15):400-2.
novel Swine-origin influenza a (h1n1) virus investigation team. emergence of a novel Swine-origin influenza a (h1n1) virus in humans. n engl J med 2. 
2009;360:2605-15.
World health organisation. World now at the start of 2009 influenza pandemic. Statement to the press by Who director-General dr margaret chan. 11 3. 
June 2009. available from: http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html
the Writing committee of the Who consultation on human influenza a/h5. avian influenza a (h5n1) infection in humans. n engl J med 2005;353:1374-85.4. 
Poland Ga, Jacobson rm, targonski Pv. vaccine 2007;25:3057-3061.5. 
Who case definition for human infections with influenza a (h5n1) virus. Geneva, World health organisation, 2006.6. 
the role of national influenza centers (nics) during interpandemic, Pandemic alert and Pandemic Periods. interim document, 2007. available from: 7. 
http://www.who.int/csr/disease/avian_influenza/guidelines/rolenicsmayf.pdf
Guidance to influenza laboratories diagnosing Swine influenza a(h1n1) infections of current concern. 25 april 2009. available from: 8. http://www.who.
int/csr/disease/swineflu/swineflu_guidance_labs_20090425.pdf
World health organisation (Who). Swine influenza. Statement to the press by Who director-General dr margaret chan. 25 april 2009. available from: 9. 
http://www.who.int/mediacentre/news/statements/2009/h1n1_20090425/en/index.html
belgian working group on influenza a(h1n1)v. influenza a(h1n1)v virus infections in belgium, may-June 2009. euro Surveill 2009;14(28):pii=19270.10. 
 11. van casteren v, mertens K, antoine J, Wanyama S, thomas i, bossuyt n. clinical surveillance of influenza a(h1n1)2009 pandemic through the network of 
Sentinel General Practitioners.
Spackman e, Senne da, myers tJ, bulaga ll, Garber lP, Perdue ml 12. et al. J clin microbiol 2002;40:3256-3260.
van elden lJr, nijhuis P, Schipper r, Schuurman r, van loon am. J clin microbiol 2001;39:196-200.13. 
centers for disease control and Prevention. cdc protocol of realtime rtPcr for influenza a(h1n1). 6 october 2009. available from: 14. http://www.who.int/
csr/resources/publications/swineflu/cdcrealtimertPcr_Swineh1assay-2009_20090430.pdf
referenceS
This surveillance program is financially supported by the Directorate-General for Primary Health Care and Crisis Management (DG2) of the 
Federal Public Service Health, Food Chain Safety and Environment and by the French and Flemish Communities. Many thanks to Mona 
abady, Jérôme antoine, Regine De bruyn, Ilham Fdillate, anneleen Hombrouck, Yvonne Ronflette and Christophe Van den Poel for their 
intensive work and their constant enthusiasm. 
acKnoWledGementS
influenza virus may cause high morbidity and lethality and present a major 
risk to public health and economy. Surveillance of epidemic and pandemic 
influenza is crucial. continuous effort to update our diagnostic methods, 
to follow the genetic variability of influenza viruses and to highlight poten-
tial resistance to antivirals, is necessary.
i m P a c t  o n  P u b l i c  h e a l t h
with pandemic strains found worldwide. 
all corresponded to the reference a/Cali-
fornia/4/09 strain. Out of the 48 samples 
analysed by the WHO Collaborating Cen-
tre, one strain isolated from an immuno-
supressed patient showed resistance to 
Oseltamivir (neuraminidase inhibitor) and 
presented the mutation H275Y in the neu-
raminidase gene.
concluSion
The introduction of the influenza 
a(H1N1)2009 virus in belgium occurred 
similarly to other European countries, ini-
tially causing a small but rapidly increas-
ing number of cases (10). In this emergency 
context, the laboratory optimised a bat-
tery of real-time RT-PCR assays, allowing 
it to perform a single-day diagnosis. The 
aim was to identify positive cases as soon 
as possible and to limit the propagation 
of the virus in the belgian population. The 
surveillance system worked in accordance 
with the NIC public health mission, demon-
strating effective collaborations between 
the different partners and national author-
ities. Until the end of 2009, the pandemic 
appeared to be less severe than initially 
predicted, with milder symptoms and a 
limited number of lethal cases. Finally its 
evolution was comparable with that of a 
classical seasonal epidemic. 
Genotypically, the pandemic influenza 
strains isolated in belgium up to now cor-
respond to those isolated worldwide. Nev-
ertheless, the a(H1N1)2009 pandemic virus 
will probably circulate for the coming 
seasons and its future evolution remains 
uncertain. Therefore a close and sustained 
monitoring of the evolution of the virus is 
required to provide an adequate response 
and surveillance system for the near future. 
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vhh-based nanobodies® selected against 
the viral spike protein can protect mice 
against lethal rabies virus challenge
v. rosseels, P. Vanlandschoot
a. Hultberg a, CT. Verrips
M. Saunders, H. de Haard
a. francart, m. Kalai
S. van Gucht
introduction
Rabies causes 55,000 human deaths per 
year (1). The virus is present in the saliva of 
infected animals and transmitted by bites. 
From the infected wound, the virus trav-
els through the peripheral nerves to the 
central nervous system and causes lethal 
brain infection. Once symptoms appear, 
the case-fatality rate is nearly 100%.
lives can be saved if the person receives 
post-exposure prophylaxis (PEP) promptly 
after exposure (2). Once the first, often non-
specific, symptoms occur, PEP is no longer 
effective. PEP involves active immunisation 
with vaccine and, for high-risk exposures, 
immediate passive immunisation treat-
ment with anti-rabies antibodies. These 
antibodies are infiltrated the wound and 
neutralise viral particles before they enter 
the central nervous system. an important 
portion of the antibodies is retained at 
the infiltration site for at least 24 hours 
(3). Thus, passive immunisation provides 
immediate protection against the virus in 
attendance of vaccine-induced antibodies, 
which take at least a week to mount.
approximately 10 million people receive 
PEP each year, of which 2-5% are also 
treated with anti-rabies antibodies (2). 
Most deaths occur in developing countries, 
where people do not receive appropriate 
PEP, due to poor availability, high cost or 
simply ignorance. Even Western countries 
report a shortage of anti-rabies antibodies 
for PEP (4).
The antibody products available on the 
market are polyclonal IgG preparations de-
rived from pooled plasmas of vaccinated 
humans or horses (5). Since large scale pro-
duction is not feasible, these are very ex-
pensive and have limited availability. batch 
to batch variations are inevitable and the 
risk of transmission of (unknown) blood-
borne pathogens or contaminants cannot 
be excluded. allergic reactions can occur, 
especially with the equine variant. They 
have a relative low neutralising potency 
requiring infiltration of a large volume in 
the wound. In small body parts, such as a 
finger, this can cause the compartment 
syndrome. Part of the immunoglobulin 
content may interfere with live vaccines, 
e.g. against measles and rubella and thus 
vaccination against these diseases should 
be postponed for at least 4 months. 
For this, the World Health Organisation 
urges the development of alternatives (6). 
Cocktails of human or (humanised) mouse 
monoclonal antibodies (Mabs) are being 
examined as alternatives for blood-derived 
antibodies (7-9). VHH-based Nanobodies® 
may be another alternative.
VHH are polypeptides derived from heavy-
chain antibodies of camels and llamas (10). 
These animals possess naturally occurring 
single heavy-chain antibodies lacking light 
chains. They are composed of a single vari-
able domain (VHH) and two constant do-
mains (CH2 and CH3). Recombinant and iso-
lated VHH are stable polypeptides (15 kDa, 
IgG = 150 kDa) harbouring the full antigen-
binding capacity of the original antibody. 
Nanobodies® are VHH-based therapeutics 
for which treatment applications for dif-
ferent types of disease are currently being 
explored. They can be composed of a single 
VHH or be multimeric constructs of several 
VHH.
Recombinant VHH present different ad-
vantages over antibodies. They have a low 
production cost, can not be contaminated 
by blood-borne pathogenic agents and are 
less likely to evoke allergic or immuno-
pathological reactions. They have good 
thermal stability, which is an advantage in 
developing countries, where the cold chain 
for distribution and preservation cannot 
always be guaranteed.
We have found that VHH, directed against 
the viral surface glycoprotein G, are capa-
ble of neutralising rabies virus in an infec-
tivity assay on baby hamster kidney (bHK-
21) cells (11). Since VHH lack the functional 
Fc region of antibodies, which activates 
complement and facilitates uptake by 
phagocytes or activation of natural killer 
cells, it was not clear whether this is suf-
ficient to provide protection in an in vivo 
system. Experimental rabies virus infection 
of mice provides an excellent tool to test 
the in vivo antiviral properties. This model 
requires only little virus to induce a lethal 
brain infection and the read out is excep-
tionally straightforward with mostly two 
outcomes: no clinical signs (protection) or 
lethal disease (no protection) (12).
Therefore the aims of this study were to ex-
amine whether (i) VHH, in single or bimeric 
conformations, are capable of neutralis-
ing rabies virus in vivo and (ii) treatment 
before or after virus exposure can protect 
against lethal infection.
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materialS and methodS
vhh and antibody
llamas were kept in the animalarium of the 
WIV-ISP and vaccinated repeatedly with 
HDCV rabies vaccine (Sanofi). Peripheral 
blood lymphocytes were isolated, RNa was 
extracted and VHH genes were amplified 
from a cDNa library. anti-rabies virus VHH 
were selected by panning phage libraries 
in 96-well plates coated with the native 
glycoprotein G (12). G forms the spikes on 
the viral surface. Most of the anti-G VHH 
were capable of neutralising rabies virus in 
a cell infectivity assay using bHK-21 cells. 
anti-G VHH were also fused with glycine-
serine (GS) linkers of variable length to 
obtain bimeric constructs directed against 
identical (bivalent) or different antigenic 
epitopes (biparatopic). Negative control 
mice were treated with phosphate-buff-
ered saline (PbS) while positive controls re-
ceived the potent rabies-virus neutralising 
Mab RV1C5 (Santa Cruz).
virus
Challenge Virus Standard (CVS)-11 is a viru-
lent genotype 1 lyssavirus obtained from 
the american Type Culture Collection (aTCC 
reference VR959). Chien beersel-1 (Cb-1) is a 
wild-type canine genotype 1 strain isolated 
from a rabid dog in belgium in 2007. CVS-
11 was grown in bHK-21 cells and Cb-1 was 
grown in mouse brain by intracerebral in-
oculation. For intracerebral and intranasal 
virus challenge, CVS-11 was used at a dose 
of 101.5 and 102.0 TCID50 respectively. For 
intramuscular virus challenge, Cb-1 was 
used in a 1/10 dilution of the supernatant 
of centrifuged brain lysate.
inoculations
Eight to ten female Swiss outbred mice 
(Harlan, The Netherlands) at the age of 6 to 
8 weeks were used per group. The experi-
mental procedure was approved by the 
local ethical committee of the institute 
(advice nr. 070515-05). Mice were anesthe-
tised by isoflurane and inoculated with 
VHH and/or virus directly into the brain by 
transcranial injection (20 µl), the muscle (50 
µl) or the nose (25 µl) (12).
clinical follow up 
Mice were observed daily throughout the 
experiment for signs of disease until 35 
days after inoculation. Scores ranged from 
0 (no disease) to 7 (severe nervous disease) 
(12). according to our experience, mice 
with disease scores of 6 to 7 die within 
one day. Therefore, mice were euthanised 
by cervical dislocation when they reached 
that disease score. Results were expressed 
as Kaplan-Meier survival curves.
reSultS
Proof of concept that vhh can neutralise 
virus particles in vivo
Contrary to irrelevant control VHH, pre-
incubation of the virus with rabies virus-
specific VHH protected mice against brain 
infection, disease and mortality upon in-
oculation of the virus-VHH mix in the nose, 
muscle or brain (Table 1). Excellent protec-
tion was obtained when bimeric VHH and 
virus were introduced simultaneously 
in the same body compartment. Similar 
results were obtained with Mab RV1C5. 
Monovalent VHH were less performant in 
the brain. This agrees with the fact that 
bimeric constructs show a massive in-
crease in neutralising potency and cross-
neutralisation of variable genotypes in 
vitro, compared to the monovalent build-
ing blocks (11, 13).
Still, the in vitro neutralising potency was 
not correlated with the level of in vivo 
protection. Rab-C12 was the most potent 
monovalent VHH in vitro, but proved less 
protective than Rab-E6 in the brain. These 
VHH recognise different epitopes (11). This 
discordance is also known for antibodies.
For further studies, the biparatopic VHH 
Rab-E8(15GS)H7 was selected because of 
its high neutralising potency in vitro and 
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a
b
good protective effect in all challenged 
body compartments.
effect of preventive treatment with vhh 
on subsequent virus challenge
Preventive administration of VHH Rab-
E8(15GS)H7 or Mab RV1C5 in the nose, 24 
hours prior to intranasal virus challenge, 
almost completely prevented disease and 
lethal infection (Figure 1a). This suggests 
that VHH remain active for at least 24 hours 
in the nose and are capable of neutralising 
at least part of the invading virus. VHH may 
therefore be suitable for passive mucosal 
immunisation against entry or local infec-
tion with viruses in the nose.
effect of post exposure treatment with 
vhh after intramuscular virus challenge
PEP by injection of the biparatopic VHH 
Rab-E8(15GS)H7 in the contralateral mus-
cle 10 minutes after intramuscular virus 
challenge reduced mortality by 50% (Fig-
ure 1b). Treatment 24 hours after virus 
challenge was no longer effective, albeit 
survival time was prolonged by one day. 
at this late time point, PEP with the Mab 
RV1C5 was still able to reduce mortality by 
30%. Results thus depended on the interval 
between the virus inoculation and the VHH 
treatment. Treatment at 10 minutes was 
able to protect part of the mice, whereas 
treatment at 24 hours was no longer ef-
fective. For both VHH and Mab, the same 
in vitro neutralising dose of one IU was 
used, which proved equally effective when 
applied prior to or simultaneous with the 
virus challenge. 
concluSion
Our results show that anti-G VHH can neu-
tralise rabies virus in an Fc-independent 
way. VHH probably hinder the recogni-
tion of cellular receptors or interfere with 
conformational changes of the G protein 
necessary to fuse viral and cellular mem-
branes. It remains unclear to what extent 
complement- or effector cell-mediated 
lyses of infected cells are also involved in 
the protective effect of antibodies. Such 
a cytotoxic effect might however not be 
desirable in humans. Optimal treatment of 
rabies favours a healthy balance between 
maximal virus neutralisation and minimal 
immunological cell damage. Indeed, intra-
venous administration of immunoglobu-
lins to symptomatic patients has been 
associated with sudden onset of muscle 
paralysis (15). Presumably, paralysis in-
volved the activation of complement by 
IgG deposits on axons containing rabies 
virus antigens (16). Some experts advise 
against the use of antibodies for treat-
ment of symptomatic patients, because 
(i) it might interfere with the ontogeny of 
the natural immune response (17) and (ii) it 
might shorten the survival time and cause 
“early death” (18). Early death might be due 
to immunopathological damage to infect-
ed neurons or, as proposed by one study, 
enhancement of infectivity by uptake of 
virus in macrophages through Fc receptor-
mediated endocytosis (19). The importance 
of this phenomenon in rabies is controver-
figure 1: 
a. Survival proportions of mice treated with the biparatopic vhh rab-e8(15GS)h7 in the nose 
 and challenged with virulent virus one day later through the nasal route(in) (preventive 
 treatment model). 
b. Survival proportions of mice treated with the biparatopic vhh rab-e8(15GS)h7 at 10 minutes 
 or 24 hours after intramuscular (im) virus inoculation (post exposure treatment model). 
 Positive and negative control mice were treated with mab rv1c5 and phosphate-buffered 
 saline (PbS), respectively.
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acKnoWledGementS
failure to rapidly obtain treatment with anti-rabies antibodies can be lethal 
in severe cases of exposure. the current post-exposure therapy requires 
blood-derived human anti-rabies antibodies which are increasingly difficult 
to obtain worldwide. our study demonstrates that recombinant vhh may of-
fer a safe, cheap and easy-to-manufacture alternative for rabies prophylaxis.
i m P a c t  o n  P u b l i c  h e a l t h
sial, but it has clinical relevance for other 
viruses, such as dengue virus (20).
VHH offer a neutralising potency per 
weight unit which is best in its class. For 
one rabies virus-neutralising unit, only 
122 µg of VHH Rab-E8(15GS)H7 is required, 
whereas for Mab RV1C5 this is 606 µg and 
for blood-derived human immunoglobu-
lins (Imogam, Sanofi) 1111 µg. This reduces 
the antigenic content and volume of the 
administration, which is beneficial for infil-
tration in small body compartments.
Still, the protective effect in the PEP experi-
ment was limited especially at the longer 
time interval of 24 hours between virus ex-
posure and subsequent treatment. In this 
experiment, the virus had the occasion to 
infect cells which in turn can release new 
virus. In such a set up, it becomes impor-
tant to neutralise the newly produced vi-
rus over a prolonged period, and not only 
the challenge virus introduced by the inoc-
ulation. Once absorbed in the blood, VHH 
are however quickly cleared by the kidneys 
resulting in a short systemic half-life of 30 
min. The half-life of VHH can easily be ex-
tended to the range of an antibody (weeks) 
by conjugation with an anti-albumin VHH 
(14). Most likely, this would improve per-
formance in the PEP model.
In conclusion, we proved that llama VHH 
can neutralise rabies virus in vivo in an Fc-
independent way. Especially the bimeric 
constructs were highly protective in dif-
ferent challenge models. The relative weak 
protection in the PEP model might be due 
to the short half-life of the VHH used. Con-
sidering that prolongation of the half-life 
of VHH is feasible by different approaches, 
VHH technology may offer perspectives as 
an alternative to antibodies for PEP.
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introduction by Ir. Joris Van loco
The Food, Medicine and Consumer Safety Directorate was established by Ministerial Order 
on 26 august 2008. The directorate’s main focus is to perform policy-supportive scientific 
research and to provide services to federal and regional partners including the Federal 
agency for Food Chain Safety (aFSCa-FaVV), the Federal agency for Medicines and Health 
Products (aFMPS-FaGG) and the Federal agency for Nuclear Control (aFCN-FaNC). The direc-
torate has modern analysis equipment and highly trained personnel. The quality of the per-
formed laboratory analyses is highly regarded and the scientific directorate has a quality 
system accredited according to the ISO 17025 standard.
The directorate works closely with belgian and international universities as a partner or 
coordinator in various externally financed scientific research projects.
medicines
description:
The Medicines division specialises in analysing medicines, including illegal and counterfeit 
medicines), medicine ingredients, magistral preparations, medicinal plant extracts, drugs 
and vitamin preparations. The section is ISO 17025 accredited and periodically participates 
in ring tests, quality control of centrally authorised products and other related activities. 
It represents belgium in the European network of Official Medicines Control laboratories 
(OMCl), which was established as part of the mission of EDQM (Strasbourg) and EMEa (of-
fice: london). 
activities:
To support the Federal agency for Medicines with laboratory activities in order to main-• 
tain the quality of medicines. These laboratory activities include inspecting medicine in-
gredients, magistral preparations and specialities, detecting counterfeit medicines and 
analysing illegal preparations;
To actively participate in the creation of monographs for the belgian and European Phar-• 
macopoeia Commissions and the Therapeutic Magistral Formulary (FTM-TMF);
To perform quality control on vitamin nutrients on behalf of aFSCa-FaVV and aFMPS-• 
FaGG;
To analyse drugs as part of a national monitoring plan on drug use.• 
food,  medicine 
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food & consumables
description:
The Food & Consumables division specialises in analysing residues and contaminants in 
food and consumables (food contact materials, piercings, cosmetics...). The division uses 
a quality system and is ISO 17025 accredited. The division is also the National Reference 
laboratory (NRl) for detecting residues of veterinary medicines, hormonal products, pes-
ticides, dioxins, polycyclic aromatic hydrocarbons (PaHs), polychlorinated biphenyls (PCbs) 
and other environmental contaminants, marine toxins and food contact materials. It works 
closely with aFSCa-FaVV and belgian laboratories in this respect. The division is also active 
in the European and National Reference laboratories working group. The division harbours 
several ongoing scientific projects in cooperation with belgian universities on environmen-
tal contaminants, toxins, pesticides and food contact materials.
activities:
The division’s reference tasks are to research and develop methods of analysis, participate 
in collaborative trials, organise interlaboratory tests and communicate and distribute re-
sults and methods on behalf of aFSCa-FaVV;
To perform routine analyses;• 
To carry out intake and exposure studies;• 
To provide scientific and technical support to the administration in case of a crisis and • 
to perform urgent analyses.
radioactivity
description:
The National Reference laboratory for Monitoring Radioactivity in the Environment works 
closely with the Federal agency for Nuclear Control (aFCN-FaNC).
activities:
To monitor radioactivity levels in the environment on belgian soil with a specific focus • 
on areas near nuclear industry;
To measure the radioactivity of food, air, precipitation, ground- and surface waters, • 
plants, sea water, sediment and biological indicators;
To make analysis and confirmatory tests of food samples and some other products;• 
To be involved in the implementation of emergency plans in case of nuclear accidents.• 
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Photoinitiators are widely used as catalysts 
for photopolymerisation. They are general-
ly used in a mixture and their role is to start 
the polymerisation process, which aims to 
harden the ink film on the substrate, for ex-
ample cardboard. Traditionally, inks were 
cured thermally and their formulations in-
cluded organic solvents, which then had to 
be eliminated with a drying process. Con-
sequently, organic solvent residues could 
contaminate the food surrounded by the 
packaging material. Therefore, UV-curing 
seemed to be a good alternative. How-
ever, the photoinitiators are not always 
completely utilised or removed after the 
printing process. as a result, low molecular 
weight photoinitiators such as benzophe-
none (bP), which are applied to the outside 
of the packaging material, may perme-
ate through the rather open structure of 
cardboard and subsequently migrate into 
the food. There is also the possibility that, 
if benzophenone residues are not com-
pletely removed from recycled paper and 
cardboard, benzophenone may persist in 
any packaging made from these recycled 
materials even if that packaging itself has 
not been printed with UV-cured inks. 
Recently, 4-methylbenzophenone (4MbP) 
was detected in breakfast cereals, leading 
to notifications in the Rapid alert System 
for Feed and Food (RaSFF). In March 2009, 
the European Food Safety authority (EFSa) 
declared that “4-methylbenzophenone 
is used as a photoinitiator of UV-cured 
printing inks and lacquers applied on the 
surface of packages, mainly cardboard 
boxes”. This press statement indicated 
that 4-methylbenzophenone may be used 
in combination with or as replacement of 
benzophenone and that, given the volatil-
ity of both benzophenone and 4-methyl-
benzophenone, both substances may mi-
grate into the package and contaminate 
foodstuffs. like benzophenone, 4-meth-
ylbenzophenone is expected to be a non-
genotoxic carcinogen.
at present, there is no specific standard-
ised EU regulatory framework for the con-
trol of inks applied to the outer surface 
of food packaging and the corresponding 
possible migration of these inks into the 
foodstuff. However, there is a resolution 
of the Council of Europe ReSap (2005) 2 on 
the use of ink, which includes 3 technical 
documents and a list of authorised sub-
stances. It should be noted that neither 
benzophenone nor 4-methylbenzophe-
none are listed. Moreover, all materials 
and articles intended to come into contact 
with food should comply with the gen-
eral criteria laid down in the relevant EC 
framework regulation 1935/2004, i.e. they 
should not transfer their constituents into 
food in quantities that could endanger hu-
man health or bring about unacceptable 
changes in composition or characteristics 
of foodstuffs. In addition to all specific 
directives related to Food Contact Materi-
als, the European Commission Regulation 
2023/2006 lays down the rules on Good 
Manufacturing Practice (GMP) for groups 
of materials and articles, intended to come 
into contact with food and details pro-
cesses involving printing inks. For the use 
of benzophenone as an additive in plastic, 
a specific migration limit (SMl) of 0.6 mg 
kg-1 has been set in the European Commis-
sion Directive 2002/72/EC. 
as a result, the optimisation and valida-
tion of methods to determine potential 
low-weight substances used in packaging 
formulations for food are essential to en-
sure the safety of packaged foods. Never-
theless, this is not easy to achieve since 
food samples are complex matrices and 
moreover, there exists a vast range of pos-
sible migrant substances, packaging mate-
rials and applications. In the specific case 
of photoinitiators, there is little informa-
tion available regarding the determination 
of these substances in food items. Most 
studies evaluated the packaging material 
or performed an extraction using a food 
simulant. Most relevant studies for the 
determination of photoinitiators in food 
have involved the determination of isopro-
pylthioxanthenone (ITX) (1-4). Up to now, 
only a few methods have been developed 
for the determination of bP in food and no 
methods have been published for the de-
termination of 4MbP in food.
In this contribution, a fast and reliable 
method for the determination of bP and 
4MbP in cereals is described. The sample 
was extracted ultrasonically using a mix-
ture of dichloromethane and acetonitrile 
(1:1), followed by purification of the extract 
by solid phase extraction. Finally, the ex-
tract was analysed by GC-MSn. The present-
ed method is in-house validated.
method and materialS
chemicals
Neat certified standards of benzophenone 
(bP) (purity 99%), 4-methylbenzophenone 
(4MbP) (99%) and benzophenone-d10 (bP-
d10) (99%) were purchased from Sigma-
aldrich (bornem, belgium). Hexane, ace-
tonitrile, methanol and ethyl acetate were 
supplied by Merck (Darmstadt, Germany). 
Dichloromethane was purchased from bio-
solve (Valkenswaard, The Netherlands). all 
solvents were HPlC grade. Stock solutions 
of each individual compound and all the 
working solutions were prepared in hex-
ane. These solutions were stored at 4°C. 
analysis of the photoinitiators  
benzophenone and 4-methyl- 
benzophenone in breakfast cereals 
e. van hoeck
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Sample preparation
Method development was done using 
5 g of cereal sample (Kellogg’s extra, Kel-
logg’s, Manchester, UK) spiked with bP, 
4MbP and the internal standard bP-d10 at 
600 µg kg-1 (ppb) (which is a sample spiked 
at the specific migration limit (SlM)). 
Next, 10 ml of an organic solvent (hexane, 
dichloromethane:acetonitrile (1:1), ace-
tonitrile and methanol) was added and this 
mixture was placed in the ultrasonic bath 
(Transsonic T780, Elma, Mettler Toledo, Za-
ventem, belgium) for 10 min. Then, the ce-
real was further extracted by shaking the 
Falcon tube for 30 min. in a rotary agitator 
(Orbital Reax 2, Heidolph instrument, VWR, 
leuven, belgium). after the extraction, 
the sample was centrifuged (8 min, 800 
rpm, -20°C) (Jouan bR4i, DJb labcare, UK). 
The liquid phase, obtained after centrifu-
gation, was then evaporated to dryness 
under a gentle stream of nitrogen at 30°C 
(Turbovap, Caliper life Science, Teralfene, 
belgium). The residue was re-dissolved in 
2 ml hexane before purification by solid 
phase extraction on a silica cartridge (1 g, 
6 ml, Si) (Varian, lake forest, Ca, USa). This 
cartridge was previously conditioned with 
3 ml hexane. Then, the extract was loaded 
and elution of the photoinitiators was 
evaluated using 2 ml of different solvents 
(acetonitrile, hexane:ethyl acetate (30:70), 
ethyl acetate). Finally, the eluate was di-
rectly analysed by GC/MSn.
instrumental
analyses were carried out on a Polaris Q 
mass spectroscopic detector combined 
with a Trace GC Ultra gas chromatograph 
equipped with aS 3000 autosampler (Ther-
mo Finnigian, austin, TX, USa). The injec-
tions were carried out in a split/splitless 
injector at 250°C. an injection volume of 2 
µl in splitless mode was used. The carrier 
gas helium was supplied in constant flow 
mode at 1.2 ml min-1. The analysis were car-
ried out on a non-polar 5% phenyl-polysil-
phenylene-siloxane SGE bPX-5 column of 
25 m l, 0.22 mm ID and a phase thickness of 
0.25 µm (SGE Incorporated, austin, TX). The 
temperature was programmed from 50°C (1 
min) to 280°C at rate of 25°C/min. This tem-
perature was then maintained for 5 min. 
Detection was carried out in MSn. For each 
analyte, two transitions were followed. 
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figure 1:
Gc-mSn total ion chromatogram for each photoinitiator from an assay on a 5 g cereal sam-
ple spiked at 10 µg kg-1 level, analysed by the optimised procedure. 
reSultS and diScuSSion
optimisation of the sample preparation
Most methods for the determination of bP 
in food utilise conventional solid-liquid ex-
traction with an organic solvent, followed 
by a purification step using solid phase ex-
traction. These types of methods are very 
time-consuming and/or consume a lot of 
toxic organic solvents. Furthermore, no 
methods are available for the determina-
tion of 4MbP. Therefore, in this contribu-
tion a method is developed for the simul-
taneous determination of bP and 4MbP in 
food using ultrasonic extraction. 
Optimisation of the extraction procedure 
was done using 5 g of breakfast cereal 
spiked with bP and 4MbP at 600 µg kg-1. 
Different solvents (acetonitrile, methanol, 
dichloromethane:acetonitrile (1:1) and 
hexane) were evaluated for the ultrasonic 
extraction of bP and 4MbP in cereals. The 
best results were obtained when the 1:1 
mixture of acetonitrile and dichlorometh-
ane was used as extraction solvent. There-
fore, this solvent was selected for further 
experiments. 
The purification step with the Si SPE car-
tridge was also optimised using 5 g of cere-
al spiked at 600 µg kg-1 of both compounds 
and 10 ml acetonitrile:dichloromethane 
(1:1) as extraction solvent. Different elution 
solvents (acetonitrile, ethyl acetate:hexane 
(7:3) and ethyl acetate) were evaluated. 
From these experiments, it can be con-
cluded that acetonitrile was the solvent of 
choice for the elution of the SPE cartridge 
and consequently, this solvent was used 
for further experiments.
The presence of a matrix effect was evalu-
ated by comparing the slopes of both so-
lution and matrix-matched calibration 
lines by means of a Student’s t-test (5). The 
calibration curves were obtained by inject-
ing a solution of standards in parallel with 
matrix-matched standards (corresponding 
to blank cereal samples fortified at the end 
of the sample preparation). Since bP-d10 is 
used as internal standard, no matrix effect 
will be observed for bP. For 4MbP on the 
other hand, a matrix-effect is present for 
4MbP. Therefore, calibration curves in ma-
trix should be used for the quantification 
of all the photoinitiators.
Performance of the method
The performance of the method was evalu-
ated by a full in-house validation of the 
method. The following performance char-
acteristics were assessed: linearity, recov-
ery, precision, specificity, limit of detection 
and limit of quantification. 
Figure 1 shows the chromatograms from a 
blank cereal sample spiked with bP, 4MbP 
and bP-d10 at a concentration of 10 µg kg
-1. 
The cereal sample was analysed in accord-
ance with the method described above. 
The different photoinitiators can very eas-
ily be detected, thus the presented method 
is very specific for these photoinitiators.
The linearity was evaluated using the Man-
del’s Fitting test (6). This test evaluates 
whether a quadratic model better fits the 
data than a straight line regression model. 
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This was done by extracting cereal sam-
ples spiked at 5 concentration levels (100-
300-600-900-1200 µg kg-1). The calibration 
curves were obtained by plotting the peak 
ratios (bP/bP-d10 or 4MbP/bP-d10) versus the 
concentrations. according to the Mandel’s 
fitting test, the straight-line regression 
model is preferred for both bP and 4MbP. 
The two photoinitiators showed good lin-
earity (R² = 0.97 for bP and 0.96 for 4MbP) in 
the investigated range. 
The recoveries obtained under op-
timised conditions, i.e. 5 g cereal ex-
tracted ultrasonically with 10 ml 
acetonitrile:dichlormethane (1:1), purifica-
tion using Si SPE cartridge, acetonitrile as 
elution solvent were measured by compar-
ison of the peak area of the solutes for a 
600 µg kg-1 spiked cereal sample with those 
obtained by direct liquid injection of 2 µl 
of a 1.5 mg µl-1. The obtained values were 
74% for bP and 98% for 4MbP. 
The repeatability (r) and the intralaboratory 
reproducibility (Rw) were evaluated by cal-
culating the coefficients of variation (CV) 
for these two parameters (CVr and CVRw) 
according to the ISO-5725-2 guidelines (7). 
From these results, it can be concluded 
that the method shows good precision at 
the levels of interest.
The sensitivity, expressed as limits of de-
tection (lOD) at S/N 3, are 2 µg kg-1 for both 
bP and 4MbP, showing excellent sensitivity 
of the method. The limits of quantification 
(lOQ) at S/N 10 were 6 µg kg-1 for bP and 8 
µg kg-1 for 4MbP.
The performed analyses are first qualita-
tively evaluated in terms of relative reten-
tion time, relative abundances of the diag-
nostic ions and the signal to noise ratio. 
The relative retention time (retention time 
of the analyte divided by the retention time 
of the internal standard) must be within 
the tolerance of ± 2.5%, when compared 
with the results of a cereal sample spiked 
at 300 µg kg-1 for each photoinitiator. The 
relative abundances of the diagnostic ions 
and the signal to noise ratios were within 
the acceptance criteria of the Commission 
a fast and reliable method for the determination of the photoinitiators ben-
zophenone and 4-methylbenzophenone in breakfast cereals has been devel-
oped. consequently, all food can now be screened for the presence of pho-
toinitiators, thus protecting consumers from these dangerous chemicals. 
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decision 2002/657/EC (8). For the signal to 
noise criterion, a minimum ratio of 3 on 
the less diagnostic ion was considered as 
acceptable. If an ‘unknown’ sample is sus-
pected to be non-compliant (concentration 
of bP and 4MbP > 600 µg kg-1), the analysis 
is confirmed including a calibration curve 
in matrix for a correct quantification of 
4MbP.
concluSion
Ultrasonic extraction, followed by solid 
phase extraction in combination with GC-
MSn is a versatile method for the deter-
mination of photoinitiators in breakfast 
cereal and may be applicable to other 
foodstuffs. 
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Chronic arsenic (as) exposure places peo-
ple at risk to multiple adverse health ef-
fects. as is a recognised human carcinogen 
(1, 2) and, moreover, several recent studies 
have shown as to be a potent endocrine 
disruptor, altering hormone-mediated cell 
signalling at very low concentrations (3, 4).
The majority of harmful exposure comes 
from drinking water that contains prima-
rily inorganic as. Other major sources are 
food, soil and air, with most people actu-
ally being exposed to dietary organic as-
forms. The inorganic as species arsenite or 
as (III) and arsenate or as (V) are generally 
held to be more acutely toxic. Moreover, 
as has a rich organic chemistry and this 
is reflected in the large diversity of identi-
fied organocompounds (5). Methylated as 
species, such as monomethylarsonic acid 
(MMa) and dimethylarsenic acid (DMa), are 
relatively non-toxic and are believed to 
contribute little to the overall risk associat-
ed with as exposure. Some researchers ar-
gue, however, that the organic metabolites 
may be the ultimate carcinogens. DMa has 
been shown to induce bladder cancer and 
to promote tumour development in other 
organs in rodents for example (6).
Human dietary exposure to as is very often 
related to the consumption of seafood. It 
is known that marine organisms exhibit 
highly variable as profiles (7, 8). arseno-
sugars are present in algae, whereas ar-
senobetaine (ab) is absent (9). However, 
ab is the predominant species in fish and 
crustaceans (10) and bivalves contain both 
ab and arsenosugars (11). Mostly, total as 
concentrations in marine food items are 
high and are therefore considered to be 
the principal public health concern.
Speciation analyses have showed that 
merely a small fraction was in the inorgan-
ic form and several laboratory approaches 
to distinguish the inorganic as fraction or 
to specify the different as species have 
been published in the scientific literature. 
as a safeguard for public health, maximum 
permissible concentrations of metals in 
food were set to limit the dietary exposure. 
Since it is nowadays well accepted that the 
chemical forms must also be considered 
when assessing health effects, the separa-
tion, identification and quantification of 
different fractions become more impor-
tant (5, 12). The present study focuses on 
the distinction between the inorganic and 
total as concentrations. Its aim is the op-
timisation and validation of a simple and 
economic determination of the inorganic 
as fraction in marine matrices and to illus-
trate its feasibility through a local market 
survey.
materialS and methodS
basically, the determination of both total 
and inorganic as relies on the reduction of 
as (V) into as (III), the subsequent conver-
sion of as into asH3 and atomisation in the 
argon plasma (13). The instrument used is 
a Perkin-Elmer ICP Optima 4300 DV induc-
tively coupled ar plasma optical emission 
spectrometer (Norwalk, CT, USa), equipped 
with an autosampler (aS 93 plus, PE) and 
with a hydride generation (HG) system 
(FIaS 400 PE) with two peristaltic pumps 
and regulated gas supply. The gas flow rate 
was set to 40 – 250 ml/min.
Prior to HG, samples for total arsenic de-
termination were mineralised in an open 
digestion system (2040 Digestor, Foss Teca-
tor) for 40 test tubes (quartz, 100 ml), with 
air cooled condensers and built-in elec-
tronic temperature and time control (13). 
determination of inorganic arsenic 
in seafood by hG-icP-oeS after  
conventional wet digestion K. boutakhrit
f. bolle
l. Goeyens
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Samples for inorganic arsenic determina-
tion were digested in a drying oven (binder 
FD 115, Tuttlingen, Germany), equipped 
with a thermostat and an integrated timer. 
Ultrasonic extractions were performed us-
ing a branson 5510 E-DTa ultrasonic clean-
er (Danbury, CT, USa) and extracts were iso-
lated using an Eppendorf 5810 R centrifuge 
(Hamburg, Germany).
all reagents and standards were prepared 
as before (13). The certified reference ma-
terials (CRM) that were used for this study 
included a dogfish muscle (DORM-2), dog-
fish liver (DOlT-3), lobster hepatopancreas 
(TORT-2), and non-defatted lobster hepato-
pancreas (lUTS-1), purchased from the Na-
tional Research Council of Canada (NRCC, 
Ottawa, Ontario). bCR 278R (mussel tissue) 
and bCR 422 (cod muscle) were purchased 
from the Institute for Reference Materials 
and Measurement (IRMM, EC, Geel, bel-
gium).
additionally, canned fish from a proficien-
cy testing exercise (fresh crab meat, FaPaS 
Series 7, Round 55, CSl, York, UK) was also 
used.
Several natural seafood samples were 
purchased at a local market. all CRMs and 
samples were homogenised by mechanical 
mixing in a high speed blender and then 
frozen at -20°C.
reSultS and diScuSSion 
optimisation of the inorganic as extrac-
tion
a variety of methods from the literature (14-
18) was tested for the extraction and solu-
bilisation of total as. Extraction with dif-
ferent methods: water or methanol:acetic 
acid mixture proved often insufficient. 
Only the methanol: water mixture (1:9,v:v) 
showed sufficient extraction efficiency, 
with 74% of total arsenic being extracted 
from TORT-2.
More aggressive methods to solubilise the 
arsenic of TORT-2 were investigated using 
nitric and hydrochloric acid with variable 
concentration and by sonication for 1h at 
40°C. The extraction efficiency ranged from 
76-83% of the total arsenic content in TORT-
2, with maximal extraction efficiency being 
obtained with HCl (0.5 M). The remaining ar-
senic may be bound to thiol groups of pro-
teins or may correspond to species such 
as arsenolipids that are not soluble (19). 
Solubilisation with nitric acid produces 
much foam when analysing inorganic as 
with HG-ICP-aES and this generates tech-
nical problems. For concentrations rang-
ing from 1-5 M, an efficiency of 80% was 
observed. Therefore, HCl was extended to 
other CRMs and optimisation of several pa-
rameters was performed such as the acid 
concentration, the sonicating time and 
temperature of the solubilisation. The ex-
traction efficiencies in the six investigated 
fish species (CRMs) ranged from 74-98% of 
the total arsenic.
as a result, hydrochloric acid extraction 
(0.5 M) is better than methanol or nitric 
acid solubilisation, however, the extraction 
of inorganic arsenic is not quantitative es-
pecially for fatty matrices such as FaPaS 
S7R55 (crab meat). These low efficiencies 
are in accordance with the findings report-
ed by other authors (11, 20).
optimisation of the inorganic as diges-
tion method
In order to facilitate the dissolution of 
fatty and proteinaceous material, the de-
velopment work was directed towards the 
use of acid digestion to improve the extrac-
tion efficiency of as. For this purpose, di-
gestion with nitric acid was performed for 
six CRMs of different matrices. The effect 
of increasing the digestion temperature 
in the range of 80-180°C was investigated 
for the Canadian CRMs. The response be-
haviour depends on the CRM matrices. For 
the same species (dogfish), we observed a 
difference in behaviour with temperature 
between muscle matrix (DORM-2) and liver 
crms reported result in mg/kg dry weight references
dorm-2
0.088
0.10 ± 0.02a
0.102 ± 0.029
0.145 ± 0.011
0.15 ± 0.01
0.19 ± 0.03
0.132 ± 0.007c 
(27)
(10)
(28)
(23)
(24)
(29)
Present work
tort-2
0.41 ± 0.03a 
0.46 ± 0.07
0.506 ± 0.031
0.581 ± 0.055
0.680 ± 0.405
1.268 ± 0.080c 
(30)
(24)
(28)
(23)
(31)
Present work
bcr 422
< 0.002
< 0.026
0.043 ± 0.013c 
(29)
(24)
Present work
faPaS S7r55
0.0851 ± 0.0176b 
0.083 ± 0.005c 
FaPaS
Present work
dolt-3
Not available
0.091 ± 0.006c 
Not available
Present work
lutS-1
Not available
0.105 ± 0.006c 
Not available
Present work
table 1: inorganic arsenic content reported in the literature and in this study for some 
 investigated crms.
a Sum of as (III) and as (V)
b assigned value; wet weight
c Standard deviation
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matrix (DOlT-3). The same goes for the 
defatted lobster hepatopancreas matrix 
(TORT-2) and the non-defatted matrix (lUTS-
1). These results can explain the difficulties 
in fully extracting the inorganic arsenic by 
using conventional methods (sonication 
and centrifugation) except for the TORT-2, 
which seems to release inorganic arsenic 
easily both for extraction and digestion 
methods.
For temperatures below 60°C, the digested 
sample produces a lot of foam in the hy-
dride generation due to non-destroyed 
proteins, which disturb the plasma and 
causes analytical errors. 
For higher temperatures, over 200°C, there 
is a risk of converting the organoarsenic 
compounds into inorganic arsenic. It was 
reported that the behaviour of cationic ar-
senic as aC and ab, in a microwave system 
with nitric acid and hydrogen peroxide, 
shows a conversion to trimethylarsine ox-
ide (TMaO) at 207°C and the latter remain 
unaltered (21). The same goes for MMa, 
DMa and as (V), in close pressurised diges-
tion systems. This is more aggressive than 
the conventional oven digestion used in 
our work. These compounds remain intact 
up to 160°C. Then at 190°C, MMa was par-
tially decomposed to arsenate whereas 
DMa and as (V) were unaltered (22). In our 
work, the optimised digestion procedure 
was applied to ab, MMa and DMa and no 
conversion to arsenate has been observed 
but unfortunately, if MMa is significantly 
present in the sample, such as seaweed, 
the proposed method can overestimate 
the inorganic as value. For the arsenosug-
ars, we have no data about their behaviour 
in acid digestion but these are not the pre-
dominant compounds in seafood.
determination of inorganic arsenic in ref-
erence samples
The two proposed methods (extraction and 
digestion) were applied to the following 
reference materials: TORT-2, DORM-2, DOlT-
3, lUTS-1, bCR 422 and the FaPaS S7R55. The 
content of inorganic arsenic in these CRMs 
is not certified and there are few previous 
references in the literature for its quantifi-
cation. Table 1 shows the results from the 
analysis of marine CRMs and also includes 
published results for inorganic arsenic in 
these samples (if data available). a large 
variability exists between the reported 
values. The results of inorganic arsenic for 
the acid extraction method are generally 
among the lowest reported for all CRMs 
with the exception for bCR 422, which is 
equal to that found by acid digestion and 
higher than that published.
The values obtained in the present study 
for the acid digestion method are within 
the range given in the literature except for 
TORT-2 which gave higher results with the 
two proposed methods.
The discrepancies between the values re-
ported in the literature are probably due to 
the different sample preparation methods 
and analysis techniques used. Indeed, after 
examining several publications, it seems 
that the HG-aaS technique gives higher 
values for the inorganic arsenic than a 
coupled technique such as HPlC-ICP-MS 
used for the speciation of as (V) and as (III), 
where the latter is often not detected.
Seafood 
products
total as found 
(mg/kg)
inorganic as found 
(mg/kg)
% of inorg. as 
Mussel 1.99 0.151 7.6
Oyster 1.85 0.073 3.9
Scallop 1.29 0.007 0.5
Prawn 0.75 0.023 3.1
Scampi 0.75 0.011 1.5
Cuttle fish 6.56 0.020 0.3
Squid 0.27 0.004 1.5
Ray 11.67 0.014 0.1
Cod 2.54 0.010 0.4
Shark 8.98 0.006 0.1
Trout 1.34 0.004 0.3
Plaice 6.55 0.004 0.1
Sole 2.44 0.004 0.2
Tuna 2.09 < l,Da < l,Da 
table 2:  determination of inorganic and total as in real samples.
a Detection limit
determination of inorganic arsenic in real 
samples
Inorganic as levels were analysed in frozen 
seafood samples of various matrices such 
as fish, crustaceans and bivalves using the 
acid wet digestion method. The results are 
given in Table 2. bivalves (mussels, oysters) 
show high levels of inorganic as compared 
to the other species but we cannot gener-
alise this observation because only one 
sample of each species was analysed. The 
values found varied between 0.004 and 
0.151 mg/kg fresh matter. Expressed as a 
percentage of total as, the inorganic as var-
ied between 0.1-7.6%, which agrees with re-
sults reported by other authors (23-26).
concluSion
Despite the high levels of total arsenic 
found in seafood samples, inorganic ar-
senic, the highly toxic form, was present at 
less than 10% of total as. Thus, there is no 
direct hazard for human health due to the 
consumption of these seafood products.
Comparing the two proposed methods, 
acid extraction and acid digestion, the 
latter shows better efficiencies and the 
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the aim of this study was to inform the consumer about the level of inor-
ganic arsenic in seafood and to confirm the very low risk of exposure for 
the population.
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acKnoWledGementS
results found for inorganic as in CRMs fall 
within the range of values reported in the 
literature. The accuracy of this method 
will be evaluated by participating in profi-
ciency testing schemes in the future. If the 
reliability and accuracy can be confirmed, 
it will be a good alternative for other labo-
rious extraction methods involving sonica-
tion, centrifugation, distillation and also 
the amount of sample handling. In the 
proposed method, the preparation of the 
sample is easy, rapid and suitable for all 
matrices of seafood and can be used as 
a routine method. Since the level of inor- 
ganic arsenic is lower in seafood, the 
sample homogeneity must be taken into 
account and can also explain the discrep-
ancies in the results found by authors, as 
these are near to the detection limit.
The use of the proposed method shows 
good mineralisation of fatty seafood with-
out conversion of the arsenical species to 
inorganic arsenic (arsenate).
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evaluation of risk of consuming 
shellfish contaminated with domoic  
acid in belgium m. andjelkovic
S. vandevijvere
J. van loco
introduction 
Domoic acid (Da) is a marine biotoxin 
causing amnesic shellfish poisoning (aSP) 
in humans. Symptoms of aSP include gas-
trointestinal effects (nausea, vomiting, di-
arrhoea or abdominal cramps) and/or neu-
rological signs (confusion, loss of memory, 
or other serious signs such as seizure or 
coma) occurring within 24 and 48 hours 
after ingestion, respectively. This toxin 
was detected by monitoring services in the 
United States, Canada and in a number of 
European countries. While the evaluation 
of the Da concentration is performed in 
many countries on a regular basis, the ex-
posure assessment of consumers to Da, 
which relies both on reported occurrences 
and consumption data, is only done upon 
request and the limited consumption data 
poses a considerable breach in evaluating 
the exposure risk of toxins present in shell-
fish products.
Several types of shellfish are consumed in 
belgium. Mussels are most frequently eat-
en, followed by scallops and oysters. How-
ever, these shellfish may sometimes be 
contaminated with aSP toxins, thus posing 
a risk to consumers. The risk was evaluated 
by linking the data of Da concentrations 
detected in shellfish samples collected 
during a limited period and consumption 
data obtained from the National belgian 
Food Consumption Survey in adults (2004). 
materialS and methodS
Samples
In this study, 42 mussel samples, 7 oyster 
samples, and 61 scallop samples were col-
lected and analysed in 2007. The samples 
originated both from National Food Con-
trol Programme and various belgian super-
markets were collected in the scope of the 
alTEVal 1 (RT project 06/5).
analytical part
The analytical part of the study included 
the development and validation of the lC-
MS/MS method for detection of domoic 
acid. The quantification of Da was done by 
collecting the data with lCQ DECa XPplus 
mass detector (Thermo Finnigan) and plot-
ting the calibration curve in the range of 
2-25 µg/ml of methanol. HPlC separation 
was done on HPlC XTerra C18 (5 µm 2.1 X 
250 mm) column with isocratic gradient 
of the mobile phase containing: 58% ac-
etonitrile and 42% water with 0.05 mM CH-
3COONH4, both with 0.05% trifluoroacetic 
acid (250 µl/min). MS conditions: electro-
spray ionisation and detection in positive 
MS2 mode; capillary temperature: 275°C; 
capillary voltage: 19 V; collision energy: 45; 
detecting parent ion (312 m/z) and transi-
tion ion (266.25 m/z).
consumption data
The consumption data were obtained 
from the belgian National Food Consump-
tion Survey (VCP-2004). aims, design and 
methods used in this survey are described 
elsewhere (1). The survey describes the 
consumption pattern of the belgian popu-
lation (all belgian inhabitants of 15 years 
or older) and includes information on the 
usual consumption of nutrients and foods, 
and information on age, sex and body 
weight of 3083 individuals. The individuals 
were selected randomly from the National 
Register. 
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figure 1: the concentration of domoic acid (da) in scallop samples collected from various 
sources in belgium. the orange horizontal line (at 20 ng/kg) represents the current european 
regulatory limit for da.
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Statistical analyses of data
Computer-based Monte Carlo simulations 
(2) for probabilistic modelling were used 
to calculate percentile intakes for domoic 
acid. These simulations generate results 
for models in which one or more inputs 
can be defined by a distribution of values 
(food intakes and toxin concentrations). 
The detected concentrations of domoic 
acid in the scallop samples were combined 
with the consumption data to generate a 
new distribution of intake values. The out-
put from the Monte Carlo simulation was 
used to assess the risk-intake by estimat-
ing percentiles of the intake distribution 
and toxin concentration. In this study, the 
95th percentile values were used as high-
end estimates. 
reSultS
domoic acid (da) concentration
In 6 out of 61 scallop samples Da was de-
tected. This represents around 10% preva-
lence. Figure 1 illustrates 5 scallop samples 
where Da level exceeded the current Euro-
pean regulatory limits of 20 mg/kg. None 
of these samples entered the market. No 
toxin was detected in mussel and oyster 
samples.
consumption
Mussels were the dominant shellfish prod-
ucts eaten by the belgian population as 
illustrated in Table 1. Out of 3,083 individu-
als who took part in the VCP-2004, 73 con-
sumed mussels (2.4%), 9 consumed oysters 
(0.3%), and 14 consumed scallops (0.5%). 
a distinction was made between raw (total 
quantity) and cooked (edible part) shell-
fish. The reported quantity of raw mussels 
used for preparation of an average portion 
was around 400 g but only 100 g of mussel 
meat was consumed. The ratio between 
raw and edible samples was estimated to 
be around 5 for mussels while both oysters 
and scallops did not have noticeable ined-
ible parts. 
 
table 1:  Shellfish consumption data in belgium (belgian food consumption survey, 2004), maximum permitted level and estimated 
 concentrations of domoic acid (da) in shellfish.
 no of con-
sumers per 
food item
% of con-
sumers per 
food item
average (g) standard 
deviation
p0 p25 p50 p75 p95 p97,5
raw
mussels 386.47 476.83 5.00 60.00 102.00 1000.00 1000.00 1500.30
oysters 103.67 101.72 5.00 21.00 52.00 180.00 252.00 252.00
scallops 64.22 55.99 4.86 30.00 50.00 87.57 200.00 200.00
cooked
mussels 73 0.04 107.93 87.81 2.90 30.00 102.00 167.50 250.00 320.00
oysters 9 0.00 103.24 102.12 5.00 21.00 52.00 180.00 252.00 252.00
scallops 14 0.01 48.39 46.86 3.40 21.00 35.00 61.30 160.00 160.00
da concentration *20 mg/kg 43.54 34.15 10.59 22.83 34.71 51.15 92.81 99.27
* EU regulatory limit
food, medicine and conSumer Safety directorate 109 
this study shed light on the risk of domoic acid in shellfish, in particular in 
scallops handled by the belgian national food control programme. the es-
timations of risk and portion size offer new insights into the protective ef-
fect of the current european union regulatory limits of some marine toxins. 
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acKnoWledGementS
concluSion
It was estimated that on average people 
in belgium eat per dish 108 g (2.9-320 g) of 
mussels, 103 g (5-252 g) of oysters, and 48 g 
(3.4-160 g) of scallops. However, higher por-
tion sizes occasionally eaten in some cases 
(maximum 320 g mussel portion) are lower 
than 400 g portion size suggested by CON-
TaM Panel of EFSa to be used in the acute 
exposure assessment of marine biotoxins 
(3). 
Consumption of 160 g of edible part of 
scallops (95th percentile of the portion size) 
containing 95th percentile of Da concen-
tration (92.8 mg/kg shellfish meat) would 
result in a dietary exposure of 14.85 mg Da 
per person. This is equivalent to an expo-
sure of 0.25 mg/kg bw (estimated for a per-
son of 60 kg) which is around eight times 
higher than the provisional acute refer-
ence dose (aRfD) for domoic acid (0.3 mg/
kg bw). The high levels of Da could pose a 
risk to some population groups. This study 
was based on a limited number of samples 
and therefore further risk assessment of 
exposure to domoic acid is necessary on a 
larger number of samples.
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introduction 
Food-borne intoxications due to bacte-
rial toxins are frequently reported in many 
countries. Several lethal cases caused 
by cereulide, the emetic toxin of bacillus 
cereus, have even been reported (1, 2). This 
emetic toxin is pre-formed in food and is 
resistant to heat and usual food prepara-
tion procedures. The existing detection 
methods for cereulide are non-specific 
and/or only semi-quantitative. Therefore 
the development of a method for sensi-
tive quantification of the emetic toxin is 
needed. The use of a lC-MS (liquid Chro-
matography Mass Spectrometry) may be a 
powerful analytical tool for the specific de-
termination of cereulide in food. This study 
details the development and validation of 
an adequate analytical method in order to 
monitor the toxin in food samples like rice 
or pasta, allowing determination of critical 
conditions for food consumption. 
method
experimental set-up
The previously described method by l. Del-
brassinne and collaborators (3) combines a 
simple extraction step from bacterial bio-
mass with lC-MS analysis. Validation exper-
iments were performed in freshly cooked 
rice inoculated with a cereulide-producing 
strain; the protocol was thus slightly modi-
fied. briefly, 3 g of the inoculated rice was 
weighed in stomacher bags (International 
Medical) and 6 ml of pure methanol was 
added to each replicate (n = 3). The homo-
genised liquid was collected in glass tubes 
and placed in boiling water for 15 min, 
followed by evaporation until dryness. 
The residue was diluted in 3 ml methanol, 
vortexed and centrifuged. The supernatant 
was collected and stored at -20°C prior to 
analysis. Valinomycin (Sigma, Fluka, Ger-
many) was used as an external standard. 
The following validation parameters were 
determined on the basis of valinomycin 
spiking: linearity, matrix effect, recovery, 
repeatability and reproducibility. The vali-
dation parameters were evaluated in ac-
cordance with the performance criteria 
suggested in 2002/657/EC (4).
method analysis
Cereulide and valinomycin contents of each 
extract were analysed by a lC-MS modified 
method as described by Haggblom et al. (5). 
The lC-MS analysis was performed on a lCQ 
Deca-XP Plus ion trap mass analyser (Ther-
moFinnigan, USa). Chromatographic sepa-
ration was done on the Symmetry C8
 col-
umn, 2.1 mm x 150 mm, 5 µm (Waters, USa). 
The mobile phase of the isocratic method 
was a mixture of 95% acetonitrile, 4.9% wa-
ter and 0.1% trifluoroacetic acid at a flow 
rate of 0.2 ml min-1 with a sample injection 
volume of 5 µl. a full mass spectrum was 
l. delbrassinne
m. andjelkovic
E. N’Guessan
n. botteldoorn
J. Mahillon
J. van loco
method development for the analysis 
of cereulide, the emetic toxin produced 
by bacillus cereus, in food
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recorded from 500 to 1300 m/z in positive 
electronspray mode (ESI+). The total ion 
chromatogram was smoothed with a Gaus-
sian function. For detection of valinomycin 
and cereulide, the monitored m/z values 
were respectively valinomycin adduct ions 
1128.5 (NH4
+ adduct) and 1149.5 (K+ adduct), 
and cereulide adduct ions 1170.4 (NH4
+ ad-
duct) and 1191.5 (K+ adduct). 
applications
as a direct application, the influence of dif-
ferent parameters (temperature, strains, 
incubation time and inoculation level) on 
cereulide production was tested in rice 
and pasta. Importance of temperature on 
cereulide production was tested in two ex-
perimental settings (in inoculated rice in-
cubated at 23°C and 30°C and in inoculated 
pasta at 4°C, 8°C and 25°C). Whereas in the 
first set of experiments in rice, the impact 
of inoculation level of b. cereus (103 or 106 
CFU g-1) on the cereulide production was 
evaluated, in a second set of experiments 
the ability of two cereulide-producing 
strains (TIaC303 and Kinrooi k5975c), iso- 
lated from different lethal food poisonings, 
was observed in pasta over time. Cereulide 
production was analysed as described 
above. The described application in rice imi-
tated a naturally occurring emetic food poi-
soning, where a healthy child died 6 hours 
after consuming leftovers of fried rice, left 
at room temperature for a whole day (2).
reSultS
validation
The linear range for the calibration curve 
of valinomycin in Full MS extended from 
1 to 1000 ng/ml. almost no matrix effect 
was observed, making additional clean-up 
of the extract unnecessary. The analytical 
figure 1:  valinomycin and cereulide representative chromatograms and mass spectra.
For detection of valinomycin and cereulide, the monitored m/z values were respectively valinomycin adduct ions 1128.5 (NH4
+ adduct) and 1149.5 (K+ 
adduct), and cereulide adduct ions 1170.4 (NH4
+ adduct) and 1191.5 (K+ adduct). 
performance was evaluated with the anal-
ysis of spiked rice samples at 100 µg/kg. 
The recoveries were between 51 and 55% 
with RSDs in repeatability and reproduci-
bility conditions below 5%. Representative 
MS chromatograms of valinomycin and 
cereulide are illustrated in Figure 1. 
applications
Regarding the effectiveness of tempera-
ture to prevent/postpone cereulide pro-
duction, 4°C and 8°C were observed to be 
safe food storage conditions, while a clear 
increase of toxin amount was noticed in 
both pasta and rice subject to temperature 
abuse. In these conditions, strains k5975c 
and TIaC303 reached the induced emesis 
dose of cereulide after only one day of 
pasta incubation. Regarding the initial in-
oculum level, much greater quantities of 
cereulide were produced at all incubation 
temperatures when the inoculation level 
valinomycin
cereulide cereulide
valinomycin
a
b d
c
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acKnoWledGementS
the emetic toxin of bacillus cereus has caused an important number of severe 
food-borne intoxications, occasionally leading to the death of young healthy 
people. as the current detection methods for cereulide are non-specific and 
only semi-quantitative, this project delivers a more sensitive alternative for 
its quantification in food and allows prompt reaction for consumer protection.
i m P a c t  o n  P u b l i c  h e a l t h
was 106 CFU g-1. The optimum for cereulide 
production in rice was observed at 23°C; 
far exceeding the levels inducing emesis 
(0.01-1.6 µg cereulide/g food) in humans 
after only 24 hours (6). Cereulide was not 
detected in the negative controls. 
concluSion
The developed lC-MS method is easily per-
formed, sensitive and capable of success-
fully analysing the impact of different fac-
tors on the production of cereulide in food 
samples. However, a better suited stand-
ard (13C labelled, chemically synthesised or 
purified cereulide) is required to improve 
current moderate recoveries. although a 
wide range of foods can be contaminated 
by bacillus cereus, rice was shown to con-
tain the highest cereulide concentration 
when artificially inoculated with emetic 
strain (6). Nevertheless, pasta as a food 
matrix also favours easy and fast cereulide 
production. Cereulide production was 
shown to be strain-dependant and some 
cereulide-producing strains, such as Kin-
rooi k5975c, may present a serious risk for 
the consumer if present in prepared meals 
left at room temperature. Temperature is 
thus an essential parameter to control and 
react to prevent/ postpone cereulide pro-
duction in food.
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Pesticide programme under 
continuous challenge
v. hanot
S. Goscinny
introduction 
Pesticides are chemical compounds de-
signed to control or minimize crop dam-
age. This chemical input makes a consider-
able contribution to agricultural yield but 
inevitably leaves traces on food crops. The 
pesticides that remain in or on foodstuffs 
are called “residue”. The tolerated levels of 
these residues (MRl = Maximum Residue 
level expressed in mg/kg of product) are 
set in Europe by the European Commission 
to ensure that they do not constitute an 
unacceptable health risk for consumers. 
To guarantee that the food on the market 
is safe for consumption, official national 
monitoring programmes have been es-
tablished on a yearly basis, with sampling 
targeting different commodities (items) 
of the diet for evaluation. laboratories 
that want to participate in the monitoring 
programme must demonstrate a certain 
level of performance (accreditation and 
participation in different proficiency or 
interlaboratory tests) with respect to EU 
guidelines for quality control procedures 
(SaNCO/10684/2009). a review of a decade 
of monitoring programme results shows 
a considerable increase in the number of 
pesticides being sought in a broader range 
of commodities and a tendency towards 
reduced time analyses. In 1997, only 13 mol-
ecules were mandatory for the monitoring 
programme, 11 years later the number is 
101. This overall trend is a challenge for 
any laboratory involved in pesticide analy-
sis. The Scientific Institute of Public Health 
is the National Reference laboratory (role 
defined in Regulation 882/04) for the fol-
lowing areas:
Pesticides Residues in Food of Plant Ori-• 
gin;
Pesticides Residues in Food of animal • 
Origin;
Pesticides Residues in Cereals;• 
Pesticides Residues, Single Methods of • 
analysis.
Our laboratory scope covers more than 
300 compounds for all the above matrices. 
However, the EU regulation has to adapt 
to new active compounds and continuous 
changes to pesticide-foodstuff combina-
tions. Consequently, official laboratories 
have to continuously upgrade their vali-
dation with the objective of gradually ex-
tending their accreditation. The present ar-
ticle provides a brief account of our major 
laboratory activities with emphasis on the 
analytical tools set-up for pesticide resi-
due analysis.
methodS
analytical methods are used to generate 
data on the basis of which the European 
Commission will assess dietary exposure 
and enforce MRls. To fulfil this objective, 
two major steps were taken by the EC:
a new regulation came into force from 1. 
1 September 2008 which completes 
the harmonisation and simplification 
of pesticides MRls for all EU countries 
and facilitates commerce with non EU-
partners.
To ensure the quality and comparability 2. 
of the data generated by laboratories, a 
guidance document on method valida-
tion and quality control procedure was 
drawn up for all control laboratories 
(latest version SaNCO/10684/2009). This 
document is complementary to and in 
synergy with ISO/IEC 17025 requirements.
This guidance document favours the “cri-
teria approach” in contrast to rigid refer-
ence methods as standard. The criteria 
approach provides remarkable versatility, 
allowing laboratories to implement their 
own methods. In our laboratory and in 
general, with over 300 compounds to be 
monitored, a multi-residue method is the 
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figure 1: Z-score plot for the euPt 10. 
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best choice in terms of cost and through-
put. This approach enables coverage of 
pesticides from different classes in a sin-
gle analysis. Single-residue methods in 
pesticide analysis are exceptional and are 
developed when the compound is not ame-
nable to multi-residue methods (e.g. dithio-
carbamates) or needs specific separation 
and/or detection conditions (e.g. bromide 
and chlormequats). These specific cases 
will not be discussed in this report as the 
intention is to give an overview of the most 
important activities of our laboratory; the 
application of multi-residue methods for 
fruit and vegetables.
In general, analytical methodology in-
cludes several steps: sample preparation, 
extraction, cleanup, and determination. 
For multi-residue methods each of these 
steps are crucial.
Sample preparation and pesticide extrac-
tion
Sample preparation is dictated by Regu-
lation 396/2005 annex 1. The extraction 
step has to take into account the polarity, 
solubility, thermolability and the detec-
tion limits required for all the pesticides 
sought, but also the nature of the matrix 
(acidic, high protein content…). We homog-
enise in a stirrer a representative portion 
of the sample with an adequate solvent 
(methanol or ethyl acetate). These solvents 
are able to extract a wide range of analytes 
with different polarity but with the draw-
back of co-extracting matrix components.
cleanup
This step should discard interfering co-
extractives. Nevertheless, all the different 
available cleanup possibilities tested ham-
per the analysis of many compounds. To 
overcome this problem we choose to skip 
this step and just dilute the crude extract. 
This approach can be applied only to lC 
system which is less sensitive to complex 
matrices resulting in faster analysis and 
reduced costs. For GC-MS/MS methods a 
cleanup by liquid-liquid partitioning was 
necessary and proved to be less deleteri-
ous to extracted pesticides compared to 
other cleanup procedures like SPE.
determination
The measurement is a combination of sep-
aration (chromatography techniques) and 
detection. In our laboratory, we use two 
complementary separation techniques: 
liquid chromatography (lC) and gas chro-
matography (GC). The latter has been the 
most widely used technique for routine 
pesticide analysis since the 1970s in com-
bination with selective detectors such as 
electron capture and nitrogen-phospho-
rus. To confirm positive results with these 
types of detectors, a second analysis was 
required with a different column. With the 
era of tandem mass spectrometers, simul-
taneous detection and confirmation is pos-
sible in one analytical run.
In 2008, with the acquisition of a GC cou-
pled with a triple-quadrupole mass spec-
trometer, we developed and validated a 
multi-residue method for 116 pesticides in 
fruit and vegetables. This was an intense 
exercise, for example in terms of number 
of peak integrations (we have around 
20,000 for the entire validation). For lC 
method, the laboratory has been accredit-
ed to use this technique for routine analy-
sis since 2006. The separation is done on an 
ultra-performance liquid chromatography 
(UPlC). This technology has the advantage 
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This work would not have been possible without the devotion and motivation of the Pesticide unit staff.
acKnoWledGement
Pesticide residue monitoring in food of plant origin belgium 2008. aFSCa
http://www.favv.be/publications-en/_documents/2008_belgium-summary.pdf
Method validation and quality control procedures for pesticide residues analysis in food and feed. Document N°. SaNCO/10684/2009.
http://ec.europa.eu/food/plant/protection/resources/qualcontrol_en.pdf
more information
Pesticides are used to guarantee agricultural yield by controlling pests and 
protecting crops during post-harvest storage. the consequence of their use 
is their inevitable presence in food, thereby enabling them to reach the pop-
ulation. to ensure food safety the european union has establish maximum 
residue limits. the analysis of pesticide residues is a crucial tool for assess-
ing the level of contamination and enabling enforcement of legislation. 
i m P a c t  o n  P u b l i c  h e a l t h
of generating narrow peaks and uses faster 
run times. In 12 minutes 120 pesticides are 
eluted and determined. During 2008, we 
extended our scope from 63 pesticides to 
120 and accreditation was obtained after 
validation. This UPlC-MS/MS has proved 
to be easily upgraded to determine more 
compounds, nevertheless validation is still 
a laborious and complex step for multi-
residue methods (7,560 peak integrations 
were necessary for this accreditation ex-
tension).
reSultS
The method is validated, meaning that it 
has successfully passed all the perform-
ance criteria detailed in the SaNCO docu-
ment. accuracy is a key parameter for 
pesticide residue analysis in fruit and 
vegetables, and can only be assessed by 
participation in the European Commission 
proficiency tests (EUPT). This particularity 
is due to the fact that no certified pesti-
cides in reference materials for fruit and 
vegetables are available. as NRl we have 
been participating in this annual EUPT 
from the beginning in 1996, and it was very 
interesting to evaluate our performance 
with the new implemented technologies. 
Our results for EUPT 2008 and EUPT 2009 
are represented in Figure 1 and Figure 2 
respectively. No false positives nor false 
negatives were reported, and from the 
2008 results only one z-score was close to 
2, but for 2009 all the results were between 
-1 and 1. This performance demonstrates 
both excellent accuracy and that the meth-
ods are ready for routine determination of 
regulatory samples.
concluSionS and PerSPectiveS for 
multi-reSidue methodS
The combination of lC-MS/MS and GC-MS/
MS is a very powerful and complementary 
technique which covers the majority of ac-
tive compounds in the pesticide field. at 
this point, the implementation to routine 
analysis was successful. However, to be 
able to continue our participation in the 
EU monitoring plan, we are aware that it 
is essential to widen our scope of target 
molecules. This is not an easy task because 
the methods used have some limitations 
in terms of number of analytes covered 
in one lC-MS/MS and GC-MS/MS run. To 
overcome this problem and still have high-
throughput methods we are currently try-
ing new instrumental technologies.
116 WIV-ISP SCIENTIFIC REPORT 2008 | 2009
food, medicine and conSumer Safety directorate
introduction 
Melamine (2,4,6-triamino-s-triazine) is a 
chemical compound that was first consid-
ered as a potential crop fertiliser and as a 
dietary non-protein nitrogen source for 
cattle because of its high nitrogen con-
tent (66.6% nitrogen by mass). However, 
these applications were discontinued due 
to the slow and incomplete hydrolysis of 
melamine. Since then, melamine has been 
successfully used in various industrial ap-
plications such as the production of glues, 
laminates, plastic resins, tableware and 
flame retardants. However, in March 2007 
(first crisis), melamine, in combination 
with cyanuric acid, was found to be re-
sponsible for the death of numerous pets 
in the United States due to renal failure. 
after investigation, the wheat gluten used 
in the pet food was identified as the source 
of contamination which was imported 
from China. 
In 2008 (second crisis), powdered infant 
formula in China was contaminated with 
melamine resulting in more than 290,000 
children being affected and 6 reported 
deaths of infants (1). Soon after, other 
products such as milk powder and related 
goods, egg powder, raising agents, protein 
powders and animal feed were also found 
to be contaminated. Due to the globalisa-
tion of trade, the crisis became an interna-
tional scare which triggered the develop-
ment of various analytical methods for the 
determination of melamine in different tar-
get food matrices and feed. lin (2) recently 
published a review on all the different 
available techniques for melamine detec-
tion in food and feed. briefly, different in-
strumental methods were reported which 
offer a panel of possibilities. For example, 
gas chromatography-mass spectrometry 
(GC/MS) has been reported despite the fact 
that it requires a time-consuming derivati-
sation step. On the other hand, liquid chro-
matography can be used with different 
detectors such as diode array detection, ul-
traviolet absorption, or coupled with mass 
spectrometry and tandem mass spectro-
metry (MS/MS) with the benefit of quali-
tative and quantitative results. Screening 
methods (NMR spectroscopy, infrared 
spectroscopy and ElISa) are also considered 
as potential solutions for fast analysis with 
the drawback of being only qualitative.
an analytical method that delivers high-
throughput analysis during crisis situa-
tion, with good identification and quanti-
fication to enable regulatory action is thus 
much needed. Moreover, sensitivity should 
be compliant with the maximum allowed 
level of 2.5 mg/kg set out in the EU Decision 
2008/921/EC. In this respect, we propose a 
rapid validated method for the determina-
tion of melamine in a wide range of food 
matrices for regulatory control.
method
Sample treatment
Samples were homogenised and 0.5 g was 
accurately weighted. Then, 10 ml of ac-
etonitrile and water (v/v 1:1) was added 
to the sample and vortex-mixed for 10 
seconds. The samples were placed in an 
ultrasonic bath for 25 minutes and cen-
trifuged for 10 minutes. The extract was 
transferred for a liquid-liquid cleanup with 
dichloromethane and HCl was added. The 
cleaned extract was diluted (factor 5) with 
water prior to injection.
chromatographic and mass spectromet-
ric settings
lC analysis was performed with an UPlCTM 
(Waters, Milford, Ma) equipped with a mass 
spectrometer Quatro PremierTM (Waters). 
a HIlIC acquityTM column (1.7 µm; 2.1 x 
S. Goscinny
v. hanot
J.-f. halbardier
J.-y. michelet
 J. van loco
rapid analysis of melamine residue in 
milk, milk products, bakery goods and 
flour by ultra-performance liquid chroma-
tography/tandem mass spectrometry: 
from food crisis to accreditation
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100 mm) was used. Only 1 µl was injected 
on the column. The sample was ionised 
with an electrospray probe in the positive 
mode. The spectrometer was programmed 
in MRM mode allowing 126.9 > 85 (quanti-
fication) and 127 > 68 (confirmation) tran-
sitions for melamine and 129.9 > 87 and 
129 > 70 transitions for 13C3-labelled mela-
mine. 
reSultS
Sample preparation optimisation
The first objective of the extraction-purifi-
cation step was to keep it as simple as pos-
sible such as a dilute and inject. Neverthe-
less, the various targeted food products 
are complex matrices with at least 3% lipid 
content. Direct injection of the crude ex-
tract would generate non-replicable quan-
titation results, matrix effect and loss of 
sensitivity. To avoid these drawbacks, we 
included a simple liquid-liquid extraction 
of fat with dichloromethane and diluted 
the extract as much as possible with water 
to lower the concentrations of potential 
interferences. To enhance protonation of 
melamine, concentrated acid was added to 
the crude extract prior to fat removal.
although vortex-mixing was found suf-
ficient for extraction of milk samples, an 
ultrasonic process was included to acceler-
ate the dissolution of melamine from the 
other matrices. In order to harmonise the 
protocol for all matrices, this latter step 
was also extended to the milk samples. The 
time in the ultrasonic bath was also opti-
mised and extraction efficiency peaked 
at 20 minutes. For sonication beyond that 
time, no significant improvement in the ex-
traction yield was noticed. 
lc and mS/mS method optimisation
Initially, HIlIC mode was directly cho-
sen because of the high polarity and hy-
drophilic properties of melamine. an UPlC 
bEH HIlIC® was found to produce good 
chromatographic peak shapes, sufficient 
retention of melamine and did not de-
mand a long reconditioning time because 
only a 2 minute total run was sufficient to 
have stable and repeatable injections with 
no sign of column deterioration. 
Melamine was tuned in ESI+ mode with m/z 
127 as the protonated molecular ion. Only 
two major product ions were observed m/z 
85 and m/z 68. as the fragment m/z 85 was 
the dominant ion, the transition 127 > 85 
was chosen for quantification and the 
transition 127 > 68 for confirmation. The 
surrogate 13C3 was monitored by the transi-
tions 129 > 89 for quantification and transi-
tion 129 > 70 for confirmation.
The combination of a simple sample treat-
ment and fast UPlC analysis offers the 
advantage of less reagent consumption as 
can be seen in Table 1.
validation 
The method was validated in-house (3) and 
included tests on specificity, linearity, ma-
trix effect, precision and accuracy.
The choice of sample material for valida-
tion was based on the ingredient compo-
sition. Industrial waffles were chosen be-
cause they contained 3 products reported 
to be contaminated: milk, egg powder and 
raising agent. blank waffle samples were 
spiked at the beginning of the extraction 
protocol at 3 concentration levels corre-
sponding to 1 mg/kg, 10 mg/kg and 30 mg/
kg and with a constant amount of surro-
gate of 2.5 mg. analyses were performed in 
triplicate over three different days, with at 
least one day in between.
• Specificity
Due to the lack of SPE in the extraction 
step, it was very important to investigate 
if the specificity of MRM with two transi-
tions was sufficient for the overall method. 
Therefore, sample blanks of different ma-
trices were performed to check for inter-
ferences. No coelution was observed from 
the chromatograms of the sample blanks at 
the retention time of melamine (Figure 1). 
• linearity
linearity was assessed at concentrations 
ranging from 0.5 mg/kg to 40 mg/kg ma-
trix equivalent. Each calibration level was 
injected in triplicate and responses were 
submitted to a Mandel’s Fitting test (4). 
This test evaluates whether an alternative 
regression model, in our case a quadratic 
model, fits the response better than a lin-
ear regression model. In our case a linear 
model was preferred.
Different weighting schemes (i.e. 1/X, 1/X2, 
1/Y and 1/Y2) were tested and the choice 
for a 1/X selection was guided by the evalu-
ation of the correlation coefficient and 
percent of recovery of back calculated 
quality controls.
• matrix effect
a blank matrix was extracted 7 times in 
order to construct a matrix-based calibra-
tion curve. Each level of matrix-match and 
solvent calibration solutions were injected 
in triplicate. Then, two calibration lines 
(solution and matrix-matched) were built 
and their slopes were compared by means 
of a Student’s t-test. There was no signifi-
cant difference between the slopes of the 
matrix-matched standard curve and the 
solvent standard curve, meaning that no 
matrix effect is present and the calibra-
tion curve was done with the analytes dis-
solved in solvent (water). 
• limit of Quantification
The limit of quantification (lOQ) for mela-
mine was established as the concentration 
organic solvent consumption acetonitrile (ml) dichloromethane (ml)
Extraction 5 0
Purification 0 10
liquid chromatography 1.26 0
Standard 0 0
table 1: the method solvent consumption.
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figure 1: mrm chromatograms for 
a: (upper panel) blank waffle and (lower panel) Spiked waffle at 1 mg/kg; 
b: (upper panel) blank milk powder and (lower panel) Spiked milk powder at 1 mg/kg; 
c: (upper panel) blank rice flour and (lower panel) Spiked rice flour at 1 mg/kg; 
d: (upper panel) blank raising agent and (lower panel) Spiked raising agent at 1 mg/kg. 
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with a signal to noise ratio of 6. This limit 
of quantification was determined to be 0.5 
mg/kg based on processed samples (9 rep-
licates) spiked at 1 mg/kg which gave sig-
nal to noise ratios of more than 13. These 
samples had recoveries of between 93.3% 
and 103.6% and a good relative standard 
deviation (< 5%).
• Precision, recovery and accuracy
Precision was assessed by analysing waffle 
samples spiked at 3 different concentra-
tions in triplicate for each level on 3 differ-
ent days. The CVr and CVRW were calculated 
as described in the ISO 5725-2 guidelines 
and ranged from 0.9% to 3.2% and from 
1.2% to 3.3% respectively. all CVs were be-
low the maximum allowed values from the 
Horwitz equation of 10.7% for repeatability 
and 16.1% for reproducibility.
apparent recovery was calculated for each 
spiked sample and ranged from 93.3% to 
103.6%. No reference material was avail-
able at the time, thus, the accuracy of the 
method was evaluated by means of partici-
pation in two Proficiency Tests (PT). The first 
one was organised by the Dienstleistung 
lebensmittel analytik GbR (Dla), in which 
51 laboratories participated worldwide, 
while the second one was coordinated by 
the European Commission Joint Research 
Centre (JRC) and the Institute for Reference 
 ministry of health P.r. china. the special topic of infant formula powder case on Sanlu (24 Jan 2009).  1. 
available from: url: http://www.moh.gov.cn/publicfiles/business/htmlfiles/wsb/pmtxwbd/200901/38923.htm
lin m. frontiers of chemical engineering in china 2009;3:427-435.2. 
 3. van loco J, beernaert h. in Proceedings of euro food chem xii: Strategies Safe food 2003; 91-94.
mandel J. the statistical analysis of experimental data. uSa: new york; 1964. 4. 
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acKnoWledGementS
melamine was implicated in a major food crisis in 2008. due to the globalisa-
tion of trade, the crisis became an international scare, which triggered the 
development of various analytical methods for the determination of mela-
mine in different target food matrices and feed. after risk assessment stud-
ies, the eu has set a limit of 2.5 mg/kg for melamine in food. in this respect, 
we propose a rapid validated method for the determination of melamine in 
a wide range of food matrices for regulatory control.
i m P a c t  o n  P u b l i c  h e a l t h
Materials and Measurements (IRMM), in 
which 120 laboratories participated world-
wide. Milk powder samples were proposed 
by both PTs but the JRC/IRMM PT also had 
a sample of baking mix. The method per-
formed well for the two PTs with z-scores 
between 0 and 1.07.
concluSion
In summary, a simple and rapid method 
for determining melamine levels in food 
matrices has been developed. The valida-
tion results demonstrate that the method 
is specific with good sensitivity and preci-
sion. The use of UPlC allows short chro-
matographic runs compared to traditional 
lC-MS/MS and is also a good alternative to 
the time-consuming derivatisation step 
prior to GC. From sample preparation to 
instrumental analysis, the protocol is eas-
ily performed and many samples can be 
analysed in parallel with a reduction in 
organic solvent consumption. Isotopic di-
lution method is particularly convenient 
allowing fast recovery with the benefit of 
reliable results, which is supported by the 
IRMM proficiency test results.
This method has successfully passed ac-
creditation and is destined to be applied in 
the framework of the national control plan 
in response to the Commission Decision 
2008/798/EC.
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introduction 
Counterfeit medicines have become in-
creasingly prevalent over the past decade. 
This is mostly due to the growth of the 
internet and the appearance of numer-
ous fraudulent websites where anyone 
can easily and anonymously buy prescrip-
tion only medicines (1, 2). In developed 
countries, the most popular counterfeit 
drugs are lifestyle medicines such as the 
phosphodiesterase type 5 (PDE-5) inhibitor 
drugs: sildenafil citrate (Viagra®), tadalafil 
(Cialis®) and, more recently, vardenafil hy-
drochloride (levitra®) (3). 
The internationally recognised definition 
of a counterfeit medicine is that of the 
World Health Organisation (WHO) (4):
“a counterfeit medicine is one which is 
deliberately and fraudulently mislabelled 
with respect to identity and/or source. 
Counterfeiting can apply to both branded 
and generic products and counterfeit 
products may include products with the 
correct ingredients or with the wrong in-
gredients, without active ingredients, with 
insufficient active ingredient or with fake 
packaging.”
In this study, 39 counterfeit and imitations 
of Cialis® and 4 genuine Cialis® were ana-
lysed by Raman-, NIR- and FT-IR-spectro-
scopy. Investigations have been carried 
out into which technique or combination 
of these techniques was the best to 1. De-
tect counterfeit Cialis® and 2. To determine 
clusters among illegal medicines which 
can be of interest for forensic investiga-
tions by the authorities. 
materialS and methodS
Samples
The counterfeit and imitation tablets of 
Cialis® were donated by the Federal agen-
cy for Medicines and Health Products in 
belgium (aFMPS/FaGG). They all come from 
postal packs ordered by individuals via in-
ternet sites. all samples were delivered in 
blisters with or without packaging. all sam-
ples, once received, were stored at ambient 
temperature and protected from light. The 
samples have been divided into groups ac-
cording to their visual appearance. Table 1 
shows the groups of Cialis®-like samples.
Eli lilly Sa/NV (benelux) kindly provided 
one batch of each commercial packaging 
of Cialis® (5 mg, 10 mg and 20 mg). Two oth-
er batches of Cialis® 20 mg were purchased 
in a local pharmacy in belgium. 
all references were delivered in sealed blis-
ters with packaging and were stored pro-
tected from light at ambient temperature.
instrumental
• raman spectroscopy 
a RamanRxn1 spectrometer (Kaiser Opti-
cal Systems, ann arbor, MI, USa), equipped 
with an air-cooled charge coupled device 
(CCD) detector (back-illuminated deep 
depletion design) was used in combina-
tion with a fibre-optic non-contact probe 
P.-y. Sacré, e. deconinck
T. De beer, P. courselle
R. Vancauwenberghe
P. Chiap, J. Crommen
J. o. de beer
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to collect Raman spectra from the core of 
the tablets. The laser wavelength during 
the experiments was the 785 nm line from 
a 785 nm Invictus NIR diode laser. all spec-
tra were recorded at a resolution of 4 cm-1 
using a laser power of 400 mW. Data col-
lection, data transfer, and data analysis 
were automated using the HoloGRaMSTM 
(Kaiser Optical Systems, USa, version 2.3.5) 
data collection software, the HoloREaCTTM 
(Kaiser Optical Systems, USa, version 2.3.5) 
reaction analysis and profiling software, 
the Matlab software (The Matworks, Nat-
ick, Ma, USa, version 7.7), and the Grams/
aI-PlSplusIQ software (Thermo Fisher Sci-
entific, Waltham, Ma, USa, version 7.02). 
Ten second exposures were used for spec-
tral acquisition. Spectra were collected at 
3 locations per tablet. Spectra were pre- 
processed by baseline correction [Pear-
son’s method, (5)], mean centred and aver-
aged before data-analysis. 
• nir spectroscopy
Diffuse reflectance NIR spectra were col-
lected per tablet using a Fourier-Transform 
NIR spectrometer (Thermo Fisher Scien-
tific, Nicolet antaris II near-IR analyser) 
equipped with an InGaaS detector, a 
quartz halogen lamp and an integrating 
sphere, which was used for NIR spectra 
collection from the tablets. Data analysis 
was done using Thermo Fisher Scientific’s 
Result software, SIMCa-P (Umetrics ab, Kin-
nelon, NJ, USa, version 11) and Matlab (The 
Matworks, Natick, Ma, USa, version 7.7). 
Each spectrum was collected in the 10,000 
– 4,000 cm-1 region with a resolution of 16 
cm-1 and averaged over 16 scans. all spec-
tra were pre-processed using standard 
normal variate transformation (SNV) and 
mean centred before data-analysis. Each 
spectrum was performed on the core of 
the tablet.
• ft-ir spectroscopy
a Spectrum 1000 (Perkin Elmer, Waltham, 
Ma, USa) FT-IR spectrometer with a DTGS 
detector was used. all spectra were record-
ed from the accumulation of 16 scans in 
4,000-400 cm-1 ranges with a 4 cm-1 resolu-
tion. Samples were prepared by compress-
ing a 0.3% mixture of pulverised tablet with 
spectral grade Kbr (Merck, Germany). Three 
spectra of each sample were obtained, nor-
malised and averaged. 
Once recorded, the spectra were normal-
ised with the Spectrum software (Perkin 
Elmer, Waltham, Ma, USa, version 5.0.1.).
data processing
The data pre-processing was performed 
using HoloREaCTTM software. For NIR and 
FT-IR spectroscopy, the three spectra of a 
sample were normalised and averaged. For 
Raman spectroscopy, the three spectra of a 
sample were baseline corrected using the 
Pearson’s method. all calculations were 
done with Matlab (The Matworks, Natick, 
Ma, version 7.9.0). The Principal compo-
nent analysis (PCa) of the data has been 
performed with algorithms based on Ker-
nel PCa (6). The Partial least Squares (PlS) 
analysis of the data has been performed 
with the algorithms described by de Jong 
(7). The algorithms are part of the ChemoaC 
toolbox (Freeware, ChemoaC Consortium, 
brussels, belgium, version 4.0). 
reSultS and diScuSSion
measurements
all IR measurements were performed in 
triplicate on the pulverised tablet. all NIR 
measurements were performed once on 
the core of three different tablets of each 
sample and all Raman measurements were 
performed on three different locations of 
the core of one tablet of each sample. Only 
Group 
number
Sample photo Symbol in 
plots
rivm class number of 
samples
1  Mixed counterfeits 5
2 X Professional imitation 4
3  Professional imitation 5
4 * Non-professional imitation 3
5 ∆ Professional imitation 13
6  Non-professional imitation and two mixed imitations 4
7  Non-professional imitation 2
other
Professional imitation and 
mixed imitations
3
genuine  4
table 1: visual classes of cialis®-like samples (for rivm classes see ref. 3).
122 WIV-ISP SCIENTIFIC REPORT 2008 | 2009
food, medicine and conSumer Safety directorate
the fingerprint region of the IR spectra 
(1,800-400 cm-1) and the 7,000-4,000 cm-1 re-
gion of the NIR spectra were used because 
of their high variability and their richness 
of information. The Raman spectra were 
taken with an exposure time of ten sec-
onds on the core of the tablets at three dif-
ferent locations per tablet.
case study two: cialis®
• Pca
PCa analysis of Raman spectroscopy did 
not enable the genuine sample to be dis-
tinguished from the imitations or counter-
feits. Therefore this technique was aban-
doned in preference of NIR and FT-IR.
PCa analysis of the Cialis® FT-IR dataset en-
abled clear identification of the counterfeit 
samples from the imitations and from the 
genuine samples. However, one group of 
imitations was not distinguished from the 
genuine samples. These imitations (group 
5 in Table 1) have different brand names 
but are visually similar and can be easily 
identified as belonging to a single group. 
analysis by HPlC and dissolution of some 
of them indicated that they are of good 
quality. This may be a result of a chemical 
composition and a manufacturing process 
very similar to that of the genuine Cialis®. 
So, PlS analysis was needed in order to dis-
tinguish these imitations from the genuine 
samples.
• PlS
1. FT-IR spectroscopy
PlS analysis enabled very good identi-
fication of the imitations and the coun-
terfeits from the genuine samples. FT-IR 
also permitted 5 clusters of samples to 
be observed. One cluster shows the imita-
tion samples that were not distinguished 
from the genuine samples by PCa. It con-
tains imitations that were visually similar: 
oval shape with E20 embossed; without 
distinction between conventional tablets 
and chewable tablets. It can therefore be 
postulated that only few chemical differ-
ences are present (flavouring agents such 
as menthol). 
a second cluster contains the counterfeit 
samples. It was very clearly separate from 
the other samples. HPlC analysis showed 
that they contain both sildenafil and 
tadalafil. This combination of aPI may ex-
plain this clear separation. another cluster 
contains samples from the same manufac-
turer (according to the packaging) that are 
visually similar: round, orange and without 
film-coating. In this case, the chewable tab-
lets were separated from other samples. 
One cluster contains samples that were 
neither counterfeit nor imitation samples. 
Once again, the chewable version of these 
tablets was not included in the cluster. 
a final cluster contains the other samples, 
except for three of them that were wide-
spread in the plot. They were not similar 
but were quite close to each other. They 
probably have the same chemical compo-
sition and the same manufacturer. 
The examination of the loadings scores 
did not permit the identification of which 
component was correlated with this sepa-
ration. 
2. NIR spectroscopy
NIR spectroscopy shows the same separa-
tion as FT-IR but the different clusters are 
closer to each other. For this reason, NIR 
spectroscopy alone has been considered 
to be less efficient than FT-IR.
3. Raman spectroscopy
Raman spectroscopy enables the distinc-
tion between genuine and counterfeit sam-
ples. This distinction was greater when the 
region between 1,400-1,190 cm-1 was stud-
ied. Therefore this region has been select-
ed for the rest of the analysis with Raman 
spectroscopy on Cialis®-like samples. One 
cluster contains the imitations from group 
5 (Table 1) and one sample from group 7. 
This sample wasn’t classified in any cluster 
by both NIR and FT-IR spectroscopy. a sec-
ond cluster contains two samples from the 
same group but no reason has been found 
for their separation from the other ones. a 
final cluster contains the remaining sam-
ples. The loadings scores didn’t permit the 
identification of which component was 
correlated with these clusters. 
4. Combination of techniques.
When the NIR and the FT-IR data were com-
bined, the plot obtained shows a separate 
cluster of the genuine samples and four 
other clusters. another cluster contains the 
professional imitations identified by both 
FT-IR and NIR (group 5 of Table 1) and it also 
contains a sample that was not included 
in a cluster by each technique separately, 
except by Raman spectroscopy. a third 
cluster contains the counterfeit samples 
and a final cluster contains the remaining 
PlS2PlS1
genuine
5
1
4
3
2P
lS
3
figure 1:
3d PlS score plot of the association of the raman spectra (region between 1,400-1,190 cm-1) 
and the nir spectra (region between 7,000-4,000 cm-1) of the cialis®-like samples. for symbol 
caption see table 1.
PlS1 PlS2
food, medicine and conSumer Safety directorate 123 
Weiss a. cleve clin J med 2006;73(3):282-288.1. 
veronin m, youan bb. Science 2004;23[305(5683)]:481. 2. 
venhuis bJ, barends dm, Zwaagstra me, de Kaste d. rivm report 370030001/2007, bilthoven, 2007.3. 
available from: url: http://apps.who.int/gb/ebwha/pdf_files/a62/a62_13-en.pdf4. 
Pearson Ga. J magn reson 1977;27(2):265-272.5. 
Wu W, massart dl, de Jong S. chemometr intell lab 1997;36(2):165-172.6. 
de Jong S. chemometr intell lab 1993;18:251-263.7. 
referenceS
this rapid detection of counterfeit medicines ensures the reliability of 
products present in the legal supply chain. it allows the population to have 
greater confidence in the fact that they are taking the exact drug that their 
physician has prescribed and not a substandard imitation of it.
i m P a c t  o n  P u b l i c  h e a l t h
samples. Only one sample stands alone but 
it has not been possible to explain why the 
association of the techniques isolated it. 
Figure 1 shows the combination of the NIR 
and Raman spectra. Three clusters are ob-
served. These clusters are the same as for 
the association of NIR and FT-IR spectro-
scopy except that the sample from group 
7 that was in cluster 1 is now separated in 
cluster 4. The sample standing alone from 
the combination of FT-IR and NIR spectro-
scopy remains alone.
The association of the three techniques 
permitted exactly the same separation as 
the association of NIR and Raman spectro-
scopy.
 
 
concluSionS
The aim of this study was to establish 
which technique or combination of tech-
niques was the most powerful in dis-
tinguishing counterfeits from genuine 
samples of Cialis®. The spectroscopic tech-
niques investigated comprised FT-IR, NIR 
and Raman spectroscopy. 
FT-IR is a widely used and relatively low 
cost technique, used for decades and 
present in each analytical laboratory. The 
main drawback of this technique is its de-
structive character.
NIR and Raman techniques are increas-
ingly used in the pharmaceutical industry 
because of their ease of use, their speed 
and the fact that they are non-destructive. 
Therefore further analysis can later be car-
ried out on the tablets analysed by NIR or 
Raman spectroscopy, which is very impor-
tant for an official analytical laboratory. 
The ability of each technique separately to 
make the distinction between genuine and 
counterfeit or imitation samples has al-
ready been demonstrated. PCa analysis of 
the data was insufficient to achieve com-
plete separation of the samples. Hence, 
PlS analysis was preferred because it is a 
powerful tool for a discrimination study 
with reference samples.
For the Cialis®-like samples, each tech-
nique separately enabled classification 
of the samples and distinction between 
genuine and illegal samples. However, 
this classification was insufficient by Ra-
man spectroscopy or incomplete by FT-IR 
and NIR spectroscopy. It is concluded that 
the association of NIR spectroscopy (re-
gion between 7,000-4,000 cm-1) and Raman 
spectroscopy (region between 1,400-1,190 
cm-1) is the most useful association of tech-
niques. This association permitted a very 
good separation between genuine and 
counterfeit or imitation samples. The clas-
sification performed allows the distinction 
between very bad counterfeits, very good 
imitations and other samples from genu-
ine samples. This is useful for its applica-
tion in a control laboratory. 
The use of spectroscopic tools allows an 
objective distinction between legal and 
illegal tablets based on chemical and 
physical information of the tablets. This 
distinction sometimes confirms the visual 
classification of the samples but most of 
the time it completes this classification. 
as has been demonstrated, it is often the 
case that many visually similar samples 
are finally classified into the same clus-
ter, which indicates that they have similar 
physico-chemical properties. This kind of 
objective classification is the most useful 
in any further investigation.
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introduction by Dr Ir. Myriam Sneyers
The Expertise, Service Provision and Customer Relations Directorate was officially 
created on 26 august 2008 by Ministerial Order. It came about following the merger of 
the Clinical biology division of the former Epidemiology-Toxicology Department and the 
biological Standardisation and biosafety & biotechnology divisions of the Microbiology 
Department.
The main tasks of this scientific directorate are:
M• anaging services geared towards the monitoring of its three functional strands: 
Clinical biology, biological Standardisation, biosafety & biotechnology;
C• onducting scientific research projects essentially aimed at improving the services 
provided by the operational divisions;
C• oordinating the preparatory tasks as regards services for the entire WIV-ISP (dispatch-
ing unit, sample preparation);
F• ormulating expert opinions for the international, European, federal and/or regional 
authorities on matters that come under its functional programmes;
C• oordinating relations with the Institute’s main customers and partners, in particular 
the FPS Public Health, Food Chain Safety and Environment, the Federal agency for 
Safety of the Food Chain (FaSFC), the Federal agency for Medicines and Health Products 
(FaMHP), INaMI-RIZIV (National Health & Disability Insurance Institute), the Communities 
and Regions;
P• roviding effective assistance to the other scientific divisions in the event of crises 
affecting public health.
biological standardisation
description:
The division has the task of monitoring the quality of biological products. It is responsible 
for expert appraisals in the area of vaccines for human use and blood products, in conjunc-
tion with the belgian and European authorities, as well as internationally. This appraisal 
consists specifically in assessing the quality part of registration files, participating in Good 
Manufacturing Practice (GMP) inspections, participating in various opinion groups and 
drafting regulatory texts on these matters.
activities:
Carrying out quality control of vaccines for human use;• 
Carrying out quality control of blood and blood products;• 
Verifying their compliance with international standards before placing on the market;• 
Providing expertise in the area of vaccines for human use and blood products.• 
exPertiSe,  Service
ProviSion and cuStomer 
relationS
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biosafety & biotechnology
description:
The directorate’s tasks include the assessment of risks associated with the use of GM 
organisms and/or pathogens and with the monitoring thereof.
activities:
Providing scientific support to the competent federal and regional authorities on • 
biosafety matters. This expert appraisal task covers the contained use of GMOs and/or 
pathogens, deliberate release and placing GMOs on the market. Essentially, it is aimed at 
the risk assessment for human health and the environment posed by such organisms; 
acting as the secretariat of the belgian Consultative biosafety Council;• 
also coordinating the national belgian GMO reference laboratory and completing an • 
analytical and research mission within laboratories covering the detection, identifica-
tion and quantification of GMOs, in particular regarding foodstuffs.
clinical biology
description:
The directorate’s main tasks include approving clinical biology laboratories on behalf of 
the Minister after verifying the official regulations, organising external assessments for 
clinical biology analyses and being the competent authority for in vitro diagnostic (IVD) 
medical devices within the framework of EU Directive 98/76.
activities:
Organises site visits to clinical biology laboratories;• 
acts as the secretariat of the Clinical biology Commission and its various work groups;• 
Manages authorisations issued to clinical biology laboratories;• 
alongside expert groups and the Clinical biology Commission, organises a national • 
compulsory programme for external quality assessment;
Notification of IVDs in belgium;• 
Organises Post-market vigilance.• 
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development of a molecular detection 
platform for Gmo detection in food 
based on “combinatory Q-Pcr” 
technology
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introduction 
The number and diversity of genetically 
modified (GM) crops are exponentially in-
creasing and are becoming a reality in agri-
culture as well in the food and feed market. 
144 GM events, representing 24 crops have 
already received worldwide regulatory ap-
proval (1). In 2008, 25 countries have culti-
vated GM crops, whereas 30 countries have 
granted regulatory approvals for their 
import for food and feed use and release 
into the environment (1). With respect to 
the introduction on the market of geneti-
cally modified organisms (GMOs), many 
countries have implemented a specific 
government policy supporting a strong 
commitment to consumer protection and 
freedom of choice (2). For this, the trace-
ability and labelling of GM products along 
the food chain is critical (2). In particular in 
Europe, testing food and feed materials for 
GMOs is regulated through EC regulations 
EC/2003/1829 and EC/2003/1830. Through 
such policies, two particular concepts 
have been elaborated: 1. The amount of 
GMO has to be calculated per ingredient 
(defined as a taxon, e.g. soya bean, maize, 
oilseed rape, etc.); 2. For authorised GMOs, 
product labelling is mandatory when ex-
ceeding a threshold above 0.9% GMO per 
ingredient.
analytical GMO detection approaches basi-
cally consist of sampling, sample grinding, 
DNa extraction and target DNa analysis by 
applying Polymerase Chain Reaction (PCR) 
assays. Due to the broad range of author-
ised GMOs on the market, typically, the 
DNa analysis firstly comprises ‘screening’ 
in which a minimum set of PCR tests (tar-
geting specific genetic elements) should 
allow conclusions to be made as to the 
absence/presence of as many GM events 
as possible. Only in the positive cases will 
a second step specifically identify and/or 
accurately determine the content of the in-
dividual event(s) that is (are) present in the 
sample (Figure 1).
Our group (GMO-lab in WIV-ISP) is the 
GMO-National Reference laboratory co-
ordinator for belgium and the founding 
member of the European Network of GMO 
laboratories and has extensive experience 
in the development, improvement and ap-
plication of molecular genetic methods 
to detect GMOs in food and feed. In this 
context, the WIV-ISP has developed a GMO 
detection approach by SYbR®Green PCR 
screening analysis. This new technology, 
designated “CoSYPS” (standing for “Combi-
natory SYbR®Green PCR Screening”) repre-
sents a novel tool facilitating the detection 
of material derived from genetically modi-
fied crops in Food/Feed matrices (Figure 
1). The full system has been submitted for 
patent protection (3) and its methodologi-
cal principle published in the literature (2). 
Here, we summarise and review all of the 
qPCR methods developed (targeting ge-
neric plant-DNa denominator, taxon-spe-
cific elements, generic recombinant DNa 
elements, recombinant trait-specific ele-
ments) and their integration in the CoSYPS 
for GMO routine analysis of food and feed 
samples in commonly applied 96-well plate 
qPCR format.
figure 1:
Schematic view of the detection of Gmo in food and feed products by enforcement labora-
tories in europe and the output of the  “coSyPS” developed by the Wiv-iSP to facilitate this 
detection.
real-time 
Pcr 
analysis of 
the dna
Gmo 
detection
dna 
extraction
regulations 
ec/2003/1829 
& ec/2003/1830
verification of Gm events present in 
sample through event-specific methods
Quantification of the authorized Gm 
events present in the sample
> 0.9% must be labelled
Potential Gm plants in the sample
Pcr screening coSyPS +
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material and methodS
Plant materials and genomic dna extrac-
tion 
Typical plant materials were Certified 
Reference Materials (CRM) from IRMM or 
aOCS. Genomic DNa (gDNa) was extracted 
form these plants using a CTab based 
method as described by barbau-Piednoir et 
al., 2010 (4). The extracted gDNa was quan-
tified using a VersaFluor™ Fluorometer 
(biorad, Nazareth, bE) and the Quant-iT™ 
PicoGreen® dsDNa assay Kit. The DNa was 
stored at -20°C.
development of primer pairs
Real-Time PCR methods and the corre-
sponding primers were chosen to target 
four different types of DNa elements 
(generic plant-DNa denominator, taxon-
specific elements, generic recombinant 
DNa elements, recombinant trait-specific 
elements). The respective primer sets were 
either retrieved from the public domain 
or specifically developed in the context of 
the CoSYPS. The new designed primers bio- 
informatic analysis and in silico specificity 
of DNa sequences was performed accord-
ing to barbau-Piednoir et al, 2010 (4).
real time Pcr
all qPCR assays were standardised to be 
performed on an abI 7300 PCR System (ap-
plied biosystems, lennik, bE) in 25 µl reac-
tion volume containing 1X SYbR®Green 
PCR Mastermix and 250 nM of each primer, 
except for the RbCl primers for which the 
primers concentration was set to 1 µM. The 
following thermal program was applied: a 
single cycle of DNa polymerase activation 
for 10 min at 95°C followed by 40 amplifica-
tion cycles of 15 s at 95°C (denaturing step) 
and 1 min at 60°C (annealing-extension 
step). Subsequently, melting temperature 
analysis of the obtained amplification 
products is performed by gradually in-
creasing the temperature from 60°C to 95°C 
over 20 min (±0.6°C/20 s). 
amplicon cloning, sequencing and plas-
mid deposit
PCR fragments obtained using the differ-
ent qPCR methods was cloned and char-
acterised by dideoxy-sequence analysis 
according to barbau-Piednoir et al. (4). The 
so-called “SYbR®Green amplicons” (abbrevi-
ated as “Sybricons”) and “pENGl plasmids” 
(= plasmid deposited in the context of the 
European Network of GMO laboratories) 
were registered under “Safe Deposit” or 
“Patent deposit” at the “belgian Culture 
Collection for Micro-organisms” (bCCM/
lMbP) (Gent, bE). 
Sybr®Green qPcr specificity assessment 
Primer pair specificity was tested by ampli-
fication of genomic DNa from various CRM. 
a sample is considered as positive and 
specific according the following criteria: 
1. an (exponential) amplification is ob-
tained with template DNa containing the 
target sequence(s) (and no amplification is 
obtained with the non target sequence), 
2. a single peak upon melting analysis with 
a unique Tm value corresponding to the 
nominal Tm value obtained with the respec-
tive Sybricon or pENGl as template DNa, 
3. a single band on agarose gel analysis 
with a molecular weight corresponding 
to the predicted size. Complete details 
concerning this assessment are described 
by barbau-Piednoir et al. (4). Only specific 
qPCR methods considered were retained.
Sybr®Green qPcr sensitivity assessment
In this study, the sensitivity of the assays 
was estimated according to the former 
aFNOR Norm XP V03-020-2 as adapted by 
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barbau-Piednoir et al. (4) and was tested 
in a dilution series of corresponding gDNa 
(20,000 haploid genome copies (HGE) to a 
single haploid genome copy) . Each dilu-
tion analysis was performed in hexapli-
cate (n = 6). The so-called “lOD6” of a qPCR 
method for detection of a particular target 
represents then the estimated haploid ge-
nome copies, at which level within a linear 
serial dilution analysis, each of the 6 re-
peats provides a specific signal (n = 6; 6/6 
specific signals).
Only methods with a high sensitivity (lOD6 
< 30 HGE) were retained.
reSultS
the qPcr methods developed for high 
coverage and discriminative detection of 
Gm plants
The aim of our research was to develop a 
tool able to detect GM plants placed on 
the market. Therefore, on the one hand, 
the qPCR methods enabling detection of 
the presence of plants (method targeting 
a plant kingdom marker, the chloroplastic 
rbcl gene) and a number of crop-specific 
methods targeting the main GM com-
modity crops (soya bean, maize, oilseed 
rape, cotton and rice) (5) and, on the other 
hand, methods enabling detection of the 
presence of GM plants were developed. 
To detect as many GM plants as possible 
(high coverage power), methods targeting 
the most represented sequences in com-
mercial GM plants (GM generic elements) 
were developed: the cauliflower mosaic 
virus promoter (p35S) and the agrobacte-
rium nopaline synthase terminator (tnos) 
(4). limiting the screening to those com-
mon targets has the disadvantage that the 
presence/absence of large numbers of GM 
plants needs to be confirmed via a second 
GM identification. Therefore, discrimina-
tive targets such as herbicide resistance 
genes and insect resistance genes (GM spe-
cific elements) were added to reduce the 
number of possible GM plants in the sam-
ple (high discriminative power). 
the coSyPS, a decision tool to conclude 
which Gm plants is present in a sample
The aim of the CoSYPS is to integrate and 
combine the results given by each qPCR 
method to predict which GM plants may 
be present in a sample.
To construct this decision support system 
of the CoSYPS, a unique prime number was 
assigned to each particular screening qPCR 
method developed (the prime number 
have by definition only two dividers, the 
prime number itself and “1”). Each GM 
plant is characterised by the presence of 
several targets and consequently, a prime 
numbers product (named “Gödel prime 
number”) can be associated (Equation 1).
When the target associated to a qPCR 
method is present (positive “correct Tm & ≥ 
lOD6” as described in materials and meth-
ods), the corresponding prime number is 
assigned to the relationship. While, when 
the target is absent, the number 1 is as-
signed to the relationship. 
For example, the GM event bT176 is trans-
formed maize comprising the generic GM 
event sequence corresponding to p35S 
and two GM specific elements correspond-
ing to the coding region of the phosphi-
notricine acetyl-transferase liberty-link 
herbicide resistance (PaT/pat) and the cod-
ing region of the bt insect resistance gene 
(CryIab). Therefore its specific Gödel prime 
number is given by the product defined in 
Example 1.
In a similar way, when using multiple qPCR 
methods for GMO routine analysis of sam-
ples in commonly applied 96-well plate 
qPCR format, the product of the prime 
numbers of the positively scored screening 
outcomes for a sample can be represented 
by the “GPNsample” product (Equation 2). 
This number comprises the targets that are 
detectable (≥ lOD6) in the sample. 
equation 2: GPnsample = ∏ GPnevent 1 to α 
Moreover, the GPN sample can be used as a 
divider to search for individual GPN (cor-
responding to specific GM plants) present 
in the sample. In the case where the result 
of the division is an integer, the specific 
GM plant may be theoretically present in 
the sample. Thus based on the GPN of the 
sample (determined experimentally as out-
Wherein, 
GPNα , Gödel prime number associated to the GM plant named α
PSp.β , Prime number corresponding to qPCR method targeting the species β
Pp35S  , Prime number corresponding to qPCR method targeting P35S
Ptnos  , Prime number corresponding to qPCR method targeting tnos
∏ Pevent 1 to Z , Product of the prime numbers corresponding to qPCR method  
  targeting GM specific elements
equation 1: GPnα = PSp.β x Pp35S x Ptnos x ∏ Pevent 1 to Z 
Wherein, 
GPNbt176 , Gödel prime number associated to the GM plant bt176
Pmaize , Prime number corresponding to qPCR method targeting the maize specie
Pp35S  , Prime number corresponding to qPCR method targeting P35S
PPaT/pat  , Prime number corresponding to qPCR method targeting PaT/pat
PCryIab , Prime number corresponding to qPCR method targeting CryIab
example 1: GPnbt176 = Pmaize x Pp35S x 1 x PPat/pat x Pcryiab
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better screening for the presence of Gmos in food and feed products will 
improve traceability issues for commercially available Gmo products and 
will reduce safety concerns related to Gmos, since unauthorised Gmo 
products have not received a safety assessment and thus may present a 
potential threat to consumer health.
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acKnoWledGementS
comes of the screening analysis) and the 
GPN of the different GM plants (theoreti-
cally determined as a function of the DNa 
element present in the sample), the possi-
ble presence of a GM plant in a sample may 
be easily determined by a simple division 
function. 
Next to this mathematical tool, for formal 
interpretation of the outcomes of the 
screening analysis, some experimental 
qPCR criteria (Tm and Ct) are used as deci-
sion values to give additional quantitative 
information on the possible GM present in 
a sample. These decision values and their 
integration in the CoSYPS are fully de-
scribed in Van den bulcke et al., 2010 (2).
concluSion
CoSYPS represent a novel real-time qPCR 
for GM plant analysis based on SYbR®Green 
technology. This decision support system 
is able to identify in a single qPCR run (96-
well plates), the potential presence of the 
GM plants in a sample. Only the proposed 
GM plants (specific events) in the sample 
will be specifically identified in a second 
step. In a third step, the identified GM 
plants will be, if necessary, quantified to 
asses if their threshold is above 0.9% GMO 
per ingredient. This system, developed by 
the WIV-ISP, is considered a versatile, cost-
effective, time efficient approach to assess-
ing the presence of GM plants in a sample, 
particularly useful in routine analysis used 
for enforcement.
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implementation of the 3rs concept 
during batch release of a dtPa-iPv 
combined vaccine at the belgian omcl
a. maes
introduction 
In general, regulations for medicinal prod-
ucts only require animal models for pre-
clinical studies in order to test the toxicity 
of the drug substance. laboratory animal 
testing is not usually required for routine 
batch release testing of these products. 
However, biological medicinal products in 
general and vaccines in particular are an 
exception as the quality of these products 
cannot usually be assessed by physico-
chemical testing alone and tests measur-
ing the biological characteristics on a rou-
tine batch to batch basis may be needed. 
Such testing includes laboratory animal 
tests for safety and potency of every batch 
(1). The necessity of developing some kind 
of efficacy assay was first seen in the late 
19th century when it was observed that the 
therapeutic effect of diphtheria antise-
rum could differ from batch to batch from 
zero to 100%. Therefore the potency assay, 
which relies in general on in vivo testing is 
still today one of the main pillars for the 
control of sera and vaccines (2).
The three Rs concept in relation to labo-
ratory animal experimentation was first 
introduced by Russell and burch in 1959. 
This concept defined ‘reduction’ as low-
ering the number of animals required to 
obtain information of a given amount and 
precision, ‘refinement’ as any development 
leading to a decrease in the incidence or 
severity of inhumane procedures applied 
to those animals which have to be used 
and ‘replacement’ as any scientific method 
employing non-sentient material to re-
place methods which use conscious living 
vertebrates (3).
These principles were the basis of Coun-
cil Directive (86/609/EEC) of 24 November 
1986 on the approximation of laws, regula-
tions and administrative provisions of the 
Member States regarding the protection of 
animals used for experimental and other 
scientific purposes (4) and Convention ETS 
123 of the Council of Europe (5).
In addition, European regulatory quality 
requirements for medicinal products in-
cluding biological medicinal products such 
as vaccines, plasma derivatives and thera-
peutic proteins are laid down in Directive 
2001/83/EC (medicinal products for human 
use), Directive 2001/82/EC (medicinal prod-
ucts for veterinary use) and the European 
Pharmacopoeia. articles 114 and 82 of the 
respective Directives state that where it 
is considered necessary in the interests of 
public health, a Member State may require 
the holder of a marketing authorisation 
to submit samples from each batch of the 
bulk and/or the medicinal product for ex-
amination by an OMCl (Official Medicines 
Control laboratory) or a laboratory that 
a Member State has designated for that 
purpose. The European Directorate for the 
Quality of Medicines (EDQM) elaborated 
an EC administrative procedure for OCabR 
which is based on article 114 of Directive 
2001/83/EC and the amended Directive 
2004/27/EC (6). 
The European Pharmacopoeia defines 
the assays to be performed on each type 
of product under the form of general and 
product specific monographs. These in-
clude in vivo assays for the quality control 
(QC) of biologicals. 
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method 
The European batch release procedure 
includes the retesting by an independent 
laboratory of each batch produced by the 
manufacturer before it may be released on 
the market. The tests to be performed by 
the OMCl are stipulated in the guidelines 
of the procedure and include in vivo po-
tency and safety tests requiring the use of 
a large number of animals. However, since 
the mid-eighties, the European Pharmaco-
poeia Commission intensified the revision 
of all animal tests in monographs in order 
to apply the 3Rs concept. WIV-ISP per-
formed validation activities and statistical 
analysis of historical data to implement 
the 3Rs measures.
reSultS 
WIV-ISP, belgian OMCl, performed valida-
tion activities to reduce the number of 
animals used during testing of a DTPa-IPV 
combined vaccine (Diphtheria, Tetanus, 
acellular Pertussis, Inactivated Poliomyeli-
tis vaccine).
validation of the single dilution assay for 
potency testing of diphtheria and teta-
nus toxoid (7-9)
Potency testing of diphtheria and tetanus 
toxoid vaccines described in the Ph. Eur. 
is based on the multiple dilution assay, re-
quiring the injection of multiple dilutions 
of the test and reference vaccine into dif-
ferent groups of animals. The number of 
surviving animals is counted 4 days after 
injection with the challenge toxin. The 
potency of the vaccine to be examined is 
calculated relative to the potency of the 
reference preparation on the basis of the 
proportion of animals surviving in each of 
the groups of vaccinated guinea pigs, us-
ing the usual statistical methods. The vac-
cine passes the test if it contains not less 
than an amount of international units (I.U.) 
as stipulated in the monographs for Diph-
theria Vaccine (adsorbed) and Tetanus Vac-
cine (adsorbed). 
The single dilution assay is based on im-
munising a group of animals with a single 
dilution of the test vaccine and a compara-
ble group of animals with one dilution of 
the reference preparation after which the 
animals are challenged with toxin. The test 
vaccine passes the test if it is demonstrat-
ed that it is significantly more potent than 
the reference preparation.
The selection of the appropriate dilution 
for the reference preparation is based on 
historical data and a dilution containing a 
number of I.U. known to elicit an immune 
response in the lower part of the dose-
response curve is considered acceptable. 
For the test vaccines, a dilution containing 
a same number of I.U. is selected based on 
the assumption that it contains exactly the 
required minimum per single human dose. 
Statistical evaluation should then demon-
strate that the survival after challenge in 
the test vaccine group is significantly high-
er than in the reference vaccine group.
The single dilution assay for D and T po-
tency testing was validated at WIV-ISP in 
1991 using results from different kinds of 
combined vaccines (T, DT and DTPw) test-
ed between 1986 and 1989. The reference 
preparation was a DT combined vaccine. 
Since the introduction of the single dilu-
tion assay for potency testing of diphthe-
ria and tetanus toxoid containing vaccines, 
a threefold reduction in the number of ani-
mals used can be observed.
validation of a single dilution immuno-
genicity test to monitor consistency of aP 
vaccine (10-12)
Testing the immunogenicity of aP vaccines 
was introduced in 1995 using a multiple 
dilution assay, consisting of the immunisa-
tion of groups of animals with 3 dilutions 
of the test vaccine and 3 dilutions of the 
reference preparation. The animals are 
bled 4-5 weeks after vaccination and the 
serum is analysed for specific antibodies 
against each aP component using enzyme-
linked immunosorbent assay (ElISa). The 
antibody titres in the sera of mice immu-
nised with reference and test vaccines are 
calculated and, from the values obtained, 
the potency of the test vaccine in relation 
to the reference vaccine is calculated by 
usual statistical methods. The in-house 
procedure used three dilutions of vaccine 
and reference preparation for vaccination 
of the animals. The Ph. Eur. mentions that 
after validation, for routine testing, a sin-
gle-dilution method may be used. 
In 1998 the single dilution assay was vali-
dated by recalculating serum titres of 6 dif-
ferent vaccinations of the 1/3 dilution. ad-
ditional criteria were established in order 
for the assay to be valid.
again, the introduction of the single dilu-
tion test for immunogenicity testing of aP 
containing vaccines reduced the number 
of animals significantly. 
validation of d and t potency testing on 
the first final bulk used in different vac-
cine batches
In the OMCl network, it is possible for an 
OMCl to submit a proposal in order to re-
duce the number of animals to be used 
during batch release. The validation was 
based on a draft document Pa/PH/OMCl 
(98) 11 PROP: “Mechanism for reducing 
in vivo testing by OMCls during batch re-
lease”.
In 2000, a validation report was submit-
ted proposing the reduction of diphtheria 
and tetanus potency testing of a DTPa-IPV 
vaccine. The validation was based on the 
demonstration of the production consist-
ency by assessing the overall statistical 
homogeneity of final bulk lots produced 
between 1998 and 1999, the statistical ho-
mogeneity of the potency data from dif-
ferent final bulks in which the same batch 
of bulk antigen is used, the compliance of 
the potency data with the Ph. Eur. require-
ments and the marketing authorisation 
and the manufacturers data on al3+ con-
tent as a parameter of the homogeneity 
of adsorption, formulation and filling. The 
above assessment is used to support the 
hypothesis that a valid potency assay per-
formed on the first final bulk that is formu-
lated with a new bulk antigen can be con-
sidered representative for the subsequent 
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figure 2:
comparison of the number of animals used for d potency testing with and without imple-
mentation of reduction scheme.
final bulks formulated with the same batch 
of bulk antigen. The proposal was accepted 
in 2001 by the OMCl network and officially 
implemented in 2003 at WIV-ISP.
diScuSSion and concluSion
although the implementation of reduc-
tion, replacement and refinement should 
be one of the goals in quality control of 
vaccines, the implementation and/or vali-
dation of alternative methods should be 
based on a scientific rationale and without 
jeopardising the quality of OCabR. Public 
health remains the most important ele-
ment when releasing vaccines for use in 
a healthy population consisting mainly of 
young children.
Since 1989, WIV-ISP has implemented 
several 3R measures, following Ph. Eur. 
principles, which are primarily based on 
the reduction of the number of animals to 
be used. 
as an example, Figure 3 shows a simulation 
of the number of animals used for release 
of a DTPa-IPV combined vaccine in the case 
where WIV-ISP would not have implement-
ed all the reductions discussed above.
as can be seen, a sevenfold reduction in the 
number of animals has been achieved for 
the release of one vaccine. When sufficient 
experience has been gained for a given as-
say and product, it can be concluded that 
the reduction in the number of animals 
used for batch release of vaccines can be 
easily implemented based on the review of 
historical data.
The 3R principle could be further achieved 
by implementing the principle of refine-
ment. The validation of a humane-endpoint 
for the execution of the lethal challenge 
potency assays for tetanus and pertussis is 
currently in progress at WIV-ISP. One of the 
hurdles delaying this implementation has 
been the availability of qualified person-
nel. The implementation of humane end-
points requires the knowledge to interpret 
clinical signs of diseases in animals. In gen-
eral, international recommendations do 
not explain in detail the clinical signs and 
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comparison of the number of animals used without and with reduction implementation.
Figures 1 and 2:
show a comparison of the number of animals used with and without the implementation 
of the reduction scheme for Diphtheria and Tetanus potency testing respectively.
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Wiv-iSP has implemented the 3rs concept via a significant reduction in the 
number of animals used for the quality control of human vaccines, without 
jeopardising the quality of those controls, a key element in authorising the 
administration of vaccines to a healthy population consisting mainly of 
young children.
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In conclusion, to encourage OMCls to 
implement 3R principles, it would be de-
sirable that the following conditions be 
fulfilled: acceptance, validation and im-
plementation of alternative methods by 
the manufacturers, elaboration of interna-
tional guidelines defining unambiguously 
humane endpoints, availability of qualified 
personnel at the level of animal caretakers, 
technicians and scientists, and the support 
of the management for investment in facil-
ities and equipment.
 
at which time-point the animals should be 
considered dead. The elaboration of such 
international guidelines would help the 
implementation of refinement measures.
The introduction of “refined” in vivo meth-
ods (e.g. the validation of the serological 
method for D and T potency for replace-
ment of the lethal challenge assay) re-
mains a great challenge for our laboratory. 
Validation of a new in vivo method requires 
the tests to be performed in parallel during 
a minimum required number of assays. For 
that purpose, one must move back from 
the established single dilution assay to 
a multiple dilution assay which – at least 
temporarily - increases the number of ani-
mals to be used. This means an increased 
burden on the animal facilities in terms of 
space and personnel. The replacement of 
in vivo test by in vitro methods could be 
considered easier as parallel testing would 
not increase the number of animals but, on 
the other hand, it may require investment 
in high technological and thus expensive 
equipment. 
One additional hurdle to introduce alterna-
tive methods exists when manufacturers 
have not validated and introduced such 
methods. Indeed, in such a case, it would 
be difficult for the OMCl to use a differ-
ent (alternative) method for the purpose 
of OCabR; the use of different methods 
by manufacturer and OMCl in general in-
creases the risk of conflicting results and 
outcomes in terms of release and rejection 
of batches.
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introduction 
Pathogenic micro-organisms receive much 
attention due to their potentially harmful 
effects on human, animal or plant health. 
Over the past few decades, this attention 
has grown due to the emergence of new 
(and known) infectious diseases inducing 
local epidemics as well as worldwide pan-
demics. along with the research and diag-
nosis of those etiological agents, (bio)safe-
ty concerns have highlighted the biological 
risks associated with their deliberate use 
in laboratories, animal facilities and pro-
duction plants, and their transboundary 
movements (import and export). This has 
led to their categorisation into risk groups 
and the elaboration of classification lists. 
Current international classification sys-
tems rely on criteria defined by the World 
Health Organisation, which cover the se-
verity of the disease the micro-organism 
might cause, its ability to spread and the 
availability of prophylaxis or efficient treat-
ment (1). animal pathogens are classified 
according to the definitions of the World 
Organisation for animal Health, which also 
consider economic aspects of disease (2).
Evolution of scientific knowledge will de-
mand regular updating of classification 
lists. This paper describes the belgian risk 
classification system and the methodol-
ogy that was used for its peer-reviewed re-
vision (with a focus on animal pathogens).
methodoloGy
belgian classification system
The belgian classification system defines 
4 risk groups, using the term “risk class”. 
The classification lists however, are limited 
to human, animal and plant pathogens, 
which are classified into three risk classes, 
as non-pathogenic organisms of risk class 1 
are not included. Pathogenic micro-organ-
isms for either humans or animals or for 
both are compiled in a single list, with risk 
classes assigned with regard to humans as 
well as with regard to animals (3).
The first belgian classification lists were 
established in 1998, taking into account 
relevant European Community legislation, 
international and national classification 
schemes as well as relevant scientific pub-
lications. Since these lists reflect the state 
of knowledge at the time they were de-
vised, they needed to be updated in terms 
of taxonomy and risk groups. The revised 
lists are not exhaustive but are intended to 
be representative in terms of the variety of 
pathogens that are prevalent and/or used 
(e.g. in research) in belgium. 
Procedure for revision
The revision of the classification lists with 
respect to taxonomy and biological risk 
class was conducted by the Division of bio-
safety and biology (Sbb) of the Scientific In-
stitute of Public Health. The lists were first 
revised taxonomically under the coordina-
tion of the bCCM (belgian coordinated col-
lections of micro-organisms) and the divi-
sion of Mycology of the Scientific Institute 
of Public Health.
as a second step, an internationally rec-
ognised expert was chosen to coordinate 
belgian animal health and biosafety ex-
perts in their review of the risk classes of 
animal pathogens in the taxonomically re-
viewed classification lists of human and/or 
animal pathogens. The experts were asked 
to focus on organisms that represented a 
risk to animal health without considering 
the risk to humans in the case of zoonotic 
pathogens (zoonotic characteristics of ani-
mal pathogens were assessed later, during 
the revision of human pathogens). Scientif-
ic knowledge was judged in the context of 
existing definitions of risk class in order to 
decide whether the assignment of a path-
ogenic organism should be modified or 
whether the lists should be extended. For 
each revision proposal, a revision form had 
to be completed that identified the given 
organism and documented the rationale for 
the proposed risk class revision. The revision 
form was also used to add organisms that 
were not previously included in the list. The 
revision forms were collated by the Sbb and 
the coordinator. a compilation document 
was established and discussed in a plenary 
meeting were unanimity was reached with 
regard to the assignment of a given patho-
genic organism to a given risk class.
criteria for revision
In the assessment of the biological hazard 
of an organism, the following elements 
were considered: 
Impact of the disease or severity of the • 
infection (pathogenicity);
Infectivity (the virulence of the strain, • 
the infective dose, the mode of transmis-
sion, natural route of infection);
* contributed equally to this work
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bacteria former risk class revised risk class
bordetella bronchiseptica 3 2
Campylobacter fetus 3 2
Clostridium chauvoei 3 2
Clostridium septicum 3 2
Francisella tularensis type b (a) 3 3
leptospira interrogans (all serotypes) 3 2
Mannheimia haemolytica 3 2
Mycoplasma gallisepticum 3 2
Mycoplasma hyopneumoniae 3 2
Mycoplasma mycoides subsp. Mycoides 4 3
Mycoplasma suis 3 2
Pasteurella multocida (a) 3 3
Salmonella (other than Salmonella enterica serovars) 3 2
Streptococcus equi subspecies zooepidemicus 3 2
Taylorella equigenitalis 3 2
viruses former risk class revised risk class
avian leukosis viruses (alV) 3 2
avian sarcoma viruses (Rous sarcoma virus (RSV)) 3 2
bluetongue virus (bTV) 4 3
border disease virus 3 2
bovine viral diarrhoea virus (bVDV) 3 2
Duck enteritis virus (DEV) 3 2
Duck hepatitis b virus 3 2
Equid herpesvirus 1 3 2
Equine arteritis virus 3 2
Feline infectious peritonitis virus (FIPV) 3 2
Fowlpox virus 3 2
Haemagglutinating encephalomyelitis virus 3 2
Infectious bronchitis virus (IbV) 3 2
Infectious bursal disease virus (IbDV) 3 2
Marek’s disease virus (MDV) 3 2
Orf virus (Contagious ecthyma of sheep) 3 2
Porcine epidemic diarrhoea virus 3 2
Pseudocowpox viruses (bovine papular stomatitis, milker’s nodes, paravaccinia) 3 2
Transmissible gastroenteritis virus 3 2
table 1: list of revised animal pathogens.
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Parasites former risk class revised risk class
ancylostomatidae (family) (a) 2 2
anisakidae (c) 2 -
ascarididae (family) 2 2
argas spp. (b) - 2
babesia gibsoni (b) - 3
Calliphoridae (family) (a) 3 3
Cryptosporidium spp. (b) - 2
Dermanyssus gallinae (b) - 2
Dipylidium caninum (b) - 2
Dirophilaria immitis (b) - 2
Eimeria spp. 3 2
Giardia duodenalis (b) - 2
Giardia spp (b) - 2
Histomonas meleagridis (b) - 2
Oestridae (family) (b)  - 2
Oxyuridae (family) (b) - 2
Neospora caninum (b) - 2
Psoroptidae (family) (b) - 2
Sarcoptidae (family) 3 2
Strongylidae (family) (b) - 2
Taenia saginata 3 2
Trichostrongylidae (family) 2 2
Wohlfahrtia (gender of the Sarcophagidae family) (b)  - 3
(a) proposal for lowering the risk class was not validated by the expert group or risk class remained unchanged
(b) added to the list
(c) removed from the list
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risk class (rc)
criteria corresponding to belgian definitions  
(in order of decreasing frequency)
additional criteria
bacteria
RC 3 => RC 2 no control or eradication programs active in belgium  • 
(e.g. Mannheima haemolytica)
no severe disease (• e.g. Mycoplasma hyopneumonia)
no epizootics (• e.g. Salmonella)
enzootics (part of normal microbiota) (• e.g. bordetella bronchiseptica)
no interspecies transmission (• e.g. Mycoplasma hyopneumonia)
limited economic impact (• e.g. Taylorella equigenitalis)
similarity to other species of • 
same genus with comparable 
biological risks (e.g. Clostridium 
septicum)
poor persistence (survival) in the • 
environment (e.g. Mycoplasma  
gallisepticum)
viruses
RC 4 => RC 3 dependence on multiple factors and the dissemination characteristics 
such as the serotypes and exclusively transmitted by an insect vector 
(e.g. bTV)
RC 3 => RC 2 no severe disease (• e.g. fowlpox virus)
no epizootics (• e.g. alV) 
no interspecies transmission (• e.g. Duck hepatitis b virus)
prophylactic or therapeutic measures (vaccines available),  • 
controlled by isolation or eradication, quarantine (e.g. IbV)
limited economic impact • 
no control or eradication programs active in belgium (• e.g.TGV)
enzootics (• e.g. bVDV, Marek's disease virus)
worldwide distribution (• e.g. bDV)
(latent) carriers (e.g. FIPV)
no reservoir (• e.g. IbV)
low (or limited) concentration  • 
of host in belgium (e.g. DEV)
sporadic occurrence of the • 
disease 
Parasites
added to the 
list: assignment 
of RC 3 (for the 
parasite alone 
or family of 
parasites)
severe illness and discomfort (• e.g. babesia gibsoni, Wohlfahrtia)
added to the 
list: assignment 
of RC 2 (for the 
parasite alone 
or family of 
parasites)
iIlness and serious discomfort • 
economic impact by loss of productivity (• e.g. Psoroptidae, Dermanys-
sus gallinae) or due to reduced growth (e.g. ascarididae) 
Widespread (• e.g. Trichostrongylidae, Giardia duodenalis)
only a threat for young or im-• 
munocompromised animals (e.g. 
Cryptosporidium spp. Giardia 
spp.)
abortions (• e.g. Neospora cani-
num)
RC 3 => RC 2 illness and serious discomfort • 
economic impact by loss of productivity (• e.g. Sarcoptidae)
asymptomatic disease (• e.g. 
Taenia saginata)
only a threat for young or im-• 
munocompromised animals 
(Eimeria spp.)
Withdrawn 
from the list 
no symptoms in the host (• e.g. anisakidae)
table 2: conclusive criteria for revising the classification of animal pathogens.
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Host range (• e.g. reservoir) and spectrum 
of specificity of target-species (age, sex);
Genetic stability;• 
Potential of survival outside host (• e.g. 
ability to form resistant spores) and 
dissemination in the community or the 
environment (e.g. zoonosis, presence of 
vectors, reservoir);
availability and effectiveness of prophy-• 
lactic or therapeutic measures (vaccina-
tion or antisera, antibiotics, chemothera-
peutic agents, taking into consideration 
the possibility of emergence of resistant 
strains);
active control or eradication programs • 
for the disease in belgium;
Production of allergens or toxins.• 
based on the aforementioned elements, 
belgian legislation defines criteria for clas-
sification of organisms into 4 biological 
risks classes, taking into account the theo-
retical maximum hazard incurred by im-
munocompetent humans, healthy animals 
and plants (4-6). They were used as a start-
ing point for revision of the classification 
of animal pathogens. 
at the start, it became evident that the 
criteria for a given risk class did not ap-
ply equally to all pathogens (due to their 
specific characteristics). It was therefore 
decided to introduce the following addi-
tional specifications for how to apply or 
weight the criteria:
The characteristics of the pathogen • 
should correspond as much as possible 
to the criteria considered for a given risk 
class.
Though all criteria should be used, some • 
criteria should be considered more im-
portant than others. This is the case for 
the epizootic, enzootic and exotic char-
acter of the pathogen (in order of impor-
tance). 
although criteria that address the eco-• 
nomic and/or sanitary importance of a 
pathogen should be taken into account, 
criteria that are inherent to the patho-
gen should be considered first and fore-
most. 
as the severity of the disease can vary • 
with different strains of a given patho-
gen, the mean pathogenicity that is 
expected and/or observed is taken into 
consideration.
reSultS and diScuSSion
rationale for the chosen methodology
In the belgian classification system, the 
assignment of a risk class depends on the 
inherent properties of the organism, inde-
pendent of the activities (e.g. diagnosis, 
research, animal experiments) undertaken 
with it. This means that a clear distinc-
tion is made between the biological risk 
class of the pathogen and the risk class 
of the activity. In a risk assessment, both 
need to be considered in order to define 
the containment level and specific safety 
measures that should be adopted in order 
to protect human health and the environ-
ment. Hence the risk class of the activity 
may be equivalent to the risk class of the 
micro-organism or it may be higher or even 
lower. Consequently, work with the same 
pathogen can be undertaken under dif-
ferent containment levels, depending on 
the risk assessment of the activity. This ap-
proach ensures the resultant classification 
lists are not bound to containment levels. 
More than 70% of new and emerging in-
fectious human diseases are known to be 
zoonotic (7). It was chosen for the belgian 
classification lists to elaborate a common 
list for human and animal pathogens. In 
addition, and if necessary, two different 
classes of risk are assigned to the same 
pathogen with respect to its pathogenicity 
for humans and/or animals. This enables 
the consideration of the risk of animal 
pathogens within a larger context and also 
ensures harmonisation between different 
regulations concerning human and animal 
health. 
revision of animal pathogens
a compilation document with the peer-re-
viewed proposals for revision of risk class 
(57 in total, see Table 1) was discussed in a 
meeting with the expert group, the coordi-
nator and the Sbb and unanimity was ob-
tained on the risk classes for the proposed 
pathogens. 
For the majority of revised pathogenic 
bacteria and viruses, lower risk classes 
were proposed and accepted. In contrast, 
parasites were often assigned a higher 
risk class and many parasites were added 
to the list. Table 2 gives an overview of the 
conclusive arguments that were used for 
revision of the risk classes for bacteria, 
viruses and parasites, illustrated by some 
examples. 
The main arguments for reducing the risk 
classes for some bacteria and viruses were 
quite similar, although they did not appear 
in the same order of frequency. For viruses 
in particular, the reasons were linked to 
the situation in belgium. For parasites, the 
main reason to either remove or add fami-
lies to the list was the degree of discomfort 
and illness. Parasites causing only slight 
discomfort and no disease were with-
drawn from the list. On the other hand, 
parasites causing very serious discomfort 
or severe illness or mortality, and causing 
significant economic impact, were added 
to the list. Depending on the severity of the 
symptoms, the host range, the geographi-
cal distribution and the economic impact, 
the parasites were either classified in risk 
class 2 or 3. The vector-borne nature of 
some pathogens was taken into account in 
the risk assignment of the pathogen itself. 
However, parasites that are only acting as 
carriers for pathogens were excluded from 
the list. In contrast, vectors producing tox-
ins or serious allergic diseases were con-
sidered for inclusion on the list. 
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classification lists provide an indispensable tool in the assessment of risks 
in order to define the specific safety measures to adopt when handling 
pathogenic organisms in research and diagnosis. hence, regular revisions 
of these lists are crucial in the framework of increased scientific knowledge 
on new and known emerging diseases.
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acKnoWledGementS
In general, the chosen set of criteria for 
assigning a risk class worked fairly well 
for the majority of micro-organisms. How-
ever, additional factors were considered 
in some cases, since a classification based 
on a single set of criteria was not always 
possible. a case by case evaluation was still 
needed for some specific pathogens, as is 
illustrated below. 
For example, although all criteria were 
considered, some criteria constituted a 
conclusive argument for assignment to 
a given risk class in some cases. This was 
illustrated by the case of the Marek’s 
disease virus, occurring worldwide and 
constituting a serious economic threat to 
poultry. The development of the disease is 
prevented by vaccination, but poultry still 
remain carriers of the virus. Due to its en-
zootic character it was decided to reclas-
sify the virus to risk class 2. 
Though the severity of the disease re-
mained at the forefront of experts’ minds, 
in some specific cases criteria address-
ing the economic impact or sanitary im-
portance of a pathogen were taken into 
account. Infection by the Duck enteritis 
virus, for example, is known to be limited 
to anatidae (ducks, geese and swans). How-
ever, since the anatidae population in bel-
gium is rather small, the economic impact 
is limited, so a reduction from risk class 3 
to risk class 2 was considered justified.
another example of weighing up different 
factors against each other is illustrated 
in the case of the bluetongue virus (bTV): 
although the characteristics of the virus 
meet all the criteria defined for risk class 
4, the virus does not cause high mortality 
or important economic losses. The dissemi-
nation of the virus is strictly dependent of 
the presence of the Culicoides insect vec-
tor. based on these factors, a reclassifica-
tion of the virus to risk class 3 was agreed. 
Nevertheless, the actual risk class will also 
depend on the potential spread of the vec-
tor due to climatic changes (8). 
concluSionS
The belgian risk classification process cate-
gorises human and animal pathogens into 
a common list using the most comprehen-
sive approach possible. The risk class of 
an organism is determined independently 
from the activities undertaken with it, al-
lowing case-by case consideration of the 
activities carried out with pathogens and 
the determination of appropriate contain-
ment measures. The strength of methodol-
ogy that was adopted during the revision 
of these classification lists lies in the peer-
review process, supported by a multidisci-
plinary panel of scientists. as the method-
ology is based on unanimously accepted 
criteria, this will greatly facilitate future 
revisions of classification lists in response 
to new scientific knowledge and environ-
mental changes in the broadest sense, 
with a particular emphasis on emerging 
infectious diseases.
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introduction 
Flow cytometry is used for the quanti-
fication and identification of leukocyte 
subsets, particularly in the diagnosis and 
monitoring of leukemias, lymphomas and 
immunodeficiency diseases. The belgian 
External Quality assessment (EQa) pro-
gramme surveys the performance of labo-
ratories for several parameters determined 
by flow cytometry (1). annually, the results 
obtained in the past three years are used to 
evaluate the long term analytical perform-
ance of the laboratories by assessing how 
well the laboratory’s reported values relate 
to the target value, after it has been set for 
each sample. This is done by fitting a linear 
regression model to the data and compar-
ing each laboratory’s regression line with 
those obtained from other laboratories. In 
theory, each regression line should corre-
spond to the 45° -line, yielding an intercept 
of zero and a slope equal to one. In practice, 
however, individual regression lines can be 
poorly estimated due to outlying observa-
tions, excessive residual variability, or gross 
systematic errors. as a consequence, the 
distribution of individual regression lines is 
overdispersed and laboratories with unac-
ceptable quality levels may escape notice.
The method proposed here is a 3-step ap-
proach which relies on robust statistics to 
combine the results of different samples 
collected over time. 
materialS and methodS
the linear model
let N denote the number of laboratories 
participating in the EQa programme and 
ni the number of EQa samples assayed by 
laboratory i (i = 1,2,...N). For each laboratory, 
the relationship between the reported val-
ues and the target values of a given para-
meter can be described by the linear model:
yij = ai + bixj + eij
(Equation 1)
where yij is the value reported by labora-
tory i (i = 1,...,N) for sample j (j = 1,...,ni), ai and 
bi the intercept and slope of the regression 
line for laboratory i, xj the target value for 
sample j and eij the residual or error term, 
assumed to be normally and independent-
ly distributed with mean 0 and variance 
σi
2. The latter is a measure of the analytical 
variability for laboratory i, whereas the pa-
rameters ai and bi reflect the laboratory’s 
bias from the 45°-line or from the mean 
regression line estimated from all labora-
tories. In this work, the target values have 
been taken as the medians of the values re-
ported by all laboratories for each control 
sample. 
The individual estimations of ai, bi and 
σi
2 and hence of their distribution over 
the population of laboratories can be ad-
versely affected by outlying results. This 
prompted us to develop a 3-step method 
to obtain unbiased estimates of individual 
regression lines, discard participants with 
excessive variability, and unveil laborato-
ries with exceeding bias.
the 3-step procedure
• Step 1: excluding outliers from individu-
al regression lines
The first step aims at excluding outliers 
from the laboratories’ individual regres-
sion lines. To exclude potential outliers, 
we propose to use a least trimmed squares 
(lTS) regression (2, 3) to obtain a rough es-
timate of the regression line which holds 
for the majority of the data points, fol-
lowed by the outlier searching algorithm 
described by atkinson (4). lTS-regression 
minimises the sum of the squared residu-
als of a predefined proportion of data, usu-
ally half of the data. Points satisfying the 
following inequality 
|eij  / si*| ≤ K
were subject to an ordinary least-squares 
(OlS) linear regression. In the above in-
equality, K is the upper α1-percentile of a 
Student t-distribution with (ni-2) degrees 
of freedom, 
(Equation 2)
and α1 is a predefined significance level. let 
rij be the residuals of the OlS regression, si 
its residual error with mi degrees of free-
dom, then outliers were defined as values 
for which  |rij | / si  √ 1 - hij   >  t*  for the points 
included in the OlS regression and
|rij | / si  √ 1 + hij   >  t*  for the points not includ-
ed in the OlS regression. The critical value 
t* is the upper-α2 percentile from a Student 
t-distribution with (mi-2) degrees of free-
dom and hij is the corresponding diagonal 
element of the hat matrix (5) from the lTS-
regression. The hij-values are the so-called 
leverages, which measure the influence of 
the individual point on the position of the 
regression line.
• Step 2: finding laboratories with high 
analytical variability
after having excluded outliers in the first 
step, a regression line is calculated for each 
laboratory separately and an estimate of 
the residual variability si
2 is obtained for 
each laboratory. The second step of the 
procedure is to depict laboratories with 
exceeding si
2  values. The method used has 
been described earlier (6, 7). It is based on 
the assumptions that both the theoretical 
residual variance δ
i
2  and the estimated re-
sidual variance si
2 are log-normally distrib-
uted. The following formula can be derived:
si* = 1.4826  (1+          ) √median eij2
5
ni - 2
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(Equation 3)
where:
k = Σ ( ni  - 1 )-1 / N, M = Mean si2, V = Var si2 
and QZ(1-α3) is the upper α3-percentile of the 
standard Normal distribution. Mean si
2 and 
Var si
2  are the mean and variance of the re-
sidual variances from the regression lines 
obtained in the first step. The value  σ2α3 will 
be taken as the critical threshold above 
which a residual variance si
2 will be con-
sidered as exceedingly large. Since some of 
the N estimates si
2 may themselves be out-
liers, a trimming procedure is performed 
before calculation by disregarding an arbi-
trary proportion of the lowest and highest 
variance values. 
• Step 3: finding laboratories with exceed-
ing bias
as before, let ai and bi be the estimated 
intercept and slope of the corresponding 
regression lines after having excluded out-
liers in the two previous steps. literature 
about regression explains how the joint 
distribution of intercept and slope can be 
considered as bivariate Normal (5) with 
mean (a, b), standard deviations (sa, sb) and 
correlation r.
When plotted on a two-dimensional graph, 
the points will be positioned in a cloud 
around which an ellipse-shaped tolerance 
region can be drawn. The centre of the el-
lipse is the intercept and slope of the mean 
regression line and the shape is character-
ised by their standard deviations (sa, sb) 
and correlation r. a point outside the el-
lipse corresponds to a laboratory with sig-
nificant outlying bias. 
also here outliers may arise. The minimum 
covariance determinant (MCD) estimator 
(8, 9) is proposed as a robust measure of 
means, standard deviations and correla-
tion of the bivariate distribution. Maha-
lanobis distances based on the MCD esti-
mator are used as a measure of individual 
outliers. Regression lines for which the Ma-
halanobis distance is larger than the upper 
α4-percentile of a Chi-square distribution 
with two degrees of freedom correspond to 
laboratories exhibiting unacceptable bias.
reSultS
example data set
To illustrate the application of the 3-step 
procedure, we used data obtained from 
the belgian External Quality assessment 
scheme for CD4. Three times per year a 
survey is organised in which 3 fresh blood 
samples are sent to participating laborato-
ries. Surveys included in the study spanned 
from 2005 to 2007. 
application of the method
Step 1: both α1 and α2 were set at 0.0005. The 
first step of the procedure revealed that 53 
(4%) out of 1,340 points were too outlying to 
be included in the individual linear regres-
sions according to the inequality given in 
the Materials and Methods section. Eight-
een of them were eventually not consid-
ered as outliers. Thus, 35 data points were 
identified as outliers and not included in 
the ordinary linear regression lines. Scatter 
plots of residual against target values sup-
ported the assumption of linearity of the 
regression model. among the 35 outliers, 3 
were clearly due to a mistake in unit report-
ing; 14 occurring together with at least one 
other outlier in the same survey may be 
caused by an accidental mistake which was 
not reproduced in other surveys. among the 
other 18 outliers, 14 had very heavy devia-
tion of at least 10 percent points between 
the reported and target value and 4 results 
occurred alone with smaller deviations.
Step 2: by selecting a value for α3 of 0.01 and 
a trimming amount of the 5% most extreme 
variances, we obtained a threshold value 
for identification of residual variability 
outlyingness of 14.76. The median residual 
variance was 3.27 and the standard devia-
tion was 3.87. One laboratory was found to 
have high residual variability. by excluding 
this laboratory, the standard deviation of 
the residual variances dropped to 3.00. If 
no trimming had been applied, the thres-
hold value would have been 17.09 and the 
same laboratory would have been indi-
cated for excessive analytical variability. 
Step 3: The results of the third step are 
graphically presented in Figure 1. a value 
for α4 of 0.001 was used. Three laboratories 
were found to have outlying bias. Two of 
them would have escaped notice if the first 
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figure 1:
distribution of intercept and slope (n = 52). the ellipse is the 99.9% tolerance region for re-
gression lines with robust mcd parameter estimates. arrows indicate outlying laboratories.
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and second steps had been omitted. The ro-
bust mean intercept and slope were  0.4529 
and 1.0114, with standard deviations equal 
to 3.66 and 0.078, respectively, and the cor-
relation was -0.94. 
diScuSSion
The proposed 3-step procedure evaluates 
single data points or regression lines as 
outliers using limits based upon statisti-
cal analysis of the performance attained. 
by this, the methodology is different from 
evaluation procedures using limits based 
upon experience or biological variability. 
The method is applicable whenever matrix 
effects can be excluded. Target values can 
be set by a reference laboratory or can be 
the consensus mean. 
The method also helps laboratories better 
understand their results and is more inform-
ative than a single parameter performance 
characteristic like total error. laboratories 
having exceeding values for the second 
step should be encouraged to control their 
random error. laboratories having exceed-
ing values for the third step should be en-
couraged to reduce their systematic error.
Without excluding outliers in the first step, 
laboratories may have a high analytical or 
bias error, while this was attributable to 
only one or a few discordant results. More-
over, the method’s ability to build up a hi-
erarchy in the identification of mistakes in 
the laboratory is a major advantage and a 
distinction of searching different types of 
outliers is, as far as we know, new and defi-
nitely useful in addressing the type of errors 
seen in EQa programs. While the first step 
evaluates single reported values and out-
liers may indicate accidental mistakes with 
a small chance of being reproduced, the 
second and third steps encompass a global 
laboratory evaluation and exceeding values 
found in these steps indicate poor overall 
laboratory performance.
Samples sent in different EQa surveys with 
different target values can be interpreted 
together and, as such, the second and third 
steps allow evaluation of laboratories for 
their analytical variability and bias over a 
longer period.
The method is flexible in terms of sensitivity 
and specificity of outlier findings by chang-
ing the values for the different α-values in 
the different steps. The purpose of the study 
should determine the choice of the differ-
ent α-values. Here we have opted to detect 
solely heavily deviating values, which re-
sulted in α-values of 0.01 or lower.
The results of the first step show that an in-
dication of outliers based on one criterion, 
as pointed in the inequality of step 1 needs 
a closer look. We found, however, that the 
lTS-regression did not always fit the major-
ity of data well enough. Changing the pro-
portion for which the lTS-regression should 
minimise the sum of squared residuals is 
advisory in that case. The exclusion of out-
liers rather has influence on the variability 
estimate than on the position of the regres-
sion line, except when outliers differ with a 
magnitude of 10 or more, as is the case for 
unit mistakes. The results of the third step 
show a similar trend: leaving out outliers 
mainly affects the standard deviations and 
the correlation in lesser extent than their 
position.
Outliers in the first step indicate accidental 
mistakes, outliers in the second and third 
step provide evidence for high analytical 
variability or bias for all samples. In general, 
we found robust statistics as a useful solu-
tion for outlier searching in EQa testing. 
this method sheds an innovative light on the statistical processing of re-
sults obtained by external Quality Programs. external Quality of clinical 
laboratories is considered as a necessary tool for control and improve-
ment of the quality of a basic process supporting patient’s diagnosis and 
follow-up.
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introduction 
In the European Union, genetically modi-
fied organisms (GMO) and genetically 
modified micro-organisms (GMM) are de-
fined respectively according to Directives 
2001/18/EC on deliberate release of GMO 
(1) and 2009/41/EC on the contained use of 
GMM (2). In accordance with the legislation, 
a GMO/GMM is defined as “an organism/ 
micro-organism ... in which the genetic ma-
terial has been altered in a way that does 
not occur naturally by mating and/or natu-
ral recombination”. This definition must 
be read together with a series of annexes 
that list techniques (i) that result in genetic 
modification, (ii) that are not considered to 
result in genetic modification, or (iii) that 
result in genetic modification but yield or-
ganisms that are excluded from the scope 
of the Directives.
a novel organism will therefore fall under 
the scope of the GMO regulation only if it 
has been developed with the use of defined 
techniques. With the advance of scientific 
knowledge, techniques which are applied 
in genetic modification of organisms have 
emerged that may challenge the current 
regulatory definition of a GMO because it 
is not always clear whether the products 
obtained through these techniques are 
subject to the prevailing European GMO 
legislation or not.
Several initiatives have been taken at the 
European level in order to evaluate some 
of these new techniques in the context 
of the existing legislative framework. The 
Division of biosafety and biotechnology 
(Sbb) is actively contributing to this work. 
neW techniQueS of Genetic modifica-
tion and the Gmo leGiSlation
The European GMO legislation was intro-
duced in 1990. at that time, the legislation 
was mainly based on the principle that an 
organism is considered to be a GMO when 
new combinations of genetic material are 
formed through the use of certain tech-
niques, in particular recombinant nucleic 
acid, injection or cell fusion techniques. 
However, with the advance of science and 
more particularly of biotechnology, new 
genetic modification techniques have 
been applied to research or commercial 
purposes since the introduction of the 
GMO legislation. There is now growing 
interest in using biotechnology in such a 
way that the resulting organism does not 
contain any added sequences, expresses 
new types of changes or bears changes 
similar to those achievable with conven-
tional breeding techniques. For some of 
these techniques, questions have emerged 
as to whether they can be considered as 
resulting in genetic modification in the 
meaning of the Directives and/or whether 
the resulting products must be character-
ised and regulated as GMOs. 
at European level, discussions on this is-
sue started in 2007 within the Competent 
authorities dealing with Directive 2001/18/
EC. In a first step, the Competent authori-
ties raised questions concerning regula-
tory and safety issues associated with the 
use of oligonucleotide-mediated mutagen-
esis (OMM) as a technique of genetic modi-
fication.
OMM (also referred to in the literature un-
der other names such as targeted nucle-
otide exchange, chimeraplasty or targeted 
gene repair) is a technique used to correct 
or to introduce specific mutations at de-
fined sites of a target gene. OMM is mediat-
ed through the introduction of an oligonu-
cleotide with homology to the target gene, 
except for the nucleotide(s) to be changed. 
The oligonucleotide hybridises at the tar-
geted location in the genome to create a 
mismatched base-pair(s) which acts as a 
triggering signal for the cell’s DNa repair 
enzymes. OMM has potential applications 
in fundamental research, medicine, agro-
food and pest control. Mutations can tar-
get any nucleotide sequence for instance 
to inactivate a deleterious gene, to induce 
local modification in expression or to 
change an amino-acid in the correspond-
ing protein resulting in a protein with pos-
sible new properties.
In april 2007, at the request of the Federal 
Public Service for Health, Food Chain Safe-
ty and the Environment, the belgian bio-
safety advisory Council* published a scien-
tific opinion on this issue followed, a few 
months later, by a scientific paper drafted 
by experts from the Sbb, members of the 
biosafety Council and scientists from bel-
gian universities. both the Council’s advice 
(3) and the scientific paper (4) provide scien-
tific arguments for not having organisms 
developed through the OMM technique 
fall within the scope of the EU regulation 
of GMOs. broadly speaking, it is considered 
that the technique does not pose biosafe-
ty questions other than those associated 
*  The belgian biosafety advisory Council is one of the two pillars (the other one being the Division of biosafety and biotechnology - Sbb) of the common 
scientific evaluation system that has been set up in belgium to advise the competent authorities about the safety of activities involving genetically modified 
organisms (GMOs) and/or pathogens. The Council consists of representatives of the Regional and Federal authorities. It is assisted by experts in its scientific 
work. The secretariat of the Council is provided by the Sbb.
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with similar techniques already listed in 
the GMO Directives, and could be consid-
ered similar to mutagenesis, a technique 
currently excluded from the scope of the 
EU GMO regulatory framework. another 
important point is that organisms devel-
oped through OMM could, in many cases, 
not be distinguished at the molecular level 
from those developed through “tradition-
al” mutation techniques (using chemicals 
or ionizing radiation). It is important to 
realise that techniques such as OMM that 
do not involve the introduction into the ge-
nome of transgenes could pose challenges 
for unambiguous detection and testing of 
the resulting organisms, and ultimately 
enforcement of the European GMO regula-
tory system.
OMM is just one amongst several tech-
niques that are challenging the approach 
followed in the EU to define a GMO. There-
fore, at the request of the Competent 
authorities, a working group of Member 
States experts was established in 2007 
to evaluate a non-exhaustive list of tech-
niques and to develop further guidance on 
how they should be considered in the con-
text of the existing legislative framework. 
The Sbb has been mandated by the federal 
and regional authorities to participate in 
this working group.
In addition to the OMM technique de-
scribed above, the following techniques 
have been considered by the “New tech-
niques working group”:
Zinc Finger Nuclease (ZFN)• , a technique 
allowing site specific mutations to be 
generated in the host genome using 
ZFN, protein chimeras composed of a 
sequence specific zinc finger based DNa 
binding domain and a DNa cleavage do-
main. The genes encoding the ZFN com-
plex are typically present and expressed 
transiently in the cell from an expres-
sion plasmid. In some applications of 
the technique, DNa fragments or gene 
cassettes can be inserted precisely at 
the level of the DNa break, thereby pro-
viding a powerful tool for targeted gene 
insertion.
Cisgenesis• , consisting of the genetic 
modification of a recipient species (so 
far, plants) with a natural gene from a 
sexually compatible donor species (as 
compared to transgenesis where genes 
come from non-crossable organisms). 
To produce cisgenic organisms any suit-
able technique used for production of 
transgenic organisms may be used.
RNa-dependent DNa methylation via • 
RNai/siRNa, a technique using small RNa 
to inhibit gene expression by methyla-
tion of the DNa. DNa methylation is one 
of the molecular mechanisms underly-
ing epigenetic effects.
Grafting• , a technique that has been used 
for centuries in plant breeding in which 
the bud-bearing part (the scion) of a plant 
is grafted onto the rootbearing part (the 
rootstock) of another plant. Proteins and 
RNas can be transported from the root-
stock through the graft junction and into 
the scion. In the specific context of ge-
netic modification, grafting can involve 
a non-GM scion onto a GM rootstock (the 
most common case) or a GM scion onto a 
non-GM rootstock.
Reverse breeding• , a technique allowing 
plant breeders to derive homozygous 
parental lines from individual hetero-
zygous plants selected for their elite 
qualities (non genetically modified). To 
obtain the homozygous parental lines, 
meiotic recombination is suppressed in 
the selected heterozygous line through 
RNai-mediated downregulation of genes. 
One of the most important characteris-
tics of the reverse breeding technique is 
that the offspring are not transgenic.
agroinfiltration• , whereby plant tissues 
are infiltrated with agrobacterium sp. 
containing a genetic construct in order 
to promote localised and transient ex-
pression of a protein. In this technique, 
there is no integration of the foreign ge-
netic material into the genome. Instead, 
the aim is to use the ability of agrobac-
terium to inject large numbers of copies 
of the foreign DNa into the plant cells 
where they are used to produce very 
high protein expression levels.
Synthetic biology• , which refers to an 
area of biological research that com-
bines different disciplines of science and 
engineering in order to design and build 
biological components and systems that 
do not already exist in the natural world, 
or to re-design and re-build existing bio-
logical systems (see e.g. http://synthetic-
biology.org/).
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Each technique has been evaluated in the 
context of the GMO/GMM definitions, the 
annexes of the Directives and the most 
recent scientific data. In this respect, fa-
miliarity with techniques already listed in 
the current Directives was considered. Ex-
perts also looked at the characteristics of 
the final product in determining whether a 
technique may be excluded or not (based 
on criteria such as transient presence of 
the transgenes or transient associated 
effect, heritability of the genetic modifica-
tion, cases where offspring from a GMO 
no longer carry the genetic construct but 
continue to bear the effect). Other consid-
erations included the extent to which the 
end-products of such techniques could be 
distinguished from products of traditional 
techniques. Safety issues were also taken 
into consideration where relevant.
In addition to and in coordination with the 
work carried out by the “New techniques 
working group”, the Joint Research Centre 
(JRC) of the European Commission has also 
been mandated to provide two reports 
dealing with the same issue:
a report on the issues presented by • 
these techniques for detection and 
monitoring of derived products. In this 
framework, an ad hoc Task Force on 
“New Techniques” has been established 
composed of selected members of the 
European Network of GMO laboratories 
(ENGl). The Sbb is participating in this 
Task Force;
a report with regard to the socio-eco-• 
nomic impacts of these techniques. This 
report will be the result of a global proc-
ess including literature search, patent 
search, a workshop and a survey sent to 
companies applying these techniques. 
The report will, among others, reflect 
on the latest and future development, 
research and implementation of the 
techniques, taking into account differ-
ent regulatory options (GMO or not). The 
Sbb will also bring its expertise to this 
process by participating in the work-
shop and contributing to the literature 
survey.
ec. directive 2001/18/ec of the european Parliament and of the council of 12 march 2001 on the deliberate release into the environment of genetically 1. 
modified organisms and repealing council directive 90/220/eec. off J eur union 2001;l 106:1-38.
ec. directive 2009/41/ec of the european Parliament and of the council of 6 may 2009 on the contained use of genetically modified micro-organisms. off 2. 
J eur union 2009;l125:75-97.
bac. advice of the belgian biosafety advisory council on the use of “targeted Gene repair” as a strategy to develop novel organisms (Wiv-iSP/bac/2007_3. 
Sc_529). belgian biosafety advisory council 2007. available from: url: http://www.bio-council.be/bac_advices.html
 4. breyer d, herman P, brandenburger a, Gheysen G, remaut e, Soumillion P, van doorsselaere J, custers r, Pauwels K, Sneyers m and reheul d. Genetic 
modification through oligonucleotide-mediated mutagenesis. a Gmo regulatory challenge? environ biosafety res 2009;8:57-64.
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concluSionS
The development of new techniques of ge-
netic modification calls for greater clarity 
and perhaps also new interpretations of 
the current GMO legislation. The final de-
cision as to whether organisms produced 
by a specific technique should fall under 
the scope of the EU regulation on GMOs is 
ultimately a matter of political and legal 
choices. These choices should be made on 
the basis of technical and scientific argu-
ments. It seems obvious that societal and 
economic aspects might also be consid-
ered, notably given the complexity and as-
sociated costs of applying the GMO legisla-
tion for developers of novel organisms.
Moreover, without similar discussions at 
an international level, it is likely that the 
same products of emerging new tech-
niques might be considered to be GMOs or 
not depending on the regulatory jurisdic-
tion. Such discrepancies should be avoid-
ed as they would pose challenges for the 
international regulation of transboundary 
movement of GMOs.
in the eu, the Gmo legislation only applies to organisms obtained through 
certain techniques of genetic modification. determining whether organ-
isms produced by some new techniques should fall under the scope of this 
regulation is of utmost importance, as this will ultimately define whether 
these organisms are subject to case-by-case safety assessment.
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The use of genetically modified organisms 
(GMO) and/or pathogens in laboratory fa-
cilities can have potential negative conse-
quences for human health and the environ-
ment, if they are not correctly handled. It is 
thus necessary to perform a risk assessment 
prior to each use of these biological agents 
in order to take precautions to confine them 
and to minimise their negative effects. 
For this purpose, in 1990, the European Com-
mission adopted the Directive 90/219/CEE 
which is currently replaced by the Directive 
2009/41/CEE (1). In belgium, the transposi-
tion of the EU Directive was operated at the 
regional level as part of the environmen-
tal legislation. Consequently, all activities 
which are performed in a laboratory (but 
also in an animal housing area, greenhouse, 
hospital room or large scale production 
facility) and involving GMO or pathogenic 
organisms must have an authorisation de-
livered by the regional authorities (2-4). The 
Division of biosafety and biotechnology 
(Sbb) acts as technical expert in this authori-
sation procedure and advisory body for the 
Regions. The presented data are based on 
the notification dossiers submitted for ad-
vice to the Sbb. 
This report presents an overview of the 
progress achieved on the high containment 
facilities in belgium, covering the period 
from 1995 to 2008.
hiGh biocontainment facilitieS
laboratories, animal housing areas and 
production facilities are classified into four 
ascending levels of containment which are 
designated as biosafety levels 1 to 4. High 
biocontainment facilities refer to the two 
highest biosafety levels, namely biosafety 
level 3 and 4 (bSl-3 and bSl-4). Since no bSl-
4 is present in belgium, this report only re-
lates to bSl-3. 
bSl-3 facilities are used for manipulating 
biological agents which may cause serious 
or potentially lethal diseases as a result of 
exposure by the inhalation route. In order 
to prevent any escape of infectious agents 
into the community and the environment, 
a bSl-3 laboratory should have special de-
sign features and protective equipment 
requirements, as well as advanced safety 
practices. The most important required 
measures are the following: 1. Negative 
air pressure relative to the immediate en-
vironment; 2. airlock; 3. Room sealability 
for decontamination by fumigation; 4. Ex-
haust air HEPa filtered; 5. Inactivation of 
solid and liquid waste before evacuation.
In belgium, since the implementation of 
the regulation imposing the notification 
of all contained uses of GMO and/or patho-
genic organisms, 79 high level containment 
facilities have been declared.  
bSl-3 can be distinguished into two cat-
egories: medical diagnostic laboratories 
and research laboratories. Most laborato-
ries assigned to research and development 
are located in universities or pharmaceuti-
cal companies. bSl-3 dedicated to medical 
diagnosis are largely located in hospitals 
or other healthcare facilities and generally 
undertake the identification of airborne 
pathogens belonging to risk group 3 (for 
example Mycobacterium tuberculosis). We 
estimate that there are currently 15 bSl-3 
diagnostic laboratories in operation. The 
activities carried out in governmental sci-
entific institutes bSl-3 (WIV-ISP, CODa-CER-
Va) are mostly diagnostic but also include 
applied research.
The 8 belgian Reference laboratories for 
the diagnosis of aIDS are included in the 79 
known bSl-3. In addition to bSl-3 contain-
ment measures, these laboratories must 
also meet very strict safety criteria defined 
by the royal decree of 8 October 1996 re-
lating to aIDS Reference laboratories (5). 
These laboratories are located in the fol-
lowing institutions: UCl Woluwe, Scientific 
Institute of Public Health, KUl-Universitair 
Ziekenhuis, Ulb-Hopital Erasme, Instituut 
voor Tropische Geneeskunde, UGent-Uni-
versitair Ziekenhuis, Ulg-CHU de liège, and 
VUb-Universitair Ziekenhuis brussel.
Geographical distribution of the high bio-
containment facilities 
The geographical distribution of bSl-3 is 
presented in Figure 1, which illustrates a 
rather homogeneous distribution of the 
high containment facilities in belgium, 
except for the province of luxembourg 
where no bSl-3 is established.
The high concentration of bSl-3 observed 
around brussels is due to the presence 
of five academic hospitals (UZ Univer-
sity brussel, Institut Jules bordet, Hôpital 
érasme, Cliniques Saint-luc and CHU Saint-
Pierre) as well as various universities and 
governmental scientific institutes (UCl, 
CODa-CERVa, and WIV-ISP). 
a large number of the high biocontainment 
laboratories in the province of Walloon 
brabant are explained by the presence of 
the big pharmaceutical company Glaxo-
SmithKline biologicals. In the province of 
antwerp, where several pharmaceutical 
companies are established such as Jansen 
Pharmaceutica and Tibotec-Virco, there 
are also a large number of bSl-3 facilities. 
on state-of-the-art high biocontainment 
facilities in belgium 
c.d. do thi
b. vanvaerenbegh
c. verheust
P. herman
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In the province of Hainaut, all the high con-
tainment facilities are concentrated in the 
Gosselies aeropole (Ulb, Henogen). 
In the province of liège, most bSl-3 are lo-
cated on the site of Sart-Tilman, where the 
university (Ulg) and its academic hospital 
(CHU liège) are located.
In the provinces of limburg, Eastern Flan-
ders and Western Flanders, bSl-3 facilities 
mainly correspond to medical diagnosis 
laboratories. In the province of Namur, 
there is only one university laboratory 
(FUNDP-Namur), several production fa-
cilities from a pharmaceutical company 
(GlaxoSmithKline biologicals) and one lab-
oratory for diagnosis.
In summary, the 79 high containment facili- 
ties are distributed in belgium as follows: 
43 are located in the Walloon Region, 21 in 
the Flemish Region and 15 in the brussels-
Capital Region.
type of installations
• large scale containment level 3 
The 11 large scale biosafety level 3 produc-
tion units are all located within pharmaceu-
tical companies. These institutions often 
simultaneously perform various activities 
such as research and development of new 
products, manufacturing and production 
of drugs and vaccines, as well as quality 
control and environmental monitoring.
large scale production that is taken into 
account in this report involves activities 
where large volumes of culture or strong 
concentrations of infectious agents are 
handled; although there is no strict defi-
nition of “large scale” activities, since the 
risks are more dependent on the agent, the 
procedures being used, and the frequency 
of activity.
• laboratory animal facilities contain-
ment level 3 (abSl-3)
laboratory animal facilities represent a 
special type of laboratory because animals 
themselves may present unique hazards 
not found in standard microbiological lab-
oratories. For example, animals may gen-
erate aerosols or shedding, may bite and 
scratch, or may be infected with zoonotic 
agents. abSl-3 is suitable for work with 
animals infected by pathogenic agents of 
risk group 3.
among the high containment laboratories 
present in belgium, 9 are animal facilities, 
which are located in the following insti-
tutions: CODa-CERVa, GlaxoSmithKline 
biologicals, Jansen Pharmaceutica, KUl, 
Tibotec-Virco, Ulg and Ulb. abSl-3 are pri-
marily made up of housing areas for ex-
perimental animals but can also include 
food storage, cloakrooms, showers, auto-
claves, etc.
manipulated organisms
The high containment activities may be 
categorised by the institutions in which 
they are performed: universities and gov-
ernmental scientific institutes, pharma-
ceutical companies, hospitals and private 
clinics. actually, the main differences that 
may be observed between these catego-
ries are related to the type of agents han-
dled, the scale of the activity or the goal 
of the operation (research, diagnosis or 
production).
Only 10 of the high containment facilities 
are used to confine genetically modified 
micro-organisms whereas 41 of them are 
used for handling non-genetically modi-
fied pathogens. The 28 remaining facilities 
are utilised for activities that simultane-
ously handle GM and non-GM agents.
There is no direct correlation between the 
risk group of an organism and the level of 
containment to be adopted. a risk assess-
ment must be carried out on a case-by-case 
basis in order to determine the appropri-
ate containment measures and working 
practices by taking into account various 
factors such as the scale of the activity, the 
type of manipulation, the biological haz-
ards inherent to the insert, etc. (6).
For example, the adoption of bSl-3 contain-
ment is mandatory for the production of 
recombinant adenoviral vectors carrying 
a potentially hazardous insert (oncogene, 
toxin, virulence gene, etc.). However, bSl-3 
is not required for the same manipulation 
if the insert does not code for a dangerous 
component.
figure 1: Geographical distribution of the high biocontainment facilities in belgium.
the blue points mark the site of bSl-3 facilities. the size of the points is proportional to the 
number of high containment facilities present in the commune or the city.
exPertiSe, Service ProviSion and cuStomer relationS directorate 149 
The diagnosis of tuberculosis constitutes 
another frequently encountered exam-
ple: diagnosis activities including primary 
cultures of clinical specimens should be 
carried out under bSl-2 containment with 
reinforced safety equipment and level 3 
working practices. On the other hand, any 
further manipulation involving opening of 
tubes containing M. tuberculosis positive 
cultures requires full bSl-3 containment (7).
history of the notifications 
Since the transposition of the EU Direc-
tive into belgian law, notifications of high 
containment laboratories did not simulta-
neously start in the 3 regions because the 
regional decrees did not come into effect 
at the same time. Indeed, the Region of 
brussels-Capital transposed the Directive 
90/219/CEE in December 1993, the Flemish 
Region in June 1995 and the Walloon Re-
gion in June 1996. Figure 2 shows the evolu-
tion of the notifications of bSl-3 contained 
use in belgium since 1994.
The notifications of bSl-3 laboratories 
started in 1995 with two dossiers in the 
Region of brussels-Capital. although no no-
tification for bSl-3 containment was intro-
duced in 1996, 21 bSl-3 facilities were no-
tified in 1997. This fact corresponds to the 
first notification by the company Glaxo-
SmithKline biologicals which, at that time, 
owned 16 bSl-3 including laboratories, ani-
mal housing and large scale facilities. 
Most universities introduced their dossi-
ers from 1998 with two peaks in 2000 and 
2002. In 2003 to 2004, bSl-3 notification 
stabilised with 8 new high containment fa-
cilities per year. Since then, the number of 
notifications has gradually reduced.
The evolution of notifications shows that 
after one period of high activity following 
the application of the belgian decrees, the 
number of new notifications decreased ap-
preciably. This is probably due to the fact 
that almost all of the high containment fa-
cilities were declared.
at the beginning of the notification pro-
cess (1994 to 1998), several requests for au-
thorisation of class of risk 3 contained uses 
were rejected because of the lack of some 
containment criteria or even because of 
the absence of bSl-3 containment. The 
most common non-conformities which 
were observed were a lack of maintaining 
negative pressure in the area, rooms not 
sealable to permit fumigation, absence 
of sink with non-manual control, or inap-
propriate waste management. Except for 
one abSl-3 animal facility, all of the labora- 
tories concerned were in compliance fol-
lowing inspection visits and interventions 
of the competent authorities and the Sbb.
In contrast, some activities that do not re-
quire a high level of containment are nev-
ertheless performed in bSl-3 containment. 
For example, these activities correspond 
to the use of animal cell cultures for anti-
body production, the production of recom-
binant retroviral vectors for clinical trials 
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bSl-3 containment is designed to minimise risks and provide secure condi-
tions to protect workers, the public and the environment from exposure to 
infectious micro-organisms that are handled in the laboratory.
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or the large scale culture of bacteria which 
are not pathogenic through aerosolisation 
(Salmonella). The adoption of more strict 
containment measures generally arises 
from the need to combine biosafety com-
pliances with quality requirements (such 
as Good Manufacturing Practices). Howev-
er, these facilities are listed in the number 
of bSl-3 in belgium since they fill all re-
quired criteria for level 3 containment.
laboratorieS for detection of bo-
vine SPonGiform encePhaloPathy’S 
aGentS (bSe)
Some high containment laboratories were 
not included in the 79 bSl-3 facilities pre-
viously mentioned. They correspond to 
laboratories performing bSE rapid test. 
These laboratories constitute a particular 
category because they do not have to meet 
all of the criteria of a conventional bSl-3 
laboratory.
The agents responsible for bSE are prions 
or unconventional agents of risk group 3 
for humans and animals. The diagnosis of 
prions by rapid test requires bSl-3 contain-
ment except for three criteria: the negative 
air pressure relative to immediate sur-
roundings, the HEPa filtering of exhaust 
air and the room sealability for decontami-
nation by a gaseous substance. However, 
special attention has to be paid to working 
practices and waste management because 
prions are very resistant to all traditional 
inactivation methods. 
In belgium, 25 laboratories for rapid detec-
tion of bSE are in operation.
concluSion
biosafety level 3 containment facilities are 
used to handle airborne agents that may 
cause serious and potentially lethal infec-
tion and require special facility design, 
practices and safety equipment that pro-
tect laboratory workers, the environment, 
and the public from harmful exposure. 
This report reveals a high number of bSl-3 
facilities present in belgium, homogene-
ously located in the 3 regions. The evolu-
tion of bSl-3 contained use notifications 
indicates that almost all high biocontain-
ment facilities are declared, authorised 
and controlled.
exPertiSe, Service ProviSion and cuStomer relationS directorate 151 
introduction 
The belgian external quality assessment 
scheme (EQaS) for Therapeutic Drug Moni-
toring (TDM) has existed since 1991 for Di-
goxin and Theophyllin. Several parameters 
have been added over recent years. It cur-
rently comprises 12 parameters and is per-
formed 4 times per year. The participation 
of belgian laboratories is mandatory and 
integrated within the laboratory license. 
The EQaS’ main objective is to evaluate the 
performance of laboratories on their abil-
ity to approach their peer group’s median 
value, taking into account the overall vari-
ability. another objective is to monitor the 
overall quality of particular measurement 
methods. 
The recent use of case reports where labo-
ratories are asked to interpret analytical 
results led us to conclude that many labo-
ratories encounter problems interpreting 
results especially when unconventional 
blood collection intervals were used. Hence, 
the belgian Health authorities decided to 
supply laboratories with pharmacokinetic 
software, free of charge, to improve TDM. 
materialS and methodS
For each survey, carried out four times per 
year, participating laboratories receive 
lyophilised or liquid samples. The laborato-
ries are surveyed for methodology and are 
asked to report the concentration of the 
drugs amikacin, carbamazepine, digoxin, 
gentamicin, lithium, paracetamol, pheno-
barbital, phenytoin, salicylate, theophyllin, 
valproic acid and vancomycin. 
The same sample material and evalua-
tion system are used for all laboratories. 
This assessment scheme, as well as other 
schemes from the belgian Health authori-
ties, is used to monitor the performance of 
laboratories. The purpose of these EQaS is 
to be educational and there is no penalty 
associated with normal, non-repetitive er-
rors.
after sending samples, laboratories have 
15 days to submit their results either by 
returning the reply form or via a dedicated 
website (1). The data are statistically pro-
cessed with the non-parametrical method 
of Tukey (2) and a draft report is written. 
after presentation and discussion with a 
committee of experts, the necessary cor-
rections are made to the report. The final 
report is then sent to the participating 
laboratories (3). In addition to the survey 
reports, once a year, a special annual report 
(4) is written and sent to the participants, 
together with their individual annual over-
all performance. 
In the global reports, for each survey and 
for each parameter, a table summarises 
the results obtained by the participating 
laboratories. They contain for each sample 
the following information: 
T• he median, standard deviation, CV and 
number of laboratories for each method 
(peer group);
F• ields that show the global results for 
all methods and all measuring systems 
combined (5, 6);
b• esides the results tables, a graphical 
representation (a “box and whisker” 
plot) is added.
From 2001, in addition to the analytical 
results, an interpretation for some para-
meters such as antibiotics has been added 
to the questionnaire.
The clinical interpretation for amikacin 
(aminoglycoside active against nosoco-
mial Gram-negative infections but nephro- 
and oto-toxic) was the first antibiotic to 
be introduced. Requests for interpreting 
vancomycin (glycopeptide active against 
Gram-positive infections but also nephro-
toxic) began in 2004. From 2008, interpreta-
tions were also requested for gentamicin 
(aminoside used against Gram-negative 
and Gram-positive bacilli and methicillin 
sensitive staphylococci but nephro- and 
oto-toxic).
For the purposes of illustration, the follow-
ing case studies for amikacin and for gen-
tamicin were proposed in the 2009 EQaS.
case 1
EQaS 2009/1 (February 2009): a man is 
treated with 1000 mg of amukin on a “once 
a day” schedule. Two blood samples were 
collected to monitor the treatment: the 
first sample was taken 2h 25m and the 
second sample 6h 30m after the drug ad-
ministration. The concentration of the first 
sample was the one used as quality control 
(= EQaS sample). The second sample con-
tained a serum concentration of amikacin 
of 17.3 µmol/l.
case 2
EQaS 2009/4 (November 2009): a 29 year old 
woman (55 kg) suffering from PID (Pelvic In-
flammatory Disease) is treated with a dose 
of 240 mg gentamicin/24h (once daily). The 
intravenous perfusion was administered 
from 13:00 to 14:00. blood was collected at 
12:55 and at 20:30.
The concentration of the peak value is 
0.4 µmol/l. The second value was the EQaS 
sample. 
using a pharmacokinetic program 
improves the results of the belgian 
antibiotics eQaS P. van de Walle
n. devleeschouwer
c. van campenhout
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reSultS
The analysis of the belgian EQaS results for 
antibiotics show that many laboratories 
encounter difficulties in some of these sur-
veys, specifically with the interpretation 
of the proposed case reports and mainly 
when interpretations of unconventional 
blood collection intervals are requested.
In 2009, four surveys were conducted: in 
February, May, September and November.
The two following results illustrate these 
interpretation difficulties.
amikacin
105 laboratories participated in these sur-
veys for amikacin in 2009. 
Four lyophilised control samples were 
used, ranging from 23.77 to 49.76 µmol/l 
(medians for all methods and all measur-
ing systems). as is often the case, the ana-
lytical results for this antibiotic were not a 
problem in 2009: the maximum observed 
CV for one measuring system was 8.1% for 
a median concentration of 47.7 µmol/l.
as shown in Table 1, for instance for the 
EQaS 2009/1 in February, analytical per-
formance is satisfactory with a global CV 
at 6.4%. 
On the other hand, many laboratories 
encountered problems interpreting the 
results for this EQa because a case report 
with unconventional sampling times was 
used (= case 1).
Despite the fact that guidelines for 
aminoglycosides monitoring have been 
published several years ago, the differ-
ences in interpretations are probably due 
to poor in-depth knowledge of clinical 
pharmacokinetics. 
67.6% of participants regarded the results 
as being non-interpretable (Table 1).
In this case, the extrapolated peak value 
at time 0 will be around 85 µmol/l and the 
through value far below 4.5 µmol/l. The 
final interpretation will depend on the tar-
get values recommended in the hospitals 
but could correspond to an appropriate 
treatment.
Gentamicin
The range of the 4 gentamicin control sam-
ples used in the 2009 EQaS lies between 9.2 
and 18.9 µmol/l (medians for all methods 
and measuring systems).
The analytical results were, as usual, ac-
ceptable to satisfactory.
as a further illustration, the results for 
the lyophilised control sample used in the 
2009/4 survey (November 2009) are shown 
in Table 2.
In addition to the analytical results, a case 
study for this aminoside was proposed to 
the 49 participating laboratories (= case 2).
71.4% of the participants responded that 
the case was non-interpretable (Table 2). 
However, sufficient information was pro-
vided to allow calculation. The concen-
tration found in the second sample is 9.4 
µmol/l (Table 2) and may indeed appear 
weak.
Many other cases have shown the same 
difficulties in interpretation.
amiKacin 
Conversion factor: µmol/l / 1.71 = µg/ml 
r/7534
method median
µmol/l
Sd
µmol/l
cv
%
median
µg/ml
n labs
001 Non-Isotopic abbott TDx 49.42 2.54 5.1 28.90 26
003  Non-Isotopic Roche Integra 47.97 2.74 5.7 28.05 32
005  Non-Isotopic Roche Hit / Mod / cobas c 50.36 1.98 3.9 29.45 32
006  Non-Isotopic Syva Emit 44.76 3.45 7.7 26.17 12
011  Non-Isotopic abbott – architect/aeroset 
54.21 
51.90
2
050  Home made 50.45 1
Global results 
(all methods and all measuring systems)
49.76 3.17 6.4 29.10 105
interpretation n median (µmol/l) pct
Inappropriate sampling/ result not interpretable  71 49.59 67.6%
appropriate treatment 17 49.76 16.2%
Subtherapeutic 11 49.76 10.5%
Toxic 3 51.47 2.9%
No answer 3 45.83 2.9%
total 105
table 1: analytical results (lyophilised sample) and clinical interpretation of the 2009/1 belgian eQaS amikacin case study  
 (unconventional sampling time).
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Gentamicin 
Conversion factor : µmol/l / 2.09 = µg/ml  
r/9243 
method median
µmol/l
Sd
µmol/l
cv
%
median
µg/ml
n labs
021 abbott - axSym/TDx/TDxFlex - 
Fluorescence polarisation immunoassay  
10.0 0.6 6.3 4.8 18
031 Coulter - Synchron lX/DxC - 
Particle enhanced immunoturbidimetry 
11.9 
9.6 
2
040 Siemens - Dimension/ Vista - PETINIa 9.9 0.5 4.7 4.8 6
072 Roche - Cobas Integra -
Fluorescence polarisation immunoassay
8.8 0.5 5.6 4.2 13
074 Roche - Hitachi/ Modular./ cobas c – 
KIMS immunoassay  
8.6 1.2 13.5 4.1 8
084 Siemens advia Centaur/CP - 
Immunochemiluminescence  
9.2    1
090 Vitros - Enzyme immunoassay - spectrometry 10.0    1
Global results 
(all methods and all measuring systems)
9.4 0.9 9.9 4.5 49
interpretation n median (µmol/l) pct
Inappropriate sampling/ result not interpretable  35 9.4 71.4%
appropriate treatment 7 10.0 14.3%
Subtherapeutic 4 8.7 8.2%
No answer 3 10.0 6.1%
total 49
table 2: analytical results and clinical interpretation of the 2009/4 eQaS gentamicin case study (unconventional sampling time).
However the interpretation is quite sim-
ple with the use of a pharmacokinetic 
program, even when the blood collection 
intervals are uncommon like in these 2 
examples. Such a computer program, Phar-
monitor, has been developed in St. luc 
Hospital (brussels, belgium) to optimise 
aminoglycosides monitoring, responding 
to the demands of most daily clinical situ-
ations (7). 
For example, for case 2, the Pharmoni-
tor software shows a peak value of 
44.66 µmol/l and a through value of 
0.42 µmol/l. The clinical pharmacokinetic 
parameters (t1/2, Vd, Cl, etc.) appear to be 
normal. The proposed scheme can there-
fore be considered suitable for treatment. 
Only 15% of participants (without the use 
of software) considered the treatment pro-
posed in this clinical case as appropriate 
and interpretable.
concluSion
Therapeutic Drug Monitoring is an impor-
tant field of clinical biology. The clinician 
expects not only a numerical result from 
the laboratory but also correct clinical in-
terpretation in order to provide adequate 
treatment to patients adapted to individu-
al pharmacological characteristics. 
For many years, TDM has been applied to 
monitor antibiotics, anti-epileptic and anti-
arrhythmic treatments as well as those in-
tended to treat cardiac decompensation.
TDM has also been introduced for the mon-
itoring of immunosuppressive drugs and 
more recently antiretroviral drugs. Many 
studies have emphasised the importance 
of the quality of the pharmacokinetic in-
terpretation during the monitoring (8-11).
a good interpretation results in an individ-
ualised regimen that improves the effec-
tiveness of the treatment and reduces the 
incidence of toxic episodes, the duration of 
treatment and overall hospital costs (12).
EQaS monitors the overall quality of the 
laboratories’ performance. Post-analytical 
error may be monitored by using case re-
ports where laboratories are asked to in-
terpret analytical results.
The examples, taken from the 2009 TDM 
belgian EQaS and depicted above, show 
the usefulness of an interpretation pro-
gram such as the Pharmonitor in answer-
ing correctly these case reports.
The difficulty of the first case report, for 
example amikacin (case 1), lies in the fact 
that the nursing staff failed to perform 
blood tests at regular sampling times (e.g. 
before the intravenous perfusion and one 
hour after the end of perfusion).
In the second case report, for example 
(case 2 – gentamicin), the time of the sec-
ond blood sample is very unusual (20:30 
instead of 15:00, for example). Various rea-
sons may explain this scheme: forgetful-
ness, overworked nursing staff, etc.
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acKnoWledGement
even when analytical performance is good, as shown by the belgian eQaS, 
many laboratories encounter problems in clinical interpretation. results il-
lustrate the added value of the use of dedicated software to improve phar-
macokinetic interpretation and to allow optimised dosage regimen avoid-
ing unnecessary blood sampling and additional testing.
i m P a c t  o n  P u b l i c  h e a l t h
These examples clearly show that compu-
terised approach to monitor antibiotics is 
mandatory. 
Software for the interpretation of TDM ex-
ists in Europe and in the United States but 
these programs are expensive.
The belgian Health authorities decided to 
finance and support the development of an 
improved version of the former Pharmoni-
tor and to supply the laboratories with this 
program free of charge (to be used for 4 
aminoglycosides – amikacin, gentamicin, 
tobramycin, netilmycin- and 2 glycopep-
tides – vancomycin, teicoplanin) (13).
This software, based on a one-compart-
ment open pharmacokinetics model, can 
calculate t1/2, Vd, Cl, Cpmax and the theo-
retical optimal dose and interval. It can 
also evaluate the creatinine clearance.
In 2009, the belgian Health authorities or-
ganised several training sessions for the 
belgian clinical laboratories and a free of 
charge copy of the pharmacokinetic soft-
ware was distributed to the participants.
Further improvement and development 
of the program is planned such as adding 
a (blood) alcohol rate calculator and using 
formulas based on population pharmaco-
kinetics and bayesian estimation.
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